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SUMMARY 
Background 
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects 
synovial joints and is the commonest form of inflammatory polyarthritis. RA 
potentially confers significant morbidity, loss of function and reduced quality of 
life. It is a multisystem disorder with extra-articular manifestations affecting skin, 
cardiovascular, respiratory and haematological systems.  
There is an associated premature mortality associated with RA which is mainly 
attributable to cardiovascular disease (CVD). Much has been published on the 
associated increased CVD risk which RA confers, which includes increased incidence 
of myocardial infarction, congestive cardiac failure and hypertension. Active RA is 
associated with a higher burden of both traditional cardiovascular (CV) risk factors 
(cigarette smoking, dyslipidaemia and hypertension) and novel risk factors 
(endothelial dysfunction, arterial stiffness and insulin sensitivity) than would be 
expected in the general population. Furthermore, chronic inflammation may be 
atherogenic. Certain drug therapies may contribute to CV risk, such as steroids and 
anti-inflammatories. Whereas other drug therapies, such as anti-tumour necrosis 
factor agents, may modulate CV risk.  
There have been many recent controversies regarding anti-inflammatories, both 
non-selective non-steroidal anti-inflammatory drugs (NSAID) and cyclooxygenase2 
(COX2) inhibitors. These include gastrointestinal system side-effects, renal 
dysfunction and hypertension. The most publicised of these issues was the 
withdrawal of rofecoxib in 2004 by its manufacturers after clinical trial data 
emerged which showed a 3.5% incidence of myocardial infarction or ischaemic 
stroke in patients with no pre-existing CVD who were receiving therapy. This lead 
to a scrupulous review in the medical journals of the relative CV risks of both NSAID 
and COX2 inhibitor groups as whole; as well as sub-analysis and comparison of 
individual preparations. In 2006 the American Heart Association recommended that 
in order to minimise CV risk, any patient prescribed an anti-inflammatory should 
have the lowest dose administered for the shortest possible time.  
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Furthermore, it is clear from the literature that it is not just underlying disease 
processes and medication that can impact on CV risk. Dietary modification can 
have a large bearing on health outcomes. Large epidemiological studies from 
Greece and other countries of southern Europe have confirmed that adherence to a 
Mediterranean-type diet is associated with increased longevity and reduced CVD. A 
Mediterranean-type diet is typically rich in olive oil, fruit, vegetables, legumes and 
fish, with a low intake of red-meat. This type of diet is often complemented by a 
modest amount of alcohol, usually red wine, taken alongside meals. This contrasts 
starkly with the typical diet of the west of Scotland – ‘famed’ for its high amount 
of saturated fat and sugar and relatively low consumption of fruit and vegetables.  
Of late, much interest has been generated regarding the potential relationship 
between social deprivation and effect on health in general, particularly: diet, 
cardiovascular disease and RA outcomes. This is of particular relevance to Glasgow 
which has some of the most deprived areas in Scotland. While traditional CV risk 
assessment calculators have focussed on traditional markers such as blood pressure 
and cholesterol, newer validated scores include a score of deprivation, higher areas 
of social deprivation are associated with higher incidence of CVD, and family 
history of CVD.  
Aims 
In this thesis my aims were to explore the effect of novel interventions on various 
aspects of RA, predominately to assess CV risk further and review whether certain 
aspects of risk could be modified.  
First of all, I investigated the feasibility and effect of anti-inflammatory withdrawal 
in patients with well-controlled RA (that is to say, patients with mild disease 
activity scores). The rationale to the NSAID withdrawal study was that removal of 
therapy plus any required active intervention would provide equivalent symptom 
control to that achieved by continuing NSAID. Other prescribed RA therapies were 
continued. The impact of this intervention was assessed by disease activity score, 
pain score and functional assessments. Secondary study outcomes included the 
effect of drug withdrawal on blood pressure control, gastrointestinal symptoms and 
renal function.  
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Subsequently, the impact of a Mediterranean-type diet on disease activity within 
the Glasgow RA population was reviewed. The study was set up to assess if existing 
resources could be used as much as possible and replicate a Mediterranean-type 
diet in a real-life setting, predominately in areas of social deprivation in the east 
end and south side of Glasgow. Feasibility and acceptability to participants was 
explored. Additionally, the impact of such a dietary intervention on disease 
activity, CV parameters and haematological markers was assessed.  
Finally, given recent evidence linking social deprivation with CV risk as well as poor 
RA outcomes, an analysis was undertaken using the cohort recruited to the 
Mediterranean-type diet. Results of CVD risk calculations according to conventional 
and new algorithms were compared.  
Results  
Thirty patients with RA and a 44-joint disease activity score of ≤2.8 were recruited 
to a 12-week anti-inflammatory withdrawal study. All completed the study period 
without requiring re-introduction of anti-inflammatories and all continued on their 
previously prescribed RA therapy. Eleven patients required a steroid injection at 
either the 6 or 12-week study visit and only 1 required escalation of disease 
modifying therapy. There was no significant deterioration in disease activity score 
or components at the 12-week assessment. A significant improvement in blood 
pressure was recorded with a maximal median reduction of 7 millimetres of 
mercury (p=0.037). 
Seventy-five patients with RA were recruited to the intervention arm of the 
Mediterranean-type dietary study and attended weekly cookery classes over a 6 
week period. Fifty-five patients with RA were recruited to the control arm and 
received basic printed information only. All routine medication was continued and 
patients assessed at baseline, 3 and 6 months. Significant benefits were seen in the 
intervention group with regards to features of RA activity: reduced duration of 
early morning stiffness at 6 months (p=0.041), patient global health assessment 
score at 6 months (p=0.002) and pain score at 3 and 6 months (p= 0.011 and 0.049 
respectively).  Then intervention group demonstrated a benefit in systolic blood 
33 
 
pressure. There was a significant increase in fruit, vegetable and legume 
consumption as assessed by food frequency questionnaire.  
The substantial amount of baseline demographic and CV data collected from the 
Mediterranean-type diet study allowed a comprehensive assessment of the 
influence of social deprivation on CV risk scores in a cohort of female patients with 
RA living in the Glasgow area to be undertaken. Three different CV risk calculators 
were used: Joint British Societies Coronary Risk Prediction, Framingham and the 
newer, Scottish, ASSIGN score which incorporates social deprivation. ASSIGN was 
more likely to classify an individual with a >20% 10-year CVD risk (23% of total 
cohort) than Framingham or JBSCRP. By using ASSIGN, an additional 16 individuals 
were identified as having a >20% 10-year CV risk than would have been identified 
by using traditional JBSCRP alone. 
Conclusions 
The anti-inflammatory withdrawal intervention was limited by an open-label design 
and small participant numbers (n=30). However, it was well tolerated and did not 
result in the need for significant medical intervention, nor loss of disease control. A 
significant improvement in systolic blood pressure was noted over the study follow-
up. To my knowledge this is the first supportive evidence to guide the limitation of 
anti-inflammatory use in patients with stable RA and should inform further work in 
this area.  
The Mediterranean-type diet intervention demonstrated that a 6-week intervention 
can prove instrumental in increasing intake of healthy foods at a relatively low 
cost. This dietary intervention was well received, on reviewing feedback, and 
resulted in beneficial effects on RA disease features as well as on blood pressure. 
This could be an area of future disease modification which is cost-effective and 
easy to implement as well as being popular with patients.  
Using the ASSIGN score allowed the identification of a greater number of study 
participants with a high 10-year CVD risk score. This is in addition to the increased 
CV risk which RA confers. Increased use of this score would allow the targeting of a 
greater number of patients to target interventions and minimise future CVD. 
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1.1 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic inflammatory multi-system disorder that 
primarily affects synovial joints and is the commonest form of inflammatory 
polyarthritis. The condition was first described as a distinct disease entity in the 
19th century (1) and the term ‘rheumatoid arthritis’ was first used by Alfred Baring 
Garrod in 1859 (2). RA potentially confers significant morbidity, loss of function 
and reduced quality of life. There is an associated premature mortality mainly 
attributable to cardiovascular disease (CVD). Active RA is associated with a higher 
burden of both traditional cardiovascular (CV) risk factors (cigarette smoking, 
dyslipidaemia and hypertension) and novel risk factors (endothelial dysfunction and 
insulin resistance) than would be expected in the general population. Furthermore, 
chronic inflammation may be atherogenic and certain drug therapies may 
contribute to or modulate CV risk.   
1.1.1 Clinical features  
RA is a symmetrical inflammatory polyarthritis which affects both large and small 
synovial joints. It manifests as pain, stiffness and swelling of these joints with 
subsequent erosive destruction of surrounding articular cartilage and bone. The 
onset of RA may occur at any stage of adult life but the most frequent time is 
during middle age; the peak occurrence in females is around the time of the 
menopause. Females are 3-4 times more likely to be affected than males. RA 
affects approximately 1% of the worldwide population (3) and has a minimum 
prevalence of 1.16% in United Kingdom (UK) females and 0.44% in UK males (4). 
In the majority of cases, RA displays a chronic course of progressive inflammation 
with periods of disease flare and quiescence. Early morning stiffness (EMS) may 
precede awareness of pain and swelling. The most commonly affected areas are 
the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints in the 
hands, wrist joints and the metatarsophalangeal (MTP) joints in the feet. Unlike in 
osteoarthritis (OA) and psoriatic arthritis (PsA), the distal interphalangeal joints are 
not affected. Although primarily affecting joints, RA is associated with extra-
articular disease which can manifest in any of the body’s organs. 
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1.1.2 Serological features  
RA can be sub-divided into the presence or absence of rheumatoid factor (RF). RF 
is associated with more aggressive and erosive disease, with increased incidence of 
extra-articular manifestations. The use of anti-citrullinated protein antibody 
(ACPA) has become established in the diagnosis of RA more recently, with a higher 
specificity but lower sensitivity than RF (5).  
1.1.3 Diagnosis  
RA is diagnosed by history, objective evidence of joint swelling and tenderness, 
immunology profile, elevated inflammatory markers and potentially by 
confirmation of radiological damage. The initial 1988 American College of 
Rheumatology (ACR) diagnostic criteria (6) have been superseded by the joint ACR 
and European League Against Rheumatism (EULAR) guidelines of 2010 in an attempt 
to facilitate earlier detection of those with inflammatory arthritis who would 
benefit from intervention (7).The diagnosis is aimed at the classification of newly 
presenting patients. The diagnostic criteria are summarised in Table 1.1; at least 1 
joint with definite clinical synovitis is required and this swelling should not be 
better explained by another condition. The new criteria have been validated in 
clinical practice with good results (8) (9).    
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Table 1.1 – 2010 ACR/EULAR diagnostic criteria for rheumatoid arthritis        
 
CRITERIA 
 
 
SCORE 
 
JOINT INVOLVEMENT 
1 large joint 
2-10 large joints 
1-3 small joints (± large joints) 
4-10 small joints (± large joints) 
>10 joints (at least 1 small joint) 
 
 
 
0 
1 
2 
3 
5 
SEROLOGY 
Negative RF and negative ACPA 
Low positive RF or low positive ACPA 
High positive RF or low positive ACPA 
 
0 
2 
3 
 
ACUTE PHASE REACTANTS 
Normal CRP and normal ESR 
Abnormal CRP or abnormal ESR 
 
0 
1 
 
DURATION OF SYMPTOMS 
<6 weeks 
≥6 weeks 
 
0 
1 
A score of ≥6/10 is required for a definite diagnosis of RA 
Adapted from (7) 
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1.1.4 Treatment  
The treatment of RA has changed dramatically in the last 3 decades. Initially, the 
focus was simply on improving symptoms by the use of analgesics and anti-
inflammatories. Currently, these therapies are likely to have been self-prescribed 
by the individual or recommended by the general practitioner (GP) before 
specialist rheumatology review occurs. 
Steroids have long been successfully employed by oral, intra-articular (IA) or 
intramuscular (IM) routes to reduce inflammation; while they are not able to be 
purchased over-the counter by the individual, they continue to be prescribed by 
GPs and rheumatologists. Low dose oral glucocorticoids given in addition to 
standard therapy in RA can reduce the rate of erosion progression, especially in 
those with a disease duration of less than 2 years (10). The adverse effects of low 
dose prednisolone are modest – the immediate concern of loss of bone mineral 
density can be addressed early on. Concerns do persist, however, regarding longer 
term adverse effects of continued glucocorticoids use, such as increased CV risk via 
hypertension (11).  
1.1.4.1 Disease modifying anti-rheumatic drugs 
The main class of drug demonstrated to improve symptoms and prevent damage 
and disability is the disease modifying anti-rheumatic drugs (DMARD). Commonly 
prescribed DMARD in the UK include: methotrexate (the most frequently used and 
so-called “anchor drug”), sulfasalazine, hydroxychloroquine, leflunomide and 
sodium aurothiomalate. They are instigated as soon as possible after the time of 
diagnosis. Combinations of DMARD are now increasingly used to gain tight control of 
RA disease activity (12) (13) with the aim of achieving “remission” of disease 
activity, as described in more detail in Section 1.1.7.  
1.1.4.2 Biological therapy 
The advent of tumour necrosis factor (TNF) inhibitors have revolutionised RA 
therapy still further. TNF and TNF inhibitors are discussed in more detail in Section 
1.2.2 and 1.2.2.1. Adalimumab, etanercept and infliximab are licenced for use 
after failure of 2 or more DMARD (one which must be methotrexate) when a patient 
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has active RA as manifest by a 28-joint disease activity score (DAS28) of >5.1 on 2 
separate occasions greater than 1 month apart. Ideally, these drugs are co-
prescribed with methotrexate but can be given alone (14). Rituximab, an anti B-
lymphocyte CD20 biological therapy, is now licenced for use in RA after failure of a 
TNF inhibitor; also ideally co-prescribed with methotrexate (15).  
1.1.5 The role of the multi-disciplinary team  
The multi-disciplinary team is of vital importance in the care of a patient with RA. 
The team members include nurse specialists, physiotherapists, occupational 
therapists and podiatrists. A shared-care arrangement between hospital and 
primary care physicians is crucial to the safe administration of drugs and follow-up 
of patients. Orthopaedic surgeons have a role in managing patients with 
significantly damaged joints in whom surgical intervention in the only remaining 
option.  
1.1.6 Outcome measures  
Outcome measures can be used to assess the efficacy of new treatments and to 
help target increasingly expensive therapies towards those with the greatest need 
and potential benefit. The ACR response criteria assesses improvement in swollen 
joints, tender joints, pain, disability, inflammatory markers and patient and 
physician global health (GH) scores (16). Other response criteria and outcome 
measures include the traditional or 44-joint disease activity score (DAS or DAS44) 
and DAS28 which are detailed in Section 2.4. Table 1.2, below, describes how any 
improvement in DAS28 from “baseline” to “endpoint” can be used to grade 
outcome. 
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Table 1.2 – Using change in DAS28 to determine outcome 
 
DAS28 at endpoint 
 
Improvement in DAS28 from baseline 
>1.2 >0.6 and <1.2 <0.6 
 
<3.2 
 
Good 
 
Moderate 
 
None  
3.2-5.1 Moderate Moderate None 
>5.1 Moderate Moderate None  
Adapted from (17) 
 
1.1.7 Remission  
Clinical remission in RA is a concept which has been developed over the last 30 
years since the publication of ACR criteria in 1981 (18). It was determined by the 
presence of at least 5 out of 6 criteria on 2 consecutive months: minimal early 
morning stiffness, low erythrocyte sedimentation rate (ESR), no fatigue and the 
absence of painful, tender or swollen joints. Basing remission on disease activity 
was developed further in the 1990s with a DAS44 of <1.6 or a DAS28 of <2.6 being 
criteria for remission (described further in Table 2.5) (17, 19) (20) (21) . More 
recently, the ACR have published definitions of remission to be used in clinical 
trials based on tender and swollen joint counts, C-reactive protein (CRP) and 
patient or physician GH assessments (22). 
 
1.2 PATHOGENESIS OF RHEUMATOID ARTHRITIS  
The onset of arthritis is preceded by a “pre-articular” period of autoimmunity 
where immunoglobulin (Ig) as RF or ACPA is present (23) (24). During this time, 
lipid dysregulation can occur, leading to the earliest initiation of CV co-morbidity 
(25). Subclinical synovitis may be present at this stage and clinically evident 
disease will follow thereafter. The triggers that lead to autoimmunity are not fully 
known. Genetic factors may account for approximately 30% of the risk of 
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developing RA. Environmental factors (e.g. known and unknown micro-organisms, 
smoking, mechanical stress) also play a key role.  
The synovial lining of a joint provides nutrients to the avascular cartilage as well as 
producing lubricants such as hyaluronic acid. In RA the synovial lining becomes 
thickened with an inflammatory infiltrate which includes B cells, T cells, 
neutrophils and macrophages. T cell infiltrates are prominent in RA synovium (26). 
The role of B cell pathology in RA is becoming clearer with clinical studies 
establishing the role for CD20 targeting, such as with rituximab (27) (28). 
Discovering the role of TNF has revolutionised thinking on the pathogenesis and 
treatment of RA, and this is described in more detail in Section 1.2.2.  
1.2.1 Genetics  
The major susceptibility genes identified for RA, as well as for inflammatory 
polyarthritis, in Northern Europeans are human leukocyte antigen (HLA)-DRB1 (29) 
and protein tyrosine phosphatase non-receptor type 22 (PTPN22), estimated to 
account for approximately 40% of total genetic risk for RA (30) (31). The majority 
of patients with RA carry the HLA-DRB1 allele. The shared epitope is a 5 amino acid 
sequence motif (32), the presence of which is associated with certain RA outcomes 
such as erosive disease and disability as well as the presence of RF and ACPA. 
The advent of the Human Genome Project allowed genome wide association studies 
(GWAS) to become the most powerful and extensively used approach in discovering 
susceptibility variants for complex disease processes, such as RA. GWAS has 
resulted in over 30 genetic loci being confidently associated with RA predisposition, 
with thousands of single-nucleotide polymorphisms (SNP) explaining an additional 
20% of disease risk (in addition to HLA-DRB1 and PTPN22) (33). These include:  V-
set domain-containing T-cell activation inhibitor 1 (VTCN1) polymorphisms – which 
play a pivotal role in regulating the immune system (34), common variants at CD40 
gene locus (35), interleukin (IL)-2 receptor alpha chain (IL2RA) (36), chemokine (C-
C motif) ligand 21 (CCL21) (35) (36) and TNF receptor alpha factor 1/complement 
component C5 (TRAF1/C5) locus on chromosome 9 – relevant to chronic 
inflammation (37). It is thought that different mechanisms may be involved in the 
development of ACPA-positive versus ACPA-negative RA (far fewer genetic risk 
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factors are associated with the latter). The genetics of RA in relation to CVD is 
discussed in more detail in Section 1.5.7.  
1.2.2 Tumour necrosis factor  
Arguably the greatest single advance in the management of RA has been the 
identification of the key role of the group of cytokines, TNF, in its pathogenesis. A 
multitude of pro-inflammatory and anti-inflammatory mediators have been 
characterized in the rheumatoid synovium, but among these, TNF, as identified in 
1985 (38), seems to be pivotal. TNF is localised in the lining layer of the synovium 
and at the cartilage pannus junction.  
In vitro administration of neutralising anti-TNF antibody to primary RA synovial 
cultures results in a marked reduction in local cytokine production (39). Transgenic 
mice that express human TNF develop an inflammatory arthritis reminiscent of RA.  
Moreover, administration of anti-TNF antibody to transgenic mice with collagen-
induced arthritis (40) resulted in a substantial reduction in inflammation and 
damage (41). This work led to the first human trials of infliximab for the treatment 
of RA, a chimeric monoclonal antibody which targets TNF; these studies 
demonstrated significant clinical benefit (42). 
TNF-alpha (α) is a homotrimeric cytokine that can influence a variety of molecular 
and cellular events that contribute to several disease states including RA (43). It is 
produced by many cells including macrophages, T cells and B cells; its roles include 
regulation of leukocyte activation and maturation as well as cytokine and 
chemokine release as illustrated in Figure 1.1. As such, it is a central regulator of 
inflammatory cascades during both initiation and amplification of inflammatory 
reactions; via the induction of IL-6 release it acts as a critical regulator of the 
acute phase response. TNF-beta (β) is also known as lymphotoxin. A large number 
of other cytokines in the TNF family have been discovered and their key uses 
identified. Throughout the rest of this work, whenever the terms “TNF” or “anti-
TNF” are used, TNF-α is specifically being referred to. 
As outlined in Figure 1.1, TNF is thought to promote the inflammatory cascade 
within the arterial wall during development of atherosclerosis, in part by promoting 
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endothelial cell injury (44), a topic which will be explored in more detail later in 
this work. It may directly promote endothelial cell apoptosis and suppress the 
activities of endothelial cell progenitors that could sustain endothelial repair (45). 
TNF has also been implicated in promoting endothelial injury through recruitment 
of immune cells, such as neutrophils, which can mediate tissue destruction (46). 
Through adipocytes, TNF might contribute to the regulation of lipid and glucose 
metabolism (47) (48) which has direct clinical implications in the acute setting (for 
the necessary responses to injury or severe infection) and in the chronic setting 
(increased vascular risk). As such, TNF is considered a pleiotropic inflammatory 
cytokine with a central role in many pathophysiologic states and in associated 
comorbidities that affect more than just the primary target tissue. 
Figure 1.1 – Actions of TNF and potential role in atherosclerosis 
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1.2.2.1 TNF inhibitors 
Until recently, only 3 TNF inhibitors (so-called anti-TNF drugs) were licensed for 
the treatment of RA: infliximab and adalimumab (both fully humanised monoclonal 
antibodies) and etanercept (a fusion protein of human soluble TNF receptor and 
the Fc component of human IgG1). All three of these biologic agents have been 
shown to be successful in controlling disease activity, improving physical function 
and attenuating radiological progression in RA (50) (51) (52). Additionally, a 
number of studies have described the effects of these agents on vascular risk 
surrogates and rates of vascular disease. Recently, golimumab (a fully humanised 
monoclonal antibody) and certolizumab (a PEGylated fragment antigen binding 
(Fab) fragment) have been added to the list of available TNF inhibitors.  
In combination with methotrexate, a 20% reduction in clinical signs and symptoms 
is achieved in up to 70% of patients with RA receiving anti-TNF therapy. This 
improvement is often accompanied by slowing of joint destruction, as seen on plain 
radiographs (53).  
Side-effects of anti-TNF include increased risk of infection, reactivation of 
tuberculosis, as well as the possibility of developing psoriasis, demyelination or 
paradoxical autoimmune features (53). Concerns were initially raised regarding 
increased incidence of malignancy with the use of these drugs. However, no overall 
conclusive evidence exists for an increased risk of solid tumours or 
lymphoproliferative disease above that which would be expected for the rest of the 
RA population (54).There is the increased risk of skin cancers (both malignant 
melanomas and non-melanotic skin cancers) with anti-TNF use; skin surveillance 
and preventative skin care is recommended. Overall vigilance is advised and 
caution should be exercised in prescribing anti-TNF therapy in patients with a 
previous malignancy or a pre-malignant condition.   
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1.3 CO-MORBIDITY IN RHEUMATOID ARTHRITIS 
A co-morbid condition is a medical disorder which coexists along with the disease 
of interest. It may represent an active, past or transient illness and might be linked 
to the primary condition or its treatment, or be completely independent. Co-
morbidities may greatly affect patients’ quality of life, prognosis of condition and 
effectiveness of its treatment. Common co-morbidities in RA include anaemia, 
cerebrovascular disease, CVD, depression, gastrointestinal (GI) ulceration, 
infection, lymphoma, malignancy, osteoporosis and pulmonary disease. These may 
be atypical in presentation leading to difficulties and delays in identification (3). 
From the American National Data Bank for Rheumatic Diseases it has been 
extrapolated that a typical patient with RA has 1.3 co-morbidities (55). RA is 
associated with a higher prevalence of hypothyroidism and such patients have an 
increased risk of CVD and metabolic syndrome compared with their euthyroid RA 
counterparts (56) (57).  
1.3.1 Early mortality  
Survival amongst those with RA is significantly poorer than those without the 
condition. Unfortunately, RA mortality has not improved over the last few decades 
(58). A widening mortality gap has developed between those with RA and the 
general population. This is largely because RA mortality has remained unchanged 
while the general population’s has improved with time (59).   
1.3.2 Increased cardiovascular risk  
The prevalence of CV traditional risk factors in patients with RA compared to 
controls has been well defined. Male gender, smoking, personal or family history of 
ischaemic heart disease (IHD), hypertension, hyperlipidaemia and diabetes, while 
important, have less of an impact on CVD in RA patients compared with non-RA 
counterparts (59). The incidence of CVD and associated death is similar to that of a 
diabetic population (60) (61). The presence of severe extra-articular manifestations 
of RA (including vasculitis, pericarditis, pleuritis, Felty’s syndrome, scleritis, poly- 
and mononeuropathy) is associated with a significantly increased risk of first ever 
CVD event (p<0.001). When controlled for age, sex, smoking, RF and erosive 
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disease the association remained significant: hazard ratio (HR) 3.25, 95% 
confidence interval (CI) 1.59-6.64 (62). 
The prevalence of CVD was determined in nearly 400 RA patients comprising the 
Dutch Cardiovascular Research and Rheumatoid arthritis (CARRÉ) study and 
compared with individuals from the Hoorn study (both diabetic and non-diabetic). 
After adjustment for conventional CV risk factors the odds ratio (OR) for CVD in 
individuals with type 2 diabetes was 2.0 (95% CI 0.9-4.5), and OR for those with RA 
was 2.7 (95% CI 1.2-5.9). The extent of the prevalence of CVD in RA patients  is at 
least comparable to those with diabetes and as such has major implications for 
primary CV prevention strategies in RA (61) (63).  
Increased CV risk in RA shall be explored in more detail in Sections 1.4 – 1.6 where 
different CV disease pathologies and their prevalence in RA will be discussed, 
possible mechanisms analysed and assessment and potential modification of CV risk 
assessment discussed. This will then lead into the presented information on anti-
inflammatory drug use and associated CV risk in Section 1.7. Thereafter, the 
potential role of dietary modification such as with a Mediterranean-type diet in 
minimising CVD risk will be outlined in Section 1.8. 
 
1.4 CARDIOVASCULAR DISEASE – CLINICAL ASPECTS 
CVD is the main cause of death in the UK, attributable to 1 in 3 deaths. In the 
period 2001-2003, death rates from all CVD were greatest in the lowest 
socioeconomic group and lowest in the highest socioeconomic group. It is much 
more difficult to document CVD morbidity than mortality. Prevalence of CVD in the 
National Health Service (NHS) region of Greater Glasgow and Clyde in the period 
2008-2009 was 4.4%, 2% for stroke and 12.5% for hypertension: and these rates are 
broadly similar to those seen throughout Scotland. Lifestyle contributes 
significantly to the high prevalence of CVD in the UK. For instance, 24% of the 
population of Scotland and Northern Ireland and 21% of the population of England 
and Wales were classified as smokers. In addition, the recommended amount of 
salt intake per day is 6 grams (g). Scottish figures of 2005 document an average 
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daily intake of 10.6g in men and 7.6g per day in women. In the same survey, only 
37% of men and 33% of women reported a fruit and vegetable intake of 5 or more 
portions per day (64).  
The World Health Organisation (WHO) Multinational Monitoring of Trends and 
Determinants of Cardiovascular Disease (MONICA) project was a 10-year study 
established in the 1980s to measure the trends in CV mortality, coronary heart 
disease (CHD) and cerebrovascular disease morbidity and to assess the extent to 
which these trends were related to changes in known risk factors, daily living 
habits, health care and major socioeconomic features measured at the same time 
in defined communities in different countries (65). Men and women aged 35 to 64 
years were studied in 38 populations from 21 countries. As illustrated in Figure 1.2, 
Glasgow had the second highest male annual event rate (second only to North 
Karelia in Finland at 915 per 100,000) and the highest female annual event rate of 
all 38 of the populations worldwide which were studied.  
 
Figure 1.2 – Age-standardised annual cardiovascular disease event rates per 
100,000 population Event rates as defined by: sum of fatal+definite, 
fatal+possible, fatal+unclear, non-fatal+definite 
Adapted from (65) 
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1.4.1 Ischaemic heart disease 
In the UK, deaths from CHD are highest in Scotland and the north of England and 
lowest in the south of England. In 2008, CHD caused 13% of all male and 9% of all 
female premature deaths (i.e. in those under 75 years old). In the under 75s, those 
living in the district of Glasgow City Council had the highest standardised death 
rate due to CHD both in Scotland and the entire UK occurring in 128.96 per 100,000 
males and 45.61 per 100,000 females. While death rates from CHD are falling 
overall, there is no narrowing of the relative difference between the most and the 
least deprived, as described in Figure 1.3. The incidence of myocardial infarction 
(MI) in the period 2005-2007 was 20-35% higher in Scotland than in England. Case 
fatality rates were also higher in Scotland: 12% of males and 9% of females died 
(64). 
 
Figure 1.3 – Ratio of cardiovascular disease deaths in Glasgow, most deprived 
compared with least deprived areas 
Adapted from (64) 
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Yusuf’s “Study of risk factors for first MI in 52 countries and over 27,000 subjects” 
is also known as the INTERHEART study. It identified that the following were 
potentially modifiable risk factors associated with MI: abnormal lipids, smoking, 
hypertension, diabetes, abdominal obesity, psychosocial factors (work, home, 
finance, depression and low self-efficacy), fruit and vegetable intake, consumption 
of alcohol and regular physical activity (66). 
1.4.1.1 Ischaemic heart disease in patients with rheumatoid arthritis 
It is recognised that patients with RA have an excess CV morbidity and mortality 
(67). Van Doornum’s group studied almost 30,000 Australian patients who had a 
first CV event (either MI or stroke) over a 2-year period. Of the total group, 1.2% 
had RA. A higher case fatality rate was demonstrated in the RA group compared 
with non-RA patients, with an adjusted OR for CV death at 30 days of 1.9 (95% CI 
1.3-2.7) (68). 
In a retrospective medical chart review, 90 patients with RA admitted with an MI 
over a 10-year period were identified and compared with 90 age and gender 
matched controls (69). It was found that the RA patients were significantly less 
likely to receive acute coronary artery reperfusion therapy compared with controls: 
16% versus 37% (OR 0.27, 95% CI 0.10-0.64). Additionally, these RA patients were 
also less likely to receive lipid-lowering therapy (40% versus 70%, OR 0.21, 95% CI 
0.09-0.46) and beta-blockers (71% versus 83%, OR 0.42, 95% CI 0.18-0.96). These 
differences may contribute to the higher fatality rates of RA patients post-MI.  
Electron-beam computed tomography can be used to establish the extent of 
coronary artery calcification by the calculation of calcium scores. A study of 227 
patients showed higher calcium scores in patients with established RA compared 
with early disease and controls (p=0.001) (70).  Coronary artery calcification was 
noted in 60.6% of patients with established RA (compared with 42.9% of those with 
early disease and 38.4% of controls, p=0.016). Smoking (OR 1.02, p=0.04) and 
elevated ESR (OR 1.02, p=0.05) were associated with more extensive coronary 
artery calcification, after adjustment for age and sex.  
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In addition, a systematic review and meta-analysis to assess CV mortality in an RA 
cohort was published in 2009 by Meune and colleagues (71). 17 studies, involving 
over 91,000 patients, were analysed. The overall pooled standardised mortality 
ratio (SMR) was 1.61 (95% CI 1.48-1.75, p<0.0001) corresponding to a 60% increase 
in risk of CV death in RA patients compared to the general population.  
Maradit Kremers and colleagues have performed a number of epidemiological 
population-based cohort studies on the topic of inflammatory arthritis and CV risk. 
One of her team’s studies assessed absolute CV risk in RA patients; this was found 
to be similar to patients without RA aged 5-10 years older, with increasing risk 
documented for the presence of additional CV risk factors, Table 1.3 (72). The 
presence of low BMI resulting in an even higher CV risk echoes the findings of this 
authors previous work (73). They have demonstrated an increased risk of CV death 
associated with markers of disease activity and extra-articular manifestations, even 
after correction for co-morbidities and traditional CV risk factors, Table 1.4 (74). 
Additionally, the group compared 603 RA patients with matched non-RA patients 
and identified increased risk of MI with subsequent hospitalisation as well as 
“silent” MI in the RA group, Table 1.5. The cumulative incidence of sudden death 
after 30 years of follow-up, after adjustment, was 6.7% in RA group and 3.8% in 
non-RA group (p=0.052). RA was associated with a higher cumulative incidence of 
“silent” MI (6%), after 30 years of follow-up than the non-RA group (3.7%), p=0.05. 
The prevalence of angina after 30 years of follow-up was 9.5% in the RA group and 
14% in the non-RA group (75).  
The potential mechanisms for such an association are detailed in Section 1.4.11. 
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Table 1.3 – Summary of Maradit Kremer et al’s work: 10-year absolute 
cardiovascular risk in RA patients 
 
Risk factor 
 
 
Absolute 10-year risk 
 
Aged 60-69 years, no other risk factors 
 
16.8% 
 
Plus smoking / diabetes / 
hyperlipidaemia / high BMI 
 
60.4% 
 
Plus low BMI 
 
86.2% 
Adapted from (72) 
 
Table 1.4 – Summary of Maradit Kremer et al’s work: Factors associated with 
risk of CV death in RA  
 
Associated risk factor 
 
 
Hazard ratio 
(95% confidence interval) 
 
ESR >60 mm/hour 
 
2.03 
(1.45-2.83) 
 
RA-associated lung disease 2.32 
(1.11-4.84) 
 
Vasculitis 2.41 
(1.00-5.81) 
 
Adapted from (74) 
52 
 
Table 1.5 – Summary of Maradit Kremer et al’s work: Risk of myocardial 
infarction and “silent” myocardial infarction in RA compared with non-RA 
matched controls 
 
Outcome 
 
 
Multivariable odds ratio 
(95% confidence interval) 
 
MI and subsequent 
hospitalisation 
 
3.17 
(1.16-8.68) 
 
“Silent” MI 5.86 
(1.29-26.64) 
 
Adapted from (75) 
 
1.4.2 Heart failure 
Heart failure (or congestive cardiac failure (CCF)), is a physiological state where 
cardiac output is insufficient to meet the body’s requirements. There are 4 grades 
of heart failure based on clinical symptoms as defined by the New York Heart 
Association (NYHA).  These range from NYHA grade I (no symptoms or limitation of 
physical activity) to NYHA grade IV (unable to carry out physical activity without 
discomfort, plus symptoms of fatigue, palpitations or dyspnoea at rest) (76). 
1.4.2.1 Heart failure in patients with rheumatoid arthritis 
It has previously been shown that patients with RA are twice as likely to develop 
CCF than those without the disease (77). Data from a retrospective cohort from 
Rochester, Minnesota, demonstrated a higher cumulative incidence of heart failure 
after incident RA than those without the disease; 34% versus 25.2% (p<0.001) (77). 
At any particular age the incidence of heart failure in patients with RA was 
approximately twice the incidence in non-RA subjects, HR 1.87, (95% CI 1.47-2.39). 
The risk of heart failure was noted to be higher in RF positive RA patients (HR 2.59, 
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95% CI 1.95-3.43) compared with RF negative RA patients (HR 1.28, 95% CI 0.93-
1.78).  
Compared with non-RA subjects, RA patients with heart failure were less likely to 
be obese, be hypertensive, have a history of IHD and display typical signs and 
symptoms of the condition. RA patients with heart failure were more likely to have 
a preserved ejection fraction (≥50%) (78).  
An echocardiographic study assessed 226 UK patients with RA, 65% of who were 
female. Definite left ventricular systolic dysfunction (LVSD), as defined by a left 
ventricular ejection fraction of <40%, was found in 5.3% of the study population, a 
standardized prevalence ratio of 3.2 (95% CI 1.65-5.59). By comparing these results 
with local population estimates, the authors extrapolated that LVSD was 3 times 
more common in patients with RA (79).  
In patients with RA who developed new-onset heart failure, the proportion with a 
significantly elevated ESR was highest in the 6 month period immediately before 
diagnosis. The proportion with anaemia also peaked in this 6 month period. These 
results suggest that inflammatory stimuli may be involved in the initiation of heart 
failure in RA (80). 
N-terminal pro-brain natriuretic peptide (NT-proBNP) is a cardiac neurohormone 
released mainly from cardiomyocytes in response to left ventricular volume 
expansion and pressure overload (81). It can be used as a biomarker for heart 
failure (82). 171 consecutive RA patients without CCF were given the anti-TNF drug 
adalimumab and serum NT-proBNP measured simultaneously on stored baseline and 
16-week samples. Circulating NT-proBNP decreased significantly after 16 weeks of 
adalimumab therapy by approximately 18% (p=0.004) (83). These interesting results 
are contrary to previously published concerns that TNF therapy may worsen left 
ventricular function in RA patients and if anything raises the possibility that TNF 
therapy may lessen CV risk.  
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1.4.2.2 Heart failure and tumour necrosis factor 
TNF, along with other inflammatory molecules, is known to alter cardiac function 
through a number of mechanisms (84). Levine’s group was one of the first to 
document the significantly elevated levels of TNF in a cohort of patients with 
chronic heart disease compared with controls (85). However, clinical trials to 
evaluate the efficacy of TNF therapy in patients with NYHA class II or greater heart 
failure were halted prematurely owing to the lack of clinical benefit and worsening 
of the patient’s conditions (86) (87). An initial case series of 47 patients with new 
onset or exacerbated heart failure secondary to anti-TNF prompted a review of 
prescribing protocols (88) and guidelines incorporated heart failure as an exclusion 
to therapy. The British Society for Rheumatology (BSR) recommend that anti-TNF 
therapy should not be used in NYHA Grade III or IV heart failure and used with 
caution in NYHA Grade I or II heart failure. Anti-TNF should be discontinued if heart 
failure develops or worsens while on treatment (54). 
1.4.3 Hypertension 
Hypertension is one of the most important modifiable risk factors for the 
development of CVD, heart failure and cerebrovascular disease (66) (89), affecting 
approximately 1 billion individuals worldwide (90). The British Hypertension Society 
(BHS) has defined hypertension as ≥140 millimetres of mercury (mmHg) for systolic, 
≥90mmHg for diastolic blood pressure (BP) and / or the use of anti-hypertensive 
medication (91). Different categories for BP have been further defined including 
“optimal” and “normal” recordings; these are outlined in Table 1.6. The National 
Institute for Clinical Excellence (NICE) and BHS have published joint guidelines for 
drug therapy and escalation (92) (93). Antihypertensive drug therapy has been 
proven to reduce the risk of stroke (by up to 40%), CHD (20% reduction in MI), heart 
failure (by greater than 50%) and total mortality (94) (95) (96). Predictive models, 
based on data from the Physicians’ Health and Women’s Health Study, have shown 
that lower levels of BP predict lower event rates for CVD and cerebrovascular 
disease. Both systolic and diastolic BP were significantly associated with event 
rates (p<0.001) in males, whereas only systolic BP was predictive in females 
(p<0.001) (97).  
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The Hypertension Optimal Treatment (HOT) study found that the lowest incidence 
of major CV events occurred at a mean diastolic BP of 82.6mmHg and the lowest 
risk of CV mortality at 86.5mmHg. The addition of aspirin reduced CV events by 15% 
(p=0.03) and of MI by 36% (p=0.002). (98).  
 
Table 1.6 – Classification of blood pressure according to the British 
Hypertension Society 
 
Category 
 
 
Systolic blood pressure 
(mmHg) 
 
Diastolic blood pressure 
(mmHg) 
 
Blood pressure 
Optimal 
Normal 
High / normal 
 
 
<120 
<130 
130-139 
 
 
<80 
<85 
85-89 
 
Hypertension 
Grade I (mild) 
Grade II (moderate) 
Grade III (severe) 
 
140-159 
160-179 
>180 
 
90-99 
100-109 
>110 
 
Isolated systolic 
hypertension 
Grade 1 
Grade 2 
 
 
 
 
140-159 
>160 
 
 
 
<90 
<90 
Adapted from (91) 
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1.4.3.1 Hypertension in rheumatoid arthritis 
The documented prevalence of hypertension in RA patients in the literature has 
varied widely. Panoulas and colleagues’ extensive review on the subject suggests 
that from community-based populations, the prevalence of hypertension in RA 
patients is in the range 52-73% and in secondary care studies from 62-70.5% which 
is higher than the general population prevalence in the UK (99). Contributing 
factors to hypertension in patients with RA are illustrated in Figure 1.4. 
 
Figure 1.4 – Potential factors contributing to hypertension in patients with 
rheumatoid arthritis 
 
Adapted from (99) 
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Panoulas’ own study of 400 consecutive RA patients identified hypertension in 
70.5% of patients; of those 61% were prescribed anti-hypertensive therapy but 39% 
were previously undiagnosed and therefore untreated. Only 21.8% of patients on 
treatment were said to be adequately controlled (100). Hypertension has been 
found to be more prevalent in RA patients with medium dose (i.e. ≥7.5 milligrams 
(mg) per day) and long term exposure to glucocorticoids compared to RA patients 
with no or limited exposure to steroids (101). Target organ damage secondary to 
raised BP is highly prevalent, as found in a study of over 200 RA patients (102).  
The Dutch Behandel Strategieën (BeST) study was a multicentre randomised clinical 
trial of DMARD-naïve patients with active RA of less than 2 years duration (103). In 
all 4 treatment strategies of the trial, systolic and diastolic BP were lower in those 
patients with a DAS28 of ≤2.4 compared with those with a higher DAS28 (104). 
Interestingly, those treated with the anti-TNF drug infliximab demonstrated an 
additional decrease in BP. The BeST study was not designed to look at blood 
pressure and as such the single BP measurements taken and the method of 
assessment may have led to inconsistencies.  
Potential pro-inflammatory properties of angiotensin II have been described in the 
literature (105) and so it is of interest that studies involving RA patients prescribed 
angiotensin II receptor blockers have demonstrated a significantly lower ESR than 
RA controls (106).  
While there are no specific randomised controlled trials of hypertension 
management in RA, Panoulas and colleagues have published valuable guidance on 
the prevention, diagnosis, risk stratification and management on this subject. This 
adds to the literature available on management of the general population with 
hypertension. It is recommended that all patients with RA be assessed for 
additional CV risk factors to allow for stratification of risk alongside BP recordings. 
Anti-hypertensive therapy should be started after exclusion of drug causes (as 
detailed in Figure 1.4) as well as any other indicated CV therapies. All patients 
with RA should have their BP checked every time they attend primary or secondary 
care, or at least every 6 months (99).  
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1.4.4 Lipids 
Chylomicrons and chylomicron remnants are the precursors of the various 
cholesterol subsets. The so –called “bad cholesterol” comprises: very low-density 
lipoprotein (VLDL) cholesterol measuring around 70 nanometres (nm), 
intermediate-density lipoprotein (IDL) cholesterol (40nm), and low-density 
lipoprotein (LDL) cholesterol (20nm). High-density lipoprotein (HDL) cholesterol 
measures around 10nm and is classified as “good cholesterol” – transporting fat 
back to the liver for excretion or to be passed to other tissues (107). An overview 
of the cholesterol pathway is illustrated in Figure 1.5. It is well established that 
elevated total cholesterol (TC) and low levels of HDL cholesterol are predictive of 
vascular event risk. The ratio of TC: HDL cholesterol is incorporated into many CV 
risk algorithms (108). Hyperlipidaemia is defined as elevated TC or LDL cholesterol, 
while dyslipidaemia refers to alterations of individual lipid components.  
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Figure 1.5 - Cholesterol synthesis pathway 
Adapted from (107) 
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1.4.4.1 Lipids and rheumatoid arthritis 
Hyperlipidaemia appears to be less common in RA patients than controls (109), 
however dyslipidaemia may affect up to half of RA patients (110) and is present in 
early disease. Blood bank samples from future RA patients had an average 4% 
higher TC, 9% lower HDL-cholesterol and 17% higher triglyceride levels compared 
with matched controls (p≤0.05) at least 10 years before the onset of symptoms 
(111). Alterations in lipid profile are well documented in RA literature; TC and LDL-
cholesterol tend to fall in the presence of high levels of inflammation alongside a 
reduction in HDL-cholesterol (112). Reduced HDL-cholesterol and elevated 
Lipoprotein (a) correlate with elevated CRP levels and therefore with inflammatory 
activity in RA (113).  
1.4.4.2 Lipids and disease modifying anti-rheumatic drugs 
Anti-rheumatic therapies may have an effect on lipid levels. A study of 100 patients 
with active RA, randomised to either oral hydroxychloroquine or IM gold found that 
former was associated with a significant rise in HDL-cholesterol with no change in 
triglyceride levels (114). 
1.4.4.3 Lipids and anti-tumour necrosis factor therapy 
Infliximab has been shown to significantly increase TC and HDL-cholesterol in 
patients with RA, (115) (116) as has adalimumab (117). Further studies suggest that 
treatment with anti-TNF results in an increase not only in HDL-cholesterol but also 
other lipid moieties, including TC and LDL-cholesterol and perhaps triglycerides 
(118) (119). Such changes in lipid levels might be the predictable response to 
attenuation of inflammation; in untreated RA, reductions in HDL-cholesterol, LDL-
cholesterol and TC have been noted (120). Moreover, these changes mirror lipid 
profile modifications associated with other pathologies and conditions that involve 
inflammation or infection, such as sepsis, cancer, trauma or post-operative state  
(121) (122) (123).  
Qualitative changes in lipid particles during inflammation complicate further 
interpretations, but it seems as if TNF blockade reverses many of the anti-
atherogenic effects of inflammation upon HDL particles (124) (125). The reduction 
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of inflammation seen in patients with severe RA given biologic therapy may be 
expected to cause a rise in lipid levels: TC, LDL-cholesterol and HDL-cholesterol 
and possibly triglycerides (126). 
1.4.4.4 Lipid lowering therapy 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are also 
known as statins. They have been shown to substantially reduce CV morbidity and 
mortality (127). However, while their effects on lipid modulation are well 
described, it has also been demonstrated that statins may have anti-inflammatory 
properties. For instance, the Trial of Atorvastatin in Rheumatoid Arthritis (TARA) 
study was a randomised double-blind placebo-controlled trial in which 58 patients 
with RA were randomised to 40mg atorvastatin and 58 patients with RA  
randomised to placebo (128). By 6 months there was a significant improvement in 
DAS28 with statin therapy (reduction of 0.5 points) compared with placebo. CRP 
declined by 50% (p<0.0001) and ESR by 28% (p=0.005). The authors suggest that 
although statins would not be appropriate for first line disease-modifying therapy 
they could be a helpful adjunct.  
Subsequently, Jick et al published a case-control study which evaluated whether 
statins were associated with a protective effect on the development of RA. 
Patients with hyperlipidaemia who were taking statins were less likely to develop 
RA than untreated patients (OR 0.59, 95% confidence interval 0.37-0.96) (129). 
Finally, the Justification for the Use of Statins in Prevention: an Intervention Trial 
Evaluating Rosuvastatin (JUPITER) study reported in 2008. Apparently healthy 
patients without hyperlipidaemia but with elevated high sensitivity CRP (hsCRP) 
were chosen, but those with RA excluded. Rosuvastatin at 20mg once daily 
significantly reduced the number of major CV events compared with placebo (130). 
1.4.5 Obesity and cardiovascular disease 
Traditionally, obesity has been defined using body mass index (BMI): weight in 
kilograms (kg) divided by the square of height in metres (m2). A normal BMI is 
classified as 20-24.9 kg/m2. However, this measure does not take into account 
muscle mass, fat mass or fat distribution.  The worldwide case-controlled 
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INTERHEART study assessed the relationship of BMI and waist to hip ratio (WHR) 
with risk of MI. Even at low levels of BMI, increased WHR resulted in an increased 
risk of MI; results were consistent to both sexes and different ages (131). A meta-
analysis of over 250,000 patients identified an increased risk for total mortality in 
those patients with a low BMI of <20kg/m2 (RR 1.37, 95% CI 1.32-1.43) and 
increased risk of CV mortality (RR 1.45, 95% CI 1.16-1.81). Patients who were 
overweight or mildly obese (BMI 25-34.9 kg/m2) had no increase in total or CV 
mortality. The authors suggest this could be as a result of BMI poorly differentiating 
between body fat and lean mass (132). 
1.4.5.1 Obesity and cardiovascular disease in rheumatoid arthritis   
RA is associated with changes in body composition. Physical inactivity leads to an 
accumulation of body fat while activation of inflammatory pathways can cause 
muscle degradation. Therefore a patient with true “rheumatoid cachexia” exhibits 
low muscle mass and high fat mass (133). Kremers et al found that RA patients with 
a low BMI at time of time of diagnosis had a significantly higher risk of CV death 
(HR 3.34, 95% CI 2.23-4.99) compared with non-RA patients with a normal BMI; 
after adjusting for age, sex, personal cardiac history, smoking, diabetes, 
hypertension and malignancy (73). Those with a normal BMI at diagnosis who 
subsequently lost weight also had a higher risk of CV death (HR 2.09, 95% CI 1.50-
2.92) than those who maintained a normal BMI during follow-up 
Increasing BMI was found to be associated with increased CVD risk independently of 
many confounders in a study of 378 RA patients (22 from the original cohort of 400 
were excluded because of a concomitant diagnosis of cancer).The authors suggest 
that RA-specific BMI categories may better identify patients in whom weight-loss 
would improve CV risk (134) and that BMI cut-off points should be reduced by 
2kg/m2 to better predict body fat from a BMI score in an RA patient (135). 
1.4.6 Exercise, cardiovascular disease and rheumatoid arthritis  
Exercise can provide significant health benefits in both the general population and 
some “at risk” subpopulations. It has been proven to reduce obesity (136), 
dyslipidaemia (137), diabetes (138) and is effective in preventing acute coronary 
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syndromes (139). Exercise rehabilitation programmes remain an important 
component in the management of a patient post-MI or acute coronary syndrome 
(140). A substantial review by Metsios and colleagues assessed the value of exercise 
interventions in patients with RA with regards to disease-related characteristics 
(141). They conclude that exercise is effective in reversing some of the joint 
damage in RA patients but that relatively little information exists on the role of 
exercise in the modification or management of CVD in inflammatory joint disease.   
1.4.7 Hyperuricaemia, cardiovascular disease and rheumatoid arthritis 
Patients with gout or asymptomatic hyperuricaemia can have clinical and 
biochemical abnormalities of metabolic syndrome including insulin resistance, 
obesity and hyperlipidaemia. All of these are linked to atherosclerosis and reduced 
life-expectancy (142). Although RA is not traditionally associated with 
hyperuricaemia (143), Panoulas and colleagues found that serum uric acid levels 
were significantly higher in RA patients with CVD compared to those without 
(p=0.001) and this was maintained after correction for CVD risk factors, physical 
function and use of diuretics and statins (OR 1.36, 95% CI 1.04-1.79, p=0.025) 
(144). The same author found that a 1mg per decilitre increase in serum uric acid 
was associated with a 1.6 increased odds of being hypertensive (145), thought 
likely due to vascular smooth muscle proliferation, activation of the renin-
angiotensin system and salt sensitivity (146). Additionally, uric acid has been found 
to be a strong independent predictor of renal dysfunction in RA (147).  
1.4.8 Renal function, cardiovascular disease and rheumatoid arthritis 
Using the CARRÉ study cohort, Dutch researchers confirmed that in RA patients, 
renal dysfunction as demonstrated by a low glomerular filtration rate (GFR) was 
associated with higher risk of CVD which was independent of traditional CV factors; 
(OR 1.30 (95% CI 1.14-1.149) per 5 millilitre (ml)/minute/1.73m2 decrease in GFR) 
(148). To describe in an alternative way, a 5ml/minute reduction in GFR was 
associated with a 30% increase in CV event rate over the 3 year follow up of the 
study.   
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In a subsequent cross-sectional single-centre study of 400 consecutive RA patients 
in whom 68% of patients had an estimated glomerular filtration rate (eGFR) of 
<90ml/minute/1.73m2 and 13% had an eGFR of <60ml/minute/1.73m2, linear 
regression was used to assess the independence of the associations between eGFR 
and other variables. There were significant associations between eGFR and age 
(p<0.001), TC (p=0.022), serum uric acid (p<0.001) and the presence of extra-
articular disease (p=0.040). The authors suggest that renal dysfunction is common 
within an RA cohort and is associated with classical CV risk factors (149). 
1.4.9 Biologic registry data on cardiovascular disease in rheumatoid arthritis 
A number of large registries of patients with rheumatic conditions receiving 
biologic therapies have been established, with aims of producing long-term data on 
efficacy and toxicity.  
1.4.9.1 Swedish registry data 
In 2005, Jacobsson and colleagues from the South Swedish Arthritis Treatment 
Group (SSATG) published available data on the first incidence of CVD related 
events and deaths in patients included in their registry (150). The age-sex adjusted 
incidence rate of first CV event among the anti-TNF treated patients (13 events 
including deaths in a cohort of 531) was 14 per 1000 person-years (95% CI 5.7-22.4) 
compared with the anti-TNF naïve group (85 events including 12 deaths in a cohort 
of 543), 35.4 per 1000 person-years (95% CI 15.5-55.4). However, the small sample 
size did not allow for subgrouping for individual CV events and data on lipid 
profiles, smoking status and BP were lacking in this report.  
1.4.9.2 British registry data 
The British Society of Rheumatology Biologics Register (BSRBR) run a UK-wide, 
prospective, observational study of patients commencing anti-TNF therapy, with a 
comparator group of biologic-naïve patients with active RA. Specific outcomes with 
regard to first MI and stroke are detailed in Table 1.7 (151) (152). First-line analysis 
of the data confirmed a reduced rate of MI and stroke in patients receiving anti-
TNF compared with those individuals only treated with DMARD. Additionally, anti-
TNF “responders” had an even lower incidence of first MI. 
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Table 1.7- Incidence rates per 1000 person-years (and 95% confidence interval) 
of first MI and stroke in DMARD and anti-TNF treated groups from the BSRBR 
  
DMARD group 
(n= 2170) 
 
Anti-TNF group 
(n=8659) 
 
MI 
 
5.9 (3.4-9.4) 
 
4.8 (3.7-6.1) 
 
         Responder  
        3.5 (2.5-4.9) 
 
Non-responder  
  9.4(5.5-15.0) 
Stroke 9.9 (5.3-16.9) 3.9 (2.9-5.3) 
 
Anti-TNF responder group, n=5877. Anti-TNF non-responder group, n=1638. 
Adapted from (151) (152) 
 
Thus information presented from registry databases has demonstrated results that 
broadly support the hypothesis that anti-TNF therapy might lessen CV risk, 
potentially through a reduction in inflammatory load.  
1.4.10 EULAR recommendations for cardiovascular disease risk management 
Given the strong and consistent evidence linking inflammatory disease with 
increased CV risk, EULAR formed a group to develop evidence-based 
recommendations for CV risk management in patients with RA and other forms of 
inflammatory arthritis – such as PsA and ankylosing spondylitis (AS). The objectives 
of the group were to identify and critically appraise evidence for specific CV 
interventions aimed at lowering CV risk, to develop specific recommendations on 
the basis of a literature search for CV risk assessment and to determine future 
research goals. The recommendations for CV management in RA, PsA and AS, as 
published in 2010 are summarised in Table 1.8 (153).  
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Table 1.8 – EULAR’s recommendations for managing cardiovascular risk in RA, 
PsA and AS 
 
Recommendations 
 
 
1. RA should be considered a condition with higher risk for CVD                           
 
2. Adequate control of disease activity lowers the CV risk 
 
3. CV risk assessment using national guidelines recommended for all patients      
with RA and repeat assessment if therapy changes 
 
4. Risk score models should be adapted for patients with RA by introducing a 
multiplication factor of 1.5 if patient meets 2 out of 3 criteria: 
Disease duration > 10 years, RF or ACPA positive, presence of certain       
extra-articular features 
 
5. TC: HDL-cholesterol used if SCORE assessment used 
 
6. Intervention carried out as per national guidelines 
 
7. Statins, angiotensin converting enzyme inhibitors                                       
and / or angiotensin-II blockers preferred treatment options 
 
8. Caution with prescribing most NSAID and COX2 inhibitors,            
especially if history of CVD or presence of CV risk factors 
 
9. Use the lowest possible dose of corticosteroids 
 
10. Recommend smoking cessation 
SCORE= Systemic Coronary Risk Evaluation                                Adapted from (153)      
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1.4.11 Mechanisms for increased cardiovascular risk in rheumatoid arthritis 
Inflamed synovium and unstable atherosclerotic plaque are very similar in a 
number of respects. In both diseased tissues, elevated levels of cytokines such as 
TNF, IL-6, IL-12, IL-15 and IL-18 have been observed, reflecting local stimulation of 
macrophages by activated T cells. TNF, IL-6, complement immune complexes, 
acute phase reactants and lipid particles have all been shown to be implicated in 
endothelial activation and destabilisation of atheromatous plaques (154). 
Additionally, T cells implicated in the pathogenesis of atherosclerosis are 
predominately of TH1 or TH17 phenotypes, which are similar to the pattern seen in 
active RA (155). Both lesions contain an exaggerated matrix response and involve 
local cellular components; in RA: synovial fibroblasts, chondrocytes and osteoclasts 
and in atherosclerosis: vascular smooth muscle, fibroblast and endothelial cells 
(156). These similarities suggest possible mechanisms whereby patients with RA 
develop an increased risk of atherosclerosis and early death. The increased 
background level of chronic inflammation might confer predisposition to CVD and / 
or augment its pathogenesis, hence putting the individual at greater risk of 
developing an acute coronary syndrome or suffering secondary complications 
thereafter.  
The concepts of endothelial dysfunction, arterial stiffness and acute-phase 
reactants are explored further in Section 1.5. 
 
1.5 CARDIOVASCULAR DISEASE – ATHEROGENESIS AND FURTHER ASSESSMENTS 
1.5.1 Biology of the atherosclerotic plaque  
The first stage in development of an atherosclerotic plaque is endothelial 
dysfunction which can develop due to numerous causes including smoking and RA. 
As a consequence, the endothelium becomes more permeable, to lipids for 
example, and becomes pro-coagulant rather than anti-coagulant. The subsequent 
inflammatory response results in the entry of inflammatory and muscle cells as well 
as foam cells and the formation of fatty streaks. As the lesion progresses, a fibrous 
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cap forms, which consists of smooth muscle cells and a collagen matrix which 
separates the atherosclerotic plaque from the arterial lumen. Atherosclerotic 
plaques can be graded from Type I to Type V (c), as per the American Heart 
Association criteria (157). Types IV and V (a) atherosclerotic plaques have a high 
extracellular lipid content and are very prone to rupture and acute thrombosis; this 
is the event which initiates coronary thrombosis and subsequently causes an MI. 
The micro-anatomical features of an atherosclerotic plaque at risk of disruption 
(the so-called “vulnerable plaque”) include a large lipid core, high macrophage 
content and a thin cap. Two major determinants of plaque vulnerability include the 
core size and cap thickness – neither of these is related to absolute plaque size or 
to the degree of stenosis (158).  
1.5.2 Endothelial dysfunction 
Endothelial dysfunction has been suggested as a possible early event in the 
evolution of atherogenesis, as well as a surrogate marker for risk of CVD. A range of 
techniques aimed at estimating endothelial function have been employed, 
including plethysmography, ultrasonography-determined flow-mediated dilation 
(FMD), laser Doppler imaging with iontophoresis and more recently, measures of 
pulse wave velocity (PWV) or arterial stiffness and pulse wave analyses. Biomarkers 
of endothelial dysfunction have been identified: vascular cell adhesion molecule 
(VCAM)-1, intercellular adhesion molecule (ICAM)-1 and endothelial cell adhesion 
molecule (ECAM)-1. 
1.5.2.1 Endothelial dysfunction in rheumatoid arthritis  
Reduced forearm blood flow has been demonstrated in studies where patients with 
either RA or systemic vasculitis were compared with healthy controls (159, 160) 
hence showing that patients with inflammatory rheumatic conditions have evidence 
of endothelial dysfunction. A study assessing the effect of infliximab on endothelial 
function in 11 patients with RA demonstrated a significantly increased FMD 
(p=0.018), along with significant reduction in ESR (p=0.04), CRP (p=0.08) and DAS 
(p=0.002) (161). An study of infliximab in RA patients confirmed an increased FMD 
after first intravenous infusion (3.7% versus 17.5%, p<0.01) with similar results after 
second and third infusions (162). Along with hsCRP, IL-1, IL-6 and TNF α, these 
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biomarkers were higher in RA patients than in controls (p<0.001). VCAM1 has been 
associated with increased carotid intima media thickness (cIMT), p=0.02 (163). CRP 
has been demonstrated to be independently associated with microvascular 
dysfunction in RA (164). 
1.5.3 Arterial stiffness 
Arterial stiffness can be measured non-invasively. PWV is a measure of the speed at 
which the arterial pressure wave travels – higher values are associated with 
established CV risk factors and with CV mortality (165). Augmentation index (AIx) is 
a quantitative index of systemic arterial compliance that refers to the difference 
between the first and second systolic peak of the central waveform, expressed as a 
percentage of the pulse pressure (166).  
1.5.3.1 Arterial stiffness in rheumatoid arthritis  
Analysis of the association between RA and arterial stiffness has confirmed an 
increased aortic (carotid to femoral) PWV compared with controls (p=0.005) and 
similar increased brachial (carotid to radial) PWV (p=0.02) with no significant 
difference in AIx or augmentation pressure observed (167). Recently, Avalos et al 
demonstrated that patients with a disease duration greater than 10 years had a 
significantly higher AIx than patients with a disease duration of less than 5 years 
(p=0.008) or controls (p<0.001) – an association which remained significant even 
after adjusting for CV risk factors (p=0.02) (168). Etanercept has been shown to 
reduce arterial stiffness (169). Patients who respond to anti-rheumatic therapy 
demonstrate an improvement in microvascular function (170). Australian 
researchers found that pulse wave analysis was a more sensitive measure of 
endothelial dysfunction than brachial artery (171). Infliximab at dose 3mg/kg has 
been shown to improve PWV in 26 RA patients treated over a 56 week period; there 
was no significant change in cIMT measurement or the presence of carotid artery 
plaque (172). 
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1.5.4 Carotid intima-media thickness 
Non-invasive B-mode ultrasonography of the carotid arterial system provides 
information on lumen diameter and intima-media thickness. It can be regarded as 
an indicator of generalised atherosclerosis (173). In 1997, a group from The 
Netherlands provided evidence that increased cIMT was associated with future CV 
and cerebrovascular events (174), further data from the United States of America 
(USA) corroborated this (175).  
1.5.4.1 Carotid intima-media thickness in rheumatoid arthritis 
cIMT is increased in patients with inflammatory conditions such as RA (176) (177), 
PsA (178), systemic lupus erythematosus (179) and also primary Sjögren’s syndrome 
(180); it has been demonstrated that cIMT severity is associated with inflammatory 
burden and disease duration (181). 
It would appear that increased cIMT develops early on in the evolution of RA. In 
one study, 79 patients from Sweden with newly diagnosed RA (and less than 12 
months of symptoms) were enrolled in a prospective study of CVD co-morbidity. 
They were matched by age and gender with 40 controls. At baseline evaluation 
there was no significant difference in cIMT or endothelial dependent FMD. 
However, by 18 months there was a significant increase in cIMT in RA patients 
(p<0.05). The cIMT thickness in both groups was associated with traditional CV risk 
factors. There was no relationship with disease activity markers in the RA group 
(182). 
A recent smaller study of 30 RA patients commencing anti-TNF (14 infliximab, 16 
etanercept) compared their disease progression and cIMT over the course of a 
year’s therapy with 10 controls. Anti-TNF therapy was associated with a significant 
reduction in cIMT after 1 year of treatment (p>0.0001); a significant correlation 
between DAS and cIMT was also found (r=0.435, p<0.05) (183). Well-designed and 
larger trials are needed to establish the true extent of benefit of anti-TNF 
therapies on cIMT.  
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1.5.5 Insulin sensitivity  
In the general population, insulin resistance is an recognised risk factor for CV 
disease and type 2 diabetes mellitus and contributes to the metabolic syndrome 
(184) (185).  
1.5.5.1 Insulin sensitivity in rheumatoid arthritis 
The issue of insulin sensitivity and RA as a potential mechanism contributing to 
increased CV risk has been investigated. In one study 94 RA patients were assessed 
to identify which factors regulate glucose metabolism (186). hsCRP was used to 
identify grading of inflammation: the authors defined hsCRP <1.92mg/litre (l) as 
“low-grade” inflammation and hsCRP >1.92mg/l as “high-grade” inflammation. 
Patients with “high-grade” inflammation had a higher BMI (p=0.03), greater waist 
circumference (p=0.01), lower HDL cholesterol p=0.03) and a higher frequency of 
impaired fasting glucose or diabetes (p=0.3) than those with “low-grade” 
inflammation. In addition, homeostatic model assessment of insulin resistance 
(HOMA-IR) associated positively with waist circumference (p<0.0001), hsCRP level 
(p=0.004), DAS28 (p=0.04) and ESR (p=0.02). The data from this study demonstrates 
that patients with higher levels of hsCRP had increased insulin resistance and 
reduced beta-cell function compared to those with “low-grade” inflammation. The 
association of higher BMI and waist circumference with “high-grade” inflammation 
was an unexpected finding, given that in the general population obesity contributes 
to both insulin resistance and reduced beta-cell function.  
Additionally, patients with RA treated with oral steroids or pulsed parenteral 
steroids demonstrated a decreased insulin sensitivity and as such authors suggest 
that steroids may contribute to increased CV risk (187). Similarly, several studies 
have confirmed an association between obesity, increased insulin sensitivity and 
elevated TNF levels (188) (189). 
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1.5.6 C-reactive protein and cardiovascular disease 
Increased CRP has been identified as an independent CV risk factor in the general 
population (190). Additionally, this acute phase reactant has been demonstrated to 
be independently associated with microvascular dysfunction in RA (164). CRP level 
at the time of diagnosis of inflammatory arthritis is an important predictor of 
subsequent death from CVD. For instance, when approximately 500 patients with 
RA were followed up for over 10 years by Goodson et al, an elevated CRP of ≥5mg/l 
predicted death from CVD as per univariate analyses: HR 3.9 (95% CI 1.2-13.4) for 
men and HR 4.22 (95% CI 1.4-12.6) for women (191). However, adiposity is also 
independently associated with CRP levels in female patients with RA and may act 
as a confounder in the estimation of RA disease activity when using CRP as a 
surrogate marker for systemic inflammation (192). Goodson’s study did not take 
BMI into account in multivariate analysis.  
1.5.7 Genetics of rheumatoid arthritis relating to cardiovascular risk  
Work by Goodson et al has shown that excess mortality in the early years of an 
inflammatory polyarthritis is limited to those who are seropositive for RF. This is 
seen in all-cause mortality (SMR males 1.51 and females 1.41) as well as CV 
mortality (SMR males 1.34, females 2.02) (193). A further study confirmed these 
findings (194). In addition, the presence of ACPA antibodies is associated with 
increased cIMT (195).  
Moreover, a study by Farragher and colleagues identified that possessing two copies 
of the shared epitope alleles predicted death from all causes (HR 1.57, 95% CI 1.1-
2.2) and from CVD (HR 1.68, 95% CI 1.1-2.7). An interaction between smoking, 
shared epitope alleles and ACPA was associated with the greatest risk of death 
from CVD (HR 7.81, 95% CI 2.6-23.2). No association of PTPN22 gene and mortality 
was identified (196).  
Additional studies in the GWAS-era have looked at other potential genetic links 
between RA and predisposition to CVD. Reports have suggested that polymorphism 
in the transforming growth factor- beta 1 (TGFB1) gene is associated with heart 
disease in the general population. Chen and colleagues have found that the 
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interaction between smoking and polymorphism in the TGFB1 gene may influence 
the risk of IHD and MI in RA patients (197). 
Levels of IL-6 are high in RA and thought to be an important contributor to the 
development of CVD. A study of 135 patients with RA demonstrated an increased 
risk of CVD in those carrying the IL6-174C-allele (p=0.041) as well as significantly 
higher levels of IL-6 (p=0.028) (198) but this genetic profile was not associated with 
an increased prevalence of hypertension (199). A further study by the same group 
found an increased prevalence of raised endothelin (ET)-1 levels in hypertensive RA 
patients and the presence of a ET-1 gene locus (EDN1) haplotype was associated 
with a 3-fold increased adjusted odds of being hypertensive(200).  Additionally, the 
authors found that TGF8697-allele carriers had a significantly increased prevalence 
of hypertension compared with CC homozygotes (p=0.023) (199). 
 
1.6 CARDIOVASCULAR DISEASE RISK ASSESSMENT 
UK guidelines recommend that all people aged 40-74 years should have a CVD risk 
assessment performed (201). Further details expanding those individuals 
potentially at increased risk are detailed in Table 1.9. This then allows the 
individual to be placed in one of 3 groups; low, moderate or high as outlined in 
Table 1.10. However, debate exists on a number of issues: should lifetime risk or 
10-year risk be the end-point, CVD versus CHD as the defined event and whether 
non-laboratory-based risk scores could be developed (i.e. without inclusion of 
cholesterol levels) (202). 
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Table 1.9 – Who should have their cardiovascular disease risk calculated? 
 
Identification of individuals 
 
 
1. All adults aged 40-74 years with no pre-existing CVD 
 
2. Strong family history: 
Father or brother with MI or CVA ≤55 years old 
Mother or sister with MI or CVA ≤60 years old 
 
3. 1st degree relative with hereditary lipid disorder 
 Adapted from (201) 
 
Table 1.10 – Classification of 10-year cardiovascular disease risk 
 
Grading of CVD risk 
 
 
% 10-year risk of developing CVD 
 
Low 
 
<10% 
Moderate 10-20% 
High >20% 
 
As per NICE guidelines, treatment is currently offered if the 10-year CVD risk score 
is >20% or if the individual has pre-existing CVD, diabetes or chronic kidney disease. 
RA and connective tissue diseases are mentioned as important factors for the 
clinician to bear in mind but do not feature in the list of “high priority” conditions. 
The treatments which are offered are listed in Table 1.11. 
 
75 
 
Table 1.11 – Therapies offered if high 10-year cardiovascular risk calculated 
 
Options for therapy  
 
Drug therapy 
Lipid lowering drugs 
Anti-hypertensives 
 
Lifestyle modifications 
Smoking 
Weight 
Diet  
Alcohol 
Exercise 
 Adapted from (201) 
 
The calculators and tools used are evolving, and are described in more detailed in 
sections 1.6.1 - 1.6.4 below. Comparison between factors used to calculate the 3 
main scores are detailed in Table 1.12.  
1.6.1 Framingham score 
The Framingham score is a standard and original score for calculating 10-year risk 
of CVD. It is based on a mainly Caucasian population in Massachusetts, USA. It takes 
into account age, gender, HDL-cholesterol and TC, smoking and systolic BP. It may 
over-predict risk in populations with low observed CHD mortality. Similarly it may 
under-predict in populations with high observed CHD mortality: British Asians, 
familial hypercholesterolaemia, the socially deprived, severe hypertension, left 
ventricular hypertrophy , type I diabetes and type II diabetes with nephropathy 
(202) (203) (204).  
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1.6.2 Joint British Societies Coronary Risk Prediction score 
The Joint British Societies Coronary Risk Prediction (JBSCRP) score, most recently 
updated in 2005, is based on Framingham data. It divides by gender, smoking status 
and diabetes. It takes into account age (<50 years, 50-59 years or ≥60 years), TC: 
HDL-cholesterol and systolic BP. The predicted 10-year risk includes all 
atherosclerotic CVD: acute coronary syndrome, cerebrovascular disease, exertional 
angina and peripheral vascular disease (108). The JBSCRP is based on untreated 
levels of BP. CVD risk is higher than indicated in the charts for positive family 
history, triglycerides >1.7millimoles (mmol)/l, BMI ≥30kg/m2, females with 
premature menopause, men with HDL <1mmol/l, women with HDL <1.2mmol/l, 
impaired glucose tolerance and certain ethnic minorities. 
1.6.3 ASSIGN score 
Recently published CV risk assessment tools have incorporated social deprivation.  
Assessing CV risk using Scottish Intercollegiate Guideline Network (SIGN) guidelines 
to assign preventative treatment (ASSIGN score) has been designed to incorporate 
deprivation into CV risk in a Scottish population. It was developed from the Scottish 
Heart Health Extended Study which followed up 12,000 patients over 10 years and 
recorded morbidity and mortality (205). This study highlighted that a large 
discrepancy in coronary risk existed in Scottish men and women which was related 
to their social status but inadequately explained by conventional CV risk factors.  
ASSIGN calculates the 10-year percentage risk of developing CVD in those disease-
free at recruitment (206). The calculated score is an actual or “absolute” risk. Two 
novel additional risk factors were added which were unique compared to other risk 
prediction tools. These are family history (of CHD or stroke in a parent or sibling 
aged less than 60 years old) and a measure of social deprivation, the Scottish Index 
of Multiple Deprivation (SIMD) as described in Section 1.10.3. The ASSIGN score 
therefore is based upon: (1) age at last birthday, (2) gender, (3) SIMD to 2 decimal 
places, (4) family history, (5) diabetes, (6) current cigarette smoking (if yes, 
number per day), (7) systolic BP, (8) TC to 2 decimal places, (9) HDL-cholesterol to 
2 decimal places. With the addition of family history and social deprivation, ASSIGN 
may score higher than Framingham, especially in older females. It has been 
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adopted by SIGN and the Scottish Government as the most appropriate CV risk 
score for current use in the Scottish population.  
Reviewers felt that ASSIGN, based on an intermediately-sized sample, is 
representative of the general population but that reporting studies do not 
comment on  external validation (207). Although it may still overestimate CV risk, 
it is still thought to be marginally better than Framingham (202). 
 
Table 1.12 – Comparison of factors included in cardiovascular risk calculations 
 
Framingham (208) 
 
 
JBSCRP (108) 
 
ASSIGN (209) 
 
Age 
Gender 
Smoking 
Systolic BP 
TC 
HDL 
 
Age 
Gender 
Smoking 
Systolic BP 
TC: HDL 
Diabetes 
 
 
Age 
Gender 
Smoking 
Systolic BP 
TC 
HDL 
Diabetes 
Family history 
Deprivation score 
 
1.6.4 Other cardiovascular disease risk scores 
Other CV risk scores which exist include the Adult Treatment Panel III, the Reynolds 
Risk Score, QRISK and SCORE (202). 
QRISK2, a calculator for an individual’s risk of developing diabetes, CHD or stroke 
over the next 10 years, was developed between 1993 and 2008 from patients living 
in England and Wales (210). It built upon the original QRISK algorithm (211) by 
incorporating family history, ethnicity and deprivation (using the Townsend index, 
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as described in Section 1.10.1). The authors felt that at 10 years, Framingham 
over-predicted CV risk by up to 35% and ASSIGN by 36%, compared to 0.4% in QRISK 
(211). However the data used to create the QRISK and QRISK2 calculations was 
validated from the same population as it was originally derived, leading to 
concerns of a “home advantage” and need for further validation.  QRISK and 
QRISK2 were derived from databases of GP attendees, which allowed the inclusion 
of substantial number of patients but were not random representative samples of 
the population.  
The Systemic Coronary Risk Evaluation (SCORE) chart is a European CVD risk 
assessor (212). In addition to standard CV risk information, it classifies European 
countries as either low risk (Belgium, France, Greece, Italy, Luxembourg, Portugal, 
Spain and Switzerland) and the remainder as high risk. SCORE has previously been 
mentioned in the context of the EULAR recommendations on managing CV risk in 
inflammatory arthritis (see Section 1.4.10 and Table 1.8).    
 
1.7 ANTI-INFLAMMATORY DRUG THERAPY 
The first synthesis of acetylsalicylic acid was performed in 1853, a compound later 
to be named aspirin in 1899 by the company, Bayer. This was the first non-steroidal 
anti-inflammatory drug (NSAID) (213). Anti-inflammatories have long been 
prescribed for symptoms of arthralgia, dental pain, dysmenorrhoea and headache, 
amongst other uses. They continue to be one of the most commonly prescribed 
classes of medication worldwide (214) and have been a cornerstone therapy in the 
treatment of symptoms of RA, OA and other arthritides.  
NSAID cross the placenta and manufacturers recommend avoiding their use during 
pregnancy. In particular they should be avoided during the third trimester: there is 
a risk of closure of the foetal ductus arteriosus and concern of subsequent 
persistent pulmonary hypertension in the new-born; additionally, labour may be 
delayed and prolonged by their use (215). 
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1.7.1 Prostaglandin biosynthesis and the role of cyclooxygenase 
Both the benefits and harm from anti-inflammatories are due to the inhibition of 
cyclooxygenase (COX) of which there are 2 isoenzymes, COX1 and COX2.  Both COX 
isoenzymes have a hydrophobic tunnel, through which the substrate accesses the 
active site.  The tunnel is larger in the COX2 isoenzyme with a side pocket, a 
property exploited in the development of specific COX2 inhibitors (216). COX is the 
rate-limiting enzyme which converts arachidonic acid to the labile intermediate 
prostaglandin (PG) H2. This is in turn converted to thromboxane A2 by 
thromboxane synthease, prostacyclin by prostacyclin synthase and other 
prostaglandins including PGE2 and PGD2. Thus the metabolism of prostaglandins is 
markedly altered by COX inhibition, as illustrated in Figures 1.6 and 1.7 (216) 
(217). 
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Figure 1.6 – Mechanism of anti-inflammatory drug action 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from (217) 
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Figure 1.7 – Differential prostanoid synthesis and action 
 
 
 
 
 
 
 
 
 
 
 
PGE2 = prostaglandin E2, PGI2 = prostaglandin I2, TXA2 = thromboxane A2 
Adapted from (216), (217) 
 
1.7.1.1 Non-steroidal anti-inflammatory drug action  
All NSAID reduce PG production and result in relief of hyperalgesia (increased 
sensitivity to pain) caused by tissue damage, see Figure 1.5. Individual compounds 
vary in their chemical structure and ability to block COX1 in preference to COX2. 
These drugs reach high concentrations in inflamed tissues, leading to an inhibition 
of prostaglandin synthesis at the desired site of action. However they also reach 
high concentrations in other organs and in the blood, leading to the side effects 
reported by patients and noted by clinicians (218). As the CV benefits of aspirin 
come from its inhibition of COX1, it would seem sensible to conclude that NSAID 
would not increase the risk of CV events. However, a near-complete inhibition of 
platelet COX1 is required for this cardio-protective benefit, something that no non-
aspirin NSAID can achieve in a sustained fashion.  No placebo-controlled trial has 
studied the CV risk of non-selective NSAID therapy.  Few of the studies that these 
meta-analyses are drawn from on this subject record the indication for NSAID use. 
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Although the size of the overall patient risk appears small, the absolute risk may be 
considerable due to the large number of patients prescribed NSAID.  
1.7.1.2 COX2 inhibitor action  
The primary property of this group of drugs is the inhibition of the COX2 enzyme; 
they are more than 100 times as selective in their ability to inhibit COX2 as 
traditional non-selective NSAID (213).  Initial research suggested that COX1 was 
continuously expressed in most tissues while COX2 was induced in inflammation, as 
illustrated in Figure 1.5. However, recent evidence has shown that COX2 is 
constitutively expressed in several organs and systems, including the kidney, 
central nervous system and vascular wall (219) and that it can adversely influence 
the prostacyclin: thromboxane (anti-thrombotic: thrombotic) ratio in the vascular 
wall (220). This may then promote platelet aggregation and atherosclerosis, 
resulting in an increased burden of CV toxicity.  
First generation COX2 inhibitors include celecoxib and rofecoxib, second generation 
include etoricoxib and valdecoxib. Celecoxib has a half-life of 11-16 hours, 
etoricoxib has a half-life of 19-32 hours (221). 
1.7.1.3 Effectiveness of COX2 inhibitors 
One of the first studies of the effectiveness of COX2 inhibitors was published in 
1999 by Emery et al, who studied the efficacy of celecoxib in patients with RA 
(222) .Three hundred and twenty six patients received celecoxib 200mg twice daily 
and 329 diclofenac 75mg twice daily for 24 weeks. There was no difference 
between the 2 drugs for visual analogue pain score, EMS or CRP.  However, the 
mean number of swollen and tender joints did decrease over the course of the 
study in both treatment groups; but again, no significant difference was seen 
between the 2 cohorts. Overall, the authors concluded that celecoxib was as 
equally effective as diclofenac in managing inflammatory joint disease, with lower 
GI side-effects. Subsequently, a systematic review of the efficacy of celecoxib 
compared with another non-selective NSAID or placebo demonstrated that the drug 
therapies were equally efficacious (223). 
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1.7.2 Co-prescription of aspirin with either NSAID or COX2 inhibitor  
The use of aspirin in primary and secondary cardio-protection is well established in 
clinical practice. Aspirin irreversibly inhibits COX1-mediated production of 
thromboxane A2; a single 325mg dose of aspirin results in 89% inhibition of platelet 
COX1 and a 650mg dose results in >95% inhibition (224). NSAIDs reversibly inhibit 
COX1 in platelets and so the subsequent effects on platelet aggregation depends on 
the half-life of the individual anti-inflammatory. It has been demonstrated that 
ibuprofen given before aspirin inhibited the beneficial effects of irreversible 
platelet inhibition (225). On the basis of this and other studies, the United States 
Food and Drug Administration (FDA) issued an advisory notice in September 2006 
regarding the co-administration of aspirin and ibuprofen (226). They recommend 
that aspirin should be taken before any NSAID or that the doses should be given 
separately.  
In 2002, Wilner et al had published results of a double-blind placebo-controlled 
trial of 16 healthy volunteers assigned to celecoxib 400mg daily or placebo for 4 
days (227). On day 5, aspirin 325mg plus either celecoxib 200mg or placebo was 
prescribed. No significant difference between the two groups in thromboxane 
inhibition was noted. Additionally, there was no significant difference in the effect 
of aspirin on platelet aggregation due to adenosine diphosphate, collagen or 
arachidonic acid between the groups. The overall summary was that celecoxib does 
not have an effect on the aspirin effects of platelet function.   
The population impact of any possible interaction is potentially large. In a sample 
of the general population prescribed COX2 inhibitors, analysed by Cox et al (228), 
48% were co- prescribed aspirin, 43% paracetamol and interestingly 10% were also 
prescribed a non-selective NSAID. Unsurprisingly the use of aspirin was associated 
with increased with increasing age.  
Levesque documented the relative risk of first acute MI in a cohort of over 113,000 
elderly patients (229). Patients prescribed celecoxib with or without aspirin were 
identified. There was no significant difference in adjusted RR of acute MI in those 
who were or were not prescribed aspirin alongside celecoxib. This differs from the 
low-dose rofecoxib group who showed a significantly reduced risk of acute MI if 
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prescribed aspirin (RR 1.0, 95% CI 0.77-1.28); the same was not true for patients on 
high-dose rofecoxib (RR 2.36, 95% CI 1.27-4.39). It is worth pointing out that the 
actual number of patients who had an acute MI while on aspirin was small and 
conclusions drawn from this study should be guarded.  
1.7.2.1 Effects of aspirin plus anti-inflammatories on the gastrointestinal system 
There have been concerns of the adverse GI effects of COX2 and aspirin versus 
NSAID and aspirin and whether gastric protection agents are required. Endoscopic 
studies have shown that the incidence of GI ulcers did not differ between patients 
on celecoxib and aspirin combination compared with those on NSAID, aspirin and 
proton pump inhibitor (230). It has therefore been suggested that the use of low-
dose aspirin with COX2 inhibitors is preferable to non-selective NSAID given similar 
anti-inflammatory properties, superior GI tolerability and absence of interaction 
with aspirin (231). Rahme et al found that the combination of celecoxib and aspirin 
was less likely to be associated with hospitalisation for GI events than NSAIDs with 
aspirin (HR 0.62, 95% CI 0.48-0.80) (232) (233). Hospitalisation rates for GI events 
were similar for celecoxib plus aspirin as NSAID without aspirin (HR 1.01, 95% CI 
0.81-1.25). A limitation of this and many similar studies was that over-the-counter 
data for aspirin were not available.  
1.7.3 Anti-inflammatory medication and the risk of myocardial infarction 
1.7.3.1 NSAID and the risk of myocardial infarction  
The risk of MI has been shown to vary between individual NSAID. The relative risk 
of MI with diclofenac, ibuprofen and naproxen as documented in 4 key meta-
analyses is detailed in Table 1.13. All showed an increased risk of MI with 
diclofenac, with RR varying from 1.4 to 1.63, but not with naproxen (234) (235) 
(236) (237). 
Large individual studies have reported on the risk of MI and subsequent death with 
traditional non-selective NSAID. Gislason et al have shown that ibuprofen or 
diclofenac use was associated with a 1.5 to 2.4-fold increased risk of death. Again, 
a strong dose-response relationship was identified. No information was given on 
concomitant use of aspirin in this study (238).
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Table 1.13 Comparison of relative risk of acute myocardial infarction with diclofenac, ibuprofen and naproxen from key 
meta-analyses 
 
Lead author 
 
Relative risk of myocardial infarction 
  
Diclofenac 
 
Ibuprofen 
 
Naproxen 
 
Hernandez-Diaz (234) ● 
16 trials 
 
1.44 
(95% CI 1.32-1.56) 
 
1.07 
(95% CI  1.02-1.12) 
 
0.98 
(95% CI 0.92-1.05) 
 
Kearney (235) ◊ 
? number of trials  
1.63 
(95% CI 1.12-2.37) 
1.51 
(95% CI 0.96-2.37) 
0.92 
(95% CI 0.67-1.21) 
 
McGettigan (236) ●  
17 case control, 6 cohort trials 
1.40 
(95% CI 1.16-1.7) 
1.07 
(95% CI 0.97-1.18) 
0.97 
(95% CI 0.87-1.07) 
 
Singh (237) ● 
14 trials 
1.38 
(95% CI 1.22-1.57) 
1.11 
(95% CI 1.06-1.17) 
0.99 
(95% CI 0.88-1.11) 
● NSAID users versus non-users, ◊ NSAID versus placebo 
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1.7.3.2 COX2 inhibitors and the risk of myocardial infarction  
The concern regarding increased risk of MI with COX2 inhibitor use stems from the 
year 2000 and an early study of major GI events, the Vioxx Gastrointestinal 
Outcomes Research (VIGOR) study. This showed an unexpected 5-fold increase in 
the risk of acute MI with subjects on rofecoxib, compared with naproxen (239). At 
the time of publication, many hypothesized that this was due to the cardio-
protective effects of naproxen. However, in September 2004 the manufacturers of 
rofecoxib withdrew the drug from worldwide sale based on the safety findings of 
the Adenomatous Polyp Prevention on Vioxx (APPROVe) study (240). This study 
demonstrated that long-term use of rofecoxib 25mg daily was associated with a 
3.5% incidence of MI or ischaemic stroke compared with placebo in patients with no 
pre-existing history of CVD (1.9% of placebo group, p<0.001). The Adenoma 
Prevention with Celecoxib (APC) study group published an interim analysis of their 
data, which showed that celecoxib at supra-therapeutic doses was also associated 
with an increased risk of CV thrombotic events (241).  
Subsequently, the FDA (242), European Agency for the Evaluation of Medicinal 
Products (243) and the UK-based Medicines and Healthcare Products Regulatory 
Agency (MHRA) (244) have all issued recommendations that COX2 inhibitors should 
not be prescribed for those with pre-existing IHD or cerebrovascular disease.  
Just as the risk of MI has been shown to vary between individual NSAID, the relative 
risk of MI varies between individual COX2 inhibitors and a clear dose-dependent 
relationship has been shown. The relative risk of MI with celecoxib and rofecoxib 
use as documented in 3 meta-analyses is detailed in Table 1.14 (234) (236) (245).  
Kearney et al (235) performed a meta-analysis of data on vascular events from 
randomized controlled trials of COX2 inhibitors (not included in Table 1.13). 
Studies included in this meta-analysis which compared a COX2 inhibitor with a 
traditional NSAID (91 trials) showed no significant difference in the risk of vascular 
events (RR 1.16, 95% CI 0.97-1.38). The risk of high dose celecoxib was confirmed 
in a pooled analysis of nearly 8000 patients enrolled in 6 placebo-controlled trials. 
Authors Solomon et al demonstrated a clear increased risk of all CV events 
including acute MI with increasing doses of celecoxib:  HR 1.8 (95% CI 1.1-3.1) for 
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celecoxib 200mg twice daily and HR 3.1 (95% CI 1.5-6.1) for the supra-therapeutic 
dose of 400mg twice daily (p=0.0005) (246). 
While the above large studies and subsequent meta-analyses focused on the risk of 
celecoxib and rofecoxib use, etoricoxib, a second-generation COX2 inhibitor has 
been studied in more detail in recent years. In the Multinational Etoricoxib and 
Diclofenac Arthritis Long-term (MEDAL) study the authors assessed the relative CV 
toxicity of diclofenac and etoricoxib in patients with OA or RA, aged 50 years or 
older (247). Patients with CV and GI risk factors were included in order to assess 
the widest possible range of comorbidities. Data were pooled from 3 separate 
pharmaceutical industry-sponsored randomised double-blind controlled trials, 
totalling approximately 25,000 OA and 10,000 RA patients. Nearly 17,000 patients 
received etoricoxib with slightly less receiving diclofenac. The numbers of 
thrombotic CV events were similar in both groups, with higher risks of upper GI 
events in the diclofenac group (0.97 per 100 patient-years). The lack of placebo 
group limits the ability to determine the absolute CV risks of the two drugs.  
The MEDAL data vary from the results of Andersohn et al’s nested case control 
study of over 3000 patients with an MI and nearly 14,000 controls. The authors 
documented that etoricoxib use was associated with a RR of 2.09 for acute MI (95% 
CI 1.1-3.97). This compared with RR of MI with other COX2 inhibitors and NSAID as: 
ibuprofen 1.04, naproxen 1.15, diclofenac RR 1.37, any dose of rofecoxib 1.29 and 
celecoxib 1.56 (248). 
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Table 1.14 - Comparison of relative risk of acute myocardial infarction with celecoxib and rofecoxib from key meta-analyses 
 
Lead author 
 
Relative risk of myocardial infarction 
 
 Celecoxib Rofecoxib 
Any dose  
Rofecoxib 
≤25mg/day 
Rofecoxib 
>25mg/day 
 
Hernandez-Diaz (234) ●  16 
trials 
 
0.96 
(95% CI 0.90-1.02) 
 
1.26 
(95% CI 1.17-1.36) 
 
1.18 
(95% CI 1.07-1.31) 
 
1.78 
(95% CI 1.36-2.34) 
 
Jüni (245) □ 
18 randomised,11 observational 
- 2.24 
(95% CI 1.24-4.02) 
1.37 
(95% CI 0.52-3.61) 
2.83 
(95% CI 1.24-6.43) 
 
McGettigan (236) ● 
9 case control, 2 cohort studies 
1.06 
(95% CI 0.91-1.23) 
1.35 
(95% CI 1.15-1.59) 
1.33 
(95% CI 1.00-1.79) 
2.19 
(95% CI 1.64-2.91) 
● COX2 users versus non-users, □COX2 versus NSAID or placebo 
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1.7.4 Anti-inflammatory medication and hypertension  
Hypertension is a common adverse event seen with NSAID and COX2 inhibitor use 
although the exact mechanism through which they may increase BP is not 
completely known. It has been speculated, however, that drug-induced 
vasoconstriction, effects on the renin-angiotensin system and direct effects on 
eGFR leading to a rise in urea and creatinine may all contribute (249) (250, 251) . 
Crucial to these mechanisms is the initiating event of prostaglandin inhibition as 
illustrated in Figure 1.8.  
 
Figure 1.8 – Possible explanations why anti-inflammatory drugs may cause 
hypertension  
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The renal-related effects on BP are relatively rare in young and healthy people in 
whom the kidneys are usually able to compensate for the effects of NSAID or COX2 
inhibitors on sodium and water retention. However, this process may be diminished 
in individuals with renal impairment, the elderly and those with CCF.  
1.7.4.1 NSAID and hypertension  
On average, most NSAIDs increase BP by 3-5mmHg (251) (253) (254). Even such a 
seemingly modest rise can significantly increase the frequency of CV events, 
including IHD and heart failure (255) (256). A systematic review of randomised 
controlled trials on the effect of at least 4 weeks therapy with NSAID demonstrated 
a mean systolic BP increase of 3.54mmHg with ibuprofen and 2.9mmHg with 
indomethacin users compared with placebo (257). 
Moreover, many studies have demonstrated that NSAID lessen the anti-hypertensive 
effects of diuretics, beta blockers, angiotensin converting enzyme inhibitors (258) 
(254) (259). However, they do not seem to have any effect on the anti-
hypertensive effects of calcium channel blockers (260) (261). 
1.7.4.1 COX2 inhibitors and hypertension  
In a meta-analysis of 19 randomised controlled trials, COX2 inhibitor use compared 
with placebo resulted in a weighted mean increase in systolic BP of 3.85mmHg and 
in diastolic BP of 1.06mmHg. This compares with an increase in systolic BP of 2.83 
mmHg and diastolic BP of 1.34mmHg when COX2 inhibitor use was compared non-
selective NSAID. COX2 inhibitors were associated with a non-significantly higher 
relative risk of causing hypertension compared with placebo (RR 1.61, 95% CI 0.91-
2.84, p=0.10) and non-selective NSAIDs (RR 1.25, 95% CI 0.87-1.78, p=0.23) (262).  
The Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial 
(CRESCENT), a double-blind randomised trial of patients with OA, assigned 
individuals to celecoxib 200mg once daily, rofecoxib 25mg once daily or naproxen 
500mg twice daily (263). Twenty four-hour ambulatory BP monitoring and arthritis 
efficacy measurements were carried out. The mean 24-hour systolic BP after 6 
weeks of therapy was increased significantly in the rofecoxib group but not 
celecoxib or naproxen groups. The BP difference between rofecoxib and celecoxib 
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was 3.78mmHg (95% CI 1.18-6.38, p=0.005), between rofecoxib and naproxen 
3.85mmHg (95% CI 1.15-6.55, p=0.005).  
In a study of NSAID and COX2 inhibitor use in normal clinical practice, no significant 
increase in BP was noted for non-selective NSAID or celecoxib use in patients 
without prior history of hypertension. However, a significant risk of BP increase 
was seen with rofecoxib (OR 2.08, 95% CI 1.41-3.06) (264). 
In a meta-analysis of 114 randomised double-blind clinical trials of COX2 inhibitors, 
rofecoxib was associated with an increased risk of hypertension (RR 1.55, 95% CI 
1.29-1.85) whereas celecoxib was associated with lower risk of hypertension than 
controls (RR 0.83, 95% CI 0.71-0.97) (265). 
A MEDAL study sub-analysis evaluated the hypertensive effects of etoricoxib and 
diclofenac. An increase in systolic BP was most highly associated with a prior 
history of hypertension (rise of 3mmHg, p<0.0001) and use of etoricoxib, compared 
to diclofenac (p<0.0001) (266). 
In summary, initial studies documented that rofecoxib, more so than celecoxib, has 
been associated with an increase in BP readings. More recently, studies have shown 
an increase in BP with etoricoxib use. Consequently, guidance has been issued that 
BP should be monitored during the use of celecoxib or etoricoxib. In particular with 
etoricoxib, BP should be checked before treatment and 2 weeks after treatment 
initiation to ensure that BP control has not been substantially disrupted (215).  
1.7.5 Anti-inflammatory medication and heart failure  
It is well established that use of NSAID increases heart failure risk. For instance, a 
nested case-control study of 1396 cases of first admission to hospital for heart 
failure showed an overall 30% increased incidence in those prescribed NSAID versus 
the control group (267). The risk of hospitalisation varied with different NSAID 
(with higher risk seen with indomethacin and naproxen) and in the presence of 
comorbidities such as hypertension and diabetes. The authors postulate that this 
equates to one extra case per year of first heart failure-related hospital admission 
for every 1000 NSAID users aged 60 to 84 years.  
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Further supporting evidence for this association as well as extending the link to 
COX2 inhibitors comes from McGettigan and colleagues who conducted a case-
control study to investigate the relationship between anti-inflammatory use and 
hospitalisation on due to CCF. Controls were subjects admitted to the same 
hospitals as the cases who did not have CCF. Anti-inflammatories had been taken 
by 23.6% of controls in the week prior to admission, 28.4% of first-time cases of 
CCF and in 15.5% of recurrent cases (p=0.0004 for difference). Adjusted relative 
risk for first admission with CCF was 1.1 for NSAID (95% CI 0.67-1.83), 1.29 for 
rofecoxib (95% CI 0.78-2.13) an 1.47 for celecoxib (95% CI 0.85-2.53) (268). 
Finally, a population based retrospective cohort study identified 2256 patients over 
the age of 66 who were prescribed celecoxib, rofecoxib or NSAID after an index 
admission for CCF. The risk of death and recurrent CCF combined was higher in 
patients prescribed NSAID or rofecoxib than those prescribed celecoxib (HR 1.26, 
95% CI 1.00-1.57 and HR 1.27, 95% CI 1.09-1.49 respectively) (269). This was borne 
out in an additional study of similar design (270). 
1.7.6 Anti-inflammatory medication and renal function  
1.7.6.1 NSAID and renal function 
A spectrum of nephrotoxicity has been documented with NSAID therapy and is 
illustrated in Figure 1.9. 
A review by Koseki et al documented an elevated creatinine in 6% of early RA 
patients taking a NSAID (271). Researchers have studied the effects of NSAID 
withdrawal on renal function: 11 patients prescribed NSAID for more than 6 months 
had therapy withdrawn. There was a subsequent significant reduction of creatinine 
(p<0.02) but a less consistent, non-significant trend in urea reduction (272). 
Interestingly, the value of creatinine may underestimate renal function in RA 
patients due to the, often significant, muscle atrophy that can occur (273). 
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Figure 1.9 – Causative factors involved in NSAID-induced nephrotoxicity 
 
 
Adapted from (274) 
1.7.6.2 COX2 inhibitors and renal function 
The interactions between COX2 and the renal system are complex and not thought 
yet to be fully understood. COX2 is known to have critical roles at the cortical thick 
ascending limb of the loop of Henle, macula densa and in the medullary 
interstitium (250). Figure 1.10 illustrates proposed physiological interactions 
between COX2, the kidney and the renin-angiotensin system and builds further on 
the initial outline of why COX1 and COX2 inhibition is linked to hypertension (as 
illustrated in Figure 1.8). 
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Figure 1.10 – Proposed physiological interactions between COX2, the kidney and the renin-angiotensin system               
Adapted from (250) (275) (276) 
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A comparable reduction in GFR was seen for both naproxen and celecoxib in a 
specific renal function outcomes study in an elderly population (252). Between-
treatment difference in creatinine clearance or serum electrolytes was seen in a 
double-blind placebo-controlled study of 85 patients assigned to naproxen, 
etoricoxib or celecoxib (277). A meta-analysis of over 100 randomised placebo-
controlled trials found that rofecoxib was the COX2 inhibitor mostly likely to 
cause renal dysfunction (RR 2.31, 95% CI 1.05-5.07) (265). 
The British National Formulary suggests that NSAID and COX2 inhibitors should 
be avoided if possible in patients with renal dysfunction; if they are prescribed, 
caution is advised and a suggestion made to use the lowest possible dose for the 
shortest possible length of time (215).  
In summary, COX2 inhibition can cause renal sequelae especially in volume 
depleted individuals and where there is reduced organ perfusion (275). 
Furthermore, COX2-induced hyperkalaemia is more likely in cases of pre-existing 
renal disease or if the patient is prescribed angiotensin converting enzyme 
inhibitor, angiotensin II receptor blocker or potassium-sparing diuretic (276). 
1.7.7 Anti-inflammatory medication and gastrointestinal side-effects  
1.7.7.1 NSAID and gastrointestinal side-effects 
The systemic effects of NSAID are largely due to the inhibition of endogenous 
prostaglandin synthesis.  When prostaglandins are inhibited there is a reduction 
in epithelial mucus, mucosal blood flow and mucosal resistance to injury 
(278).There is a spectrum of NSAID-related GI injury from subepithelial 
haemorrhages through to erosions and ulcerations. Additionally they can cause 
small-bowel ulceration, exacerbations of inflammatory bowel disease, 
significant haemorrhage and death (279). GI damage does not occur in all 
patients taking NSAID and is not readily predicted by symptoms. It is therefore 
important to attempt to identify individuals potentially at risk. Definite risk 
factors include: advancing age, previous history of GI ulceration, high doses of 
NSAID, use of multiple NSAID, comorbid conditions and concomitant use of 
steroids or anticoagulants. Helicobacter pylori infection, smoking and alcohol 
use are additional risk factors (213). 
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Serious GI complications occur in 1-4% of NSAID users per annum (213) (280). A 
large retrospective review of nearly 3000 cases of upper GI bleeding in Spain has 
given valuable real-life information on this clinical problem (281). 24% of the 
patients with bleeding had taken non-aspirin NSAID in the week prior to 
admission. Naproxen was associated with the highest risk of bleeding (RR 7.3, 
95% CI 4.7-11.4). The combination of NSAID plus low-dose aspirin increased the 
risk still further (RR 12.7, 95% CI 7-23). The study identified that ibuprofen and 
diclofenac had the lowest risk profile of the traditional NSAID for upper GI 
bleed. Proton pump inhibitors have consistently been shown to be more 
effective than H2-receptor antagonists and prostaglandin analogues in the 
prophylaxis and management of GI damage in patients who require continuous 
NSAID therapy (282) and additionally are well tolerated with an excellent safety 
profile.  
It is commonplace to prescribe cardio-protective low-dose aspirin to some 
patients at risk of CVD. This, in addition to NSAID therapy, increases the risk of 
acute upper GI bleeding from an OR of 4 for aspirin alone (95% CI 3.2-4.9) to 
17.5 (95% CI 11.9-25.8) in combination with NSAID (283). The addition of a 
proton pump inhibitor to this combination reduces the OR to 1.1 (95% CI 0.5-
2.6). Therefore, careful consideration of the addition of a proton pump inhibitor 
should be given to all patients prescribed NSAID and aspirin. A Cochrane review 
supports the safety of this approach (284). An additional potentially modifiable 
risk factor is Helicobacter pylori infection. Chan et al have shown that in the 
short term, Helicobacter pylori eradication decreases the incidence of peptic 
ulcer disease in patients who begin NSAID therapy (285). 
1.7.7.2 COX2 inhibitors and gastrointestinal side-effects  
A superior GI safety profile was at the crux of initial marketing of COX2 
inhibitors, based on 2 large GI outcome studies (239) (286). The Successive 
Celecoxib Efficacy and Safety Study I (SUCCESS-I), a large multi-national 
randomized double-blind controlled trial, compared the upper GI safety of 
celecoxib with naproxen and diclofenac in a cohort of more than 13000 patients 
with osteoarthritis (287). Of the group randomized to celecoxib, 37.2% had GI 
symptoms compared to 40.3% in the NSAID group (p<0.001), with an OR for 
complicated upper GI side-effects of 6.02 (95% CI 1.5-34.57) in the NSAID group. 
Celecoxib was found to be as effective as traditional NSAID in efficacy for 
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treating OA symptoms. SUCCESS-I conclusively established the GI safety profile 
of celecoxib. Other large outcome studies have shown no difference in 
complicated GI events between etoricoxib and diclofenac (288).  
The combination of COX2 inhibitor plus proton pump inhibitor has been 
evaluated in patients with an upper GI bleed secondary to NSAID-induced 
ulceration (289). Two hundred and seventy three patients were randomised to 
celecoxib plus omeprazole or placebo. None of the patients who received COX2 
inhibitor plus proton pump inhibitor and 12 of the patients who received 
celecoxib alone had further bleeding (p=0.0004). A limitation of this study is the 
lack of NSAID comparator. Details of co-prescription of aspirin, in the context of 
CV risk, are also missing from data analysis.  
The initial COX2 inhibitor studies assessing prevention of adenomatous polyps 
(APPROVe (240), APC (241) and Prevention of Colorectal Sporadic Adenomatous 
Polyps (PreSAP) (290)) showed a reduction in rate of adenoma formation. It was 
these studies which documented the associated increased rate of CV events. 
Their withdrawal from the market meant that this avenue of chemoprevention 
was not further pursued.  
It is vital to pay attention to the comparator NSAID in studies showing a GI 
safety advantage of COX2 inhibitors, as traditional NSAID vary in their risk of 
serious GI side effects. “GI toxic” NSAID such as naproxen are more likely to 
show a statistical significance over COX2 inhibitors, as in VIGOR study (239). 
This is in comparison with “less toxic” NSAID such as diclofenac, used in the 
MEDAL study (247). Head-to-head clinical trials may be required to highlight any 
differences between the GI safety profiles of individual COX2 inhibitors.  
A 6 month double-blind trial randomised analysed over 4000 patients with RA or 
OA in 32 countries to celecoxib 200mg twice daily or diclofenac slow release 
75mg twice daily plus omeprazole 20mg once daily (Celecoxib versus 
Omeprazole and Diclofenac in patients with Osteoarthritis and Rheumatoid 
arthritis, CONDOR) (291). 0.9% of patients receiving celecoxib and 3.8% of 
patients receiving diclofenac had an upper or lower GI event (HR 4.3, 95% CI 
2.6-7.0, p<0.001). This is one of the first studies to assess for adverse events 
throughout the length of the GI tract.  However, patients taking aspirin were 
excluded and the decision of presumed occult GI blood loss in an anaemic 
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patient, without confirming the source of the blood loss does limit full 
interpretations of the results. The study authors confirm that the trial was not 
designed nor powered to assess CV outcomes.  
1.7.8 Anti-inflammatory medication and cerebrovascular disease 
In the APC study, the number of nonfatal strokes within the placebo group was 
identical to the events in the celecoxib 200mg twice daily group (n=3). In the 
400mg twice daily group, there were 5 nonfatal strokes (241).  
However, there is convincing evidence linking anti-inflammatory use and 
increased risk of cerebrovascular disease. For instance, a subsequent large case-
control study assessed nearly 500,000 patients from the UK GP research 
database between 2000 and 2004. The researchers found that current use of 
rofecoxib and etoricoxib was associated with significantly increased risk of 
ischaemic stroke (multivariate OR 1.71 and 2.38 respectively) and that this risk 
was dose-dependent (292). The risk was maintained even if the patient had no 
pre-existing history of cerebrovascular disease, hypertension or atrial 
fibrillation. It is, however, possible that the differences in stroke rates reflect 
the differential effect on BP of these drugs.  
In addition, Haag et al followed 7636 patients from a prospective population-
based Rotterdam Study, from baseline in 1991-1993 for incident stroke until 
2004 (293). In the 70,000 person-years of follow-up, 807 patients developed a 
stroke. Current users of non-selective NSAID and COX2 inhibitors had a greater 
risk of stroke; adjusted HR 1.72 (95% CI 1.22-2.44) and adjusted HR 2.75 (95% CI 
1.28-5.95) respectively. Naproxen and rofecoxib were associated with the 
greatest risk of stroke.  
Nested case-control analyses were performed within the longitudinal American 
National Data Bank for Rheumatic Diseases (294). Two hundred and sixty nine 
cases of first-ever strokes were identified, 67 were ischaemic in aetiology. The 
OR for all types of stroke in RA was 1.64 (95% CI 1.16-2.30, p=0.005) and for 
ischaemic stroke 2.66 (95% CI 1.24-5.70, p=0.012). Ischaemic stroke was 
predicted by hypertension, MI, low-dose aspirin, health assessment 
questionnaire (HAQ) score and presence of total joint replacement. There was 
no association between anti-TNF therapy and ischaemic stroke. Roumie et al in 
a retrospective cohort study calculated the rate of stroke as 4.51 per 1000 
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person years in those not taking anti-inflammatory, 5.15 with rofecoxib, 4.66 
with celecoxib, 4.05 with naproxen and 5.61 with indomethacin. None of the 
increase seen with non-selective NSAIDs was significant (295). 
1.7.9 Anti-inflammatories and hepatic side effects 
Diclofenac is principally metabolised in the liver and drug-induced hepatitis is a 
relatively commonly seen adverse effect (296). Hepatotoxicity is usually seen 
within 12 weeks of starting the causative drug and liver function abnormalities 
generally settle within 4-6 weeks of stopping the drug (297). A review of adverse 
drug reactions in France demonstrated that 14% of all NSAID-related reports 
were for abnormal liver function (298). Two lumiracoxib-related studies 
published in the Lancet in 2004 reported a reduction in GI ulcer complications 
with no apparent evidence of increased MI (299) (300). However in November 
2007, this drug was withdrawn in the UK by MHRA (301). This was due to 159 
reported episodes worldwide of adverse liver reactions attributed to this drug, 
two of which were fatal.  In large-scale investigatory studies such as the 
Celecoxib Long-term Arthritis Safety Study (CLASS) and SUCCESS-I, there was no 
significant elevation in aminotransferases (286) (287). Traditional NSAID and 
COX2 inhibitors should be used in caution in patients with hepatic impairment 
due to the increased risk of GI bleeding, fluid retention and worsening of 
hepatic function. All anti-inflammatories should be avoided in severe liver 
disease (215). A report of a case / non-case analysis has shown that overall 
COX2 inhibitors are thought to have fewer hepatic side effects than NSAIDs 
(302). 
1.7.10 Summary of anti-inflammatory side-effects and options for patients 
A summary of the main side-effects of non-selective NSAID and COX2 inhibitors 
is detailed in Table 1.15. Patients who are felt to require an anti-inflammatory 
can have the options discussed with them based on their individual CV and GI 
risk, as outlined in Table 1.16. 
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Table 1.15 - Overview of anti-inflammatory side-effects 
 
System 
 
NSAID 
 
COX2 inhibitor 
 
Cardiovascular 
 
Hypertension 
(257) (Fig 1.7) 
 
Myocardial infarction 
Diclofenac > ibuprofen (Table 1.13) 
 
Heart failure 
(267) (268) 
 
Hypertension 
Etoricoxib and rofecoxib (262) (Fig 1.7) 
 
Myocardial infarction 
Rofecoxib > celecoxib (Table 1.14) 
 
Heart failure 
(268) 
 
Renal 
 
↑creatinine 
(252) (271) (277) (Fig 1.8) 
 
↑creatinine 
(252) (265) (277) (Fig 1.9) 
 
Gastrointestinal 
 
Spectrum of GI side-effects 
Naproxen highest risk (279) (281) 
 
Less GI side-effects than NSAID 
(239) (281) (286) (287) 
 
Cerebrovascular 
 
Risk of ischaemic stroke 
More so with naproxen (293) 
 
Risk of ischaemic stroke 
Etoricoxib and rofecoxib (292) 
 
Hepatic 
 
Hepatic dysfunction 
Especially with diclofenac (296) 
 
Overall fewer side-effects than 
NSAID (302) 
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Table 1.16 - Anti-inflammatory treatment options for patients 
 
Patient risk status 
 
 
Choices 
 
No GI or CV risk 
 
Ibuprofen, diclofenac, naproxen 
Can be used in combination with paracetamol / weak opioids 
Avoid concomitant use of aspirin with ibuprofen (226) 
 
GI risk, no CV risk 
 
Celecoxib  
  (+/- proton pump inhibitor) (289) 
Ibuprofen + proton pump inhibitor 
 
GI and CV risk Assess each patient individually 
Avoid if possible / use lowest dose for shortest period of time 
Adapted from (303) 
 
1.8 MEDITERRANEAN-TYPE DIET  
The Mediterranean region of Europe stretches from Portugal and Spain in the 
west, through the south-coast of France, Italy and finally to Greece and its 
numerous islands in the east, Figure 1.11. The temperate climate of the region 
has benefited farm-land, resulting in rich and fertile conditions for growing 
produce. A Mediterranean-type diet is typically rich in fruit, vegetables and 
legumes (FVL), with a moderate to high intake of fish, a low intake of dairy 
produce and red meat and a high intake of unsaturated fats, especially olive oil. 
The higher intake of fish than meat is likely a reflection of the previous high 
cost of meat and proximity to the sea to obtain seafood. This type of diet is 
usually complemented by a modest amount of alcohol, mainly in the form of red 
wine and almost always taken during meals. The content of this diet has 
remained fairly constant over time. Although different regions in the 
Mediterranean area have their own diet, it is valid to consider them as 
variations of a single entity (304). 
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Figure 1.11 – Map of the Mediterranean region 
Image from: http://www.freeusandworldmaps.com/html/WorldRegions/WorldRegions.html 
 
The characteristic diet of individuals living in the Mediterranean region 
contrasts starkly with that of Northern Europeans. The British diet suffers from 
a poor international reputation with a narrow range of heavy foods, high meat 
intake and is considered rather tasteless (305). The Scottish diet in particular 
has been shown to have a low ratio of polyunsaturated to saturated fats and low 
antioxidant content. These dietary traits are more pronounced in individuals 
who live in socially deprived areas (306).  
A number of authors over the centuries have tried to alter the British mind-set 
on diet and food choices. One of the earliest recorded examples of this is the 
Italian Giacomo Castelvetro, who in 1614 tried to encourage Londoners to eat 
more fruit and vegetables similar to the dietary intake in his home-land (307). In 
the post-war years of the 1950s, Elizabeth David was formally credited with 
trying to transform post-war British eating habits with her publication of her 
book on Mediterranean foods (308).The Mediterranean-type diet has recently 
been recognized by the United Nations Educational, Scientific and Cultural 
Organisation (UNESCO) as a worthy example to be added to the worldwide 
Representative List of Intangible Cultural Heritage (309). 
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Over the last few decades much interest has been generated around the 
potential health gains, in particular to the CV system, of adhering to such a 
diet. A large number of studies have been undertaken to assess the benefits of 
this type of lifestyle intervention – both in epidemiological and controlled trial 
settings. 
1.8.1 Mediterranean diet score 
The Mediterranean diet score is a tool frequently used in studies to assess intake 
of component foods. It allows comparison between individuals, between cohorts 
(e.g. between countries) and between interventions (310) and is frequently used 
in epidemiological studies. The simplest version of the score varies from 0-9, 
more complex scores range from 0-55. It is based upon the analysis of 
completed food-frequency questionnaires (FFQ), a sample page excerpt of 
which is included in Appendix I and discussed further in Section 2.8. There are 
some concerns with using a FFQ to estimate adherence to a Mediterranean diet 
as it was originally developed to assess the intake of total energy and 
macronutrients (fat, protein, carbohydrates) and not individual components 
such as FVL consumption (311). 
One point is given for intake at or above the gender-specific median amount of 
the components considered healthy. One point is given for intake less than the 
median for components considered unhealthy, such as meat and dairy products. 
An additional point can be gained for alcohol consumption within a specific 
range. Higher values of this score indicate greater adherence to a 
Mediterranean diet.  
1.8.2 Overall benefits of a Mediterranean-type diet 
One of the first studies of the potential benefits of adherence to a 
Mediterranean diet was carried out by Trichopoulou and colleagues in the early 
1990s (310). The subjects comprised 182 residents (equal numbers male and 
female) of 3 Greek villages. Median age at recruitment was 75.4 years. Dietary 
habits were recorded over a 2 year period and on revisiting the villages 3 years 
later, 53 of the subjects had died. Food diaries were reviewed and when a 
Mediterranean diet score applied, a 1-point increase was associated with a 17% 
reduction in overall mortality (rate ratio 0.83, 95% CI 0.69-0.99) and a greater 
than 50% reduction per 4-point increase.  
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Trichopoulou expanded her initial work by prospectively studying over 22,000 
healthy Greek adults aged 20-86 years. When their Mediterranean-diet scores 
were reviewed, a 2-point increase was associated with a 25% reduction in total 
mortality, over a median 44 months follow-up (312). 
The Healthy Ageing: a Longitudinal study in Europe project followed up over 
2000 apparently healthy men and women aged 70-90 years in 11 European 
countries. Adherence to a Mediterranean-type diet was associated with a lower 
risk of all-cause 10-year mortality: HR 0.77, 95% CI 0.68-0.88 (HR adjusted for 
age, gender, years of education, BMI and other factors). This was compared to 
moderate alcohol consumption (HR 0.78, 95% CI 0.67-0.91), physical activity (HR 
0.63, 95% CI 0.55-0.72) and non-smoking (HR 0.65, 95% CI 0.57-0.75) (313). 
A recently published meta-analysis of prospective cohort studies assessed the 
relationship between adherence to a Mediterranean diet, mortality and 
incidence of chronic diseases in a primary prevention setting. This covered over 
half a million subjects and over 33,000 deaths. Greater adherence to a 
Mediterranean diet was associated with a significant reduction in overall 
mortality (9%), mortality from CVD (9%), incidence of or mortality from cancer 
(6%) and incidence of Parkinson’s Disease and Alzheimer’s Disease (13%) (314). 
It is not certain whether adhering to a Mediterranean diet has any benefits for 
those aged over 80 years (315) as an increase in Mediterranean diet score  in 
this age group was not associated with any reduction in overall mortality.  
1.8.3 Cardiovascular benefits of a Mediterranean-type diet 
The Seven Countries Study by Keys et al is comparable to the Framingham Study 
in being one of the largest, longest and most important epidemiological studies 
of recent times.  The aim of the Seven Countries Study was to discover if diet 
could influence life expectancy. Over 11,000 men aged 40-59 years from the 
USA, Japan, Finland, Italy, Greece, The Netherlands and the former Yugoslavia 
were studied. None had previous history of heart disease or cancer. Marked 
differences were seen in the different regions after 15 years of follow-up. The 
male residents of the Greek island of Crete, who had a plentiful intake of fruit, 
vegetables, fish and olive oil, had a death rate of 38 per 10,000. Finland, by 
comparison, with a diet rich in meat, saturated fat and refined sugar, had a 
death rate of over 1200 per 10,000.  Age, BP, smoking status, serum cholesterol, 
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and the ratio of monounsaturated: saturated fat accounted for 96% of the 
differences between death rates for CHD. This ground-breaking work became 
the template for other prospective studies of a Mediterranean-type diet (316) 
(317). 
A number of studies have assessed the impact of this type of diet on CV 
mortality in non-Mediterranean Europeans, Americans and Australians. 
Trichopoulou’s research team took their work to 9 European countries and 
assessed over 74,000 patients aged greater than 60 years, with no prior history 
of CVD, stroke or cancer. Here, a 2-point increase in Mediterranean-diet score 
was associated with a statistically significant 8% increase in survival (95% CI 3-
12%) (318). Similar results were observed in the USA where over 200,000 males 
and 166,000 females were followed up prospectively for 5 years – reduced CV 
mortality was noted in patients with higher Mediterranean-diet scores 
(multivariate HR 0.78, p value for trend <0.001) (319). Two Australian studies 
have also demonstrated reduced mortality with higher Mediterranean diet 
scores (320) (321). Interestingly, the latter of those 2 studies demonstrated that 
migrants to Australia from the Mediterranean area had a lower mortality than 
native-born Australians.  
A Mediterranean-type diet is usually rich in fish and this specific aspect has been 
studied with regards to CVD. Researchers have demonstrated a reduced 
incidence of sudden cardiac death (multivariate RR 0.48, 95% CI 0.24-0.96, 
p=0.04), in male patients with no prior history of IHD or stroke, who consumed 
more than one fish containing meal per week, when compared with men who 
consumed fish less than once per month (322). A significant 29% reduction in 
mortality in patients in the fish group was demonstrated.  
There can be little doubt that adherence to a Mediterranean-type diet and / or 
a diet rich in fish is associated with significant long-term health benefits.  
1.8.3.1 Use of a Mediterranean-type diet in patients with pre-existing 
cardiovascular disease. 
While the above studies were epidemiological and looked at populations as a 
whole, recent work has focussed on asking patients to adhere to a specific diet 
after a primary CVD episode. The Lyon Diet Heart Study followed 605 patients 
who were randomly assigned to either a low-fat (n=302) or a Mediterranean-type 
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diet (n=303) after a first MI (323). The study was terminated early due to a 
significant reduction in cardiac events in the Mediterranean group: 1.24 cardiac 
deaths or non-fatal MI per 100 patients per year compared with 4.07 in the 
control group. The authors proposed that the mechanism for such an effect may 
be due to the cardio-protective effects of omega-3 fatty acids and antioxidant 
vitamins found in abundance in the Mediterranean diet (324). The cardio-
protective benefits were maintained up to 4 years after the first MI (325), with 
fewer cardiac deaths (326).  
Two groups have studied the potential benefit of fish and fish oils in patients 
with pre-existing CVD. Firstly, the Gruppo Italiano per lo Studio della 
Sopravvivenza nell’Infarcto miocario (GISSI-Prevenzione) trial reviewed the 
effects of fish oil supplementation in a post-MI cohort. A 20% reduction in 
overall mortality and a 45% reduction in sudden cardiac death was demonstrated 
on those on supplements (327). Secondly, the Diet and Reinfarction Trial (DART) 
studied patients for 2 years post MI and randomised them to either normal diet 
or a fish and fish oil supplemented diet  (328).  
However, a recently published study from The Netherlands assessed the effect 
of n-3 fatty acid supplementation in margarine versus placebo, given to early 
5000 patients post-MI. There was no reduction in the primary end-point of rate 
of major CV events (329). 
1.8.3.2 Effect of a Mediterranean-type diet on blood pressure 
Several studies have examined the relationship between adherence to a 
Mediterranean-type diet and BP. The original Seven Countries Study gave a 
potential explanation for the lower CV mortality rates with lower levels of BP 
and lower BMI protecting against atherosclerosis (316). A significant reduction in 
systolic BP was noted in a Mediterranean-type diet study where either olive oil 
or mixed nuts were compared with a low-fat diet (mean reduction of 5.9mmHg 
and 7.1mmHg respectively and p<0.001 for both) (330). Alonso demonstrated 
that a high fruit and vegetable intake was inversely associated with BP levels 
(331). 
In a converse design to usual Mediterranean diet studies, a research group in 
Italy assigned 57 normotensive volunteers to a 6-week intervention period of a 
70% increase in energy from saturated fatty acids and decrease in carbohydrate 
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and mono-unsaturated fat.  By the end of the intervention, systolic BP increased 
by 2.6mmHg in men (p<0.05) and by 4.8mmHg in women (p<0.01) when 
compared with the 2 week baseline period on their customary Mediterranean 
type diet. Diastolic BP did not significantly increase. After returning to their 
usual diet, BP readings reverted to baseline. The authors postulate that changes 
in the saturated fatty acid content of the diet has a significant impact on BP 
control (332). 
1.8.3.3 Diabetes  
Researchers have shown a reduced risk of diabetes with a 2-point increase in 
Mediterranean diet score (35% relative reduction, incidence rate ratio 0.65, 95% 
CI 0.44-0.95) (333). The metabolic syndrome describes a group of major risk 
factors for CVD such as dyslipidaemia, obesity, hypertension and diabetes (334). 
A reduced incidence of the metabolic syndrome has been demonstrated with a 
diet high in cereals and a high monounsaturated: saturated fat ratio (335). 
Karvounaris found no significant overall increase in metabolic syndrome 
prevalence in a cohort of 200 RA patients than in a group of 400 age and sex-
matched controls (44% versus 41%, p=0.5) (336). 
1.8.3.4 Potential mechanisms for cardiovascular benefits of a Mediterranean-
type diet 
The effects of dyslipidaemia are well-documented and a Mediterranean diet 
looks to have potential benefits on lipid profile with reductions in mean LDL-
cholesterol (337), by as much as 11.3% in one study (338). In addition, reduced 
TC: HDL-cholesterol ratios have also been shown (330).  
Endothelial dysfunction has been mooted as a possible early event in the 
evolution of atherogenesis as well as being a novel predictor of CVD risk. 
Improved endothelial function, as measured by FMD of the brachial artery has 
been demonstrated in a study of males with hypercholesterolaemia assigned to 
a Mediterranean diet (339). A significantly improved endothelial function score 
(a measure of BP and platelet aggregation) has been documented in patients 
assigned to a Mediterranean diet when compared to a control diet (340).  
Finally, reduced markers of inflammation and coagulation (e.g. CRP, fibrinogen, 
IL-6 and homocysteine) have also been documented with adherence to such a 
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diet (341). Work from Kang and Leaf has demonstrated the electrical 
stabilization of cardiomyocytes by n-3 fatty acid which may go some way to 
explain the benefits of a high dietary fish intake (such as in a Mediterranean-
type diet) or fish oil supplementation (342). 
1.8.4 Mediterranean-type diet and inflammatory arthritis 
1.8.4.1 Prevention of inflammatory arthritis 
A number of associations between dietary intake and the development of 
inflammatory arthritis have been postulated. Researchers have shown the 
potential benefits of a Mediterranean-type diet in the prevention of RA. FFQ 
from 145 patients with RA were compared with those of 188 controls. The risk of 
developing RA was inversely and significantly associated with the consumption 
of cooked vegetables and olive oil (OR 0.38 and 0.24 respectively by multiple 
logistic regression analysis) (343).  
UK epidemiologists based in Manchester proposed 2 similar theories. In the first, 
a lower intake of fruit, vegetables and vitamin C was associated with an 
increased risk of developing inflammatory arthritis (344). The second 
demonstrated that patients who consumed a high amount of red meat and 
protein were also at increased risk for developing inflammatory arthritis (345). 
A Mediterranean diet is naturally rich in fruit and vegetables and contains a 
lesser amount of red meat; therefore the work by Pattison and colleagues 
confirm the potential protective merits of adopting such a diet.  
1.8.4.2 Improvement in inflammatory joint disease control 
Swedish investigators conducted a study involving RA patients with established 
disease who strictly attended a hospital canteen for 2 meals per day (346). 
Twenty-six received a Cretan Mediterranean diet and 26 a control diet. The 
intervention group demonstrated a significant reduction in DAS28 by 0.56 
(p<0.001) and in HAQ score by 0.15 (p=0.02), whereas the control group showed 
no benefit. Additionally, a study of a vegan diet, free of gluten, demonstrated a 
higher number of RA patients achieving an ACR 20% improvement in disease 
activity than patients in a control group (347).  
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1.8.4.3 Potential mechanisms for arthritis disease activity benefits of a 
Mediterranean-type diet 
Oleocanthal, a compound found in olive oil, has been found to cause dose-
dependent inhibition of COX1 and COX2 activities. This mimicry of the 
pharmacological benefits of ibuprofen may explain some of the health benefits 
listed in the sections above (348).  
IL-6 is secreted by T cells and macrophages and is an important mediator of 
fever and acute phase response. It has an important role in the pathology of RA 
and as such, tocilizumab the first IL-6 receptor monoclonal antibody has been 
produced (349). Elevated plasma levels of IL-6 have been associated with a 
greater risk of CV and non-CV death in a cohort of elderly patients (350). 
Researchers have demonstrated that adherence to a Mediterranean-type diet 
was associated with a significant reduction in IL-6 (340) (341) (351) (352).  
Fish oils have been proposed as potentially contributing to the health benefits of 
a Mediterranean-type diet (as documented in Sections 1.8.3.1-1.8.3.4) and this 
is especially pertinent to inflammatory control. n-3 (also known as omega-3) is a 
fatty unsaturated acid. It is derived mainly from ingested α-linolenic acid and 
eicosapentanoic acid from fish. Fish especially rich in n-3 include salmon, 
herring, mackerel, sardines and anchovies, and to a lesser extent, tuna. Another 
important source of n-3 is flax seeds (also known as linseed). This type of fatty 
acid has the capacity to modulate a number of inflammatory markers central to 
causing tissue damage; it has been shown to suppress IL-1β (353), TNF (354), as 
well as ICAM-1 (355).  
1.8.4.4 Potential role of fish and fish oils in rheumatoid arthritis 
A double-blind placebo-controlled study randomised RA patients to 540mg γ-
linolenic acid (in the form of evening primrose oil), 240mg fish oil (containing 
eicosapentaenoic acid) plus 450mg γ-linolenic acid or placebo. Results at 12 
months demonstrated that those patients taking either fish oil or evening 
primrose oil managed to reduce their NSAID intake without any deterioration in 
disease activity (356). Sixty-six RA patients enrolled in a double-blind 
randomised placebo-controlled study were given either corn oil or fish oil in 
addition to diclofenac and the NSAID substituted for placebo at either week 18 
or 22 while fish oil supplementation continued for another 8 weeks. Corn oil use 
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had no improvement in clinical parameters. Fish oil resulted in significant 
decrease in tender joint count and duration of EMS. There continued to be a 
significant reduction in tender joint count after diclofenac substitution             
(-7.8±2.6, p=0.011) (357). A double-blind placebo-controlled randomised trial 
assigned 97 patients with RA to either 10g of cod-liver oil containing 2.2g of n-3 
essential fatty acids or an air-filled identical placebo capsules (358), 60% 
completed the study. 39% in the cod liver oil group and 10% in the placebo group 
managed to reduce their daily NSAID requirement by >30% (p=0.002) without 
deterioration in disease control. The authors postulate that supplements rich in 
n-3 could be used as NSAID sparing agents in RA patients. 
Despite these positive results, and those published by others (359), relatively 
few patients with RA take fish oil supplements (360).The risk of developing RA is 
reduced by taking 2 or more fish meals per week compared with taking just one 
(adjusted OR 0.57, 95% CI 0.35-0.93) (361). This would again suggest a potential 
benefit of a Mediterranean type diet.  
1.8.5 Mediterranean-type diet and weight 
In subjects who were initially overweight at enrolment in the Spanish cohort of 
the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 
Mediterranean-diet adherence was associated with a significantly lower 
likelihood of becoming obese during the 3-year follow-up (318, 362). Adhering 
to a very low calorie diet results in both weight loss and a reduction in IL-6 
levels, suggesting that circulating IL-6 levels may partly reflect adipose tissue 
production  (363). A 2-year study was performed in over 300 moderately-obese 
patients assigned to 1 of 3 diets: low-fat and calorie-restricted, Mediterranean 
or low-carbohydrate with no calorie restriction. The most significant weight loss 
was seen with the latter 2 diets at 4.6kg and 5.5kg respectively in those who 
completed the 2 year intervention. The maximum weight loss was between 
months 1 and 6 and was also associated with increased dietary fibre (364). 
However, in studies focusing on the effect of a Mediterranean diet on RA, it has 
not been thought that weight loss contributed to an improvement in the joint 
disease – one may expect that weight reduction would lead to a reduction in 
mechanical stresses on joints in the lower limbs especially (365).  
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1.8.6 Other potential health benefits of a Mediterranean-type diet 
1.8.6.1 Cancer 
There is a significant evidence base suggesting that adherence to a 
Mediterranean-type diet may reduce cancer risk. For example, of over 65,000 
females in the Etude Edpidémiologique auprès de femmes de l’Education 
Nationale arm of the EPIC (E3N-EPIC) cohort, 2381 cases of post-menopausal 
invasive breast cancer cases were identified over a median follow up period of 
9.7 years. Adherence to a Mediterranean-type diet showed a negative 
association with breast cancer risk, especially oestrogen-positive and 
progesterone-negative (HR 0.85, 95% CI 0.75-0.95, p=0.003 for linear trend). A 
diet high in processed foods, fats and alcohol had a positive association with 
breast cancer risk (HR 1.20, 95% CI 1.03-1.38, p=0.007 for linear trend) (366). 
The EPIC cohort had over 485,000 subjects, 30% of which were male, aged 
between 35 and 70 years in 10 European countries. An 18-unit relative 
adherence to a Mediterranean diet score was used to estimate adherence to 
diet type. A high score was associated with a significant reduction in gastric 
adenocarcinoma risk (HR 0.67, 95% CI 0.47-0.94). A 1 unit increase in this score 
was associated with a reduced risk of gastric adenocarcinoma of 5% (95% CI 
0.91-0.99) (367). 
1.8.6.2 Asthma and allergy  
The link between diet, atopy (allergic hypersensitivity) and asthma control has 
been explored over recent years. In one study, 174 adult asthmatics were 
defined as controlled or non-controlled and dietary intake assessed by FFQ and 
subsequently Mediterranean diet score calculated (368). Controlled asthmatics 
(23% of total) had a significantly higher Mediterranean diet score than non-
controlled asthmatics. The higher intake of fresh fruit decreased the probability 
of having non-controlled asthma (OR 0.29, 95% CI 0.10-0.83, p for trend=0.015).  
A cross-sectional survey of nearly 700 children aged 7-18 years living in rural 
Crete examined the relationship between diet, respiratory and allergic 
symptoms (369). 80% of children ate fresh fruit daily and 68% ate vegetables 
daily. A high level of adherence to a Mediterranean diet was protective for 
allergic rhinitis (OR 0.34, 95% CI 0.18-0.64). A high consumption of nuts, in 
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particular, was found to be inversely associated with wheezing (OR 2.19, 95% CI 
0.20-0.98).  
1.8.7 Problems with dietary studies 
Clinical trials of dietary interventions are associated with a set of potential 
problems different from pharmaceutical drug trials. Recruitment can be much 
more difficult as the patients require undertaking some form of lifestyle 
modification, with associated impact on their day to day social activities. It is 
very difficult to monitor compliance in a dietary intervention study. 
Unfortunately, dropout numbers can be high in such clinical trials. A study 
investigating the effect of a particular diet cannot be performed in a double 
blind fashion. There are usually no direct commercial interests linked to a 
dietary study and consequently funding can be difficult.   
 
1.9 SCOTTISH DIETARY POLICIES 
Many aspects of social and economic policy impact on food consumption, diet 
and health. By the beginning of the 21st century, the Scottish diet was described 
as being not only worse than the closely neighbouring countries of England and 
Wales, but also worse than that of almost any other country in the Western 
world (370). Even today, many children are noted to be failing to eat enough 
fruit and vegetables and childhood obesity is rising. Sugar consumption is high 
with a subsequent legacy of dental disease.  This is in spite of published 
evidence derived from the north Glasgow MONICA population surveys suggesting 
that there was increasing trends in the reported consumption of fruit and 
vegetables and oil-rich fish over the 10-year period 1986-1995 (371). A study of 
Scottish diet from the early 1990’s as part of the Scottish Heart Health Study 
demonstrated that men and women in manual occupations had a poorer quality 
diet than those in non-manual occupations (306). 
1.9.1 The James Report 
In the early 1990s it was becoming increasingly apparent that the unhealthy 
Scottish diet was impacting on the wellbeing of the population. In 1992, the 
Chief Medical Officer for Scotland established a working group chaired by 
Professor Philip James to survey the diet of the Scottish people in a bid to assess 
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the relevance of diet to health and to make suggestions, if appropriate, for 
improvements and to assess their likely impact. “The Report on the Scottish 
Diet” was presented in 1993 and highlighted the need for a substantial change in 
Scotland’s consumption of food and nutrients to bring about significant 
measurable population health benefits. The James Report (as it became known) 
heralded an important shift in public health policy (372). 
1.9.2 The Scottish Dietary Action Group and subsequent health studies 
The Scottish Diet Action Group (SDAG) was set up in 1994 with the task of 
preparing an action plan to meet the series of targets set out in the James 
Report of the previous year. National recommendations were outlined which 
included targets for dietary improvement in Scotland by the year 2005. The 
average intake of fruit, vegetables, wholemeal and brown breads, rice, pasta 
and oily fish needed to increase. It was vital that the average intake of salt, 
saturated fatty acids and sugar reduced significantly.   
The traditional Mediterranean-type diet is consistent with the recommendations 
of the SDAG. Scottish nutritionists designed a 6-month study to evaluate the 
effectiveness of an internet-based tailored-feedback intervention promoting 
four key components of the Mediterranean diet (vegetables, fruit, legumes and 
monounsaturated: saturated fatty acid) (373). Those in the intervention group 
had significantly increased their consumption of the key components (p= 0.002, 
0.025, 0.001 and <0.001 respectively). The authors reported that this 
intervention was easy to set up and implement with significant changes in 
participants eating habits.  
The Scottish Health Survey of 2008 (374) demonstrated that there had been no 
significant increase in fruit and vegetable consumption between the surveys of 
2003 and 2008. The average number of fruit or vegetable portions consumed per 
day was 3.4 for females and 3.1 for men. 24% of females and 20% of males 
consumed 5 or more portions per day. The percentage not consuming any fruit 
or vegetables per day was higher in the most deprived SIMD quintile compared 
with the least (19% versus 4%). Alcohol consumption was also higher in the most 
deprived group with 11% consuming more than 50 units per week (compared 
with 5% in the least deprived group).  
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1.9.3 Health Promotion within NHS Greater Glasgow & Clyde 
Greater Glasgow Health Board was created in 1974 and became NHS Greater 
Glasgow in 2003. In 2006 it was renamed NHS Greater Glasgow and Clyde. The 
Health Promotion Department embarked on playing a leading role in improving 
health for all those living in the area, by working in active partnership with 
individuals, communities and organisations.  They describe two main aims; 
firstly, to enable those who live (or work) in Glasgow to improve their health 
and that of the local population and secondly, to reduce inequalities in health in 
Glasgow. The remit of the nutrition team includes: to increase awareness of 
what constitutes a healthy diet and to increase access to information and 
services related to food. The affordability and availability of healthy food for all 
is paramount. 
 
1.10 SOCIAL DEPRIVATION 
1.10.1 Townsend Index 
The Townsend Index was derived in 1988 to provide a measure of deprivation 
and disadvantage in England (375). Four variables (unemployment, non-car 
ownership, non-home ownership and household overcrowding) combine to form 
an overall score. The higher the Townsend Index score, the more deprived and 
disadvantaged an area is thought to be. Different areas can be ranked in 
relation to one another.   
1.10.2 Carstairs Index 
The Carstairs Index is an score of deprivation to identify socio-economic 
confounding (376). It was developed for Scotland as an alternative to the 
Townsend Index based upon the 1981 census data. It is based upon 4 census 
indicators: low social class (class 4 or 5), lack of car ownership, overcrowding 
and male unemployment. Areas are then split by postcode.  A composite score is 
created and the deprivation score divided into 7 separate categories ranging 
from very high (category 6 and 7) to very low deprivation (category 1 and 2).  
Scores were recalculated in 1991 using more up to date census information.  
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1.10.3 Scottish Index of Multiple Deprivation 
SIMD has recently been adopted as a tool by the Scottish Government, local 
authorities, the NHS and government bodies (377). It combines 37 indicators 
across 7 domains (current income; employment; health; education, skills and 
training; housing; geographic access and crime). The driving principle behind 
this index is to target government action to the areas of greatest need by 
identifying small area concentrations of multiple deprivations across Scotland. 
SIMD scores range from 0.54 (least deprived) to 87.60 (most deprived) and 
scores can be divided into quintiles of least to most deprived, as detailed in 
Table 1.17. 
 
Table 1.17 – SIMD quintiles 
 
Population fifth 
 
SIMD range 
 
1st  
 
0.54-7.63 
2nd 7.64-13.49 
3rd 13.50-21.16 
4th 21.17-33.93 
5th  33.94-87.60 
Where 1st quintile is the least deprived and 5th quintile is the most deprived 
Adapted from (377) 
 
1.10.4 Rheumatoid arthritis and social deprivation 
Evidence suggests that social deprivation associates with poor outcome in RA. 
For instance, a cohort of 200 RA patients in the West of Scotland recruited to a 
DMARD study was followed prospectively for 12 years (378). 47.5% of patients 
died in the follow up period, with 57% dying from a cardiorespiratory cause and 
21% from a neoplasm. The median age of death was lower and the percentage of 
deaths higher in the most deprived patients (Carstairs groups 6 and 7). This 
Carstairs grouping had a 1.66 times greater mortality than the least deprived 
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group, Carstairs 1 and 2 (95% CI 0.74-3.69). It is thought that some of this excess 
risk may be due to cigarette smoking. Another study from the West of Scotland 
confirmed poorer function and increased medical need in a 5 year follow up of 
over 400 patients with RA (379). Similar finding of a worse clinical course in 
nearly 900 English patients with RA has been reported (380).   
1.10.5 Cardiovascular disease and social deprivation 
CHD has been found to be associated with socioeconomic deprivation across the 
world (381). O’Flaherty et al found that the overall age adjusted CHD mortality 
in the over 35s between 1986 and 2006 had decreased (by 61% in men and 56% in 
women)  (382). However they determined that the rate of decline of mortality 
was slowing down in young women more so than in young men. Up to a 6-fold 
differential in CHD mortality was apparent between least and most deprived 
areas; this difference disappeared in the over 85 year old group.  
 
1.11 POTENTIAL MODIFICATION AND FURTHER ASSESSMENT OF 
CARDIOVASCULAR RISK IN RHEUAMTOID ARTHRITIS 
1.11.1 Hypothesis under investigation 
In this thesis I aim to explore the effect of novel interventions on various 
aspects of RA. Specifically I will investigate the feasibility and effect of anti-
inflammatory withdrawal in patients with well-controlled RA as well as the 
impact of a Mediterranean-type diet on disease activity within the Glasgow RA 
population. Finally, given recent evidence linking social deprivation with CV risk 
as well as poor RA outcomes, this will be explored further by comparing 
outcome in an RA cohort according to conventional and new CV risk algorithms.  
The rationale to the NSAID withdrawal study was that removal of this therapy 
plus any required active intervention would provide equivalent symptom control 
to that achieved by continuing NSAID as assessed by DAS, pain score and 
functional assessments. The Mediterranean-diet study was set up to assess if 
existing resources could be used as much as possible. 
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1.11.2 Aims of investigations 
1. To assess the tolerability and impact of NSAID withdrawal from a group of RA 
patients with low disease activity – the primary outcome being DAS44, secondary 
outcomes being effect on BP, GI symptoms and renal function. 
2. To explore the feasibility and acceptability of introducing a Mediterranean-
type diet in females with RA, predominantly from areas of social deprivation in 
Glasgow. Additionally, to assess the impact of such a dietary intervention on 
disease activity, CV parameters and haematological markers.  
3. To examine the impact of social deprivation on cardiovascular risk scores 
using the Mediterranean-diet cohort, and compare the outcome of using a newer 
CV risk score (ASSIGN) with traditional scores (Framingham and JBSCRP). 
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CHAPTER 2 
Patients and Methods 
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2.1 SUMMARY 
This chapter provides a description of the general protocols and the clinical 
techniques used in the studies detailed in this thesis. 
 
2.2 ETHICAL GUIDANCE AND APPROVAL 
Approval for both the NSAID withdrawal study and the Mediterranean-type diet 
study was granted by the Local Research Ethics Committee (LREC) at Glasgow 
Royal Infirmary. All patients gave written informed consent after having 24 
hours to review the Patient Information Sheet before making a decision.  
All research using samples from controls and patients was in accordance with 
the World Medical Association (WMA) Declaration of Helsinki - Ethical Principles 
for Medical Research Involving Human Subjects, most recently amended by the 
59th WMA General Assembly in Seoul, October 2008 (383).  
 
2.3 PATIENT RECRUITMENT 
2.3.1 Non-steroidal anti-inflammatory drug withdrawal study 
Patients were recruited from clinics of 2 Consultant Rheumatologists at Glasgow 
Royal Infirmary. Suitable patients were either identified during the clinic 
consultation or approached staff themselves after viewing a recruitment poster 
(Appendix II) in the clinic waiting area. If thought appropriate they were invited 
to take part in the study and were provided with a Patient Information Sheet 
(Appendix III). Potential recruits were telephoned at home to invite them to a 
baseline assessment if they wished to proceed with study involvement. Inclusion 
and exclusion criteria are detailed in Sections 3.2.1 and 3.2.2. All patients gave 
written informed consent (Appendix IV).   
2.3.2 Mediterranean-type diet study 
Female patients with RA were recruited over a nine month period. Three 
hospital sites in Glasgow were used: Royal Infirmary, Southern General and 
Stobhill Hospital. These sites were chosen with the aim of recruiting patients 
from within one of the Social Inclusion Partnership areas in Glasgow, these are 
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areas of social deprivation (384) (385). Suitable patients were either identified 
during the clinic consultation or from within multi-disciplinary team discussions. 
If thought appropriate they were invited to take part in the study and were 
provided with a Patient Information Sheet (Appendix V). Potential recruits were 
telephoned at home to invite them to a baseline assessment if they wished to 
proceed with study involvement. Inclusion and exclusion criteria are detailed in 
Sections 4.2.1 and 4.2.2. All patients gave written informed consent (Appendix 
VI).   
 
2.4 ASSESSMENT OF DISEASE ACTIVITY 
The relationship between joint swelling and tenderness can vary from person to 
person and at different time points. It has become accepted practice to assess 
both swelling and tenderness when examining a patient with inflammatory 
arthritis (386). Methods have changed of evaluating disease activity with 
variations in: number of joints assessed, which joints are assessed and scoring 
system (e.g. graded scale or abnormal versus normal).  
DAS has become the preferred combined index to include clinical and laboratory 
parameters. DAS dates back to 1983 when a small clinical trial modified an 
existing disease activity index. This allowed classification into either high or low 
disease activity and included the views of both patient and doctor (387). 
Further work developed the DAS to cover a number of variables to discriminate 
between different levels of disease activity (388).  
Thus the commonly used DAS is a statistically derived index combining tender 
joints, swollen joints, ESR (or CRP) and patient GH (389). DAS values are 
continuous, normally distributed and are well validated in clinical trials. The 
component parts to the DAS are described below. Tenderness and swelling are 
assessed separately in each joint. Tenderness is more sensitive to change and 
correlates with pain, while swelling correlates with acute phase reactants and 
radiographic progression. Tender and swollen joint count contributes 
numerically to approximately 50% of the DAS. 
Common to both DAS44 and DAS28 is the patient’s assessment of GH. It is 
measured on a 100mm visual analogue scale (VAS) (r=0.995, random 
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measurement error=0.12). This is a reliable and reproducible method of 
following the course of pain and disability (390). While a pain score is not part 
of the formal calculation of either DAS44 or DAS28, it can be helpful as part of a 
general assessment of the patient and monitoring of a therapeutic intervention. 
Pain score is graded on a VAS from 0-100mm.  
2.4.1 Disease Activity Score-44 
DAS based on 44-joint count for swelling is known as the DAS44 or “original” 
DAS. It gives a numerical score on a scale from 1-9. It is calculated using a 
mathematical formula detailed in Table 2.1, when 4 components are available: 
Ritchie Articular Index (RAI), 44-swollen joint count, ESR (or CRP) and patient 
GH score.  
When global disease activity assessment is not available, a 3 component DAS can 
be calculated using an alternative formula, also detailed in Table 2.1.  
While the 28-joint count is the basis for deciding on possible escalation of 
therapy to anti-TNF (14), in daily clinical practice a joint count which includes 
the feet joints (such as the DAS44) is felt better by some clinicians to follow the 
course of the disease of individual patients.  
DAS44 was used in the non-steroidal withdrawal study, described in Chapter 2, 
to better capture changes in a larger number of joints than using DAS28 would 
allow. 
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Table 2.1 - Equations for calculating 44-joint disease activity score (DAS44) 
 
Equations for calculating DAS44 
 
 
4 components (ESR): 
 DAS44 = 0.53938√(RAI)+ 0.06465(SW44)+0.33Ln(ESR)+0.00722(GH) 
4 components (CRP): 
DAS44 = 0.53938√(RAI)+ 0.06465(SW44)+0.17Ln(CRP+1)+0.00722(GH)+0.45 
3 components (ESR):  
DAS44= 0.53938√(RAI)+ 0.06465(SW44)+0.33Ln(ESR)+0.224 
3 components (CRP):  
DAS44= 0.53938√(RAI)+ 0.06465(SW44)+0.17Ln(CRP+1)+0.65 
 
 
Where: RAI= Ritchie Articular Index (53 joints in 26 “units” or “blocks”, graded 
for tenderness), SW44= 44 joint count for swelling, LnESR= natural logarithm of 
Westergren’s erythrocyte sedimentation rate (mm/hour) and GH= global health 
(or patients’ global assessment of disease activity) on a visual analogue scale of 
100mm.  
Adapted from (389) (391) 
 
2.4.1.1 Ritchie Articular Index   
The RAI grades tenderness in 53 joints including the feet (389) (392). The 
method is sensitive to detect even small changes in joint tenderness. The 
reproducibility when used by one observer is satisfactory, but the inter-observer 
variation can be higher. All 53 joints included in the RAI are assessed separately. 
However the MCP and PIP joints of each hand, MTP joints of each foot, 
temperomandibular joints, sternoclavicular joints and acromioclavicular joints 
are calculated as a single unit – the highest score for a single joint gives the 
score for the unit. The joints are graded for tenderness on a 0-3 scale defined 
as: (0) no tenderness, (1) pain on pressure, (2) pain and winced and (3) winced 
123 
 
and withdrew. Pressure to elicit tenderness is exerted by the examiner’s thumb 
and index finger (at a sufficient pressure to cause “whitening” of the examiners’ 
nail beds). The 53 joints involved are detailed in Table 2.2.  
2.4.1.2 44-swollen joint index  
When a synovial effusion is present the joint is invariably swollen. Joint swelling 
is detectable along the joint margins and fluctuation is a characteristic feature. 
Joint swelling may influence the range of joint movement. Bony swelling, 
deformity and oedema surrounding the joints do not constitute joint swelling for 
the purposes of this score. 
All joints are assessed separately. The joints are scored for swelling on a 0-1 
scale: (0) no swelling and (1) swelling. The individual joint scores are summed.  
The 44-swollen joint count is assessed in the same joints as the RAI, with the 
exclusion of 9 joints in which swelling is difficult to detect: temperomandibular 
joints, cervical spine, hips, subtalar joints and midtarsal joints. The 44 joints 
involved are detailed in Table 2.2. 
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Table 2.2 - A comparison of the joints included in DAS44 for pain (Ritchie 
Articular Index) and swelling (44-swollen joint count) 
 
Joints included 
Ritchie Articular Index 44-swollen joint count 
 
10 PIP joints 
 
10 PIP joints 
10 MCP joints 10 MCP joints 
2 wrist joints 2 wrist joints 
2 elbow joints 2 elbow joints 
2 glenohumeral joints 2 glenohumeral joints 
2 acromioclavicular joints 2 acromioclavicular joints 
2 sternoclavicular joints 2 sternoclavicular joints 
2 temperomandibular joints 2 knee joints 
Cervical spine 2 ankle joints 
2 hip joints 10 MTP joints 
2 knee joints  
2 ankle joints  
2 subtalar joints  
2 midtarsal joints  
10 MTP joints  
Note: The cervical spine and hip joints are not examined directly for joint 
tenderness; the patient is asked if they have pain in the posterior cervical spine 
or pain in the groin on hip movement.  
Adapted from (389) 
 
 
 
 
 
 
125 
 
2.4.2 Disease Activity Score-28 
The DAS28 is based on tenderness and swelling in 28 joints and each feature is 
assessed separately in each of the joints (389) (393). Joints are scored for 
swelling on a 0-1 scale: (0) no swelling and (1) swelling. Joints are scored for 
tenderness on a 0-1 scale: (0) no tenderness and (1) tenderness. The 28 joints 
comprising this index are detailed in Table 2.3. DAS28 was used in the 
Mediterranean-type diet study described in Chapter 4 to allow a more rapid 
follow up of a greater number of patients. 
 
Table 2.3 - The 28 joints assessed for swelling and tenderness in DAS28 
 
Joints involved - 
Tender and swollen joint count 
 
10 PIP joints 
10 MCP joints 
2 wrist joints 
2 elbow joints 
2 glenohumeral joints 
2 knee joints 
Adapted from (389) 
 
DAS28 based on 28-joint count for swelling and tenderness, in addition to ESR 
(or CRP) and patient GH score is calculated using a mathematical formula 
detailed in Table 2.4. Where patient GH score is not available, a 3 component 
DAS28 can be calculated using an alternative formula, also detailed in Table 
2.4. It gives a numerical score on a scale from 0.49-9.07.  
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Table 2.4 - Equations for calculating 28-joint disease activity score (DAS28) 
 
Equations for calculating DAS28 
 
 
4 components (ESR):  
DAS28 = 0.56 √(TEN28)+0.28√(SW28)+0.70Ln(ESR)+0.014(GH) 
4 components (CRP):  
DAS28 = 0.56 √(TEN28)+0.28√(SW28)+0.36Ln(CRP+1)+0.014(GH)+0.96 
3 components (ESR):  
DAS28 = [0.56 √(TEN28)+0.28√(SW28)+0.70Ln(ESR)]+0.16 
3 components (CRP):  
DAS28 = [0.56 √(TEN28)+0.28√(SW28)+0.36Ln(CRP+1)]x1.10+1.15 
Approximate conversion from DAS44:  
DAS28= 1.072(DAS44)+0.938 
 
Where TEN28= 28 joint count for tenderness, SW28= 28 joint count for swelling, 
LnESR=natural logarithm of Westergren’s erythrocyte sedimentation rate 
(mm/hour) and GH=global health (or patients’ global assessment of disease 
activity) on a visual analogue scale of 100mm.  
Adapted from (389) (391) 
 
2.4.3 Comparison of DAS44 and DAS28 
The 2 commonly used disease activity scores differ in which joints are assessed 
(Table 2.2 and Table 2.3) and also in their numerical outcome. The DAS44 with 
its more comprehensive joint count is not interchangeable with the DAS28. The 
DAS28 gives higher values than the original DAS. An approximate DAS28 can be 
converted from DAS44 by an additional formula detailed in table 2.4. Different 
numerical ranges are used for DAS44 and DAS28 to define the level of disease 
activity exhibited, as detailed in Table 2.5. 
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Table 2.5 – Comparison of disease activity ‘criteria’ between DAS44 and 
DAS28 
  
DAS44 
 
DAS28 
 
High disease activity 
 
>3.6 
 
>5.1 
 
Moderate disease activity 2.4-3.6 3.2-5.1 
 
Low disease activity 1.6-2.4 2.6-3.2 
 
Remission <1.6 <2.6 
 
Adapted from (17) (21) 
 
2.5 FUNCTIONAL ASSESSSMENTS 
Functional assessments are frequently used in research but used less often in 
clinical practice (394), except as part of the assessment for suitability for 
biologic therapy (14).  
2.5.1 Short Form 12-item    
The short form 12-item study (SF-12) was designed to measure general health 
status from the patient’s point of view. It is based upon the more in-depth SF-
36, which is the most widely evaluated generic patient assessed health outcome 
measure (395) (396). It is a quick survey for the patient to complete with most 
finding that it only takes a few minutes to perform. The SF-12 includes 8 health 
concepts or “domains” commonly represented in health surveys and also 
featured in the SF-36. One or 2 questions cover each of these domains: physical 
functioning, physical role, bodily pain, general health, vitality, social 
functioning, emotional role and mental health.  
Results are expressed in terms of 2 meta-scores: the physical component 
summary (PCS) and the mental component summary (MCS). A high score 
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indicates better functioning. Test items are scored and normalised in an 
algorithm via a computer program (397). Both PCS and MCS were designed to 
have a mean score of 50 and a standard deviation of 10 in a representative 
sample of the population of the USA; therefore scores of over 50 represent 
above average health status. PCS scores are expected to decline with age more 
than MCS scores would. A sample of the SF-12 form patients completed in the 
NSAID withdrawal study is documented in Appendix VII.   
2.5.2 Health Assessment Questionnaire   
The HAQ originated in the late 1970s from Rheumatologists in the USA (398) 
(399). It was one of the first self-reported functional disability measures. The 
most commonly used version is the “short” or “2-page” HAQ which is completed 
by the patient. It rates the degree of difficulty experienced with everyday tasks 
and takes account of the need for adaptations and help from carers. It contains 
the HAQ disability index, visual analogue pain scale and patient GH scale. It 
does not capture disability associated with sensory organ dysfunction or 
psychological dysfunction. A sample of the HAQ form patients completed in the 
Mediterranean-type diet study is documented in Appendix VIII.  
2.5.3 Comparison of SF-12 and HAQ 
HAQ is a quick guide to identifying problems with activities of daily living but is 
not very sensitive to change. The SF12 is less valuable than HAQ in reviewing 
problems with activities of daily living but is more sensitive to change in 
physical function over time (400).  
 
2.6 INDICES OF SOCIAL DEPRIVATION  
A number of different indices are used in the UK. These include the Carstairs 
Index, the Townsend Index and SIMD. All analyse patterns of deprivation across 
geographical areas. In Sections 2.6.1 and 2.6.2 below, the indices used within 
the studies included in this work are discussed. 
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2.6.1 The Carstairs Index 
The Carstairs Index is an score of deprivation to identify socio-economic 
confounding (376). It was developed for Scotland as an alternative to the 
Townsend Index based upon the 1981 census data. It is based upon 4 census 
indicators: low social class (class 4 or 5), lack of car ownership, overcrowding 
and male unemployment. Areas are then split by postcode.  A composite score is 
created and the deprivation score divided into 7 separate categories ranging 
from very high (category 6 and 7) to very low deprivation (category 1 and 2).  
Scores were recalculated in 1991 using more up to date census information.  
2.6.2 Scottish Index of Multiple Deprivation 
SIMD has recently been adopted as a tool by the Scottish Government, local 
authorities, the NHS and government bodies (377). It combines 37 indicators 
across 7 domains (current income; employment; health; education, skills and 
training; housing; geographic access and crime). The driving principle behind 
this index is to target government action to the areas of greatest need by 
identifying small area concentrations of multiple deprivations across Scotland. 
SIMD scores range from 0.54 (least deprived) to 87.60 (most deprived) and 
scores can be divided into quintiles of least to most deprived as illustrated 
previously in Table 1.15. 
Information regarding SIMD was calculated using the postcode from the patient 
address given at study commencement and displayed as part of the ASSIGN score 
calculator (401).  
 
2.7 BLOOD SAMPLES 
Peripheral venous blood was drawn into Vacutainer® tubes and analysed as per 
individual study protocol detailed in sections 2.7.1 and 2.7.2 below.  
2.7.1 Non-steroidal anti-inflammatory drug withdrawal study  
A clot-activated blood sample was sent to the clinical biochemistry laboratory of 
Glasgow Royal Infirmary for measurement of CRP, lipid profile and urea and 
electrolytes via the routine service. eGFR has become a standard method of 
estimating renal function and forms the basis of chronic kidney disease staging 
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(402). Normal eGFR is approximately 100 ml/min/1.73m2. In this study, eGFR 
was calculated for each individual patient at the 3 time-points using the 
abbreviated modification of diet in renal disease (MDRD) equation:  
eGFR (ml/min/1.73m2) = 
186 x (creatinine / 88.4)-1.154  x (age)-0.203  (x 0.743 if female) 
An additional multiplication factor of 1.210 did not have to be used in this 
cohort as all patients were white (403). 
An ethylenediaminetetraacetic acid (EDTA) sample was sent to the clinical 
haematology laboratory of Glasgow Royal Infirmary for measurement of ESR by 
the Westergren method via the routine service.  
2.7.2 Mediterranean-type diet study  
A clot-activated blood sample was sent to the clinical biochemistry laboratory of 
the hospital where the patient was being assessed (either Glasgow Royal 
Infirmary, Southern General Hospital or Stobhill Hospital) for measurement of 
CRP, lipid profile and urea and electrolytes via the routine service. An EDTA 
sample was sent to the clinical haematology laboratory of the hospital for 
measurement of ESR by the Westergren method via the routine service.  
 
2.8 FOOD FREQUENCY QUESTIONNAIRES 
No dietary assessment method is faultless. The FFQ was used in the 
Mediterranean-type diet study on the advice of the University of Glasgow Human 
Nutrition Departments to give, what is at best, an approximation food intake of 
the study participant. The FFQ is a validated questionnaire originally developed 
to assess total intake of energy and macronutrients (protein, fat and 
carbohydrate) at a time when antioxidants were not a focus of interest. Many 
variations do exist (311). 
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2.8.1 Benefits of the food frequency questionnaire 
FFQ can be used in a variety of research settings: cross-sectional or 
surveillance, case control (retrospective), cohort (prospective) or in an 
intervention study. The individual’s usual intake is documented and information 
on total diet obtained. There are low investigator costs and the administration 
of such a questionnaire tends not to affect the patient’s eating behaviour (404).  
2.8.2 Drawbacks of the food frequency questionnaire 
Use of the FFQ is associated with an amount of measurement error, due to the 
limitation in its ability to estimate usual intake accurately. There can be 
problems with administering an paper-based FFQ in patients with poor vision or 
cognitive difficulties. A specific FFQ designed for use in a general population 
may be suboptimal in a patient with ethnic eating patterns. The estimation of 
portion size can be difficult for a patient and many FFQ designs have attempted 
to address this issue. FFQ generally include more than 100 individual line items 
and as such can take 30-60 minutes to complete – this raises concerns about the 
reliability of responses and response rates (404).  
2.8.3 Analysis of the food frequency questionnaire in the Mediterranean-
type diet study 
A sample page of the FFQ (incorporating drink and fruit intake only) is included 
in Appendix I; due to limitation of space in this manuscript a full questionnaire 
is not included. Additional questions about fruit intake were included in the 
adapted FFQ for this study.  These questions were analysed separately using the 
Diet5 computer package and the nutrient data added to the data estimated by 
DietQ to calculate the daily intake of vitamins A, C and E. Questionnaires were 
analysed by students in the Human Nutrition Department of the University of 
Glasgow. The computer packages apply different weightings to the answers of 
different questions, meaning that analysis of a completed paper version of the 
FFQ is not as straight-forward as one might assume. The main elements 
extracted from the FFQ for this study were: (a) fruit, vegetable and legume 
consumption, (b) Vitamin A, C and E intake, (c) monounsaturated fat 
consumption and (d) saturated fat consumption.  
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2.9 STATISTICAL ANALYSIS  
The variables from each data-set (outlined in Chapter 3, 4 and 5) did not follow 
normal distribution and therefore non-parametric tests were used. 
Wilcoxon signed-rank test is a non-parametric statistical hypothesis test used to 
compare two related samples to assess if their population mean ranks differ 
(i.e. a paired difference test). Additionally this test can be used as an 
alternative to the paired Student’s t-test when the population cannot be 
assumed to be normally distributed or the data is on the ordinal scale. This test 
was used for comparing results within the same treatment group. 
The Mann-Whitney U test is also known as the Mann-Whitney-Wilcoxon or 
Wilcoxon rank-sum test. It is also a non-parametric statistical hypothesis test for 
assessing whether one of two samples of independent observations tends to 
have larger values than the other, i.e. comparing results between intervention 
groups. 
A result is of statistical significance if it is unlikely to have occurred purely by 
chance. The amount of evidence required to accept that an event is unlikely to 
have arisen by chance is known as the p-value or the significance level. 
Choosing a level of significance has previously been thought of as arbitrary; for 
many applications a level of 5% (=0.05) is chosen.  
Statistical Package for the Social Science (SPSS) version 15 was used throughout. 
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CHAPTER 3 
A Pilot Study of Non-Steroidal Anti-Inflammatory Drug 
Withdrawal in Patients with Stable Rheumatoid Arthritis 
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3.1 INTRODUCTION 
DMARD are now introduced early in modern management of RA to reduce 
disease activity and disease progression. Many patients continue to take anti-
inflammatory drug therapy regularly, despite good control of their arthritis 
while taking DMARD. Given the controversies and debate surrounding the CV and 
GI safety of NSAID and COX2 inhibitors, a study was designed around the 
withdrawal of these drugs in a specific group of patients with RA attending 
Glasgow Royal Infirmary’s Rheumatology out-patient department.  
The objective of this study was to assess the feasibility and acceptability of an 
abrupt cessation of anti-inflammatory drugs while maintaining good symptom 
control, if necessary by undertaking a program of alternative alleviate 
symptoms and if necessary introduce additional therapies.  
 
3.2 JUSTIFICATION OF STUDY DESIGN AND PROTOCOL 
The rationale to this study was that the withdrawal of NSAID plus any required 
active intervention would provide equivalent symptom control to that achieved 
by continuing NSAID as assessed by DAS, pain score and functional assessments. 
The primary outcome of this study was the effect on DAS following NSAID 
withdrawal at 12 weeks. Secondary outcomes were the effects on BP, GI 
symptoms and renal function at 12 weeks.  
As this was an open labelled observational feasibility study, no specific power 
calculations were performed. It was felt that a sample size of 30 would be large 
enough to provide helpful results, but small enough to allow rapid and 
comprehensive follow-up. This would facilitate evaluation of either a future 
larger study or rolling-out NSAID withdrawal in a mainstream clinical setting.  
Our initial study design had been to randomise patients on NSAID to either 
continuing this therapy or switching to placebo. We concluded that obtaining 
matching placebo tablets would be difficult given the many different NSAID 
preparations used by patients. Thus, the study design was changed to an open 
label pilot of NSAID withdrawal in all participants. Had we found that we were 
unable to recruit the required number of participants or if a large number of 
135 
 
study participants were unable to adhere to the study protocol, the pilot study 
would have been terminated.   
3.2.1 Inclusion criteria  
Patients aged 18 years or older were considered for inclusion if they: (a) had a 
greater than 6 month history of RA (diagnosis made by a Consultant 
Rheumatologist), (b) had been seropositive for RF at some point in their disease 
course, (c) had good control of the inflammatory component of their RA, as 
demonstrated by a DAS44 ≤2.8, (d) NSAID therapy on ≥25 out of 30 days in an 
average month, (e) were on a stable DMARD dose for ≥1 month and (f) if 
prescribed prednisolone, taking ≤10mg per day. RF was chosen as an inclusion 
criteria as ACPA was not routinely being tested for in our department at time of 
study recruitment. 
To recap section 2.3.1, patients were recruited from clinics of 2 Consultant 
Rheumatologists at Glasgow Royal Infirmary. Suitable patients were either 
identified during the clinic consultation or approached staff themselves after 
viewing a recruitment poster (documented in Appendix II) in the clinic waiting 
area. If thought suitable they were invited to take part in the study and were 
provided with a Patient Information Sheet (Appendix III). Potential recruits were 
telephoned at home to invite them to a baseline assessment if they wished to 
proceed with study involvement. The study was approved by the LREC and 
patients gave written informed consent (Appendix IV).  
The original protocol which was put forward did not specify a DAS44 level in the 
inclusion or exclusion criteria. The inclusion criteria was modified to include a 
DAS44 of ≤2.8 after discussion with the LREC; the Committee were concerned 
that withdrawing NSAID from patients with a higher disease activity level may 
have been detrimental to their disease control and hence led to unacceptable 
adverse effect on quality of life. A DAS44 of ≤2.8 falls within the range for 
‘moderate’ disease activity, as previously illustrated in Table 2.5.  
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3.2.2 Exclusion criteria 
Inability to give written informed consent resulted in exclusion of participation. 
Patients with a planned operative intervention during the duration of the study 
were disqualified since it was anticipated that increased use of analgesia, for 
reasons other than inflammatory joint symptoms, may have occurred. Patients 
were excluded if specific concurrent medical problems were present that may 
have influenced the assessment of disease activity by causing an increase in 
analgesia requirements: viz fibromyalgia, severe osteoarthritis, dysmenorrhoea 
and menorrhagia.  
 
3.3 SAFETY AND MEDICATION DOCUMENTATION 
3.3.1 Safety 
Any adverse event, including the onset of a new illness and the exacerbation of 
pre-existing conditions were reported and documented in study notes and in 
medical case records: nature of event, start and stop dates, severity, 
relationship to intervention and outcome. Any serious adverse event such as 
death, life-threatening adverse event or significant disability or incapacity was 
to be notified to the Chief Investigator within 24 hours. This would then be 
discussed with the local Ethics team. Planned surgery or hospitalisation, agreed 
upon before inclusion in the study, was not classified as a serious adverse event. 
We followed the local recommendations for increasing doses and monitoring of 
DMARD therapy. Significantly abnormal laboratory value(s), which are seen on 
occasion with standard DMARD dose escalation, were documented and acted 
upon as clinically appropriate.  Possible interventions included DMARD dose 
reduction, DMARD being withheld for a period of time and withdrawal of therapy 
altogether.  
3.3.2 Medication documentation 
At baseline, the patient’s full list of prescribed medications and any other 
supplements was documented. They were then asked to stop taking their 
prescribed NSAID. This was an abrupt cessation of treatment; no tapering of 
dose was advised. The patient’s GP was contacted by letter to confirm the 
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above intervention and asked not to prescribe NSAID for the duration of the 12-
week study period. The patients themselves were asked not to purchase or take 
over-the-counter NSAID from a pharmacy; this was made clear in the Patient 
Information Sheet. They were reviewed at 6 and 12 weeks and were able to 
make telephone contact with the study physician or nurse for further advice if 
required between visits. A formal additional review could be undertaken if 
appropriate. Patients were continued on all pre-existing DMARD, anti-TNF, 
analgesic medication plus any established prednisolone therapy.  
3.3.3 Escalation of analgesia and DMARD therapy 
The regimen for escalation of other therapies, if required for increase in RA 
disease activity or increase in pain, was as noted below: 
Step 1 
Increase of a peripherally acting or codeine-based analgesic to a maximum 
tolerated dose (paracetamol could be used in combination with dihydrocodeine 
or tramadol, compound agents such as co-codamol could only be used 
individually): 
• Paracetamol 1g - 4 times daily 
• Co-Codamol 8/500 - 8 tablets daily 
• Co-Codamol 30/500 - 8 tablets daily 
• Co-Dydramol 10/500 - 8 tablets daily 
• Dihydrocodeine 30-60mg - 4 times daily 
• Tramadol 50-100mg - 4 times daily 
Step 2 
Corticosteroids could be given by one of two routes; IM injection for a 
generalised flare, e.g. 80mg of triamcinolone acetonide (Kenalog®), or IA 
injection of a symptomatic swollen joint unless it had been injected in the 
previous 3 months, e.g. 5-40mg of triamcinolone acetonide: the choice of dose 
depended on the size of the inflamed joint. The method of corticosteroid 
administration was discussed between physician and patient. A maximum of 3 
joints could be injected per visit, to a maximum total dose of 120mg 
triamcinolone acetonide.  
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Step 3 
Depending on the initial therapy, DMARD therapy was optimised as outlined: 
• Methotrexate – increments of 2.5mg per week at monthly intervals to a 
maximum dose of 25mg per week 
• Sulfasalazine – increments of 500mg weekly to a maximum daily dose of 
≤4g  
• Sodium aurothiomalate (myocrisin) – increase frequency to a maximum 
dose of  50mg per week 
• Leflunomide – maximum daily dose 20mg 
• Hydroxychloroquine – maximum daily dose 400mg 
Those who failed on mono-DMARD therapy would be offered combinations of 
DMARDs which have been shown to be of benefit in clinical studies (12).  
 
3.4 STUDY ASSESSMENTS 
3.4.1 General 
Patients were seen at the Centre for Rheumatic Diseases at Glasgow Royal 
Infirmary by the study physician and Rheumatology Nurse Specialist acting as 
metrologist. The study duration was 12 weeks with clinical and laboratory 
assessments made at 0, 6 and 12 weeks. Patients were given the option of 
contacting the study team at any point for advice and given the opportunity to 
drop-out at any time.  
At the baseline assessment written informed consent was obtained from the 
patient if entry criteria were met. Current medication, relevant past medical 
history, alcohol consumption and smoking status were documented. DAS44 was 
calculated on the basis of RAI, swollen joint count, patient global assessment 
(VAS / 100mm) and ESR, as detailed in Section 2.4.1. BP, height, weight, ESR 
and renal function were recorded. Additionally, SF-12 questionnaire was 
completed (as detailed in Section 2.5.1). 
At 6 and 12-week assessments the following measurements were recorded: SF-
12 questionnaire, DAS44, ESR, renal function, BP and updated medication list. 
The patients’ analgesia diary, completed over the preceding 6 weeks was 
139 
 
reviewed. Intervention as deemed necessary could be performed at this stage 
(IM or IA steroid injection, escalation of analgesia and / or alteration of DMARD 
therapy).  
3.4.2 Blood pressure recordings  
An A&D digital BP monitor (model UA-767) was utilised throughout the study; 
this was a BHS approved monitor. A standard adult cuff (size 22-32cm) was used 
along with this. The BHS guidelines for the measurement of BP using an digital 
monitor were followed (405) (406). Firstly, the patient was seated in a quiet 
room for at least 5 minutes; relaxed, not speaking or moving. The patient’s arm 
was supported at the level of the heart and any tight clothing constricting the 
arm was removed. The BP cuff was placed around the patient’s upper arm with 
the indicator mark on the cuff over the brachial artery – the bladder encircling 
at least 80% of the arm but not exceeding more than 100%. At the baseline visit, 
BP was tested in both arms. The arm with the highest reading was recorded. 
That arm was then used in all subsequent measurements for the patient. BP 
monitoring was repeated 3 times and the average of the 3 readings 
documented.  
3.4.3 Other documentation 
BMI, defined as weight (kg) divided by the square of height (m2) was recorded.  
Upper GI symptoms over the preceding 6 weeks were documented as: (a) nil, (b) 
occasional, (c) regular or (d) daily.  
Average alcohol intake was documented as: (a) nil, (b) 1-10 units per week, (c) 
11-20 units per week or (d) >21 units per week.  
Current dietary olive oil use and supplementary fish oil use was documented.  
Two descriptive scores of deprivation were calculated and documented for each 
participant: Carstairs Index (376) and SIMD (377) (407). Deprivation was 
documented in part to assess whether this contributed to any difference in CV 
risk factors. 
 
 
140 
 
3.5 STATISTICAL METHODS 
SPSS version 15.0 software was used for statistical analysis. As outlined in 
Section 3.2, no specific power calculations were carried out. Wilcoxon signed-
rank test was used as a non-parametric hypothesis test to compare two related 
results (e.g. baseline and 6 weeks, baseline and 12 weeks, 6 and 12 weeks) to 
assess whether their mean ranks differed. Statistical significance was set as a p-
value of <0.05 (see also Section 2.9 for additional statistical information).  
 
3.6 RESULTS 
3.6.1 Patient recruitment 
Seventy-five patients expressed an initial interest in participating in the study or 
were approached by medical staff. Twenty-three were not willing to participate 
for reasons which included subsequent loss of interest in the study and 
difficulties coming up to the hospital unit for the study visits. Twenty-two did 
not meet inclusion criteria for reasons which included a higher DAS than allowed 
by inclusion criteria or too infrequent use of NSAID. A consort diagram 
illustrating recruitment is documented, Figure 3.1. All 30 patients who were 
recruited completed the 12-week intervention period.  
 
Figure 3.1 – NSAID withdrawal study consort diagram  
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3.6.2 Study demographics 
Of the 30 patients recruited to our cohort, 27% were male (n=8). The mean age 
of the patient cohort was 56.9 years (range 33-73 years), comparable to and 
typical of our clinic population. The median disease duration for the whole 
group was 11 years (range 1-40 years). The majority of recruited patients were 
towards the deprived end of the spectrum: median SIMD for the whole group 
32.42 and 90% of the patients were in Carstairs group 3 or higher, as detailed in 
Table 3.1.  
 
Table 3.1 – Deprivation scores of study participants  
 
Deprivation Score 
 
All (n=30) 
 
Male (n=8) 
 
Female (n=22) 
 
Carstairs groupings 
1 & 2 
 
 
10% 
 
 
25% 
 
 
4% 
3, 4, 5 50% 37.5% 55% 
6 & 7 40% 37.5% 41% 
 
Median SIMD               
(and range) 
 
32.42 
(2.92-76.1) 
 
33.995 
(2.92-75.51) 
 
32.415 
(4.4-76.1) 
Where Carstairs group 1 is the least deprived and Carstairs group 7 the most 
deprived 
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3.6.2.1 Alcohol consumption  
A question about alcohol intake was included as a general study demographic as 
it was felt that there may be implications on GI symptoms depending on amount 
consumed. Alcohol intake was more than 20 units per week in only a small 
proportion of participants (<10%), Figure 3.2. The majority of female 
participants did not drink any alcohol.  
 
Figure 3.2 – Alcohol consumption of study participants 
 
 
3.6.3 Drug therapy at baseline 
All patients were taking regular prescribed NSAID and this met study inclusion 
criteria; different preparations prescribed are documented in Table 3.2. 
Etodolac was the most frequently taken prescribed anti-inflammatory and this is 
discussed further in Section 3.7.2.1. The only ‘true’ COX2 inhibitor taken by 
patients recruited to the study was etoricoxib, taken by only 1 female. 
 
0%
10%
20%
30%
40%
50%
60%
70%
0 units 1-10 units 11-20 units >21 units
Units of alcohol consumed per week 
All
Male
Female
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Table 3.2 – Baseline anti-inflammatory therapy prior to study inclusion 
  
All (n=30) 
 
Male (n=8) 
 
Female (n=22) 
 
Anti-inflammatory 
use 
 
Diclofenac 
Etodolac 
Etoricoxib 
Meloxicam 
Nabumetone 
Naproxen 
 
100% 
 
 
10% (n=3) 
60% (n=18) 
3% (n=1) 
10% (n=3) 
10% (n=3) 
7% (n=2) 
 
100% 
 
 
12.5% (n=1) 
87.5% (n=7) 
0 
0 
0 
0 
 
100% 
 
 
9% (n=2) 
50% (n=11) 
4% (n=1) 
14% (n=3) 
14% (n=3) 
9% (n=2) 
 
Only 1 patient was prescribed prednisolone before study recruitment, at a dose 
of 2.5mg per day. The dose of prednisolone was maintained at 2.5mg per day 
throughout study duration. Seven patients reported regular fish oil supplement 
consumption (5 males and 2 females).  
Table 3.3 documents DMARD and biologic prescription of the study cohort. The 
median prescribed dose of methotrexate at study enrolment was 20mg per 
week; 21.25mg per week for males and 15mg per week for females. The median 
prescribed dose of sulfasalazine at study enrolment was 2.5g per day; 2.75g per 
day for males and 2g per day for females. Over 50% of study participants were 
prescribed combination DMARD therapy, again reflective of routine practice 
within the unit. All patients treated with gold received IM sodium 
aurothiomalate.  
Of the 4 patients prescribed anti-TNF therapy, 3 were co-prescribed triple 
DMARD combination (methotrexate, sulfasalazine and hydroxychloroquine) and 
one co- prescribed methotrexate alone; all 4 of these patients were taking 
≥20mg methotrexate per week. Of the anti-TNF drugs used, adalimumab was 
the commonest. None were prescribed etanercept and there were no other 
biologic therapies, such as rituximab, being used. 
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Table 3.3 – Disease modifying therapy prior to study inclusion 
  
All 
 
 
Male 
 
Female 
 
 
Single DMARD 
 
MTX 
SSZ 
LEF 
 
33.3% (n=10) 
 
7% (n=2) 
23% (n=7) 
3% (n=1) 
 
50% (n=4) 
 
0 
37.5% (n=3) 
12.5% (n=1) 
 
27% (n=6) 
 
9% (n=2) 
18% (n=4) 
0 
 
 
Combination 
DMARD 
 
MTX+SSZ 
SSZ+HCQ 
MTX+HCQ 
MTX+HCQ+SSZ 
MTX+gold 
 
53.3% (n=16) 
 
 
23% (n=7) 
3% (n=1) 
10% (n=3) 
10% (n=3) 
7% (n=2) 
 
25% (n=2) 
 
 
25% (n=2) 
0 
0 
0 
0 
 
64% (n=14) 
 
 
23% (n=5) 
4.5% (n=1) 
14% (n=3) 
14% (n=3) 
9% (n=2) 
 
 
Anti-TNF 
 
Adalimumab 
Infliximab 
 
13.3% (n=4) 
 
10% (n=3) 
3% (n=1) 
 
25% (n=2) 
 
25% (n=2) 
0 
 
9% (n=2) 
 
4.5% (n=1) 
4.5% (n=1) 
 
HCQ = hydroxychloroquine, LEF = leflunomide, MTX = methotrexate,               
SSZ = sulfasalazine  
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3.6.4 Baseline cardiovascular demographics and risk factors  
Table 3.4 documents the baseline CV information recorded at study 
commencement. Of the study participants, 20% were current smokers. Of the 
female participants, 18% were pre-menopausal and 82% post-menopausal. The 
median BMI for both males and females would be classified as “overweight” as it 
falls in the range 25-29.9 kg/m2. 
Median BP recording for the whole group was 141/87mmHg. According to the 
BHS classification guidelines (Table 1.6, (91)) this would be categorised as a 
Grade I (mild) hypertension for systolic BP reading and a high-normal diastolic 
BP reading. The range of both systolic and diastolic BP readings was from 
optimal to Grade III systolic and optimal to Grade II diastolic. Males had a higher 
median systolic BP than females, though females had a greater range of 
readings.  
The median TC was elevated at >5mmol/l. Median HDL-cholesterol was 
surprisingly favourable at >1mmol/l, resulting in a TC: HDL ratio of <4 (except in 
males). Only 20% of the whole group were prescribed statins.  
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Table 3.4 – Cardiovascular demographics 
  
All (n=30) 
 
Male (n=8) 
 
Female (n=22) 
 
 
Age  
years 
 
60 
(33-73) 
 
62 
(53-73) 
 
55 
(33-70) 
 
Current smoker 
 
 
20% (n=6) 
 
25% (n=2) 
 
18% (n=4) 
Systolic BP 
mmHg 
141 
(109-190) 
143 
(128-156) 
139.5 
(109-190) 
Diastolic BP 
mmHg 
87 
(72-103) 
85 
(75-103) 
87 
(72-101) 
Hypertension 
diagnosis 
50% (n=15) 75% (n=6) 41% (n=9) 
 
Total cholesterol 
mmol/l 
 
5.15 
(3.4-7.4) 
 
5.45 
(3.4-6.2) 
 
4.9 
(3.4-7.4) 
HDL cholesterol 
mmol/l 
1.4 
(0.8-3.2) 
1.2 
(0.9-1.7) 
1.5 
(0.8-3.2) 
TC:HDL ratio 
 
3.4 
(1.0-5.6) 
4.25 
(2.5-6) 
3.2 
(1-5.1) 
Triglycerides 
mmol/l 
1.05 
(0.5-3.6) 
1.5 
(0.8-2.3) 
1.0 
(0.5-3.6) 
Statin therapy 
 
20% (n=6) 37.5% (n=3) 13.6% (n=3) 
 
Weight 
kg 
73.5 
(53-117) 
83 
(70-117) 
68 
(53-98) 
BMI 
kg/m2 
26.57 
(22.04-44.74) 
27.40 
(22.84-33.1) 
26.56 
(22.04-44.74) 
 
Medians (and ranges) shown 
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3.6.5 Primary outcome 
3.6.5.1 Overall DAS44 
There was no significant difference in DAS44 from baseline to 12 weeks, Table 
3.5. A slight upwards trend was seen between baseline and 6 weeks in the 
overall group and in females. Comparing 6 and 12 week DAS44, a downwards 
trend was seen which was significant (p=0.033 whole group, p=0.012 females). 
The median baseline DAS44 readings would classify the patients as having low 
disease activity (as previously described in Table 2.5). In the overall cohort at 
baseline, 7 were in remission (DAS44 <1.6), 16 had low disease activity (DAS44 
1.6-2.4) and 7 moderate disease activity (DAS44 2.4-3.6); the inclusion criteria 
stipulated a DAS44 ≤2.8. By 12 weeks, 11 were in remission, 12 had low disease 
activity and 7 moderate disease activity. 
There was no overall change in DAS44 components (ESR, swollen joint count, RAI 
or patient GH) over the 12 week intervention period and this will be discussed 
further in Sections 3.6.5.2-3.6.5.5.  
 
Table 3.5 – DAS44 results 
  
Baseline 
 
6 weeks 
 
12 weeks 
Wilcoxon  
signed-rank test 
 
DAS44 
All 
 
2.08 
(0.26-2.79) 
 
2.19 
(0.65-5.08) 
 
1.79 
(0.76-2.05) 
 
0-6 weeks p=0.130 
0-12 weeks p=0.781 
6-12 weeks p=0.033 
 
DAS44 
Male 
 
1.70 
(0.26-2.79) 
 
1.52 
(0.65-3.25) 
 
1.61 
(0.76-2.78) 
 
0-6 weeks p=0.674 
0-12 weeks p=0.401 
6-12 weeks p=0.779 
 
DAS44 
Female 
 
2.13 
(0.94-2.63) 
 
2.35 
(1.09-5.08) 
 
1.88 
(0.76-2.95) 
 
0-6 weeks p=0.110 
0-12 weeks p=0.405 
6-12 weeks p=0.012 
Medians (and ranges) shown 
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3.6.5.2 Components of DAS44 – ESR  
ESR levels were low overall and remained so throughout the study; despite the 
anti-inflammatory intervention, Table 3.6. There was only a slight increase in 
ESR in the female participants between baseline and 6 weeks; this was only by 
1.5mm/1st hour (p=0.039) and by 12 weeks had returned to baseline values. 
 
Table 3.6 – ESR  
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
ESR 
mm/1st hour 
All 
 
5 
(2-35) 
 
8 
(2-51) 
 
7 
(2-38) 
 
0-6 weeks p=0.104 
0-12 weeks p=0.152 
6-12 weeks p=0.613 
 
ESR 
mm/1st hour 
Male 
 
5 
(2-35) 
 
5 
(2-22) 
 
5 
(2-33) 
 
0-6 weeks p=0.684 
0-12 weeks p=0.671 
6-12 weeks p=0.399 
 
ESR 
mm/1st hour 
Female 
 
7 
(2-31) 
 
8.5 
(2-51) 
 
7 
(2-38) 
 
0-6 weeks p=0.039 
0-12 weeks p=0.163 
6-12 weeks p=0.280 
 
Medians (and ranges) shown 
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3.6.5.3 Components of DAS44 – Ritchie Articular Index 
There was no significant difference in RAI by the 12-week point. Although the 
scores in the cohort overall increased marginally from baseline to 6 weeks, this 
was not statistically significant, Table 3.7. Females had an increase in this 
tender joint index from baseline to 6 weeks (p=0.039); however by 12 weeks 
this had returned to baseline levels (difference from 6-12 weeks, p=0.049). 
 
Table 3.7 – Ritchie Articular Index 
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
RAI 
All 
 
2.5 
(0-10) 
 
4 
(0-17) 
 
2 
(0-15) 
 
0-6 weeks p=0.234 
0-12 weeks p=0.422 
6-12 weeks p=0.062 
 
RAI 
Male 
 
2 
(0-10) 
 
1 
(0-15) 
 
1 
(0-15) 
 
0-6 weeks p=0.730 
0-12 weeks p=0.785 
6-12 weeks p=1 
 
RAI 
Female 
 
3 
(0-8) 
 
4.5 
(0-17) 
 
2 
(0-7) 
 
0-6 weeks p=0.039 
0-12 weeks p=0.403 
6-12 weeks p=0.049 
 
Medians (and ranges) shown  
RAI = Ritchie articular index 
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3.6.5.4 Components of DAS44 – 44 swollen joint count 
There was no significant difference in 44-swollen joint count by the 12-week 
point. There was a non-significant rise in median number of swollen joints from 
4 to 5 between baseline and 6 weeks in the whole group, Table 3.8. Analysis of 
the female group confirmed that this was just significant (p=0.042). This was 
followed by a 2-joint decrease from 6 to 12 weeks (p=0.025) in the whole group. 
 
Table 3.8 – Swollen joint count 
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
Swollen 
joints 
All 
 
4 
(0-10) 
 
5 
(0-16) 
 
3 
(0-9) 
 
0-6 weeks p=0.098 
0-12 weeks p=0.489 
6-12 weeks p=0.025 
 
Swollen 
joints 
Male 
 
2 
(0-5) 
 
2 
(0-6) 
 
3 
(0-7) 
 
0-6 weeks p=0.730 
0-12 weeks p=0.863 
6-12 weeks p=0.059 
 
Swollen 
joints 
Female 
 
4 
(0-10) 
 
5 
(2-16) 
 
4 
(1-9) 
 
0-6 weeks p=0.042 
0-12 weeks p=0.362 
6-12 weeks p=0.07 
 
Medians (and ranges) shown 
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3.6.5.5 Components of DAS44 – Patient global health assessment 
There was no significant difference in patient GH from baseline to the 12-week 
point and by then median GH assessment score had fallen to less than baseline 
levels in all 3 groups. Table 3.9 details a rise in patient GH assessment by a 
median of 14 points in the overall group by 6 weeks (p=0.009) and by 20 points 
in the female group (p=0.038). From 6 to 12 weeks there was a significant 
reduction in the whole and female groups, with patient GH scores falling by a 
median of 18 and 23 points respectively.  
 
Table 3.9 – Patient global health assessment   
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
PGHA 
VAS/100mm 
All 
 
29 
(4-61) 
 
43 
(7-77) 
 
25 
(1-55) 
 
0-6 weeks p=0.009 
0-12 weeks p=0.592 
6-12 weeks p=0.003 
 
PGHA 
VAS/100mm 
Male 
 
32 
(4-45) 
 
32 
(7-70) 
 
31 
(14-55) 
 
0-6 weeks p=0.093 
0-12 weeks p=0.042 
6-12 weeks p=0.674 
 
PGHA 
VAS/100mm 
Female 
 
27 
(4-61) 
 
47 
(11-77) 
 
24 
(1-55) 
 
0-6 weeks p=0.038 
0-12 weeks p=0.733 
6-12 weeks p=0.001 
 
PGHA = patient global health assessment. VAS = visual analogue score.           
mm = millimetres 
Medians (and ranges) shown 
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3.6.5.6 Components of DAS44 – pain score  
There was no significant difference in pain score from baseline to 12 weeks. In 
the overall group, a significant increase in pain score was seen from baseline to 
6 weeks, in addition to the separate analysis for females (p values <0.0001 and 
0.001 respectively), Table 3.10. This reflects a median score rise of 17 points in 
the overall group and 20 points in the female group. However, the rise in male 
pain score was only by 1 point, yet was still significant (p=0.035). A subsequent 
significant fall in pain score was then seen from 6 to 12 week assessments 
(p=0.008). What remains uncertain is the impact of the therapeutic 
interventions given (discussed later in Sections 3.6.11 and 3.7) and whether they 
were implicated in the large rebound in figures.  
 
Table 3.10 – Pain score    
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
Pain score 
VAS/100mm 
All 
 
20 
(4-53) 
 
37 
(7-72) 
 
25 
(1-72) 
 
0-6 weeks p<0.001 
0-12 weeks p=0.118 
6-12 weeks p=0.008 
 
Pain score 
VAS/100mm 
Male 
 
32 
(4-51) 
 
33 
(7-66) 
 
34 
(6-70) 
 
0-6 weeks p=0.035 
0-12 weeks p=0.123 
6-12 weeks p=0.574 
 
Pain score 
VAS/100mm 
Female 
 
18 
(4-53) 
 
38 
(8-72) 
 
23 
(1-72) 
 
0-6 weeks p=0.001 
0-12 weeks p=0.436 
6-12 weeks p=0.002 
 
VAS = visual analogue score, mm = millimetres 
Medians (and ranges) shown 
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3.6.6 Secondary outcome – blood pressure 
A significant reduction in systolic BP was observed with anti-inflammatory 
withdrawal by 7mmHg from baseline to 12 weeks (p=0.037), Table 3.11. 
Maximum systolic BP recordings fell over time – at baseline, maximal reading 
was 190mmHg and by 6 and 12 weeks this was 170 and 171mmHg respectively. 
However, no significant change in diastolic BP was recorded, Table 3.12.  
Twelve patients were on antihypertensive therapy at study commencement (3 
mono-therapy and 9 combination therapy). Those on anti-hypertensives showed 
a greater reduction in systolic BP than those who were not prescribed this 
therapy but this change was, however, not significant (p=0.071).  
Changes in systolic BP over the course of study participation for each individual 
participant are documented in Figure 3.3. Twelve patients demonstrated the 
largest drop in systolic BP from baseline to 6 weeks (numbers 
2,3,6,9,13,15,17,18,19,21,24 and 25). Of these, 7 were on anti-hypertensive 
treatments (numbers 2,3,13,15,17,18 and 24). 
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Table 3.11 – Changes in systolic blood pressure 
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
Systolic BP 
mmHg 
All (n=30) 
 
141 
(109-190) 
 
136 
(104-170) 
 
133.5 
(106-171) 
 
0-6 weeks p=0.025 
0-12 weeks p=0.037 
6-12 weeks p=0.888 
 
Systolic BP 
mmHg 
Male (n=8) 
 
143 
(128-156) 
 
133 
(123-151) 
 
134 
(118-169) 
 
0-6 weeks p=0.123 
0-12 weeks p=0.674 
6-12 weeks p=0.674 
 
Systolic BP 
mmHg 
Female (n=22) 
 
139.5 
(109-190) 
 
140 
(104-170) 
 
134 
(106-171) 
 
0-6 weeks p=0.107 
0-12 weeks p=0.015 
6-12 weeks p=0.626 
 
BP = blood pressure, mmHg = millimetres of mercury 
Medians (and ranges) shown 
 
 
 
 
 
 
 
 
 
 
 
155 
 
Table 3.12 – Changes in diastolic blood pressure 
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
Diastolic BP 
mmHg 
All (n=30) 
 
87 
(72-103) 
 
85 
(66-99) 
 
84 
(72-105) 
 
0-6 weeks p=0.015 
0-12 weeks p=0.245 
6-12 weeks p=0.319 
 
Diastolic BP 
mmHg 
Male (n=8) 
 
85 
(75-103) 
 
86 
(71-92) 
 
85 
(76-98) 
 
0-6 weeks p=0.207 
0-12 weeks p=0.888 
6-12 weeks p=0.723 
 
Diastolic BP 
mmHg 
Female (n=22) 
 
87 
(72-101) 
 
84 
(66-99) 
 
83 
(72-105) 
 
0-6 weeks p=0.027 
0-12 weeks p=0.144 
6-12 weeks p=0.414 
 
BP = blood pressure, mmHg = millimetres of mercury 
Medians (and ranges) shown 
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Figure 3.3 – Individual participants and changes in systolic blood pressure over course of study 
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3.6.7 Secondary outcome – gastrointestinal symptoms 
At 63%, the majority of patients did not report any GI symptoms at baseline, 
Figure 3.4. This figure increased to 77% at 6 and 12 weeks. The number of 
patients reporting regular or daily upper GI symptoms (e.g. reflux, heartburn or 
indigestion) fell from 27% at baseline to 16% at 6 weeks and 14% at 12 weeks.  
 
Figure 3.4 – Gastrointestinal symptoms 
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3.6.8 Secondary outcome – renal function 
Males had a higher median baseline urea (7.8 mmol/l) compared with females 
(5.45 mmol/l), data not shown. A significant reduction in urea was seen within 
the whole group from baseline (5.95 mmol/l) to 12 weeks (4.8 mmol/l), 
p=0.018. No significant change in eGFR was shown (Table 3.13). 
 
Table 3.13 – Changes in eGFR 
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
eGFR 
ml/min/1.73m2 
All 
 
71.5 
(35-94) 
 
73.5 
(41-111) 
 
72.5 
(36-93) 
 
0-6 weeks p=0.246 
0-12 weeks p=0.284 
6-12 weeks p=0.801 
 
eGFR 
ml/min/1.73m2 
Male 
 
72 
(65-83) 
 
75.5 
(68-81) 
 
72.5 
(71-87) 
 
0-6 weeks p=0.438 
0-12 weeks p=0.041 
6-12 weeks p=0.595 
 
eGFR 
ml/min/1.73m2 
Female 
 
71.5 
(35-94) 
 
73 
(41-111) 
 
70 
(36-93) 
 
0-6 weeks p=0.475 
0-12 weeks p=0.751 
6-12 weeks p=0.972 
Medians (and ranges) shown 
eGFR as calculated by the abbreviated MDRD equation (403) 
 
3.6.9 Secondary outcome – functional assessment 
The results detailed in Table 3.14 show that at baseline, the median physical 
component summary score below 50 and therefore below average physical 
function. The median mental component summary scores were all above 
average as shown in Table 3.15. There was no significant change in physical or 
mental scores from baseline to 12 weeks. There was a non-significant trend 
towards a reduction in physical component score from 0 to 6 weeks. By 12 
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weeks there was a significant improvement in this parameter in all groups to a 
median score higher than baseline and closer towards an average physical 
function score expected for the general population.  
 
Table 3.14 – SF-12: physical component  
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
PCS 
All 
 
37.4 
(24.5-56.6) 
 
34.3 
(24.5-55.1) 
 
40.25 
(31.6-56.7) 
 
0-6 weeks p=0.449 
0-12 weeks p=0.30 
6-12 weeks p=0.001 
 
PCS 
Male 
 
37.35 
(25.2-46.6) 
 
32.7 
(28-44.7) 
 
38.75 
(33.8-43.1) 
 
0-6 weeks p=0.401 
0-12 weeks p=0.208 
6-12 weeks p=0.017 
 
PCS 
Female 
 
37.4 
(24.5-56.6) 
 
37.2 
(24.5-55.1) 
 
40.45 
(31.6-56.7) 
 
0-6 weeks p=0.677 
0-12 weeks p=0.072 
6-12 weeks p=0.012 
 
PCS = physical component summary                          Medians (and ranges) shown 
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Table 3.15 – SF-12: mental component  
  
Baseline 
 
6 weeks 
 
12 weeks 
 
Wilcoxon 
 
MCS 
All 
 
54.35 
(30.4-66.5) 
 
54 
(27.1-63.4) 
 
54.5 
(38.4-66.1) 
 
0-6 weeks p=0.682 
0-12 weeks p=0.478 
6-12 weeks p=0.673 
 
MCS 
Male 
 
55.7 
(30.4-60.4) 
 
58.1 
(38.1-61.3) 
 
50.3 
(38.4-62.2) 
 
0-6 weeks p=0.028 
0-12 weeks p=0.779 
6-12 weeks p=0.161 
 
MCS 
Female 
 
54.05 
(37.9-66.5) 
 
52.8 
(27.1-63.4) 
 
54.75 
(40.1-66.1) 
 
0-6 weeks p=0.543 
0-12 weeks p=0.638 
6-12 weeks p=0.192 
 
MCS = mental component summary                           Medians (and ranges) shown 
 
3.6.10 Safety and tolerability 
All 30 patients completed the study without requiring re-introduction of NSAID. 
No adverse effects from routine DMARD or anti-TNF therapy were documented. 
3.6.11 Interventions required and corticosteroid administration  
All patients kept a diary in which they recorded on how many days they needed 
to take non-NSAID analgesia. In the 42 days between visits 1 and 2, and visits 2 
and 3, the patients took analgesia on a mean of 12 and 10 days (respectively).    
The number of steroid injections administered and any changes in DMARD were 
also recorded and are displayed in Figure 3.5. Seven IM and 6 IA steroid 
injections were administered to 11 patients from a total of 60 follow-up visits.  
At the 6 week visit, 6 IM and 3 IA steroid injections were given. At the 12 week 
visit, 1 IM and 3 IA steroid injections were given. Conversely, at the 6 and 12 
week visits, 70% and 87% respectively did not require any intervention.  
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Figure 3.5 – Interventions required 
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3.7.1 Demographics 
3.7.1.1 General  
27% of the recruited cohort were male, a higher proportion than is often seen in 
RA investigatory cohorts. In previously published general RA studies, the male 
participation rates have usually been lower than female; the MASCOT study had 
a male population of 22% of total (408). The significance of this difference is 
uncertain and could be interpreted as a patient’s interest to participate in a 
study where less rather than more medication is taken.  
The high median SIMD and Carstairs groupings reflected the population 
demographics of the recruiting hospital.  The low alcohol intake statistics are 
likely in part to reflect advice given about minimising alcohol consumption when 
taking DMARD therapy, especially methotrexate.  
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3.7.1.2 Cardiovascular  
47% were ever smokers (data not shown) and 20% current smokers – this mirrors 
average Scottish national figures as previously discussed in Section 1.4 (64). The 
post-menopausal status of over 80% of the female participants reflected the 
median age of 55 years. The hormonal changes after a female passes through 
the menopause, namely oestrogen withdrawal, is a documented risk factor for 
CVD – oestrogen reduction is said to have a unfavourable effect on CV function 
and associated metabolism  (409). The prescription of statins in only 20% of the 
cohort is perhaps a surprisingly low figure given the recent emphasis on 
monitoring and addressing this CV risk factor in the primary care setting; 
however the lower median age of the female participants may partly explain 
this lower figure.  
3.7.2 Drug therapy 
3.7.2.1 Anti-inflammatories 
60% of the total group were prescribed etodolac as their anti-inflammatory. This 
is reflective of the prescribing practice of the Centre for Rheumatic Diseases at 
Glasgow Royal Infirmary at the time of study recruitment. Etodolac is an 
interesting anti-inflammatory as while it is classed as a traditional non-steroidal 
anti-inflammatory; it does have significant COX2 inhibition properties including 
less GI side-effects than other non-selective NSAID (410) (411) (412) (413) (414).  
3.7.2.2 DMARD 
Methotrexate use was at the level of 70% in this cohort, either as mono-therapy 
or in combination with another DMARD and / or anti-TNF. The median dose for 
the whole group was 20mg per week (as discussed in section 3.x) with the range 
being 12.5-25mg per week in males and 5-27.5mg per week. The higher upper 
limit of the ranges does reflect the use of this DMARD at the time of study 
recruitment, where doses in excess of 25mg per week were occasionally used 
within the department: of note is that as per Section 3.3.3 (Step 3) we did not 
escalate beyond 25mg per week if there was loss of disease control, however, 
the patient prescribed 27.5mg per week was already established on this dose 
and it was not increased further during the study. Additionally, the 2.5mg per 
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week per month dose escalation of methotrexate would now be considered 
unnecessarily slow, but again reflects policy of the unit at that time. 
Sulfasalzine was also prescribed in 70% of the cohort as mono-therapy or in 
combination with another DMARD and / or anti-TNF at the time of recruitment. 
Currently within the unit, methotrexate would be used preferentially to 
sulfasalazine, especially as mono-therapy.  
3.7.3 Primary outcome 
There was no significant difference in DAS44 from baseline (median 2.08) to 12 
weeks (median 1.79). The individual DAS44 components (ESR, RAI, 44-swollen 
joint count and patient GH score) did not change between these 2 time-points. 
When the 6-week results are looked at, there was often a rise seen at this point 
only which then fell back to baseline values by 12 weeks.  
The low overall ESR levels were to be expected in a group with a well-controlled 
inflammatory component of their disease. While the female cohort showed a 
significant increase in median patient GH from baseline to 6 weeks, 
interestingly, the male group showed no change. This may be due to a higher 
median baseline DAS44 score in the females, reflecting a higher level of disease 
activity in our female compared to our male cohort (2.13 versus 1.70). It is 
possible that at the mid-way visit at 6 weeks, our discussions regarding use of 
analgesia and review of the individual’s progress went some way to reassure 
them and altered the patient reported scores of GH and pain.  
3.7.4 Secondary outcomes 
3.7.4.1 Blood pressure 
There was a 5mmHg reduction in systolic BP (p=0.037) from baseline to 6 weeks 
and a 7mmHg reduction in systolic BP from baseline to 12 weeks (p=0.025); no 
change in diastolic BP was seen. It is not certain whether anti-inflammatory 
drug withdrawal alone contributed to this impressive reduction. A contributing 
factor may have been patients becoming accustomed to the study environment 
in the 6 and 12 week visits, feeling more relaxed and subsequently lower BP 
recordings documented. An increase in median pain score at 6 weeks was 
discussed in Section 3.6.5.6; one may have expected this clinical feature to be 
associated with a higher BP reading in the absence of any other intervention. 
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3.7.4.2 Gastrointestinal symptoms 
By 12 weeks, the percentage of patients reporting GI symptoms had reduced 
from 37% to 23%. The lesser reporting of clinically noticeable GI irritation, after 
withdrawal of anti-inflammatory medication mirrors clinical studies, as 
previously discussed in Section 1.7.7.   
3.7.4.3 Renal function 
The relationship between anti-inflammatory use and renal function has been 
outlined previously in Section 1.7.6. The data presented here varies slightly 
from previously published work where the effect of NSAID withdrawal on renal 
function was studied: Unsworth et al had documented a significant reduction in 
creatinine and a trend of urea reduction, although not significant (272). The 
lack of association between urea and creatinine  / eGFR reduction in this study 
may be explained in part by the differing preparations of anti-inflammatory 
previously taken, co-prescription of medication (e.g. antihypertensives, other 
cardiac medications), state of hydration or indeed differing muscle mass or 
degree of muscle atrophy in each participant (273). We did not document the 
trend in renal function prior to study involvement.  
3.7.4.4 Functional assessment 
The below average physical function scores could easily be attributed to the 
effect RA has on the participants’ daily function due to joint disease.  The 
median disease duration of study participants was 11 years (as described in 
Section 3.6.2) and it is likely that patients had a degree of secondary 
mechanical as well as inflammatory pathology affecting their joints, in turn 
contributing to a higher physical component score. 
3.7.5 Interventions 
Unfortunately, no pre-study analgesia diary was available with which to make a 
comparison. While we asked the patients to document use of analgesia for 
musculoskeletal pain, we cannot exclude use for dysmenorrhoea, dental pain 
etc.   
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It seems unlikely that the small amount of steroids given at the 6 and 12 week 
time-points would have been sufficient to have caused the overall dramatic 
reduction in patient GH Assessment scores.  
We did see patients for symptoms that would not necessarily be attributed to 
increased activity of their RA, e.g. headache and neck pain. The patient who 
reported increased headache after anti-inflammatory withdrawal was examined 
further, appropriate investigations ordered and a neurology opinion sought (no 
significant intra-cranial abnormality was found on computed tomography scan of 
head).  
 
3.8 LIMITATIONS OF THE STUDY 
The study was open labelled, non-randomised and included only 30 subjects. 
Twelve weeks is possibly too short an interval to assess whether a more 
extended NSAID withdrawal can be achieved and maintained in the long term. 
NSAID was discontinued at study enrolment (the baseline visit) – NSAID differ in 
their half-lives and by the 6-week visit it is possible that some patients will have 
had a slower initial effect of NSAID withdrawal than others due to different 
preparations prescribed (221) (296). Any difference in this regard would have 
been eliminated by the time of 12-week review.  
There was no control arm in the study. In order for a fair assessment if we were 
to have carried out a study comparing patients continuing NSAID versus those 
whose therapy was discontinued, each ‘study patient’ would have needed to be 
matched with a ‘control’ taking the exact same preparation and dose of NSAID. 
This would have been a logistical problem. Additionally, the preparation and 
dose of DMARD or steroid would have needed to be identical also. Perhaps an 
alternative approach may have been to use the patients as their ‘own control’, 
comparing observations from before anti-inflammatory withdrawal with those 
after.  
One other proposed methodology discussed was to randomise patients to either 
continuation of NSAID or switch to placebo to induce NSAID withdrawal. This 
would have involved converting all study participants to the same NSAID prior to 
introducing placebo to half of them, or obtaining multiple matching placebos to 
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account for all of the different NSAID preparations and doses the patients were 
taking. Unfortunately due to the time, practical and financial constraints of this 
study we were unable to adopt any of these suggestions.  
Only patients with moderately active (or less) RA were enrolled. The LREC were 
opposed to our initial intention of withdrawing NSAID from patients with more 
active RA; we therefore specified in our inclusion criteria a DAS44 of ≤2.8 to 
gain approval to commence the study (see section 3.2.1). As well as recording 
DAS44 and pain scores, the additional documentation of EMS may have been 
informative as a patient-reported variable of inflammatory disease activity. 
The relationship between withdrawal of NSAID and reduction in systolic BP 
remains hypothetical. A randomised controlled trial would be helpful to clarify 
this further, but there would be inevitable difficulties of conducting such a 
study, as highlighted above. There is a possibility that the reduction in systolic 
BP may have been a routine observation over time and perhaps a more 
prolonged charting of BP pre- and post-withdrawal may have been helpful. 
There is a possibility that the participants may have become accustomed to the 
study environment during the course of their visits, with resultant relaxation 
and drop in BP. The study is too small to reliably investigate whether the BP 
changes were confined to particular levels or ranges. 
We did not have a pre-study review of whether the 13 steroid injections, 
administered at the 6-week visit, were different from the patients’ usual 
requirements. Even a medical case-note review of a set time period before 
study enrolment may not be accurate, as GPs may have given steroid injections 
in the community without our knowledge.  
With regards to change in renal function we did not document the individual’s 
state of hydration nor make any review with regards to the stability of urea or 
creatinine prior to enrolment in study.  
In broader terms, we have not been able to confirm if these patients are a true 
representation of a typical RA cohort – all were RF positive, but information on 
previous DMARD and presence of erosions is not available.  
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3.9 BENEFITS IDENTIFIED 
These are discussed further in Section 6.1.2. It is reasonable to expect that 
these results could allow the design of a larger and more comprehensive study 
to inform the management and treatment of patients with RA. This study was 
designed as a feasibility study intended to inform future work. 
The early increase in pain scores after discontinuing NSAID suggests that a 
tapered withdrawal might be associated with less of an increase in discomfort. 
Overall the intervention was well accepted by patients once enrolled; there 
were no drop-outs and all completed the 12-week intervention period without 
recommencing NSAID. Additionally, there was a maintained trend in reduction of 
reported upper GI symptoms. BP was the only CV risk factor which changed with 
this intervention. 
Despite the above limitations this is the first supportive evidence to implement 
guidance of limiting NSAID use in patients with low DAS score without adversely 
affecting their quality of life or disease control. Additionally, there was no need 
for significant additional input. We have demonstrated additional benefits on 
systolic BP control that has important implications for reducing CV risk. Future 
studies of CV risk in RA should take into account the influence of NSAID-induced 
hypertension.  
 
3.10 SUMMARY  
This study confirms that anti-inflammatory withdrawal was acceptable to and 
achievable by patients, alongside support from medical staff, at up to 12 weeks 
of follow-up. The rationale that NSAID withdrawal plus intervention would 
provide equivalent symptom control to that achieved by continuing therapy has 
been borne out by the reassuring minimal changes in DAS44 (and individual 
components) and relatively few interventions required from baseline through to 
12 weeks. There was an impressive reduction in systolic BP seen with this 
intervention which raises many interesting issues for future management of 
patients with inflammatory arthritis with regards to the advancing area of CV 
risk management. A reassuring profile of improvement in GI symptoms was also 
noted. The results of this study pose a further question, which is not able to be 
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answered within the confines of this research, which is, do patients with a low 
DAS require NSAID therapy at all?  
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CHAPTER 4 
A Pilot Study of a Mediterranean-Type Diet Intervention 
in Female Patients with Rheumatoid Arthritis 
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4.1 INTRODUCTION 
A Mediterranean-type diet has been shown to have many potential health 
benefits. These include reduction in CV risk (318) (319) (330) and improvement 
in RA disease activity (346) as previously outlined in Section 1.8. It is not clear, 
however, whether such a diet could achieve beneficial results in patients with 
RA in a true to life setting, particularly in a population with high levels of social 
deprivation such as Glasgow. It is well established that any intervention 
requiring a change in lifestyle or behaviour, especially those which may be life-
long and culturally driven, is difficult to achieve and sustain.  
 
4.2 JUSTIFICATION OF STUDY DESIGN AND PROTOCOL 
The primary outcome of the pilot study was to assess the influence of a 
Mediterranean-type diet intervention on clinical and laboratory parameters of 
RA disease activity and the CV system at 6 months. The secondary outcomes 
were to assess the influence of this diet on food intake frequencies at 3 months 
and the overall practicality to participating patients by obtaining specific 
feedback. Existing resources were targeted to be used as much as possible. 
One hundred and thirty female patients with RA aged between 30 and 70 years 
old were recruited over a 9 month period. Females were chosen rather than 
males as it was felt that recruitment to a dietary lifestyle study would have 
been quicker due to the demographics of patients served by the hospitals.  
Three hospital sites in Glasgow were used: Royal Infirmary, Southern General 
and Stobhill Hospital. These sites were chosen with the aim of recruiting 
patients from within one of the Social Inclusion Partnership areas in Glasgow, 
areas of social deprivation (384) (385).  
The study was approved by the LREC and patients gave written informed 
consent.  
4.2.1 Inclusion criteria 
Female patients aged between 30 and 70 years old with a diagnosis of RA made 
by a Consultant Rheumatologist were considered for inclusion. All were under 
the care of 1 of the 3 hospital rheumatology departments noted above and were 
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able to give written informed consent. There were no specific stipulations 
regarding RA therapy. To recap Section 2.3.2, suitable patients were either 
identified during the clinic consultation or from within multi-disciplinary team 
discussions. If thought appropriate they were invited to take part in the study 
and were provided with a Patient Information Sheet (Appendix V). Potential 
recruits were telephoned at home to invite them to a baseline assessment if 
they wished to proceed with study involvement. All recruited patients gave 
written informed consent (Appendix VI).   
4.2.2 Exclusion criteria 
Males, pregnant women or women contemplating pregnancy were excluded from 
this study. Inability to give written informed consent resulted in exclusion from 
participation in the study also.  
4.2.3 Allocation to intervention or control groups 
We aimed to recruit 180 participants but were limited to 130 within the 
constraints of the study time period. The intention had been for random 
allocation of patients to intervention and control groups. However, a major 
limiting factor of the study was the availability of the weekly cookery courses in 
a location close to the patient’s home and at a time suitable to them. 
Consequently a more pragmatic approach was necessary. This resulted in those 
able to attend on certain course dates being allocated to the intervention group 
and those unavailable on dates of programmed courses, for whatever reason, 
becoming the control group. Transport was provided in a small number of cases 
to allow easier access to classes.  
The 75 patients allocated to the intervention group attended 2 hour sessions on 
a weekly basis over a 6-week period. There was a maximum of 10 participants in 
each group to encourage interaction and promote a relaxed environment. The 
sessions were called “Get Shopping, Get Cooking” and were delivered by 
nutritionists and teaching staff from NHS Greater Glasgow’s Health Promotion 
Department. Occupational Therapy staff advised on the provision of aids for 
food preparation, primarily to help patients with impairment of hand function 
due to their arthritis. The course content included food hygiene, food storage 
and nutrition labelling. Advice was also given regarding shopping and local 
access to affordable ingredients. During the programme, activities such as blind 
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tasting and practical cooking sessions allowed a variety of different foods to be 
rated for appearance, taste and texture. Each week the participants in the 
cooking classes prepared and cooked a meal which they were then able to take 
home and share with family or friends. This hands-on cooking and discussion was 
backed-up with written information (Appendix IX and X). Each folder contained 
information on a Mediterranean-type diet, healthy eating and recipes which 
promoted the increased consumption of fruits, vegetables and legume, along 
with the substitution of saturated fat with monounsaturated fat in the form of 
olive oil or spreads containing olive oil. The cost per patient for the 6 week 
course was £84 and this was met by the Greater Glasgow Health Board’s Health 
Board Promotion Department.  
The 55 patients in the control group received readily available written 
information on healthy eating only and did not attend the cookery course 
(Appendix IX and X). 
 
4.3 SAFETY AND MEDICATION DOCUMENTATION  
Any adverse event, including the onset of a new illness and the exacerbation of 
pre-existing conditions were to be reported and documented in study notes and 
in medical case records: nature of event, start and stop dates, severity, 
relationship to intervention and outcome. Any serious adverse event such as 
death, life-threatening adverse event or significant disability or incapacity was 
to be notified to the Chief Investigator within 24 hours. This would then be 
discussed with the local Ethics team. Planned surgery or hospitalisation, agreed 
upon before inclusion in the study, was not classified as a serious adverse event. 
Any increase in DMARD dose or change in therapy was allowed to be undertaken 
by any Rheumatologist routinely reviewing the patient in clinic. Local 
recommendations for increasing doses and monitoring of DMARD therapy were 
adhered to. If significantly abnormal laboratory values occurred (which are seen 
on occasion with standard DMARD dose escalation) they were documented and 
acted upon as felt appropriate.  Possible subsequent interventions included 
DMARD dose reduction, DMARD being withheld for a period of time and 
withdrawal of therapy altogether.  
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4.4 STUDY ASSESSMENTS 
Patients in both groups were assessed on four occasions: screening, baseline 
(=0), 3 and 6 months. At the screening visit, the study was explained to the 
patient. Printed information previously provided was reviewed and written 
informed consent obtained. Food diaries were issued and their completion 
discussed. Patients were allocated to intervention or control groups as detailed 
above.   
4.4.1 Demographics 
Baseline demographic information was collated: age, disease duration,  height 
and weight (and hence BMI), smoking status, alcohol consumption and Carstairs 
scores  (for the purposes of analysis, groups 1 & 2, 3 4 & 5 and 6 & 7 were 
combined) (376). 
4.4.2 Clinical and laboratory assessments 
Clinical features were documented at 0, 3 and 6 months: 28 swollen and tender 
joint count, patient GH score (VAS/100mm), calculated DAS28, patient global 
pain score (VAS/100mm), duration of early morning stiffness (minutes), HAQ and 
BP. At the same time points the following laboratory variables were 
documented: ESR, CRP, TC, HDL cholesterol and TC: HDL ratio. 
4.4.3 Dietary assessments 
Dietary assessments included:  FFQ, additional questions regarding fruit 
consumption, the intake of selected nutrients and food groups (to specifically 
assess Vitamin A, C and E intake, through food diaries) and documentation of 
the number of servings per week of fruit, vegetables and legumes, as well as 
combined amounts (FVL).  
 
 
 
 
 
174 
 
4.5 STATISTICAL METHODS 
SPSS version 15.0 software was used for statistical analysis.  Non-parametric 
statistical tests were used. Wilcoxon signed-rank test was used for within-group 
comparison at different time points. Mann-Whitney U test was used for 
comparison between intervention and control groups. Statistical significance 
was set as a p-value of <0.05 (see also Section 2.9 for additional statistical 
information). 
 
4.6 RESULTS 
4.6.1 Study demographics 
Disease duration and BMI were similar in both intervention and control groups, 
Table 4.1. The median age of the control group was 53 years, which compared 
with 58 years in the intervention group. This was, however, not significant 
(p=0.131). 
By designing this study to include individuals from Social Inclusion Partnership 
areas, it was foreseeable that a high proportion of participants would come 
from the most deprived social groups: 56% of the intervention group were in 
Carstairs group 6 or 7. Only 16% of the intervention group and 20% of the control 
group were in Carstairs group 1 and 2. These results are illustrated in Figure 4.1. 
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Table 4.1 – Baseline demographics for intervention and control groups 
  
Intervention (n=75) 
  
Control (n=55) 
 Median 
 
Mean 
 
Range 
 
 
 
Median 
 
Mean 
 
Range 
 
 
Age 
years 
 
58 
 
55 
 
30-70 
  
52 
 
53 
 
30-71 
Disease duration  
years 
7 9.3 0.8-30  7 9.6 1-39 
Height 
metres 
1.61 1.60 1.45-1.75  1.62 1.61 1.48-1.73 
Weight 
kg 
66 66.4 65.1  70 70 72.5 
BMI 
kg/m2 
25.86 26.75 18-47  27.65 27.95 17-45 
kg = kilograms, m= metres  
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Figure 4.1 – Deprivation categories of enrolled patients 
 
 
4.6.2 Drug therapy 
DMARD treatment over the duration of the study was reviewed, with escalation 
or additional treatment being noted. Within the 6 month study period, 21% of 
the intervention group and 24% of the control group had such a change in their 
treatment. At baseline, 48% of the intervention group and 46% of the control 
group were prescribed methotrexate. By the time of study completion, these 
figures were 44% and 51% respectively, no statistically significant difference 
between the time points. A lower percentage of patients were taking 
methotrexate in the Mediterranean-type diet study than in the NSAID 
withdrawal study – this likely reflects the prescribing patterns of the earlier 
recruitment time of the dietary intervention study.  
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4.6.3 Primary outcomes 
4.6.3.1 Clinical parameters 
Intervention and control groups were relatively well matched at baseline 
(despite the previously described enforced pragmatic approach to 
randomisation) with regards to HAQ, pain score, tender and swollen joint counts 
and calculated DAS28.  
Clinical assessments are shown in Table 4.2 and demonstrate a significant 
benefit in certain parameters in the intervention group compared with control 
group (Mann-Whitney calculations). At 6 months there was an improvement in 
patient GH assessment by 5 points in the intervention group, which compares 
with a deterioration of 9 points in the control group (p=0.002). There was no 
significant difference in DAS28 overall, or components of swollen or tender joint 
count. 
Between group analyses confirmed a significant improvement in pain score 
between intervention and control groups at 3 and 6 months (p=0.011 and 0.049 
respectively), in HAQ at 3 months (p=0.03) and in EMS at 6 months (p=0.041), 
Table 4.3. Wilcoxon signed ranks test analysis of the intervention arm 
demonstrated a significant reduction in EMS between 0 and 6 months (p=0.013).  
4.6.3.2 Laboratory parameters 
The control group at baseline demonstrated a much narrower range of ESR and 
CRP readings, which was not seen at other time points, Table 4.4. Although 
there was a numerical reduction in median ESR in each group by 6 months, this 
was not significant (p=0.234 intervention, p=0.485 control by Wilcoxon signed 
ranks test). There was no statistically significant difference in either ESR or CRP 
when intervention and control groups were compared. Therefore no direct 
conclusions on the benefit of a Mediterranean-type diet on haematological 
parameters in the form of inflammatory markers can be drawn
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Table 4.2 - Clinical parameters: DAS28  
  
Intervention (n=75) 
 
Control (n-55) 
 
Mann Whitney  
 Baseline 
 
3 months 
 
6 months Baseline 3 months 6 months (between groups) 
 
DAS28 
 
4.7 
(1.5-7.13) 
 
4.5 
(1.75-8.01) 
 
4.4 
(1.04-7.14) 
 
5.0 
(1.12-6.9) 
 
4.7 
(0.49-7.13) 
 
4.8 
(0.14-7.04) 
 
3 months p=0.439 
6 months p=0.143 
 
Tender joint 
count 0-28 
 
5 
(0-28) 
 
5 
(0-26) 
 
4 
(0-26) 
 
6 
(0-28) 
 
6 
(0-21) 
 
6 
(0-28) 
 
3 months p=0.823 
6 months p=0.088 
 
Swollen joint 
count 0-28 
 
6 
(0-16) 
 
5 
(0-15) 
 
4 
(0-14) 
 
6 
(0-17) 
 
5 
(0-12) 
 
5 
(0-18) 
 
3 months p=0.629 
6 months p=0.676 
 
Patient GH VAS 
0-100mm 
 
50 
(0-100) 
 
50 
(0-100) 
 
45 
(0-95) 
 
54 
(10-95) 
 
55 
(0-100) 
 
63 
(10-85) 
 
3 months p=0.60 
6 months p=0.002 
 
GH= global health, VAS = visual analogue score, mm = millimetre                                                                   Median (and ranges) shown 
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Table 4.3 – Other clinical parameters of disease activity and function 
  
Intervention (n=75) 
 
Control (n-55) 
 
Mann Whitney  
 Baseline 
 
3 months 
 
6 months Baseline 3 months 6 months (between groups) 
 
Pain score VAS 
0-100mm 
 
50 
(0-100) 
 
50 
(0-100) 
 
50 
(0-100) 
 
55 
(16-87) 
 
62 
(0-100) 
 
63 
(0-100) 
 
3 months p=0.011 
6 months p=0.049 
 
Early morning 
stiffness mins 
 
30 
(0-720) 
 
30 
(0-720) 
 
15 
(0-720) 
 
60 
(0-720) 
 
30 
(0-720) 
 
30 
(0-720) 
 
3 months p=0.156 
6 months p=0.045 
 
HAQ 
 
1.75 
(0.2-2.875) 
 
1.625 
(0.125-2.875) 
 
1.625 
(0-3) 
 
1.75 
(0.2-2.875) 
 
1.875 
(0-2.875) 
 
1.875 
(0-3) 
 
3 months p=0.032 
6 months p=0.79 
 
mm = millimetre, mins= minutes                                                                                                                  Medians (and ranges) shown 
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Table 4.4 – Inflammatory markers 
  
Intervention (n=75) 
 
Control (n-55) 
 
Mann Whitney  
 Baseline 
 
3 months 
 
6 months Baseline 3 months 6 months (between groups) 
 
ESR 
mm/1st hour 
 
19 
(2-101) 
 
20 
(1-105) 
 
19 
(1-54) 
 
55 
(16-87) 
 
19 
(2-65) 
 
16 
(1-92) 
 
3 months p=0.738 
6 months p=0.312 
 
CRP 
mg/l 
 
30 
(0-720) 
 
30 
(0-720) 
 
15 
(0-720) 
 
60 
(0-720) 
 
30 
(0-720) 
 
30 
(0-720) 
 
3 months p=0.485 
6 months p=0.530 
 
mm = millimetres, mg= milligrams, l=litre                                                                                                     Medians (and ranges) shown  
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4.6.3.3 Cardiovascular parameters 
64% of the intervention group and 62% of the control were ever smokers.  
There was no significant difference in median or range of BP readings between 
the intervention and control groups at the 3 assessment time points. Within 
group analysis was performed to see if there was evidence of a more subtle 
change in BP over time within the intervention group. Wilcoxon signed-rank 
analysis revealed a significant reduction in systolic BP by 4mmHg at 6 months in 
the intervention group (p=0.016), while the control group showed no such 
difference (p=0.968). This is as documented in Table 4.5 below.  
 
Table 4.5 – Within group analysis of systolic BP changes 
 
Systolic BP 
 
Baseline 
 
 
3 months 
 
 
6 months 
 
Wilcoxon 
 
Intervention 
mmHg 
 
132 
(96-193) 
 
130 
(98-190) 
 
128 
(100-195) 
 
 
p=0.016 
Control 
mmHg 
 
130 
(99-191) 
129 
(87-190) 
130 
(97-130) 
p=0.968 
mmHg= millimetres of mercury 
Medians (and ranges) shown 
 
Table 4.6 documents clinical CV parameters recorded during study visits. The 
within group analysis of BP has already been discussed above. Using Mann-
Whitney analysis, there were no significant differences in cholesterol or BP 
readings between groups.  There was a non-significant reduction in weight in 
the intervention group.  
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Table 4.6 - Clinical cardiovascular parameters  
  
Intervention (n=75) 
 
Control (n-55) 
 
Mann Whitney  
 Baseline 3 months 
 
6 months Baseline 3 months 6 months 
 
(between groups) 
 
 
Systolic BP 
mmHg 
 
132 
(96-193) 
 
130 
(98-190) 
 
128 
(100-195) 
 
130 
(99-191) 
 
129 
(87-190) 
 
130 
(97-130) 
 
3 months p=0.386 
6 months p=0.349 
 
Diastolic BP 
mmHg 
 
85 
(60-105) 
 
78 
(54-95) 
 
80 
(60-100) 
 
80 
(58-103) 
 
79.5 
(52-100) 
 
78 
(56-120) 
 
3 months p=0.790 
6 months p=0.548 
 
TC 
mmol/l 
 
5.5 
(3.4-8.05) 
 
5.3 
(3.4-7.25) 
 
4.9 
(3.2-8.1) 
 
5.3 
(3-7.6) 
 
5.175 
(3-8.2) 
 
5.4 
(2.9-7.3) 
 
3 months p=0.303 
6 months p=0.994 
 
HDL-C  
mmol/l 
 
1.55 
(0.7-2.6) 
 
1.6 
(0.5-2.6) 
 
1.6 
(0.9-4) 
 
1.5 
(0.85-3.3) 
 
1.46 
(0.8-2.8) 
 
1.5 
(0.9-2.7) 
 
3 months p=0.411 
6 months p=0.640 
 
TC: HDL ratio 3.43 
(1.8-10.93) 
3.39 
(1.9-12.4) 
3.36 
(1.7-6.55) 
3.5 
(1.52-8.12) 
3.52 
(1.77-9) 
3.23 
(2.18-8.11) 
3 months p=0.411 
6 months p=0.640 
 
Weight 
kg 
66 64.4 65.1 70 70 72.5 3 months p=0.255 
6 months p=0.339 
 
mmHg= millimetres of mercury, TC= total cholesterol, HDL-C= HDL-cholesterol, mmol/l= millimol per litre, kg= kilograms, m= metres 
Medians (and ranges) shown for BP and cholesterol, medians only for weight  
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4.6.4. Secondary outcomes 
4.6.4.1 Food intake frequency  
Data regarding food intake frequency is only available to 3 months. It was 
identified that consumption of FVL was below the recommended minimum of 5 
portions per day (415) in both groups at baseline, Table 4.7. By 3 months this 
had improved significantly in the intervention group who were attending cooking 
classes. This group had a significant increase in both fruit and combined FVL 
consumption (p=0.029 and p=0.016 respectively, Wilcoxon signed-rank test). No 
such increase was seen in the control group who only received printed 
information on the benefits of a healthy diet. 
The recommended daily intake for females for vitamins A, C and E are 600mcg, 
40mg and 3mg respectively (416) (417) (418). The study participant’s intake of 
these vitamins was calculated from the FFQ at baseline and at 3 months, all 
groups achieved a greater than recommended amount. There was a non-
statistical increase in Vitamin A intake in both groups and in Vitamin C intake in 
the intervention group. The reasons for the small reduction in Vitamin E intake 
in both groups by 3 months cannot readily be explained; Table 4.8.  
Monounsaturated fats are fatty acids which have a single double bond in the 
fatty acid chain and all of the remaining carbon atoms in the chain are single-
bonded.  Polyunsaturated fats, by contrast, have more than one double bond. 
Common monounsaturated fatty acids are palmitoleic acid and oleic acid. Olive 
oil is approximately 75% monounsaturated fat while lard is approximately 40% 
monounsaturated fat.   Natural sources of monounsaturated fats therefore 
include olive oil, olive oil based spreads and avocados.  The intervention group 
who were educated on the benefit of olive oil and other related products 
demonstrated a significant improvement in the ratio of monounsaturated: 
saturated fat consumption (p=0.022, Wilcoxon signed rank test), Table 4.9, and 
thereby increased their intake of ‘good fats’. 
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Table 4.7 – Intake of fruit, vegetables and legumes as calculated by FFQ analysis 
  
Intervention (n=75) 
 
Control (n-55) 
Servings per 
week 
Baseline 
 
3 months 
 
Wilcoxon Baseline 3 months Wilcoxon 
 
Vegetables 
 
 
10.1 
 
11.1 
 
p=0.061 
 
9.6 
 
10.3 
 
p= 0.226 
Legumes 
 
2.2 2.2 p=0.976 2.5 2.9 p=0.177 
Fruit 11.2 12.7 p=0.029 9.1 9.9 p=0.299 
 
Total FVL 
 
23.5 
 
26 
 
p=0.016 
 
21.5 
 
23 
 
p=0.84 
 
Medians shown 
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Table 4.8 – Intake of vitamins A, C and E as calculated by FFQ analysis 
  
Intervention (n=75) 
 
Control (n-55) 
 Baseline 
 
3 months 
 
Wilcoxon Baseline 3 months Wilcoxon 
 
Vitamin A 
mcg / day 
 
 
1108 
 
1246 
 
p=0.101 
 
922 
 
974 
 
p= 0.403 
Vitamin C 
mg / day 
 
94 104 p=0.081 94 94 p=0.929 
Vitamin E 
mg / day 
7 6.8 p=0.636 5.8 5.5 p=0.448 
       
mcg= micrograms, mg=milligrams 
Medians shown   
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Table 4.9 – Monounsaturated fat consumption as calculated by FFQ analysis 
  
Intervention (n=75) 
 
Control (n-55) 
 Baseline 
 
3 months 
 
Wilcoxon Baseline 3 months Wilcoxon 
 
Monounsaturated 
fats:  
saturated fats 
 
 
0.86 
 
0.92 
 
p=0.022 
 
0.82 
 
0.83 
 
p= 0.726 
Medians shown  
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4.6.4.2 Alcohol consumption 
In the UK, 1 unit of alcohol is defined as 10ml of pure alcohol (ethanol). Figure 
4.2 demonstrates both total alcohol and red wine consumption in both 
intervention and control groups over the 6 month study period. 
Alcohol consumption was low in both groups with a mean consumption of 1.5 
units per week in the intervention group and 1.9 units per week in the control 
group. This tends to be common in females of this age and may also reflect 
advice given about minimising alcohol intake when taking DMARD therapy 
(especially when methotrexate is prescribed). Overall alcohol consumption fell 
slightly in both groups from baseline to 6 months. There was a slight increase in 
red wine consumption in the intervention group which may reflect the 
discussions from the cookery course. None of these figures were significant. 
 
Figure 4.2 – Alcohol intake 
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4.6.4.3 Feedback from participants 
All 75 participants in the cookery classes were invited to fill in a questionnaire 
about their experience of attending the six week cookery course. A total of 57 
responses (76%) were received.  
The overall consensus was that the classes were very enjoyable. The majority of 
the participants felt that the recipes given were straightforward to make and 
affordable. Only 3 respondents stated that they were unable to purchase the 
necessary ingredients for the recipes used, either because they were too costly 
or they were unavailable in their local shops. Other positive feedback included 
benefits from getting out to attend the classes, moving around more and 
enjoyment from social interaction with other patients with RA. Most individuals 
had made changes to their diet and approach to cooking. Fifty-three out of the 
57 the respondents (93%) had tried the recipes again at home. Most felt they 
had learnt new skills or tips in preparing and using food. A number reported an 
increase in confidence and self-esteem. 
There was minimal negative feedback on the structure of the courses except for 
a desire for an opportunity for more time in the cooking class and a longer 
programme. A number of participants reported a degree of difficulty in 
preparing some of the ingredients, e.g. vegetables. Ways around this included 
support from occupational therapy, tutors and from other participants. The use 
of tinned or frozen ingredients provided an alternative to preparing meals from 
completely fresh ingredients, Table 4.10 and Figure 4.3. 
A short interview was carried out with 3 of the tutors. Attendance at all the 
courses was high. There was some drop off due to specific reasons, e.g. illness, 
hospitalisation, holidays. Tutors reported gaining a greater insight and increased 
awareness of the issues facing individuals with a disability and in particular RA. 
One felt that it would be useful to know more about the effects of diet on 
illness and on occasions felt unable to answer some of the more specific 
questions posed by participants. It was felt that 6 weeks was enough time for 
the participant to get into a routine. 
The pilot project highlighted that within Glasgow there is a shortage of suitable 
venues and particularly trained tutors to meet the demand for such courses.  
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In conclusion, both participants and tutors felt that the course had a beneficial 
effect on individual knowledge and had encouraged the majority of participants 
to make positive changes to their diet. An equally important message expressed 
by many of the participants was having the opportunity to socialise and meet 
with people who faced similar problems, to be able to share experience and 
information about their illness and to build new friendships.  
 
Table 4.10 – Feedback from cookery courses 
 
Positive feedback 
 
Negative feedback 
 
 
Enjoyable classes 
 
Straightforward recipes 
 
Affordable ingredients 
 
Social interaction within classes 
 
New friendships made 
 
Made changes to diet and approach to 
cooking 
 
Learning new food skills 
 
Improved confidence and self-esteem 
 
 
Unable to purchase ingredients (n=3) 
 
Class too short 
 
Programme too short 
 
Difficulty preparing vegetables 
 
Need for a greater rest period within 
class  
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Figure 4.3 – Quotes from cookery course feedback  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.7 DISCUSSION 
In this study we sought to assess whether we could modify disease activity and 
CV risk as well as nutritional patterns in female patients with RA living in areas 
of social deprivation by introducing them to a Mediterranean-type diet. Cookery 
classes to provide “hands-on” experience of this type of diet and cooking were 
an essential element in increasing knowledge and confidence in the 
participants.  
The study has shown that female patients with RA following a Mediterranean-
type diet derive modest benefits across a range of areas, suggesting that this 
type of intervention may be a useful therapeutic adjunct to conventional DMARD 
which could be popular with patients. While setting up cookery classes and 
encouraging patients to attend may prove initially difficult to facilitate, 
I’m starting to cook 
meals instead of using 
ready-prepared ones. 
I found it really interesting. It made me think 
about what I was eating and what to buy. I’m 
now trying to change my ways. 
I enjoyed the challenge 
and that people cared. 
I feel that I could have done with more time in the 
class. It helped because, apart from cooking, we were 
moving around more. It brightened up my life talking 
to others and helping each other as we went along. 
I have started cooking with olive oil 
now. I didn’t normally cook for 
myself but I now know that I can. I 
still have the folder to help me.  
Getting out early in the morning 
and going somewhere to meet 
people like myself as sometimes 
I feel I am the only one in pain. 
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information from the courses could be incorporated into patient information 
given at diagnosis or on follow-up visits to the out-patient clinic.  Issues 
regarding set up of further dietary programmes are discussed in Section 6.1.3.  
4.7.1 Influence on disease activity 
Like previous investigators (346), we have shown a modest improvement in a 
number of measures of disease activity with such a dietary intervention. Pain 
score was significantly better in the dietary intervention group than in the 
controls at 3 and 6 months. Patient GH assessment and reported EMS were 
significantly better at 6 months. Patient function, as reported by the HAQ score, 
was also better in the intervention group at 3 months. Overall the DAS28 score 
remained unchanged in both groups, but despite this, patients in the 
intervention group clearly felt healthier. The reasons for this are likely to be 
multifactorial and may in part reflect increased confidence and self-esteem as 
well as the actual dietary intervention. As it is impossible to conduct this type 
of study in a double-blind fashion, the possibility of a placebo-response cannot 
be entirely excluded. This does seem less likely as the same trend was seen over 
a number of measurements and was sustained.  
4.7.2 Influence on cardiovascular risk 
Patients with RA are at increased risk of CV events and we aimed to assess if we 
could modify this tendency in our patients. The intervention group lost weight 
(median 0.9kg over the 6 month period) whereas the control groups showed a 
weight gain (median 3kg). This difference was however not statistically 
significant. Cholesterol levels (at baseline and 6 months) and smoking status did 
not differ between the groups. We noted a small but significant reduction in 
systolic BP (mean 4mmHg) in the intervention group. The magnitude of change 
is what perhaps may be achieved with the introduction of a mild anti-
hypertensive agent in routine practice. The benefit here is that this was 
achieved without the addition of any other drugs.  
 
 
 
192 
 
4.7.3 Influence on dietary patterns 
The study demonstrates that this intervention was achievable and well received 
by patients. Intake of fruit, vegetable and legumes increased significantly over 3 
months in the intervention group. The use of monounsaturated compared with 
saturated fats improved. The majority of the participants felt that recipes were 
straightforward to make and affordable. Only 3 stated that they were unable to 
purchase the necessary ingredients, either because they were too costly or were 
unavailable in their local shops. There were also wider social benefits in that 
most felt they had learnt new skills in food use and preparations. Some women 
also noted an improvement in confidence and self-esteem as they were now 
able to contribute more to cooking for themselves and their families at home. 
We did not see an improvement in the intake of the antioxidant vitamins A, C 
and E. Possibly the FFQ was not sufficiently sensitive to detect changes in the 
actual nutrient intake. The FFQ was originally developed to assess the intake of 
total energy and macronutrients (protein, fat and carbohydrate) at a time when 
antioxidants were not the focus of interest (311). The number of fruit and 
vegetables represented in the FFQ is relatively limited and it is possible that 
participants increased their intake with items not listed on the FFQ. A more 
accurate assessment of nutrient intake might have been achieved by using a 7-
day weighed or estimated food diary. However, this method places a heavy 
burden on the participant; this was thought inappropriate for use in this study 
given the age and health of our subjects. These diaries are expensive and time 
consuming to analyse; these resources were unavailable to us. 
 
4.8 LIMITATIONS OF THE STUDY 
The female-only recruitment policy of this study does raise concerns that the 
influence of this type of dietary intervention may not be applicable across the 
spectrum of patients with RA. Unfortunately dietary information was only 
available to 3 months, while clinical and laboratory parameters were available 
to 6 months – data on the former would have given valuable information on the 
longevity of patients adhering to the diet. The availability of weekly courses in a 
location close to the patients’ home and at a convenient time did pose some 
restriction in allocating participants to intervention or control groups.   
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4.9 SUMMARY 
The initial objectives when designing this study were to assess if lifestyle, 
disease activity or CV risk might be altered by this type of dietary intervention. 
The results show that this is indeed achievable at low cost and is acceptable to 
patients with RA. To act on and implement these findings we have approached 
local and national (Scottish) public health authorities to inform them of the 
results and discuss the potential impact of assessment in a larger population.  
We disseminated results to other patients attending our general rheumatology 
clinics. We decided that a simple document, displayed as a poster or given as a 
hand-out, would convey the results well to those who were interested (Appendix 
XI). 
The then Director of Public Health for NHS Greater Glasgow was informed of the 
positive outcomes of the study. These were then relayed to the Scottish Diet Co-
ordinator in Edinburgh to review the results and assess if applicable to Scotland 
as a whole.   
 
4.10 ACKNOWLEDGEMENTS 
I would like to specifically thank Dr Elaine Morrison, Consultant Rheumatologist, 
Southern General Hospital and Dr Anne McEntegart, Consultant Rheumatologist, 
Stobhill Hospital. They have been generous with their time and expertise in the 
analysis and presentation of the data from this study. Sisters Rosemary Hampson 
and Geraldine Mackle were integral in patient recruitment and study co-
ordination. Ms Ann Tierney was crucial for study administration and later 
additional statistical support. Sisters Fiona McDonald, Elizabeth McIvor and 
Audrey Rowan carried out metrology for this study. Mrs Dorothy McKnight 
provided initial statistical help for this study. The project could not have been 
completed without the community nutrition tutors. Dr Janet A Scott and 
students from the Human Nutrition Department of the University of Glasgow 
provided expert nutritional knowledge and analysis of FFQ.  
 
 
194 
 
  
 
 
CHAPTER 5 
The Influence of Social Deprivation on Cardiovascular Risk 
Factor Scores in a Population with Rheumatoid Arthritis 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
195 
 
5.1 INTRODUCTION 
A risk factor can be defined as characteristic of an individual that is associated 
with the subsequent development of disease. Risk scores cannot predict 
absolute risk but are useful for assessing or estimating the possibility of disease; 
they can also assist in prioritising treatment. Well documented risk factors for 
CV disease include hypertension, hyperglycaemia and hypercholesterolemia. 
However, one BP reading is only ever a single snapshot of a fluctuating risk 
factor; additionally, it is impossible to predict the behaviour of individual 
atheroslerosclerotic plaques in a patient with hypercholesterolaemia (419).  
The standard JBSCRP score and Framingham score for predicting 10-year CV risk 
have been described earlier (see Section 1.6). The Framingham score was the 
original CV risk equation, with versions produced in 1991 and 1998 (203, 204). 
The calculations were based mainly on data from Caucasians living in 
Massachusetts, USA. In February 2010, NICE withdrew their previous 
recommendation that the Framingham risk equation should be the equation of 
choice for assessment of CVD risk, but comment further that it could be 
considered as a possible equation to use (201).  
The JBSCRP charts were subsequently based on Framingham and divide by 
gender, age, smoking and diabetes (420) (see Appendix XII, chart used with 
permission from the British Medical Journal Publishing Group Ltd). This 
assessment tool calculates a 10-year risk of all atherosclerotic disease; including 
acute coronary syndrome, angina pectoris, cerebrovascular disease and 
peripheral vascular disease. Both JBSCRP and Framingham under-predict in 
populations with high CHD mortality.  
The recent development of the ASSIGN score, based on Scottish population data, 
allows for the calculation of CV risk with the additional information of family 
history and deprivation, using SIMD score (205, 206).  
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5.2 JUSTIFICATION OF STUDY DESIGN AND PROTOCOL 
The substantial amount of baseline demographic and CV data collected from the 
Mediterranean-type diet study of Chapter 4 allowed us to undertake a 
comprehensive assessment of the influence of social deprivation on CV risk 
scores in a cohort of female patients with RA living in the Glasgow area.  
A comparison of CV risk scores using three different methods (JBSCRP, 
Framingham and ASSIGN) was undertaken to identify any significant differences 
in the cohort of female patients with RA recruited to the Mediterranean-type 
diet study. While the CV risk assessment scores were designed to be used in 
clinical practice for individuals without prior history of hypertension or CV 
disease, they were applied here to give an indication of risk in this study 
population.  
Baseline CV risk based on BP, age, presence or absence of diabetes and smoking 
status was calculated using the readily available JBS validated graphs (see 
Appendix XII, chart used with permission from the British Medical Journal 
Publishing Group Ltd.) and Framingham calculator (208). Not all of the data 
required to calculate ASSIGN was collected at study enrolment. Therefore these 
scores were determined retrospectively. Information regarding SIMD was 
calculated using the postcode from the address given at study commencement 
and displayed as part of the ASSIGN score calculator (401). Information on 
family history of IHD or stroke (in a parent or sibling aged <60 years) was 
obtained via telephone interview.   
 
5.3 RESULTS 
Data was available to allow calculation of CV risk scores in 113 out of 130 
participants from the Mediterranean-type diet study (17 participants could not 
be contacted by telephone resulting in missing data of family history; therefore 
they were excluded from CV risk analysis using all 3 modalities).  All scores were 
calculated from baseline variables. For the purposes of analysis, risk scores 
were grouped into 3 sections: (1) <10% 10-year CV risk, (2) 10-20% 10-year CV 
risk and (3) >20% 10-year risk (as previously detailed in Table 1.10). 
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None of the recruited patients had a known diagnosis of diabetes mellitus (type 
I or type II) at time of study enrolment. None had a documented history of MI or 
stroke.  
5.3.1 Comparison of JBSCRP, Framingham and ASSIGN scores in whole cohort 
As can be seen from Figure 5.1, JBSCRP was more likely to classify an individual 
with a <10% 10-year CV disease risk (60.2% of total) than Framingham (50.4% of 
total) or ASSIGN (47.8% of total). Conversely, ASSIGN was more likely to classify 
an individual with a >20% 10-year CV disease risk (23% of total) than Framingham 
(14.2% of total) or JBSCRP (8.8% of total). By using ASSIGN, an additional 16 
individuals were identified as having a >20% 10-year CV risk than would have 
been identified by using traditional JBSCRP. Although the ASSIGN score could 
still possibly under-estimate, in this cohort it identified additional patients with 
increased risk. This sub analysis highlights the advantage to our population of 
using a CV risk score that encompasses family history and deprivation measures.  
5.3.2 ASSIGN scores 
Table 5.1 documents the demographic and traditional CV risk factors as per 
ASSIGN 10-year CV risk grouping. A greater predicted CV risk was associated 
with a higher median SIMD score, which would be expected by the design of the 
ASSIGN score, and age. This also correlates with a higher median Carstairs 
grouping for the subsets. Those with an ASSIGN score of <10% 10-year CV risk 
had a lower median SIMD (25.95, range 2.70-79.83) than in the same grouping of 
JBSCRP or Framingham. 
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Figure 5.1 – Outcome of cardiovascular risk calculation using three different scores
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Table 5.1 – Demographic details and traditional CV risk factors as per ASSIGN 
score  
  
10-year cardiovascular risk 
 <10% 
(n=53) 
10-20% 
(n=32) 
>20% 
(n=28) 
 
Carstairs group 
 
4 (1-7) 
 
5 (1-7) 
 
6 (1-7) 
 
SIMD score 25.95 (2.7-79.83) 42.28 (2.92-77.53) 54.89 (3.08-76.74) 
 
Age 
years 
46 (30-62) 58 (47-71) 65 (55-69) 
Systolic BP 
mmHg 
129 (96-191) 137 (111-193) 150 (112-190) 
TC 
mmol/l 
5 (3.2-8.05) 5.65 (3.4-7.6) 5.9 (4.75-7.4) 
HDL 
mmol/l 
1.62 (0.7-3.3) 1.5 (0.9-2.3) 1.65 (1.2-2.6) 
BMI 
kg/m2 
25.68 (17-47) 28.00 (21-45) 25.96 (18-42) 
ESR 
mm/1st hour 
18 (1-46) 19 (1-54) 20 (2-101) 
CRP 
mg/l 
7 (6-45) 10 (6-106) 10 (6-132) 
Dis. duration 
years 
8 (1-25) 6 (1-39) 8 (1-20) 
   Ex-smoker 
Current smoker 
30% 
20% 
30% 
36% 
50% 
39% 
 
Statin therapy 
 
4% 
 
0 
 
4% 
 
NSAID therapy 
 
76% 
 
73% 
 
65% 
Dis. duration = disease duration                     Medians (and ranges) shown 
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5.3.3 Discrepancies between calculated cardiovascular risk results 
A comparison of whether using the traditional JBSCRP score “matched” the 
calculated Framingham and ASSIGN score was undertaken. Twenty-four 
individuals (21% of the cohort) had a Framingham and ASSIGN score which 
differed from the grouping of the JBSCRP chart. In 15 cases this was when the 
JBSCRP risk was <10% but both ASSIGN and Framingham calculated a higher risk. 
In 7 cases this was when the JBSCRP risk was in the grouping 10-20% and both 
ASSIGN and Framingham calculated a risk >20%.  
In 2 cases, JBSCRP gave a higher calculated risk than ASSIGN and Framingham. 
In the first case, JBSCRP scored a risk of >20%, Framingham 10-20% and ASSIGN 
<10% (patient number 4 on figure). In the second case, JBSCRP scored a risk of 
10-20% and both Framingham and ASSIGN were <10% (patient number 24 on 
figure), see figure 5.2. Further analysis of these 2 cases did not reveal any 
striking disease patterns to explain the discrepancy. Both were normotensive, 
aged ≤40 years, smoked 20 cigarettes per day and had disease durations of ≤4 
years. There was, however, a striking disparity in SIMD, DAS28, pain scores and 
patient GH scores between the 2 patients.  
The differences between the groups were interrogated in more detail and are as 
documented in Table 5.2. The discrepancy was more closely associated with 
increasing age (median age 63 years in “no match” group, 52 years in “match” 
group, p=0.001) While the JBSCRP can only give a range of CV risk (i.e. <10%, 
10-20% or >20%), ASSIGN and Framingham can give a specific percentage for CV 
risk over the next 10 years. When JBSCRP matched ASSIGN and Framingham 
grouping, the median ASSIGN score was 8%; when there was no match, the 
median ASSIGN score was 19% (p<0.001). A similar pattern was observed with 
Framingham percentages. This gives weight to the argument that using JBSCRP 
alone will underestimate CV risk in a proportion of this cohort.  There was no 
significant difference in factors relating to RA control such as ESR or DAS28.  
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Figure 5.2 – Differing CV risk groupings for individual patients where JBSCRP does not match Framingham or ASSIGN 
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Table 5.2 – Interrogation of patient characteristics comparing a match versus 
non-match of JBSCRP with ASSIGN and Framingham  
  
JBSCRP GROUPING 
DOES NOT MATCH 
ASSIGN & 
FRAMINGHAM 
 
JSCRCP GROUPING 
MATCHES 
ASSIGN  & 
FRAMINGHAM 
 
 
n (%) 
 
24 (21%) 
 
89 (79%) 
 
 
Age years 63 (34-71) 52 (30-71) p=0.001 
 
SIMD 49.21 (2.92-79.83) 40.60 (2.70-77.53) p=0.242 
 
Exact ASSIGN 
score 
19% (8-43) 8% (1-41) p<0.001 
Exact Framingham 
score 
 
12% (9-25) 7% (0-37) p=0.003 
DAS28 5.03 (1.5-6.61) 4.59 (1.12-7.13) p=0.087 
 
ESR mm/1st hour 28 (1-101) 19 (1-69) p=0.036 
 
Systolic BP mmHg 130 (111-177) 134 (96-193) p=0.070 
 
% smokers 42% 26% p=0.132 
Medians (and ranges) shown  
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5.4 DISCUSSION 
Calculating CV risk is easy to perform with readily available clinical information 
and at its most accessible form is through the British National Formulary- the 
JBSCRP charts are at the back of the book (215). 
In this analysis, using 3 different CV risk calculations (JBSCRP, Framingham and 
ASSIGN) the majority of cases will result in identical 10-year CV risk grouping: 
<10%, 10-20% or >20%. However, 21% of this cohort of 113 female patients with 
RA had a discrepancy between results. Most commonly this was when JBSCRP 
scored lower than ASSIGN and / or Framingham.  These patients tended to be 
older (p=0.001) and have a higher calculated median ASSIGN score (p<0.001). 
Smoking was more prevalent in these patients. ESR was also higher in the group 
with discrepancy in CV risk score (p=0.036). Additionally, DAS28 was numerical 
higher in this “non-match” group, but this was not statistically significant.  
In 2 cases, however, JBSCRP scored lower than ASSIGN and / or Framingham. 
Further analysis of these 2 individual cases did not reveal any striking disease 
patterns to explain the discrepancy.  
Interestingly, a low percentage of this cohort were prescribed statins – this was 
likely because the initial recruitment of the study came at a time where interest 
in primary and secondary prevention through modulation of lipid levels was just 
coming to the fore. Additionally, the TARA study, regarding use of statins in RA 
patients, had just reported in 2004 (128). 
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5.5 SUMMARY 
Review of this cohort demonstrates an increased risk of CVD before the 
additional risk of RA is taken into account. We have demonstrated that the 
application of the ASSIGN score in this population provides a more individualised 
and accurate reflection of CV risk than use of JBSCRP charts alone.  
Individuals from deprived socioeconomic groups are clearly at increased CV risk 
than previously indicated by application of traditional estimating tools. We 
advocate that the ASSIGN score be used in our population for a more detailed 
assessment of CV risk; this would be in keeping with the EULAR 
recommendations for managing CV risk in patients with inflammatory arthritis 
(153). 
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CHAPTER 6 
Conclusions 
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6.1 THE ASSESSMENT AND MODIFICATION OF CARDIOVASCULAR RISK IN 
INFLAMMATORY ARTHRITIS 
There is an associated premature mortality associated with RA which is mainly 
attributable to CVD. It is apparent from the literature that this risk is 
multifactorial. Potentially modifiable components include manipulation of 
medication, whose use confers additional risk, as well as addressing issues of 
smoking, hypertension, poor diet and social deprivation.  
The aims of this thesis were to explore the effect of novel interventions on 
various aspects of RA, predominately to assess CV risk further and review 
whether certain aspects of risk could be modified. 
6.1.1 Cardiovascular risk calculation 
The substantial amount of baseline demographic and CV data collected from the 
Mediterranean-type diet study allowed a comprehensive assessment of the 
influence of social deprivation on CV risk scores in a cohort of female patients 
with RA living in the Glasgow area to be undertaken. Three different CV risk 
calculators were used: Joint British Societies Coronary Risk Prediction, 
Framingham and the newer, Scottish, ASSIGN score which incorporates social 
deprivation. ASSIGN was more likely to classify an individual with a >20% 10-year 
CVD risk (23% of total cohort) than Framingham or JBSCRP. By using ASSIGN, an 
additional 16 individuals were identified as having a >20% 10-year CV risk than 
would have been identified by using traditional JBSCRP alone. 
I undertook a literature review which could not identify any other published 
studies which compared different CV risk prediction scores within a cohort of 
patients with RA or any other disease processes. The authors of the ASSIGN 
score had proposed a head-to-head comparison with QRISK but the latter study 
was rapidly published before this could be undertaken  (421). 
Use of the ASSIGN score allowed the identification of a greater number of study 
participants with a high 10-year CVD risk score. This was a factor which is 
addition to the increased CV risk which RA confers. Increased use of this score 
would allow the targeting of a greater number of patients to target 
interventions and minimise future CVD. 
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6.1.2 Manipulation of medication and potential effect on CV risk 
The feasibility and effect of anti-inflammatory withdrawal on patients with 
well-controlled RA was investigated. The initial study proposal was amended 
after discussion with LREC, and resulted in patients with higher levels of disease 
activity being excluded. A sudden discontinuation of NSAID was undertaken and 
30 patients followed up for 12 weeks. All completed the intervention period 
with minimal medical intervention – only 11 patients required steroid injections 
(this comprised 7 IM and 6 IA steroid injections given over a total of 60 follow up 
visits) and only 1 patient required an escalation of DMARD therapy to maintain 
good control of their inflammatory disease. None chose to leave the study to 
restart anti-inflammatory medication. There was no significant deterioration in 
DAS44 or components by the end of the intervention. There was a trend in 
reduction of reported upper GI symptoms. 
A significant improvement in BP was noted with a maximal median reduction in 
systolic BP of 7mmHg (p=0.037) from baseline to 12 weeks. The relationship 
between withdrawal of NSAID and reduction in systolic BP remains hypothetical; 
we cannot exclude that patients became accustomed with the study 
environment and that this contributed to the sequential fall in BP readings.   
The study is limited by its lack of control arm, small size (a larger observational 
study would have been the preferred option to a blinded trial) and the absence 
of understanding as to whether the steroid administration or non-NSAID 
analgesia use represented a change from the norm for each individual patient. 
Nevertheless, this was a feasibility study and it is reasonable to expect that 
these results could be applicable to a larger population. The early increase in 
pain scores after discontinuing NSAID suggests that a tapered withdrawal might 
be associated with less discomfort. 
This is the first published supportive evidence to implement guidance of limiting 
NSAID use in patients with RA and low DAS44 scores without adversely affecting 
quality of life or disease control. The impact this intervention had on BP 
readings has implications on future CV risk. 
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6.1.3 Influence of diet on cardiovascular risk in female patients with RA 
The impact of a dietary intervention on disease activity and CV parameters was 
studied in a population of female patients with RA living in areas of 
socioeconomic deprivation in Glasgow. No other interventions beyond standard 
care for their arthritis were undertaken. Seventy-five patients were recruited to 
the intervention group who attended the cookery classes and 55 to the control 
group who received basic information only. Of the intervention group, 56% were 
in Carstairs group 6 or 7, being the most deprived.  
Comparing intervention with control groups over the 6-month follow up, there 
was a significant improvement in pain score (p=0.011 at 3 months, p=0.049 at 6 
months), in functional assessment (reduction in HAQ score at 6 months, p=0.03) 
and in EMS (p=0.041 at 6months). The intervention group demonstrated a 
benefit in systolic BP. There was no significant reduction in inflammatory 
markers. There was a significant increase in fruit and vegetable consumption as 
assessed by food frequency questionnaire.  
This study demonstrated that a cheap and easily delivered 6-week intervention 
can prove instrumental in increasing a cohort’s intake of healthy foods with the 
subsequent potential health benefits, including impact on CVD. The study was 
however limited to 75 patients, and the majority had similar social 
circumstances.   
This type of intervention has potential public health implications. The results 
were disseminated to the Director of Public Health in Glasgow and subsequently 
to the Scottish Diet Co-ordinator in Edinburgh. After the paper relating to this 
work was published, much interest was generated by health and diet related 
websites and forums, indicating the general population’s interest in dietary 
interventions.  
Information on diet is available from charitable resources to aid patients and 
carers make healthy eating choices. Arthritis Research UK entitle their booklet 
“Diet and Arthritis” and comment on a number of important issues highlighted 
in the Introduction of this thesis, such as: maintaining a healthy weight, mono-
unsaturated versus polyunsaturated fats, fish oil supplements and interestingly, 
the most recent version details “the potential benefits of a Mediterranean style 
diet” (422). Arthritis Care entitle their booklet “Healthy Eating and Arthritis” 
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(423) and details controlling weight as well as tips on maintaining a healthy diet 
(e.g. planning shopping trips, storing healthy food in the freezer, organising the 
kitchen to make food preparation easier). Fish oils and fish liver oils are 
discussed. Uniquely, advice is given on avoiding unpasteurised cheese and milk 
and uncooked meats if taking immunosuppressant therapy.  
 
6.2 FUTURE WORK 
On the basis of the work reported in this thesis, areas have been highlighted 
which warrant further assessment. 
6.2.1 Anti-inflammatory use 
On a day-to-day basis this research work has informed my daily practice in a 
rheumatology out-patient clinic, and hopefully that of my co-workers. I will 
continue to strive to address anti-inflammatory use in all patients with 
inflammatory arthritis that I see, in order to ensure that the risk versus benefit 
ratio of such therapy is at the forefront of discussion. The result of the work 
reported in the thesis is simple to convey to patients: participants with good 
control of their arthritis were able to safely withdraw anti-inflammatory drug 
use without significant flare of their disease and with major potential health 
benefits such as reduction in BP and upper GI symptoms.  
From a clinical study perspective, the monitoring of a larger group over a more 
prolonged period would undoubtedly give a more robust understanding on the 
effect of the intervention on BP as well as monitoring disease activity. hsCRP, 
specific circulating cytokines or thrombotic variables (such as fibrinogen, von 
Willebrand factor or D-dimers) could potentially be monitored in a larger study. 
A further question that could be answered by more research in this area is, if 
NSAID were to be re-introduced at a later stage, what might the effect be on BP 
and pain score? 
The fact that minimal medical intervention was required should give 
reassurance that the amount of extra resources needed would likely be small.  
Extending such a study to other patients with higher levels of disease activity 
and including types of inflammatory pathologies such as PsA and / or AS would 
be helpful. The documented tolerance of such an intervention by patients would 
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hopefully encourage any future Ethics Committee review that this is an 
achievable target to minimise CV, GI and renal complications in patients with 
inflammatory arthritis.  
6.2.2 Dietary intervention 
Firstly, this study informs daily practice when engaging with patients on the 
topic of self-management of their RA: advising on a healthy diet can make an 
impact on general health and well-being as potentially acting as an adjunct to 
RA disease control and reducing CV risk. 
Additional clinical research work developing on from this Mediterranean-type 
diet would be extremely useful.  There is scope to extend the project out to 
involve males (with the potential need to address the issue of how to make this 
an attractive study to them) and other types of inflammatory pathology or even 
connective diseases; systemic lupus erythematous is also associated with 
increased CV risk. Having a larger number of study participants and a wider 
socioeconomic mix would prove that the results were also applicable to the 
wider RA population. Laboratory based work could potentially explore the 
impact of dietary intervention on endothelial function, arterial stiffness and 
provide further information on thrombotic variables and anti-oxidants. 
The question then arises of how best to implement such dietary changes in the 
RA population. A number of publications have detailed the benefit of medical 
student-led teaching in an undergraduate setting (424); such a peer-supported 
process could be applied to the teaching of nutritional and cooking skills by 
patients with RA to others with the condition. This could perhaps be done in 
conjunction with arthritis patient support groups, with training put in place for 
the ‘tutors’. This would potentially allow further implementation of such a diet 
in a community setting.  
Hand function in relation to ability to undertake food preparation and cooking 
was not taken into account within inclusion or exclusion criteria for this diet 
study. Occupational Therapy staff at the 3 recruiting hospital advised on the 
provision of aids for food preparation where necessary, although the data 
relating to how much input was required is not available. It is perhaps 
reasonable to think that any further dietary study of this nature may wish to 
specifically take hand function into account as part of recruitment into a dietary 
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study; a patient with poor hand function may find such an intervention difficult 
to undertake and subsequently have worse outcomes.  
Most functional scales for assessing disability in the rheumatoid hand use 
standardised tasks required specialist equipment, trained personnel or both; 
they are often complicated for routine use. A more amenable assessment which 
could be used is the Cochin Scale (425).  This comprises 18 questions concerning 
activities of daily living graded from 0 (performed without difficulty) to 5 
(impossible to do), giving a disability score out of 90. It only takes 3-4 minutes 
to perform and can be done without equipment or trained physicians. On 
reflection, use of the Cochin Scale in this study would have been feasible to 
undertake at time of study recruitment and could be used in further research 
work of this nature.   
6.2.3 Cardiovascular risk assessment 
If patients were to have specific CV risk calculations carried out on a regular 
basis in the rheumatology out-patient clinic, this would adhere to the EULAR 
recommendations outlined in Section1.4.10 and allow interventions to be 
targeted where needed. This means that close monitoring of BP and lipid levels 
need to be performed in the clinic or done in conjunction with the patient’s GP 
surgery.  
Ideally, patients who have a full CV risk assessment carried out could be 
monitored over time to assess if MI or stroke has occurred. While this may be 
difficult in routine practice due to numbers involved, it is possible that patients 
starting anti-TNF or other biologic therapy could be followed up more easily, 
due to the often frequent and specialist nature of their subsequent reviews. The 
ASSIGN score would be the appropriate assessment of CV risk in the recruiting 
rheumatology unit, as it takes into account social deprivation. 
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APPENDIX I - SAMPLE PAGE FROM FOOD FREQUENCY QUESTIONNAIRE 
Please ensure you have a tick () on every line         Adapted from (311) 
FOODS & AMOUNTS AVERAGE USE 
 Never / 
less 
than 1 
per 
month 
1-3 
per 
month 
Once 
per 
week 
2-4 
per 
week 
5-6 
per 
week 
Daily  4-5 
per 
day 
6+ 
per 
day 
DRINKS 
Tea - cup         
Coffee (instant/ground) - cup         
Coffee (decaffeinated) – cup         
Cocoa / hot chocolate – cup         
Horlicks / Ovaltine – cup         
Wine – glass         
Beer / lager / cider – half pint         
Port / sherry / liqueur – glass         
Spirits (gin / vodka / whisky) – glass         
Low calorie / diet fizzy drink – glass         
Fizzy soft drink – glass         
100% pure  fruit juice – glass         
Fruit squash / cordial – glass         
FRUIT 
Apples         
Pear s         
Oranges / Satsumas / mandarin s         
Grapefruits         
Bananas         
Grapes         
Melon         
Peaches / plums / apricots         
Strawberries / raspberries / kiwi          
Tinned fruit         
Dried fruit (raisins / prunes)         
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APPENDIX II – NSAID WITHDRAWAL STUDY PATIENT RECRUITMENT POSTER 
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APPENDIX III – NSAID WITHDRAWAL STUDY PATIENT INFORMATION SHEET 
 
 
PATIENT INFORMATION SHEET 
 
A PILOT STUDY TO ESTABLISH IF IT IS POSSIBLE TO WITHDRAW                             
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FROM PATIENTS WITH 
RHEUMATOID ARTHRITIS (RA) 
 
You are being invited to take part in a research study which is investigating whether 
withdrawing non-steroidal anti-inflammatory drugs will alter the way your joints feel or 
lower your blood pressure. Before you decide, it is important for you to understand why 
the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it friends, 
relatives or your GP if you wish. It tells you about the study and will answer some 
questions that you may have.  Please ask us if there is anything that is not clear or if 
you would like more information.  We want to be sure that you understand what the 
study is about.  A leaflet entitled ‘Medical Research and You’ which gives information 
about medical research is available from Consumers for Ethics Research (CERES).  If you 
would like a copy, please ask us for one. 
Please take some time to decide whether or not you wish to take part in this study.  
Thank you very much for reading this. 
 
What is the purpose of the study? 
Many people take non-steroidal anti-inflammatory drugs (NSAIDs) every day for their 
rheumatoid arthritis (RA). Examples of these tablets include: ibuprofen (Brufen), 
diclofenac (Voltarol) and etodolac (Lodine). Recent studies have shown that regular use 
of this type of drug may cause a slight rise in blood pressure or cause symptoms such as 
heartburn. We would like to see what happens to your symptoms of arthritis and blood 
pressure if we withdraw these drugs in a controlled manner. If we think that your RA 
has flared up as a result of this change, we have a programme to alter your other drugs 
/ inject the troublesome joints. 
 
Why have I been chosen? 
You have been chosen because you have RA, and are currently being prescribed a NSAID 
as part of your treatment for this. This study is taking place at Glasgow Royal Infirmary 
and at Stobhill Hospital. We aim to recruit a total of 30 patients into this study. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
What will happen to me if I take part?                                                                      
If you are suitable for the study and are happy to take part, you will begin by signing an 
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informed consent form. You will be given a copy of the information sheet and the 
signed consent form to keep. You will then attend a screening visit which will assess 
your eligibility for the study in more detail. If after this you fit the eligibility criteria 
and are still happy to take part, you will enter the study and be asked to stop taking 
your NSAID.  
 
We will ask you to completely stop taking NSAIDs from the time you enter our study - 
we do not wish you to gradually reduce the dose as this may cause confusion with 
interpreting the results of the study. We will ask your general practitioner (GP) by 
letter not to prescribe any NSAIDs while you are participating in this study and kindly 
ask that you do not take NSAIDs that have been bought over-the-counter from a 
pharmacy.  
 
You will still take other medicines prescribed for your RA (eg. Sulphasalazine, 
Hydroxychloroquine or Methotrexate) and you will still be allowed to take other 
painkillers such as Paracetamol or Co-Codamol. Your involvement in the study will last 
for 12 weeks and you will need to make 3 visits to hospital. At the end of these visits 
you will be followed up at a routine rheumatology out patient appointment. 
 
What do I have to do? 
 Baseline visit After you have given written, fully informed consent, your study 
doctor or nurse will assess your arthritis by counting your tender 
and swollen joints and asking you to complete some 
questionnaires. Your blood pressure will be measured three 
times and we will record the average of these measurements. A 
blood sample (about 20ml or about 4 teaspoons full) will be 
taken and sent for laboratory testing to measure the levels of 
inflammatory proteins in your blood. These may be higher than 
normal because of your rheumatoid arthritis. Details of your 
medications will be recorded. We’ll also record your weight, 
height, waist and hip measurements. You will be given a diary 
where we will ask you to record the days on which you may 
have had to take extra pain-killers. 
Visit 2       
(week 6) 
Your study doctor or nurse will assess your arthritis by counting 
your tender and swollen joints and asking you to complete some 
questionnaires. Your blood pressure will be measured three 
times and we will record the average of these measurements. A 
blood sample (about 20ml or about 4 teaspoons full) will be 
taken and sent for laboratory testing to measure the levels of 
inflammatory proteins in your blood related to your rheumatoid 
arthritis. Details of your medications will be recorded and any 
additional, supporting medication you are taking will also be 
noted. We will review your diary where you may have marked 
when you have had to take extra pain-killers. 
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Visit 3       
(week 12)    
Your study doctor or nurse will assess your arthritis by counting 
your tender and swollen joints and asking you to complete some 
questionnaires. Your blood pressure will be measured three 
times and we will record the average of these measurements. A 
blood sample (about 20ml or about 4 teaspoons full) will be 
taken and sent for laboratory testing to measure the levels of 
inflammatory proteins in your blood related to your rheumatoid 
arthritis. Details of your medications will be recorded and any 
additional, supporting medication you are taking will also be 
noted. We’ll also record your weight. We will review your diary 
where you may have marked when you have had to take extra 
pain-killers. 
 
What are the alternatives to taking part in this study? 
Currently, the recommended standard of care is that you continue receiving 
medications which your GP and rheumatologist have advised. If you decide not to take 
part you will continue to receive the best standard of care available at the hospital. 
The standard of care will not be affected in any way if you decide not to take part.  
 
What are the risks of the study? 
The main concern would be that you would feel your joints a bit stiffer or your RA 
would flare after stopping taking the NSAIDs. This is the main reason for monitoring you 
closely in the study - we would wish to act quickly and try additional methods to ease 
your joint pain. 
 
Are there any benefits to taking part in the study? 
We hope that you may experience an improvement in your blood pressure but we 
cannot guarantee this and you may experience no benefits at all. In addition, you may 
feel less gastro-intestinal side-effects off these drugs. By taking part, however, you will 
be helping to provide information that may assist others with rheumatoid arthritis in 
the future. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available. If this happens, you will receive the information in writing.  This may change 
the way you feel about taking part in the study and you are free to withdraw at any 
time.  If you decide to withdraw, your study doctor will make arrangements for 
alternative care.  If you decide to remain in the study you will be asked to sign an 
updated consent form to confirm that this new information has been explained to you. 
Also, on receiving new information your doctor might consider it to be in your best 
interests to withdraw you from the study.  They will explain the reasons and arrange 
for your care to continue. 
 
What happens at the end of the study? 
You will continue with your normal hospital treatment, medication and care as your 
rheumatologist advises. We will send you a letter to inform you of the study’s overall 
results. 
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What if I want to stop taking part in this study? 
Your participation is completely voluntary and you can decide not to take part in the 
study at any time.  This will not affect your care in any way, either now or in the 
future.  If your personal circumstances change and you no longer wish to be involved 
you may leave at any time.  You do not have to give a reason and this will not affect 
how your doctor cares for you.  If at any time you decide to stop taking part in the 
study, you should inform the study doctor. Your study doctor may ask you for the 
reason you wish to stop participating but you should not feel that you have to tell 
him/her. 
What happens if something goes wrong? 
The sponsor of this study, Glasgow Royal Infirmary has insurance which covers legal 
liability for any injuries caused to trial participants arising out of this research.  If you 
are harmed due to someone’s negligence, then you may have grounds for legal action.  
Regardless of this, if you have cause to complain about any aspect of the way you have 
been approached or treated during this study, then normal National Health Service 
complaint mechanisms are available to you. 
What about confidentiality? 
If you wish to take part in the study we will let your GP know, with your consent. In 
addition, we will ask your GP to let us know of any relevant medical problems that we 
may not know about. This would only be in relation to any problems that could 
influence how we interpret the results of this study and would again only be done with 
your consent. 
Members of the research team from the Glasgow Royal Infirmary/Stobhill Hospital will 
need to inspect your health records, relevant to this study.  In certain circumstances 
your records or results may be looked at by members of appropriate regulatory bodies, 
for purposes of checking that the study is being done correctly.  By signing the consent 
form, you are agreeing to let these people see your medical notes. Confidentiality is 
promised in all cases and your identity and address will not be disclosed.  Any 
information that may leave the hospital, apart from that we send to your GP, will have 
your name and address removed and you will only be identified by your initials and 
study number. You will not be identified in any report/publication resulting from the 
research. Under the UK Data Protection Act (1998), you may ask to see your study 
records. Coded data about you collected during the study will be stored on password 
protected computerised systems for the purpose of processing, analysis, etc. by 
authorised study personnel. 
 
Who is organising and funding the research?                                                          
The Centre for Rheumatic Diseases is organising this research study. The research is 
being sponsored by Glasgow Royal Infirmary and is being supported in part by an 
educational scholarship from the Royal College of Physicians & Surgeons in Glasgow, 
which is contributing to the salary of Dr Gayle McKellar The study objectives and its 
proposed conduct has been reviewed by the Glasgow Royal Infirmary Research Ethics 
Committee and has given approval for the study on 18th September 2006.  
 
What will happen to the results of the research study?                                           
The results of this study will be part of work that will be published in scientific and/or 
medical journals. You will not be identified in any paper or publication. In addition, the 
results of this study may form part of a submission for a higher degree for Dr Gayle 
McKellar. 
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Who do I call if I have any questions or problems? 
Please contact the study doctor or nurse below at any time, if you would like more 
information about any part of this study or if you would like more information about 
what to do in case of a study related injury or receive a copy of Consumers for Ethics 
Research (CERES) 
 
Contact names and numbers                                                                                      
If you need any further information please do not hesitate to contact Dr Gayle 
McKellar, Professor Hilary Capell and Dr Rajan Madhok (Glasgow Royal Infirmary) or Dr 
Anne McEntegart and Dr Hilary Wilson (Stobhill Hospital).  You should also contact your 
GP for independent advice should you so desire. 
 
Dr Gayle McKellar            Tel: 0141 211 4000 (page 1106) 
Professor Hilary Capell         Tel: 0141 211 4965 
Dr Rajan Madhok             Tel: 0141 211 4966 
Dr Anne McEntegart      Tel: 0141 211 3306 
Dr Hilary Wilson          Tel: 0141 211 3306 
Sister Rosie Hampson  Tel: 0141 211 4408 
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APPENDIX IV – NSAID WITHDRAWAL STUDY CONSENT FORM 
 
 
A PILOT STUDY TO ESTABLISH IF IT IS POSSIBLE TO WITHDRAW                             
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FROM PATIENTS WITH 
RHEUMATOID ARTHRITIS (RA) 
Chief Investigator: Dr Gayle McKellar 
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 84 Castle Street,                   
Glasgow, G4 0SF 
 
INFORMED CONSENT FORM 
Please read the following statements and initial the box beside the statement if you 
agree with it. 
1. I confirm that I have read and understand the information sheet dated 12.09.06 
(version 2.0) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason and without my medical care or legal rights 
being affected. 
 
3.   I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking part 
in this research. I give permission for these individuals to have access to my 
records.                             
 
4. I agree to my GP being informed of my participation in the study and being 
asked to provide any information relevant to this study that we may not be aware 
of. 
 
5.   I agree to take part in the above study.    
 
 
 
________________________ _______________                 _______________  
Name of Patient Date Signature 
________________________ _______________                 _______________  
Name of Person taking consent Date Signature 
 
When completed –  
1 copy for patient, 1 copy for researcher site file, 1 copy (original) to be kept in 
medical notes
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APPENDIX V – MEDITERRANEAN-TYPE DIET PATIENT INFORMATION SHEET 
 
PATIENT INFORMATION SHEET 
 
A PILOT STUDY OF THE EFFECT OF MEDITERRANEAN DIET INTERVENTION ON DISEASE 
ACTIVITY AND HAEMATOLOGICAL MARKERS OF CARDIOVASCULAR RISK IN FEMALE 
PATIENTS WITH RHEUMATOID ARTHRITIS (RA) 
 
Lay Title: Does changing to a Mediterranean Diet alter blood markers of cardiovascular 
risk and rheumatoid arthritis activity in female patients with Rheumatoid Arthritis? 
 
 
We would like to invite you to help with the above research study. Before you 
decide it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information and discuss 
it with friends and relatives if you wish. Ask us if there is anything that is not clear 
or if you would like more information. Take time to decide whether or not you wish 
to take part. 
 
What is the purpose of the study? A recent Swedish study showed that taking a 
Mediterranean-type diet (ie. high in vegetables, fruits, nuts, beans, pulses and fish but 
low in meat and high-fat dairy products) was helpful to patients with rheumatoid 
arthritis in reducing joint inflammation and in improving physical function and energy 
levels. We would like to study whether the same is true in Glasgow patients as this 
might prove a useful form of therapy in addition to currently available treatments. 
The Mediterranean Diet also benefits health in other ways and is associated with lower 
levels of heart disease. We also plan to study and measure some aspects of this. 
Why have I been chosen? We are inviting 180 female patients with rheumatoid 
arthritis attending the rheumatology clinics at the Southern General Hospital, Glasgow 
Royal Infirmary and Stobhill Hospital to take part in the study (60 patients at each 
hospital). 
Do I have to take part? It is up to you to decide whether or not to take part. If you do 
wish to take part you will be given this information sheet to keep and be asked to sign a 
consent form. You are still free to withdraw at any time and without giving a reason. A 
decision not to take part, or a decision to withdraw at any time, will not affect the 
standard of care you receive. 
What will happen to me if I decide to take part? We are comparing the effects of the 
Mediterranean diet with an ordinary diet. Patients will be allocated at random to either 
the treatment group (Mediterranean Diet) or control group (ordinary diet). 
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The study will last for 6 months. 
If you are allocated to the Mediterranean diet group you will be asked to do the 
following : 
1. Attend a "Get Cooking, Get Shopping" course run by nutrition (food) specialists and 
organised by the Health Promotion Department of Greater Glasgow Health Board. 
The course is free and will provide you with all the information you need about the 
Mediterranean Diet to allow you to change your current diet to a healthier diet in 
the long term. It involves one two hour session per week for 6 weeks and you will be 
able to take part in cooking as well as discussion and will be given some written 
information. The course will be held locally and will involve 10 people at a time.  
 
2. Attend the hospital on 4 occasions (at the start of the study, after two weeks, 3 
months & 6 months) for assessment by a nurse. At the screening visit the study will 
be explained again and you will be issued with a food diary to record your food 
intake and be shown how to complete the diary.   At each subsequent visit the 
activity of your arthritis will be assessed, you will be asked to complete a health 
assessment questionnaire, your weight will be checked and the nurse will go over 
your food diary.  
 
In addition, a blood sample (25mls = 1 & ¾ tablespoonful in total) will be taken to 
check the ESR and CRP (markers of the inflammation associated with arthritis), 
FRAP test (a marker of fruit and vegetable intake), thrombotic or “clotting” test 
(markers of heart disease risk) and lipid (blood fat) levels.  
 
3. A note will be made of any other illnesses you have and of the medications you are 
taking. 
 
4. Smoking history and alcohol intake will also be noted. 
 
If you are allocated to the ordinary diet group: 
At the screening visit the study will be explained again and you will be issued with a 
food diary to record your food intake and be shown how to complete the diary. You will 
be given written information about healthy eating but will not attend the "Get Cooking, 
Get Shopping" course. You will be asked to attend for the same assessments at the 
hospital outlined above. 
(NB. You will be offered delayed entry into the Mediterranean Diet part of the study at 
a later date if you wish.). 
Will my usual arthritis treatment be affected?   No. Your medications and other 
treatments (eg. physiotherapy, occupational therapy) will stay the same.   However, 
we would like, if possible, to avoid steroid injections (into the joints or muscles) within 
4 weeks of an assessment. 
What are the possible risks of taking part?  There are no known risks associated with 
taking part in the study.  A healthy diet is likely to prove beneficial to general health. 
What are the possible benefits? We hope that the Mediterranean Diet will help 
rheumatoid arthritis. However, this cannot be guaranteed. The information we get 
from the study may help us with the future treatment of patients with rheumatoid 
arthritis.  
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Will my taking part in this study be kept confidential?  Yes.  All information which is 
collected about you during the course of the study will be kept confidential. 
What will happen to the results of the research study? Once all of the results have 
been analysed we may seek to publish them in an anonymous format in a medical 
journal. There are no immediate plans to link this piece of research with other research 
ongoing within our department. However it is possible that this may be considered in 
the future and you should be aware that the information gathered during this study 
may be held indefinitely and linked anonymously to other pieces of research in the 
future. 
Who has reviewed the study? Members of the Local Research Ethics Committee at 
Glasgow Royal Infirmary have reviewed the study.  
Who do I contact for further information about this study? Thank you for taking the 
time to read this information sheet. If you have any concerns or questions about the 
study at any time you can discuss these with the study team  
Doctor:  Hilary Capell   Telephone: 0141-211-4965 
Sister:  Rosie Hampson  Telephone: 0141-211-4408 
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APPENDIX VI – MEDITERRANEAN-TYPE DIET STUDY CONSENT FORM 
 
 
A PILOT STUDY OF THE EFFECT OF MEDITERRANEAN DIET INTERVENTION ON DISEASE 
ACTIVITY AND HAEMATOLOGICAL MARKERS OF CARDIOVASCULAR RISK IN FEMALE 
PATIENTS WITH RHEUMATOID ARTHRITIS (RA) 
Lay Title: Does changing to a Mediterranean Diet alter blood markers of cardiovascular 
risk and rheumatoid arthritis activity in female patients with Rheumatoid Arthritis? 
 
Chief Investigator: Dr Hilary A Capell 
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 84 Castle Street,                   
Glasgow, G4 0SF 
 
INFORMED CONSENT FORM 
Please read the following statements and initial the box beside the statement if you 
agree with it. 
 
1. I confirm that I have read and understood the Patient Information Sheet dated 
September 2003 (version 2) for the above study and have had the opportunity to 
ask questions  
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected. 
 
3.   I agree to take part in the above study.    
 
 
 
 
________________________ _______________                 _______________  
Name of Patient Date Signature 
________________________ _______________                 _______________  
Name of Person taking consent Date Signature 
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APPENDIX VII – SAMPLE SF-12 FORM Adapted from (395) 
This survey asks for your views about your health. This information will help keep 
track of how you feel and how well you are able to do your usual activities. Answer 
every question by selecting the answer as indicated. If you are unsure about how 
to answer a question, please give the best answer you can. 
1. In general, would you say your health is: 
Excellent ⃝ Very good ⃝ Good ⃝ Fair ⃝ Poor ⃝ 
 
2. The following questions are about activities you might do during a typical day.       
Does your health now limit you in these activities? If so, how much? 
 Yes, limited  
a lot 
Yes, limited  
a little 
No, not at all 
limited 
Moderate activities such as moving 
a table, pushing a vacuum cleaner, 
bowling or playing golf? 
     
              ⃝ 
 
                ⃝ 
 
              ⃝ 
 
Climbing several flights of stairs? 
 
     
              ⃝ 
 
                ⃝ 
 
              ⃝ 
 
3. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular activities as a result of your 
physical health? 
 All of the 
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
Never 
Accomplished less 
than you would 
have liked 
 
     
         ⃝ 
 
           ⃝ 
 
             ⃝ 
     
          ⃝ 
 
       ⃝ 
Were limited in the 
kind of work or 
activities 
     
         ⃝ 
 
           ⃝ 
 
             ⃝ 
     
          ⃝ 
 
       ⃝ 
 
4. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result of 
any emotional problems (such as feeling depressed or anxious?) 
 All of the 
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
Never 
Accomplished less 
than you would 
have liked 
 
     
         ⃝ 
 
           ⃝ 
 
             ⃝ 
     
          ⃝ 
 
       ⃝ 
Limited in the kind 
of work / activities 
     
         ⃝ 
 
           ⃝ 
 
             ⃝ 
     
          ⃝ 
 
       ⃝ 
      
5. During the past 4 weeks, how much did pain interfere with your normal work 
(including work outside the home and housework)? 
Not at all ⃝ A little 
bit 
⃝ Moderately           ⃝ Quite a 
bit 
⃝ Extremely ⃝ 
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6. These questions are about how you feel and how things have been with you 
during the past 4 weeks. For each question, please give the one answer that 
comes closest to the way you have been feeling. How much of the time during 
the past 4 weeks... 
 All of the time Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
 
Have you felt 
calm and 
peaceful 
 
 
          ⃝ 
 
            ⃝ 
 
           ⃝ 
 
           ⃝ 
 
           ⃝ 
Did you have 
a lot of energy 
 
 
          ⃝ 
 
            ⃝ 
 
           ⃝ 
 
           ⃝ 
 
           ⃝ 
Have you felt 
downhearted 
and 
depressed 
 
          ⃝ 
 
            ⃝ 
 
           ⃝ 
 
           ⃝ 
 
           ⃝ 
 
7. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting friends 
and family) etc? 
All of the       
time 
⃝ Most of 
the 
time 
⃝ Some of 
the time 
⃝ A little of 
the time 
⃝ None of 
the time 
⃝ 
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APPENDIX VIII – SAMPLE HAQ FORM Adapted from (399) 
Please place an “X” in the box which best describes your abilities over the last 
week 
 Without any 
difficulty 
With some 
difficulty 
With much 
difficulty 
Unable to 
do 
DRESSING & GROOMING     
Are you able to: 
Dress yourself, including 
shoelaces and buttons? 
⃝ ⃝ ⃝ ⃝ 
Shampoo your hair? ⃝ ⃝ ⃝ ⃝ 
ARISING     
Are you able to: 
Stand up from a straight chair? 
⃝ ⃝ ⃝ ⃝ 
Get in and out of bed? ⃝ ⃝ ⃝ ⃝ 
EATING     
Are you able to: 
Cut your own meat? 
⃝ ⃝ ⃝ ⃝ 
Lift a full cup or glass to your 
mouth? 
⃝ ⃝ ⃝ ⃝ 
Open a new milk carton? ⃝ ⃝ ⃝ ⃝ 
WALKING     
Are you able to: 
Walk outdoors on flat ground? 
⃝ ⃝ ⃝ ⃝ 
Climb up five steps? ⃝ ⃝ ⃝ ⃝ 
 
Please mark any AIDS or DEVICES that you usually use for any of the above 
activities: 
Devices used for dressing       ⃝ Built up or special utensils       ⃝ Crutches             ⃝ 
Walking stick           ⃝ Wheelchair            ⃝ Zimmer / frame            ⃝ 
Special / built up chair            ⃝   
 
Please mark any categories for which you usually need HELP FROM ANOTHER 
PERSON: 
Dressing and 
grooming        ⃝ 
Arising            ⃝ Eating            ⃝ Walking            ⃝ 
 
Please rate HOW WELL YOU ARE on a scale of zero to 100  
How much PAIN have you had in the PAST WEEK on a scale of zero to 
100  
 
 
 
 
 
 
   
   
228 
 
       
Please place an “X” in the box which best describes your abilities over the last 
week 
 Without any 
difficulty 
With some 
difficulty 
With much 
difficulty 
Unable to 
do 
HYGIENE     
Are you able to: 
Wash and dry your body? 
 ⃝ ⃝ ⃝ ⃝ 
Take a tub bath? ⃝ ⃝ ⃝ ⃝ 
Get on and off the toilet? ⃝ ⃝ ⃝ ⃝ 
REACH     
Are you able to: 
Reach and get a bag of sugar 
from above your head? 
⃝ ⃝ ⃝ ⃝ 
Bend down to pick something 
off the floor? 
⃝ ⃝ ⃝ ⃝ 
GRIP     
Are you able to: 
Open car doors? 
⃝ ⃝ ⃝ ⃝ 
Open previously opened jars? ⃝ ⃝ ⃝ ⃝ 
Turn taps on and off? ⃝ ⃝ ⃝ ⃝ 
ACTIVITIES     
Are you able to: 
Run errands and shop? 
⃝ ⃝ ⃝ ⃝ 
Get in and out of a car? ⃝ ⃝ ⃝ ⃝ 
Do household chores like 
vacuuming? 
⃝ ⃝ ⃝ ⃝ 
 
Please mark any AIDS or DEVICES that you usually use for any of the above 
activities: 
Raised toilet seat       ⃝ Bath handles       ⃝ Bath seat             ⃝ 
Long handled appliances for 
reach           ⃝ 
Long handled appliances in 
bathroom            ⃝ 
Jar opener (for jars previously 
opened)            ⃝ 
 
Please mark any categories for which you usually need HELP FROM ANOTHER 
PERSON: 
Hygiene       ⃝ Reach             ⃝ Gripping and opening 
things         ⃝ 
Errands and 
chores          ⃝ 
 
To what extent are you able to carry out your EVERYDAY PHYSICAL ACTIVITIES 
such as walking, climbing stairs, carrying groceries or moving a chair? 
Completely        ⃝ Mostly        ⃝ Moderately       ⃝ A little       ⃝ Not at all       ⃝ 
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APPENDIX IX – HEALTHY EATING INFORMATION SHEET 
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APPENDIX X- SELECTED PAGES 
FROM PATIENT DIETARY 
INFORMATION PACK 
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APPENDIX XI – MEDITERRANEAN-
TYPE DIET RESULTS POSTER  
WHAT IS A MEDITERRANEAN-TYPE DIET? 
This is a diet common to areas around the 
Mediterranean Sea: including parts of Spain, 
France, Italy and Greece. It is typically rich 
in olive oil, fish, fruit and vegetables and 
low in saturated fats. It has been 
associated with health benefits for the 
heart, blood vessels and joints. 
OUR STUDY 
We designed this study to try to overcome 
obstacles to healthy eating in some areas of 
Glasgow. 
130 females with rheumatoid arthritis who 
attended rheumatology clinics at Glasgow 
Royal, Stobhill or Southern General 
Hospitals volunteered for this study. 55 
were given written information only on diet, 
while the other 75 attended cookery classes 
for 6 weeks on the Mediterranean-type diet. 
Everyone had their arthritis and blood 
pressure monitored, as well as completing 
food diaries. 
RESULTS OF OUR STUDY 
The diet group ate significantly more fruit 
and vegetables and lost more weight than 
the other group. Their blood pressure fell: 
the systolic blood pressure (the top number) 
fell from an average of 132 to 128. While 
this may not look that impressive on paper, 
even a small drop in blood pressure can 
have beneficial effects on your heart and 
blood vessels 
With regards to arthritis, the diet group felt 
their joints were less painful, stiff and 
swollen and that they were less stiff in the 
morning. 
IMPORTANCE OF THIS STUDY 
We think that this is an important study and 
are encouraging all of our patients to look 
at how they could make improvements to 
their diet to help their arthritis and 
potentially their blood pressure. Diet will 
never cure arthritis nor replace all of your 
drug treatments, but it can make a big 
difference to how you are feeling. 
 
 
PYRAMID OF FOOD INTAKE 
You should take less of the items at the top 
of the pyramid and more from the bottom. 
 
 
Adapted from: WC Willett et al, “Mediterranean diet 
pyramid: a cultural model for healthy eating”. 
American Journal of Clinical Nutrition 1995 61(6 
Suppl):1402S-1406S 
Red 
meat 
Sweets 
Eggs 
Poultry 
Fish 
Dairy 
products 
(milk, 
cheese, 
yoghurt) 
Olive oil 
Fruit Vegetables  
Beans Nuts 
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APPENDIX XII – JOINT BRITISH SOCIETIES CORONARY RISK PREDICTION CHART 
Taken from (108) and reproduced with permission from the British Medical Journal 
(BMJ) Publishing Group Ltd.
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Background: A Mediterranean-type diet rich in fish, fruit and vegetables and low in saturated fats has been
associated with health benefits, including improved cardiovascular profile and benefit in RA.
Objective: To overcome obstacles to healthy eating by a community-based intervention promoting a
Mediterranean-type diet in patients with RA living in socially deprived areas of Glasgow.
Methods: 130 female patients with RA aged 30–70 years (median 55), disease duration 8 years were
recruited from three hospital sites. The intervention group (n = 75) attended weekly 2-hour sessions for
6 weeks in the local community, including hands-on cooking classes backed up with written information. The
control group (n = 55) were given dietary written information only. Both groups completed food frequency
questionnaires (FFQs), and clinical and laboratory measures were assessed at baseline, 3 and 6 months.
Results: Significant benefit was shown in the intervention group compared with controls for patient global
assessment at 6 months (p = 0.002), pain score at 3 and 6 months (p = 0.011 and 0.049), early morning
stiffness at 6 months (p = 0.041) and Health Assessment Questionnaire score at 3 months (p = 0.03). Analysis
of the FFQs showed significant increases in weekly total fruit, vegetable and legume consumption and
improvement in the ratio of monounsaturated:saturated fat intake and systolic BP in the intervention group
only. The cooking classes were positively received by patients and tutors; cost/patient for the 6 week course
was £84 (J124).
Conclusions: Results demonstrate that a 6 week intervention can improve consumption of healthier foods. If
implemented more widely it may prove a popular, inexpensive and useful adjunct to other RA treatment.
I
n the 1950s, the cook and writer Elizabeth David introduced
A Book of Mediterranean Food1 to a postwar Britain still under
food rationing and so started our enthusiasm for this
delicious cuisine. More recently, the health benefits of the
Mediterranean diet have emerged. Characteristically this type
of diet includes a high intake of fruit, vegetables, legumes, a
moderate to high intake of fish, a low intake of dairy products
and red meat and a high intake of unsaturated fats (especially
olive oil) complemented by a modest amount of alcohol
(mainly in the form of wine).
A Mediterranean diet has been associated with increased
survival in older people in a large, prospective cohort study
involving nine European countries2 and has proved an effective
intervention in both the primary3 and secondary4 prevention of
coronary heart disease. An improved cardiovascular risk profile
is probably mediated through a number of factors, including
modification of hyperlipidaemia, hypertension and obesity as
well as reduction in C reactive protein.5 This last effect is
potentially important in arthritis. A prospective, nested, case–
control study6 identified a high level of red meat consumption
as a dietary risk factor for the development of inflammatory
polyarthritis, while a similar study7 noted that patients with a
low intake of fruit and vitamin C (exogenous antioxidants)
were more likely to develop arthropathy than matched controls.
The precise mechanism of this effect is uncertain; these factors
may be acting as markers in a group of people at increased risk
from other, possibly lifestyle-related, factors. Indeed a recent
cross-sectional study has shown that wine buyers purchase
more healthy food items than people who buy beer.8
A 12 week randomised trial of Mediterranean diet interven-
tion in 51 patients with RA demonstrated positive benefits,
with a reduction in disease activity (measured by the 28 joint
count Disease Activity Score (DAS28)), an improvement in
physical function (Health Assessment Questionnaire (HAQ))
and increased vitality,9 effects likely to be multifactorial.
Further analysis showed an increase in reported consumption
of antioxidant-rich foods during the Mediterranean diet
intervention.10 Intriguingly, the discovery of ibuprofen-like
activity in extra-virgin olive oil may help to explain its effect.11
It is not clear, however, whether a Mediterranean-type diet
could achieve similar results in patients with RA in a true-to-
life setting, particularly in a population with high levels of
social deprivation such as Glasgow, the largest city in Scotland.
Any intervention requiring a change in lifestyle or behaviour,
especially those which may be life long and culturally driven, is
difficult to achieve and sustain. However, behavioural counsel-
ling to increase consumption of fruit and vegetables in lower
income adults in the general population has led to sustained
increases in intake.12
The gain from a Mediterranean-type diet intervention in
patients with RA is potentially twofold. Firstly, improvement in
disease activity and secondly, reduction in cardiovascular risk—
people with RA are known to be at increased cardiovascular
risk13–15 and have increased cardiovascular disease mortality.16
Social deprivation has an additional negative impact on both
RA17 and cardiovascular risk.18
Abbreviations: DAS28, 28 joint count Disease Activity Score; DMARD,
disease modifying antirheumatic drug; EMS, early morning stiffness; FFQ,
food frequency questionnaire; GGHBHPD, Greater Glasgow Health
Board’s Health Promotion Department; HAQ, Health Assessment
Questionnaire; IL6, interleukin 6
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In this study we wished to explore the feasibility of
introducing a Mediterranean-type diet to our female patients
with RA living in areas of social deprivation and to assess
change, if any, in lifestyle, disease activity and cardiovascular
risk.
METHODS
One hundred and thirty female patients with RA aged 30–70
years were recruited over 9 months from three hospital sites—
we aimed at recruiting residents from within any of the Social
Inclusion Partnership areas in Glasgow, which are areas of
social deprivation.
Intervention group
Patients in the intervention group (n = 75) attended a 6 week
cookery course (with emphasis on a Mediterranean-type diet)
organised by Greater Glasgow Health Board’s Health Promotion
Department (GGHBHPD) and delivered by nutritionists and
teaching staff from local colleges. Occupational therapy staff
advised about provision of aids for food preparation. The
patients attended a weekly 2 hour cookery class, with a
maximum of 10 participants in each session. Participants
received a folder with written information on a Mediterranean-
type diet, healthy eating and recipes which promoted the
increased consumption of fruits, vegetables and legumes, along
with the substitution of saturated fat with monounsaturated
fat in the form of olive oil or spreads containing olive oil. In
addition to ‘‘hands-on’’ food preparation, cooking and tasting,
the participants received information about food hygiene,
nutrition and local accessibility of affordable ingredients.
Control group
Control patients (n = 55) received readily available written
information on healthy eating only.
Allocation
We originally intended to allocate patients randomly to
intervention and control groups. However, a limiting factor
proved to be the availability of a cookery course in a venue close
to the patient’s home at a time suitable to them. A more
pragmatic approach was necessary, resulting in those able to
attend on certain dates being allocated to the intervention
group and those unavailable on dates of programmed courses
becoming the control group.
Patient assessment
Patients in both groups were assessed at baseline, 3 and
6 months.
Clinical features
Tender and swollen joint count, patient global pain score,
duration of early morning stiffness (EMS), DAS28, HAQ score,
erythrocyte sedimentation rate, C reactive protein, and inter-
leukin 6 (IL6) were measured. IL6 is a proinflammatory
cytokine and acts as a mediator in the acute phase response
(higher levels of IL6 are present in more active disease).
Cardiovascular risk
Assessment included documentation of smoking habits, sys-
tolic and diastolic blood pressure, total and high-density
lipoprotein cholesterol, glutathione and body mass index.
Glutathione has important roles in preventing oxidative stress,
metabolising nutrients and regulating cellular events. A
deficiency of glutathione contributes to oxidative stress and
can be implicated in the pathogenesis of heart disease.
Dietary assessment
Dietary data were collected using a previously validated food
frequency questionnaire (FFQ),19 which was completed by
participants at the clinical assessment visits. The Mediterranean
diet is rich in fruits, vegetables and legumes, which are good
sources of the antioxidant vitamins A, C and E. If the
intervention were successful in promoting dietary change, we
would expect to see increases in intake of these food groups as
well as the associated nutrients. A composite score of the
weekly total number of servings of the three food groups was
calculated. Additional questions about fruit intake were
included in the FFQ as the DietQ FFQ collects only limited
data on fruit consumption. These questions were analysed
separately using the diet 5 computer package, and the nutrient
data added to the data estimated by DietQ to calculate the daily
intake of vitamins A, C and E.
Deprivation
The Carstairs grouping for each patient was noted20 (derived
from postcode, based on male employment, overcrowding, car
ownership and social class).
Statistical analysis
A Wilcoxon matched-pairs signed-ranks test was used for
within-group analyses and a Mann–Whitney U test for
comparison between intervention and control groups.
Ethics
Local ethics committee approval was given before staring this
study.
Table 1 Group demographics at baseline
Demographics
Intervention (n = 75) Control (n = 55)
Median Mean Interquartile range Median Mean Interquartile range
Age (years) 58 55 47–64 52 53 45–61
Disease duration (years) 7 9.3 3.5–14 7 9.6 4–12
BMI (kg/m2) 25.86 26.75 22–33 27.65 27.95 24–31
BMI, body mass index.
Figure 1 Influence of deprivation.
1240 McKellar, Morrison, McEntegart, et al
www.annrheumdis.com
 on 16 August 2007 ard.bmj.comDownloaded from 
RESULTS
Table 1 shows that age, disease duration and body mass index
were similar in both intervention and control groups.
As expected by the design of the study, the patients in the
intervention group were more likely to be in the most deprived
social classes 6 and 7, living in a Social Inclusion Partnership
area (fig 1). Baseline cardiovascular risk based on blood
pressure, age and smoking status was calculated for all patients
using readily available and validated graphs21; none of the
recruited patients had diabetes mellitus. Sixty per cent had a
calculated cardiovascular disease risk of ,10% over the next 10
years, 30% a risk of 10–20% and 10% a .20% risk.
Consumption of fruit, vegetables and legumes was below the
recommended minimum of five portions a day, in both groups
at baseline. By 3 months this had improved significantly in the
intervention group who were attending cooking classes
(table 2).
At the same time, this group also had a significant
improvement in the ratio of monounsaturated:saturated fats
consumed. Alcohol consumption was low in both groups with a
mean consumption of 1.5 units/week in the intervention group
and 1.9 units/week in the control group. We reviewed disease
modifying antirheumatic drug (DMARD) treatment, examining
any escalation of dose or addition of extra DMARD over the
study period. Within the 6 months, 21.3% of the intervention
group and 23.6% of the control group had such a change in
their treatment.
Clinical assessments showed a significant benefit in the
intervention group compared with the control group for patient
global assessment at 6 months (p = 0.002), pain score at 3 and
6 months (p = 0.011 and 0.049), EMS at 6 months (p = 0.041)
and HAQ at 3 months (p = 0.03)—Mann–Whitney calculations
(table 3).
Evaluation of cardiovascular risk factors showed a significant
drop in systolic blood pressure by an average of 4 mm Hg in the
intervention group (p = 0.016), while the control group showed
no change. No significant change in cholesterol or glutathione
levels was found with this intervention (table 4).
The cost per patient for the 6 week cookery course was £84
(J124) (met by the GGHBHPD).
DISCUSSION
In this study we sought to assess whether we could modify
dietary lifestyle, disease activity and cardiovascular risk in
female patients with RA living in areas of social deprivation by
introducing them to a Mediterranean-type diet. Cookery classes
to provide ‘‘hands-on’’ experience of a Mediterranean-type diet
were an essential element in increasing knowledge and
confidence in the participants.
This study shows that this intervention was achievable and
well received by patients. Intake of fruit, vegetables and
legumes increased significantly over 3 months in the interven-
tion group and the use of monounsaturated compared with
saturated fats improved. The majority of the participants felt
that the recipes were straightforward to make and affordable.
Only three stated they were unable to purchase the necessary
ingredients, either because they were too costly or were
unavailable in their local shops. There were also wider social
benefits in that most felt they had learnt new skills in food use
and preparation. Some women also noted an improvement in
confidence and self-esteem as they were now able to contribute
more to cooking for themselves and their families at home.
We failed to see a significant improvement in the intake of
the antioxidant vitamins A, C and E. Possibly, the FFQ was not
sufficiently sensitive to detect changes in the actual nutrient
intake. The FFQ was originally developed to assess the intake of
total energy and macronutrients—protein, fat and carbohy-
drate—at a time when antioxidants were not the focus of
interest.19 The number of fruits and vegetables represented in
the FFQ is relatively limited and it is possible that participants
increased their intake with items not listed on the FFQ. A more
accurate assessment of nutrient intake might have been
Table 2 Food frequency diaries at baseline and 3 months in the two groups
Intervention (n = 75) Control (n = 55)
0 3 Months p Value 0 3 Months p Value
Fruit, vegetables and legumes (portions/week) 23.5 26 0.016 21.5 23 0.84
Monounsaturated fats:saturated fats 0.86 0.92 0.022 0.82 0.83 0.726
Vitamin A (mg/day) 1108 1246 0.101 922 974 0.403
Vitamin C (mg/day) 94 104 0.081 94 94 0.929
Vitamin E (mg/day) 7.0 6.8 0.626 5.8 5.5 0.448
Results are shown as medians.
Table 3 Baseline Disease Activity Scores (DAS) and clinical outcomes at baseline, 3 and 6 months
Intervention (n = 75) Control (n = 55)
Mann–Whitney between
groups0 3 Months 6 Months 0 3 Months 6 Months
Tender joint count (0–28) 5 5 4 6 6 6 –
Swollen joint count (0–28) 6 5 4 6 5 5 –
Patient global VAS (0–100 mm) 50 50 45 54 55 63 6 Months 0.002
Pain score VAS (0–100 mm) 50 50 50 55 62 63 3 Months 0.011
6 Months 0.049
EMS (min) 30 30 15 60 30 30 6 Months 0.041
HAQ score (0–3) 1.75 1.625 1.625 1.75 1.875 1.875 3 Months 0.03
DAS28 4.7 4.5 4.4 5.0 4.7 4.8 –
ESR (mm/1st h) 19 20 16 19 19 16 –
CRP (mg/l) 10 10 10 8.5 8 8 –
IL6 (pg/ml) 4.7 3.85 3.35 4.1 3.8 5.3 NS
Results are shown as medians.
VAS, visual analogue scale; EMS, early morning stiffness; HAQ, Health Assessment Questionnaire; DAS28, 28 joint count Disease Activity Score; ESR, erythrocyte
sedimentation rate; CRP, C reactive protein; IL6 interleukin 6; NS, not significant.
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achieved by using 7-day weighed or estimated food diaries.
However, this method places a heavy burden on the participant,
which we did not think was appropriate given the age and
health of our subjects. In addition, they are costly and time
consuming to analyse: we did not have the funds to employ the
specialist skills required to code and analyse food diaries.
We, like previous investigators,9 have shown a modest
improvement in a number of measures of disease activity.
Pain score was significantly better in the Mediterranean diet
group than in the controls at 3 and 6 months. Patient global
assessment and reported EMS were significantly better at
6 months. Patient function, as assessed by the HAQ score, was
also better in the intervention group at 3 months. Overall the
DAS28 score remained unchanged in both groups, but despite
this, patients in the intervention group clearly felt better. The
reasons for this are likely to be multifactorial and may, in part,
reflect increased confidence and self-esteem as well as dietary
intervention. As it is impossible to conduct this type of study in
a double-blind fashion, we cannot entirely exclude the
possibility of a placebo response, but this seems less likely as
the same trend was seen over a number of measurements and
was sustained.
Patients with RA are at increased risk of cardiovascular
events13 14 and we also aimed to assess if we could modify this
tendency in our patients. The intervention group lost weight
(median 0.9 kg over the 6 month period), whereas the control
group showed a weight gain (median 3 kg). However, this
difference was not statistically significant. Cholesterol levels (at
baseline and 6 months) and smoking status did not differ
between the two groups. We noted a small (mean 4 mm Hg)
but significant reduction in systolic blood pressure in the
intervention group. This was not attributable to the prescription
of, or changes to, anti-hypertensive treatment. However, the
magnitude of the change noted is perhaps what we might
achieve with the introduction of a mild anti-hypertensive agent
in routine practice. The benefit to patients is that this was
achieved without an addition to their drugs.
This study has shown that female patients with RA following
a Mediterranean-type diet derive modest benefits across a range
of areas, suggesting that this type of intervention may be a
useful therapeutic adjunct to conventional DMARDs, feasible in
routine clinical practice and popular with patients.
The initial objectives when designing this study were to
assess if lifestyle, disease activity or cardiovascular risk might
be altered by this type of intervention. The results show that
this is indeed achievable at low cost and is acceptable to
patients with RA.
To act on and implement these findings we have approached
local and national (Scottish) public health authorities to inform
them of the results and discuss the potential impact of
assessment in a larger population.
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Nonsteroidal Antiinflammatory Drug Withdrawal in
Patients with Stable Rheumatoid Arthritis 
GAYLE E. McKELLAR, ROSEMARY HAMPSON, ANN TIERNEY, HILARY A. CAPELL, and RAJAN MADHOK
ABSTRACT. Objective. To evaluate the effect of nonsteroidal antiinflammatory drug (NSAID) withdrawal on blood
pressure (BP), 44-joint Disease Activity Score (DAS44), and functional assessments in patients with
stable rheumatoid arthritis (RA).
Methods. NSAID was withdrawn from 30 patients with stable RA (DAS44 ≤ 2.8). Other prescribed
medication continued. Clinical and laboratory measures were taken at baseline, 6 weeks, and 12 weeks.
Results. No participants required NSAID reintroduction during the study period. Significant improve-
ment in systolic BP was noted: maximal median reduction was 7 mm Hg (baseline to 12 weeks). There
was no significant deterioration in DAS44 or function. Eleven participants required additional
 intervention.
Conclusion. NSAID withdrawal resulted in improvement in BP without loss of disease control. 
(First Release July 1 2011; J Rheumatol 2011;38:2150–2; doi:10.3899/jrheum.101162)
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The morbidity and mortality associated with rheumatoid
arthritis (RA) is well documented; life span is reduced by
3–18 years1. This excess mortality is due to cardiovascular
(CV) events, secondary to atheromatous vascular disease.
Inflammatory mechanisms are a key response in the initial
endothelial damage and the subsequent progression of athero-
matous plaques. General population estimates calculate that >
70% of those with atheroma-related CV disease have ≥ 1 tra-
ditional Framingham risk factor2.
Nonsteroidal antiinflammatory drugs (NSAID) are fre-
quently prescribed to patients with RA. Most of these drugs
raise blood pressure (BP) by about 5 mm Hg3. Accumulating
evidence has implicated cyclooxygenase-2-specific and non -
selective NSAID with an increase in acute myocardial infarc-
tions4,5. In 2006, the American Heart Association advised that
to minimize CV risk, anyone prescribed an NSAID should
have the lowest dose administered for the shortest possible
time6.
Although clinical experience and expert opinion advise
that NSAID should be withdrawn in patients with RA who
have well controlled disease7, there is no evidence that this
improves the risk/benefit ratio associated with their use. Our
aim with this study was to evaluate the feasibility of NSAID
withdrawal and to identify potential benefits from withdrawal
in patients with stable RA, focusing on disease activity and
BP control.
MATERIALS AND METHODS
Local ethics committee approval was given. Study enrollment is documented
in Figure 1 and inclusion and exclusion criteria in Table 1. Thirty patients
were recruited and gave written informed consent. As this was an open-label
observational feasibility study, no specific power calculations were per-
formed. A sample size of 30 patients was considered large enough to provide
helpful results but small enough to allow rapid followup.
Patients were asked to stop prescribed NSAID abruptly, without tapering
the dose. Disease-modifying antirheumatic drug (DMARD) therapy was con-
tinued. General practitioners were asked not to prescribe NSAID for the
 duration of our study and patients were requested not to self-administer 
over-the-counter NSAID, as explained in the patient information sheet. Use
of acetaminophen or codeine-containing compound analgesia was allowed.
Patients were encouraged to make telephone contact if further advice was
required between scheduled visits. If appropriate, steroid injection or dose
escalation of DMARD could be arranged (as per study regimen).
These clinical features were documented at baseline, 6 weeks, and 12
weeks: tender and swollen joint count, erythrocyte sedimentation rate, patient
global assessment of disease activity (visual analog scale, VAS), DAS44, pain
score (VAS), and Short Form-12 v2 Health Survey (SF-12) functional assess-
ment8.
These CV risk factors were documented: smoking habits, systolic and
diastolic BP, total and high-density lipoprotein cholesterol, triglycerides, and
body mass index (BMI). A British Hypertension Society (BHS)-approved
digital sphygmomanometer was used throughout the study to record BP. BHS
guidelines were followed for BP recordings9.
SPSS version 15.0 software was used for statistical analysis.
RESULTS
Baseline demographic and clinical characteristics are docu-
mented in Table 2. Forty-seven percent of participants were
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ever-smokers and 20% were current smokers. One-third were
classified as obese (BMI > 30 kg/m2). One patient was pre-
scribed low-dose prednisolone and 3 patients antitumor necro-
sis factor therapy at study outset. All 30 patients completed
the 12-week study without reintroduction of NSAID.
A significant reduction in systolic BP was observed with
NSAID withdrawal at Week 6 (median reduction of 5 mm Hg;
p = 0.025) and Week 12 (median reduction 7 mm Hg com-
pared with baseline; p = 0.037; Table 2). No significant
change in diastolic BP was recorded. Of the patients pre-
scribed antihypertensives (40%), none had their regimen
altered during the intervention period. Changes in systolic BP
over the course of study participation for each patient are doc-
umented in Figure 2.
There was no overall change in DAS44. A significant
increase was seen in patient global assessment and pain score
from baseline to 6 weeks (p = 0.009 and p < 0.0001, respec-
tively), but there was a significant reduction in both measures
back to near baseline values by 12 weeks. At baseline, the
median SF-12 physical score was < 50, representing a
below-average physical function. There was a nonsignificant
trend in reduction in physical component score from baseline
to 6 weeks. By 12 weeks there was a significant improvement
in this measure. 
A total of 13 steroid injections were given to 11 study par-
ticipants over the entire intervention period. Only 1 partici-
pant required increased DMARD dose.
DISCUSSION
We have demonstrated that NSAID withdrawal is feasible in
this group, with minimal additional intervention. No signifi-
cant deterioration was noted in self-assessed function, as
measured by SF-12.
Hypertension is one of the most important Framingham
risk factors contributing to overall CV risk. It was therefore
relevant that we found NSAID withdrawal resulted in a medi-
an 7 mm Hg fall in systolic BP at 12 weeks compared to base-
line. A 3 mm Hg rise in systolic BP increases the occurrence
of congestive cardiac failure by 10%–20%, the risk of stroke
by 15%–20%, and angina by 12%10. A larger randomized
 controlled study may go some way to explain the cause of the
improved BP, which at the moment remains hypothetical. One
possibility is that the patients may have become acquainted
with and relaxed within the study environment, with reduction
in BP ensuing. We do not know whether BP changes are lim-
ited to certain levels. The early increase in pain and patient
global scores may have been minimized by a tapered dose
reduction of NSAID.
We acknowledge the limitations of our open-label, nonran-
domized study, with small numbers and short duration. Data
regarding steroid injection requirements pre-NSAID with-
drawal may have aided comparison. Ours was a preliminary
study intended to inform future work. We proposed to study
patients with RA with a low to moderate DAS, but the local
ethics committee advocated restricting the study to patients
with low DAS. This is to our knowledge the first supportive
evidence to guide the limitation of NSAID use in stable RA.
We demonstrate that it is possible to withdraw NSAID in
patients with a low DAS without adversely affecting their
quality of life or disease control and without the need for sig-
nificant additional input. We have also demonstrated addition-
al benefits on systolic BP control that has important implica-
tions for reducing CV risk. Future studies of CV risk in RA
should take into account the influence of NSAID-induced
hypertension. 
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Table 2. Demographic and clinical variables at baseline, 6 weeks, and 12 weeks. Data are median (range) unless
otherwise specified.
Variables Baseline Week 6 Week 12
Age, yrs 59 (33–73) — —
Disease duration, yrs 11 (1–40) — —
Female sex, % 73 — —
Total cholesterol, mmol/l 5.15 (3.4–7.4) — —
High-density lipoprotein, mmol/l 1.4 (0.8–32) — —
Triglycerides, mmol/l 1.05 (0.5–3.6) — —
Body mass index, kg/m2 26.6 (22.04–44.74) — —
Systolic BP, mm Hg 141 (109–190) 136* (104–170) 134** (106–171)
Diastolic BP, mm Hg 87 (72–103) 85 (66–99) 84 (72–105)
DAS44 2.08 (0.26–2.79) 2.19 (0.65–5.08) 1.79 (0.76–2.95)
ESR, mm/1st h 5 (2–35) 8 (2–51) 7 (2–38)
Patient global assessment, VAS 100 mm 29 (4–61) 43*** (7–77) 25† (1–55)
Pain score, VAS 100 mm 20 (4–53) 37†† (7–72) 25# (1–72)
SF-12 physical component 37.4 (24.5–56.6) 34.4 (24.5–55.1) 40.3 (31.6–56.7)
SF-12 mental component 54.4 (30.4–66.5) 54.0 (27.1–63.4) 54.5 (38.4–66.1)
Compared with baseline data (Wilcoxon matched-pairs signed-rank test): * p = 0.025 (improvement); ** p =
0.037 (improvement); *** p = 0.009 (deterioration); †† p < 0.0001 (deterioration). Compared with 6-week data
(Wilcoxon matched-pairs signed-rank test): † p = 0.003 (improvement);  # p = 0.008 (improvement). BP: blood
pressure; DAS44: 44-joint Disease Activity Score; ESR: erythrocyte sedimentation rate; VAS: visual analog
scale; SF-12: Medical Outcomes Study Short Form-12 Health Survey. 
Figure 2. Systolic blood pressure (SBP) readings for individual patients at baseline, 6 weeks, and 12 weeks.
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Patients with rheumatoid arthritis and osteoarthritis have 
relied upon NSAIDs as a cornerstone of their analgesic 
regime for decades. The choice of anti-inflammatory 
agents broadened for this group of patients when the 
selective inhibitors of cyclooxygenase-2 enzyme were 
developed. Much has been published in the past few 
years regarding the superior gastrointestinal safety of this 
class of drugs when compared with traditional NSAIDs. 
Their triumphant debut was swiftly followed by the 
emergence of data detailing their associated increased 
serious cardiovascular risks. This also led to a reevalu-
ation of data concerning more traditional NSAIDs, and 
surprisingly, a similar trend was seen. The US Food 
and Drug Administration has recommended that both 
classes of drugs carry a black box warning with regard 
to gastrointestinal and cardiovascular risks.
Introduction
The scale of the arthritides is huge: in the United States, 
rheumatoid arthritis (RA) affects around 2 million peo-
ple; osteoarthritis affects around 20 million people [1]. 
Consequently, NSAIDs have become and remain one of 
the most commonly used classes of medication prescribed 
worldwide for pain and inflammation [2] and are fre-
quently prescribed by rheumatologists and primary care 
physicians. Their gastrointestinal toxicity is now well-
documented, and this evidence warrants further review. 
The introduction of selective cyclooxygenase-2 (COX2) 
inhibitors, such as rofecoxib and celecoxib, was heralded 
as a new dawn in anti-inflammatory therapy because of 
their superior gastrointestinal safety profile.
In September 2004, Merck and Company volun-
tarily withdrew rofecoxib because of an increased risk 
of myocardial infarction (MI) and stroke [3]. Soon 
after, the US Food and Drug Administration (FDA), 
in a public health advisory, placed strict limitations on 
the use of other NSAIDs, including celecoxib [4], and 
valdecoxib was withdrawn from the market. Subse-
quently, this has led to the review and identification of 
similar risk with a number of traditional NSAIDs. We 
review the recently published literature and discuss the 
evidence behind these risks.
NSAIDs
Scientific information
All NSAIDs reduce prostaglandin production and result 
in relief from hyperalgesia (increased sensitivity to pain) 
caused by tissue damage [5]. Individual compounds vary 
in their chemical structure and ability to block COX1 
in preference to COX2. These drugs reach high con-
centrations in inflamed tissues, leading to inhibition of 
prostaglandin synthesis at the desired site of action; how-
ever, they also reach high concentrations in other organs 
and in the blood, leading to the side effects that can be 
experienced by patients [6].
Cardiovascular
Because the cardiovascular benefits of aspirin come from 
its inhibition of COX1, it seems sensible to think that 
NSAIDs would therefore not increase the risk of cardio-
vascular events. However, a near-complete inhibition of 
platelet COX1 is required for this cardioprotective benefit, 
something that a non-aspirin NSAID cannot accomplish 
in a sustained fashion. No placebo-controlled trial has 
ever studied the cardiovascular risk of non-selective 
NSAID therapy. However, it seems unlikely that such a 
trial would ever be funded in the current climate; it would 
be unethical to randomize patients to an intervention that 
may be potentially harmful.
Several meta-analyses have concluded from review of 
observational studies that the risk of MI varies between 
individual NSAIDs [7,8••,9••]. McGettigan and Henry 
[9••] reviewed 23 studies’ databases and showed that 
diclofenac had a relative risk (RR) for MI of 1.4 (95% 
CI = 1.16–1.7), higher than other traditional NSAIDs. 
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A further meta-analysis, looking at both COX2 
inhibitors and traditional NSAIDs [10], reviewed the 
specific comparison of NSAIDs with placebo in detail. 
Differences were again shown between individual prepa-
rations—naproxen was associated with the lowest risk 
(RR = 0.92, 95% CI = 0.67–1.21), and ibuprofen and 
diclofenac with the highest (RR = 1.51 [0.96–2.37] and 
1.63 [1.12–2.37], respectively). The Multinational Etori-
coxib and Diclofenac Arthritis Long-term (MEDAL) 
study [11••], discussed later in this paper in more detail, 
demonstrated similar rates of thrombotic cardiovascular 
events between etoricoxib and diclofenac.
Gislason et al. [12] reported on the risk of death or re-
infarction associated with non-selective NSAIDs as well 
as selective COX2 inhibitors in patients discharged from a 
Danish hospital after an MI. A substantial risk was again 
confirmed with traditional therapies; ibuprofen or diclo-
fenac were associated with a 1.5- to 2.4-fold increased 
risk of death. Again, a strong dose-response relationship 
was identified. With any observational study, such as this, 
unmeasured confounders cannot be accounted for. No 
information was given on concomitant use of aspirin in 
this study. Few of the studies that the meta-analyses were 
drawn from recorded the indication for or duration of 
NSAID use. Although the size of the overall patient risk 
appears small, the absolute risk may be considerable due to 
the large number of patients prescribed NSAIDs.
The adverse event of hypertension is common with 
NSAID and COX2 inhibitors. Most NSAIDs increase 
blood pressure by 3 to 5 mm Hg [13,14], and even such 
a modest rise can significantly increase the frequency of 
cardiovascular events, including ischemic heart disease 
and heart failure [15,16]. A nested case-control study of 
1396 cases of first admission to hospital for heart fail-
ure showed an overall 30% increase in those prescribed 
NSAIDs, versus the control group [17]. The risk of hospi-
talization varied with different NSAIDS, with higher risks 
seen with indomethacin and naproxen, and in the pres-
ence of comorbidities such as hypertension and diabetes. 
The authors postulate that this equates to one extra case 
per year of first heart failure–related hospital admission 
for every 1000 NSAID users aged 60 to 84 years.
Gastrointestinal
The problem of oral NSAID therapy and associated 
gastrointestinal adverse effects is great and well-docu-
mented in the medical literature. Serious gastrointestinal 
complications occur in 1% to 4% of NSAID users per 
year [18–22]. A large retrospective review of nearly 
3000 cases of upper gastrointestinal (UGI) bleeding in 
Spain has given valuable real-life information regarding 
this clinical problem [23]. Twenty-four percent of the 
patients with bleeding had taken a non-aspirin NSAID 
in the week before admission. Naproxen was the NSAID 
associated with the highest risk of bleeding (RR = 7.3, 
95% CI = 4.7–11.4). The combination of NSAID plus 
low-dose aspirin increased this risk even further (RR = 
12.7, 95% CI = 7–23). This study also identified that 
diclofenac and ibuprofen had the lowest risk profile of 
the traditional NSAIDs for UGI bleed. These data are 
corroborated in work data from Singh et al. [24]—mul-
tivariate adjusted rate ratios: ibuprofen = 1.57 (95% CI 
= 1.41–1.74, P < 0.0001), diclofenac = 1.72 (1.49–1.98, 
P < 0.0001), naproxen = 3.07 (2.74–3.44, P < 0.0001). 
Proton pump inhibitors have consistently been shown 
to be more effective than H2-receptor antagonists and 
prostaglandin analogues in the prophylaxis and treat-
ment of gastrointestinal damage in patients who require 
continuous NSAID therapy [25].
It is commonplace to prescribe a cardioprotective 
dose of aspirin to some patients; this, in addition to 
NSAID therapy, increases the risk of acute UGI bleed 
from an OR of 4 for aspirin alone (95% CI = 3.2–4.9) 
to 17.5 (11.9–25.8) [26]. The addition of a proton pump 
inhibitor to this combination reduces the OR to 1.1 
(0.5–2.6). Therefore, careful consideration of adding a 
proton pump inhibitor should be given to all NSAID 
patients who are also prescribed aspirin. A Cochrane 
review supports the safety of this approach [27]. 
An additional potentially modifiable risk factor is 
any Helicobacter pylori infection; Chan et al. [28] 
have shown that in the short term, H. pylori eradica-
tion decreases the incidence of peptic ulcer disease in 
patients who begin NSAID therapy.
COX2 Inhibitors
Scientific information
The primary property of this class of drugs is the inhibi-
tion of the COX2 enzyme. Initial research postulated that 
COX1 was continuously expressed in most tissues, whereas 
COX2 was induced in inflammation. Recent evidence has 
shown that COX2 is constitutively expressed in several 
organs and systems, including the kidney, central nervous 
system, and vascular wall [29], and that it can adversely 
influence the prostacyclin:thromboxane (anti-thrombotic:
prothrombotic) ratio in the vascular wall [30]. This may 
then promote platelet aggregation and atherosclerosis, 
resulting in an increased burden of cardiovascular toxicity.
Cardiovascular
In 2000, an early study of major gastrointestinal events 
showed an unexpected fivefold increase in the risk of 
acute MI with rofecoxib, compared with naproxen. At 
the time of publication, many hypothesized that this 
was due to the cardioprotective effect of naproxen, 
rather than prothrombotic side effects of rofecoxib [31]. 
However, in September 2004, rofecoxib was eventually 
withdrawn from worldwide sale based on the safety 
findings of the Adenomatous Polyp Prevention on Vioxx 
(APPROVe) study [32]. In this study, long-term use of 
rofecoxib, 25 mg daily, showed a 3.5% incidence of 
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MI or ischemic stroke when compared with placebo in 
patients with no pre-existing history of cardiovascu-
lar disease (1.9% of placebo group, P < 0.001). A few 
months later, the Adenoma Prevention with Celecoxib 
(APC) study group [33] published an interim analysis of 
their data, which showed that celecoxib at supra-thera-
peutic doses was also associated with an increased risk 
of cardiovascular thrombotic events. Promptly there-
after, the National Institutes of Health halted a trial 
involving research of COX2 inhibitors in Alzheimer’s 
disease because of their cardiovascular safety. The 
FDA, European Agency for the Evaluation of Medicinal 
Products, and the Medicines and Healthcare Products 
Regulatory Agency have all issued recommendations 
that COX2 inhibitors should not be prescribed for those 
with pre-existing ischemic heart disease or cerebrovas-
cular disease [34–36].
Kearney et al. [10] have undertaken a meta-analysis of 
data of vascular events from randomized controlled tri-
als of COX2 inhibitors. In all studies, COX2 inhibitors 
increased the risk of vascular events, mainly acute MI, by 
42% (RR = 1.42, 95% CI = 1.13–1.78). Studies that com-
pared a COX2 inhibitor with a traditional NSAID (91 
trials) showed no significant difference in the risk of vas-
cular events (RR = 1.16, 95% CI = 0.97–1.38). In a similar 
meta-analysis, McGettigan and Henry [9••] reviewed 
23 studies’ databases and confirmed the dose-related 
increased risk with rofecoxib (≤ 25 mg/day: RR = 1.33, 
95% CI = 1–1.79; ≥ 25 mg/day: RR = 2.19, 1.64–2.91).
It is worth interrogating the data of the MEDAL 
program in more detail, in which the authors set out to 
assess the relative cardiovascular toxicity of diclofenac 
and etoricoxib in patients with RA aged older than 50 
years [11••]. Patients with cardiovascular and gastroin-
testinal risk factors were included in order to assess the 
widest possible range of comorbidities. Data were pooled 
from three separate pharmaceutical industry–sponsored 
randomized double-blind clinical trials, totaling approxi-
mately 25,000 osteoarthritis and 10,000 RA patients. 
Nearly 17,000 patients received etoricoxib, and slightly 
fewer received diclofenac. The numbers of thrombotic 
cardiovascular events were similar in both groups, with 
higher risks of UGI events in the diclofenac group (0.97 
per 100 patient-years). The lack of placebo group limits 
the ability to ascertain the absolute cardiovascular risks 
of the two drugs. The MEDAL data vary from the results 
of the nested case control study by Andersohn et al. [37], 
in which etoricoxib was associated with an RR of 2.09 
for acute MI (95% CI = 1.1–3.97) and diclofenac with an 
RR of 1.37 (1.17–1.59).
Cerebrovascular
Until 2006, there had been few data published regarding 
the risk of ischemic stroke with COX2 inhibitors. A large 
case-control study [38] found that current use of rofecoxib 
and etoricoxib was associated with a significantly increased 
risk of ischemic stroke (multivariate OR = 1.71 and 2.38, 
respectively); the risk was maintained even if the patient had 
no pre-existing history of cerebrovascular disease, hyperten-
sion, or atrial fibrillation. Singh et al. [39] presented data this 
year from a nested case-control study reviewing the risk of 
stroke with COX2 inhibitor and NSAID therapy in patients 
with arthritis. This showed the highest risk was with rofe-
coxib (multivariate-adjusted stroke rate ratio = 1.26 [95% CI 
= 1.17–1.36; P < 0.0001]) and valdecoxib (RR = 1.22, 1–1.5, 
P < 0.05). The NSAIDs, including celecoxib, which exert less 
effect on blood pressure, did not increase the risk of stroke 
(RR = 0.97, 0.91–1.05).
Gastrointestinal
One advantage of COX2 inhibitors over NSAIDs is a 
better gastrointestinal safety profile, and this attractive 
selling point was at the crux of initial marketing of this 
class of drug, on the basis of two large gastrointesti-
nal outcome studies [31,40]. The Successive Celecoxib 
Efficacy and Safety Study I (SUCCESS-I), a large mul-
tinational, randomized, double-blind, controlled trial, 
compared the UGI safety of celecoxib with naproxen 
and diclofenac in a cohort of more than 13,000 patients 
with osteoarthritis [41]. Of the randomized celecoxib 
group, 37.2% had gastrointestinal symptoms, com-
pared with 40.3% in the NSAID group (P < 0.001), 
with an OR for complicated UGI side effects of 6.02 
(95% CI = 1.5–34.57) in the NSAID group. Encour-
agingly, celecoxib was found to be as effective as 
traditional NSAIDs in efficacy for treating osteoarthri-
tis symptoms. The SUCCESS-I study is the first such 
large trial to conclusively establish the gastrointestinal 
safety profile of celecoxib; other large outcome stud-
ies had shown no difference in complicated UGI events 
between etoricoxib and diclofenac [42].
The initial study of COX2 inhibitors for prevention 
of adenomatous polyps first brought their potential car-
diovascular effects into the public domain. These studies 
included APPROVe [32], APC [33,43], and Prevention of 
Colorectal Sporadic Adenomatous Polyps (PreSAP) [44]. 
Although they showed a reduction in the rate of adenoma 
formation, the documented associated increased rate of 
cardiovascular events caused their withdrawal from the 
market, and this avenue of chemoprevention was not 
further pursued.
It is important to pay close attention to the compar-
ator NSAID in studies showing a gastrointestinal safety 
advantage of COX2 inhibitors because traditional 
NSAIDs vary in their risk of serious gastrointestinal 
side effects [24]. “Gastrointestinal toxic” NSAIDs 
such as naproxen are more likely to show a statistical 
advantage over COX2 inhibitors, as in the Vioxx Gas-
trointestinal Outcomes Research (VIGOR) study [31]. 
This is in comparison with less “toxic” NSAIDs, such 
as diclofenac (used in the MEDAL study [11••]). Head-
to-head clinical trials may be required to highlight any 
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differences between the gastrointestinal safety profiles 
of individual COX2 inhibitors.
Conclusions
There is considerable evidence to suggest that the 
gastrointestinal toxicity profiles of NSAIDs vary widely—
naproxen has a consistently high gastrointestinal toxicity, 
whereas diclofenac and ibuprofen are less injurious to the 
gastrointestinal tract. Thus, it is imperative to consider 
the comparator NSAID when evaluating the gastrointesti-
nal toxicity of any new COX2 inhibitor preparation.
Both nonselective NSAIDs and COX2 inhibitors effec-
tively reduce joint pain and inflammation. Gastrointestinal 
risk factors for each patient need to be identified and used 
in treatment decisions because both carry a gastrointestinal 
hazard (albeit lesser in the COX2 inhibitor group).
In this complex milieu, physicians need to balance each 
patient’s personal gastrointestinal and cardiovascular risks, 
the potential benefit of treatment, and ultimately, the cost 
effectiveness of such a strategy. Patients with gastrointes-
tinal risk and no cardiovascular risk may benefit from a 
nonselective traditional NSAID with gastroprotection. 
Those with gastrointestinal and cardiovascular risk who 
require the prescription of aspirin also require gastropro-
tection with whichever anti-inflammatory is used, but 
perhaps a better option may be a short course of lowest-
dose NSAID [45]. By considering all of the factors involved 
and the well-judged use of NSAIDs and gastroprotection, 
patients can still receive treatment that gives them the most 
benefit while minimizing their individual risk profile.
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Purpose of review
In the last 2 years, there have been numerous publications on the safety of nonsteroida
anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors. An evaluation of the potentia
risks and benefits of other analgesics has also followed. In this time of greater analysis o
analgesic use, this study seeks to present the most recent evidence.
Recent findings
Concerns of potential hepatotoxicity of therapeutic doses of paracetamol have been
highlighted in the last 18 months. The ongoing efficacy and risks of long-term opioid use
has also been reevaluated. The debate over nonsteroidal anti-inflammatory drug and
cyclo-oxygenase-2 inhibitor safety continues.
Summary
Recent evidence has prompted a reassessment of the safety of paracetamol in certain
groups of patients. Further clarification on the risks of nonsteroidal anti-inflammatory
drug and cyclo-oxygenase-2 therapy for individuals is covered. Their use, increased
cardiovascular risk and long-term implications need to be evaluated.
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1040-8711Introduction
Systemic pain control in rheumatic diseases is achieved
by combining the use of peripherally and centrally acting
analgesics, along with nonsteroidal anti-inflammatory
drugs (NSAIDs) and drugs that modify the underlying
disease process. Recently, concerns over the safety and
toxicity of analgesics and NSAIDs have been raised. We
review studies that have highlighted these issues over the
last 18 months.Pain control in the rheumatic disorders
The impact of poorly controlled pain on our patients is far-
reaching. Eighty-eight percent of female respondents in a
rheumatoid arthritis (RA) study in Ireland reported that
pain was their major health impairment [1]. Deterioration
in health status as a result of pain was a common percep-
tion. The link between pain and psychological symptoms
cannot be ignored: a cohort of 238 patients was reviewed
from this perspective [2]. Thirty percent of the respon-
dents had a visual analogue scale pain score of more than
40mm.Five to thirteenpercent hadhighdepression scores
but 20–30%had high anxiety scores. It is thus advised that
pain-related outcomes should be studied in more detail
by researchers.1040-8711  2008 Wolters Kluwer Health | Lippincott Williams & Wilkinsl
l
fAcetaminophen/paracetamol
Acetaminophen or paracetamol is the first-line analgesic
recommended by the American College of Rheumatol-
ogy for the treatment of osteoarthritis [3]. Although its
exact mode of action remains unclear, it is thought to
cause selective inhibition of prostaglandins within the
central nervous system and cause peripheral analgesia. It
has been shown to reduce the production of prostaglandin
E2 [4]. Interestingly, a recently published study shows
that paracetamol inhibits cyclo-oxygenase-2 (COX2) to a
degree comparable with NSAIDs and COX2 inhibitors.
COX1 blockade of more than 95%, important for a cardio-
protective effect by platelet suppression, was not achieved
[5].
Theonset of actionof paracetamol is approximately 30min
with a short terminal elimination phase half-life (approxi-
mately 2 h after therapeutic doses). It therefore requires to
be taken frequently, with a maximum of 1 g four times
daily. Longer acting preparations, such as 650 or 1300mg
extended release three times daily, have been evaluated.
One such study [6] confirmed that a total of 3900mg
extended release reducedWestern Ontario andMcMaster
Universities Osteoarthritis (WOMAC) pain and physical
function scores compared with placebo in patients with
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with multiple dosing of standard tablets.
Paracetamol and hepatic abnormalities
Paracetamol first prepared commercially in 1950 in the
United States. It was not until 1966 that concerns were
raised that overdose, with its narrow therapeutic window,
could cause hepatotoxicity and nephrotoxicity. Uninten-
tional overdose of paracetamol has become one of themost
important causes of acute liver failure; subsequently, a
limit has been imposed on the amount of paracetamol that
can be purchased over the counter in theUnitedKingdom.
Recently, concerns have been published on the potential
of liver injury with therapeutic paracetamol doses. It
has been demonstrated that patients with viral hepatitis
who were given standard doses of paracetamol had an
additional increase in transaminases and prothrombin
time [7]. The hepatotoxic potential of paracetamol is
thought to be influenced by a number of factors including
microsome-inducing drugs, underlying disease, malnu-
trition, acute or chronic alcohol use, ethnicity and age.
Watkins et al. [8] have looked into the effects of thera-
peutic paracetamol doses on transaminases either alone or
in combination with opioids. They designed a random-
ized single-blinded placebo controlled trial in which
145 healthy adult volunteers were randomized to five
parallel treatment groups: placebo, paracetamol, parace-
tamol and morphine, paracetamol and hydromorphone,
and paracetamol and oxycodone. All received standar-
dized, catered meals; none had access to alcohol for the
14-day study duration. Of the 39 patients in the placebo
group, only one had an elevation of serum alanine ami-
notransferase (ALT) greater than five times the baseline
value. Over 19% of the 105 participants in the active
groups, however, had an ALT greater than five times
the baseline value. This was in the absence of a plasma
paracetamol level that would be considered hepatotoxic.
In all cases, ALT decreased to normal on completion of
the study.
Further work is required on the potential hepatotoxicity
of therapeutic doses of paracetamol. This has particular
implications on patients who misuse alcohol, are mal-
nourished and are on therapies that may induce liver
enzymes [9].
Paracetamol and renal function
The Nurses Health study [10] examined the association
of ‘lifetime intake of paracetamol’ and change in esti-
mated glomerular filtration rate (eGFR) over an 11-year
period. Those who took at least 3000 g of paracetamol had
a multivariate adjusted odds ratio of 2.19 (P< 0.001) for
reduction of 30 l/min or more of eGFR compared with
those who took less than 100 g over the period (odds ratio1.00, referent). Patients with established renal impair-
ment were not specifically studied and this warrants
further assessment in future studies.
Paracetamol and gastrointestinal side effects
Little has been recently published on this controversial
subject. A nested case–control study [11] used infor-
mation from the UK General Practice Research Database
in the1990s. Paracetamol exposure was ascertained for
those patients who had suffered upper gastrointestinal
complications. Analysis of 1494 cases and 9532 controls
was performed. Paracetamol use was associated with
small elevated risk of upper gastrointestinal compli-
cations: relative risk (RR) 1.3 (95% CI: 1.1–1.5). RR
increased to 3.6 if more than 2 g paracetamol was con-
sumed per day. Patients who took both NSAIDs and
paracetamol at doses higher than 2 g per day had a RR of
13.2 (95% CI: 9.2–18.9) compared with those who did not
use either of these drugs. Paracetamol, however, could
have been given preferentially to patients with a history
of dyspepsia or peptic ulcer disease.
Paracetamol and hypertension
Analysis of the Nurses Health Study II [12] demon-
strated that more than 500mg per day of paracetamol
was associated with a higher risk of incident hyperten-
sion (multivariate RR 1.99, P< 0.001). The Health Pro-
fessionals Follow-Up study [13] looked at associations
between frequency of paracetamol, NSAID and aspirin
use and the risk of hypertension during a 4-year period.
Frequency of analgesic use at baseline and at 2 years was
recorded for sixteen thousand and thirty-onemale health
professionals who did not have a history of hypertension
at baseline. One thousand nine hundred and sixty-eight
cases of incident hypertension during 4 years of follow-
up were identified. Men who used paracetamol six or
seven times per week had a multivariable adjusted RR
of hypertension of 1.34 (95% CI: 1.00–1.79) compared
with nonusers (P¼ 0.01 for trend). The association
between paracetamol and risk of hypertension was
greater in men with a body mass index of less than
25; the mechanisms for this are unclear. One would
anticipate that given that all participants were health
professionals, the self-reported ‘hypertension’ label
would be fairly reliable. The fact that patients took
regular doses of analgesics may be an additional con-
founding factor in this analysis.Nonsteroidal anti-inflammatory drugs and
cyclo-oxygenase-2 inhibitors
When rofecoxib was withdrawn in 2004, much was pub-
lished in medical and lay press on the potential risks
of anti-inflammatory therapies. Since then, the number
of publications on this subject has continued to increase.
BOR/289; Total nos of Pages: 7;
Risks and benefits analgesics in rheumatic disorders McKellar et al. 3Cardiovascular risk
Several meta-analyses [14–16] of observational studies
have concluded that the risk of myocardial infarction
(MI) differs between individual NSAIDs and COX2s.
McGettigan and Henry [17] confirmed that diclofenac
had a relative risk of 1.4 (95% confidence interval¼ 1.16–
1.7), which is higher than that for other traditional
NSAIDs.
Hepatic risk
Back in the 1980s, a number of NSAIDs were withdrawn
because of cases of fatal hepatotoxicity. A recent review
[18] of adverse drug reactions in France confirmed that
14%of allNSAID reportswere for abnormal liver function.
Two lumiracoxib-related studies published in Lancet in
2004 [19,20] reported a reduction in gastrointestinal ulcer
complications and no apparent evidence of increased risk
of MI. In November 2007, however, the Medicines and
Healthcare products RegulatoryAuthority in theUKwith-
drew this drug because of 159 episodes recorded world-
wide of adverse liver reactions attributed to this drug, two
ofwhichwere fatal [21].Thesepublications emphasize the
importance of prompt review of patients on NSAID or
COX2 who develop abnormal liver function and consider-
ation given to immediate withdrawal of therapy.
Upper gastrointestinal risk
Serious gastrointestinal complications of NSAID use are
well documented in the medical literature. There is now
considerable evidence to suggest that the gastrointestinal
toxicity profiles of NSAIDs differ. Lanas et al. [22] found
that naproxen was associated with the highest risk of
gastrointestinal bleeding (RR¼ 7.3, 95% CI: 4.7–11.4).
The combination of NSAID and low-dose aspirin
increased the risk even further (RR¼ 12.7, 95% CI:
7–23). Diclofenac and ibuprofen were observed to have
the lowest risk of gastrointestinal bleeding. A recently
published study [23] evaluated the combination of
COX2 and proton pump inhibitor (PPI) in patients with
upper gastrointestinal bleeding secondary to NSAID-
induced ulceration. Two hundred and seventy-three
patients were randomized to celecoxib and esomperazole
combinationorplacebo.Noneof thepatientswho received
COX2 and PPI combination had further upper gastroin-
testinal bleeding, whereas 12 of the patients who received
celecoxib alone had bleeding (P¼ 0.0004). This study
suggests a review of the guidelines of PPI prescription
in those requiring a COX2 who are at high risk of further
gastrointestinal bleeding. A limitation of this study is the
lack of nonselective NSAID comparator. Details of the
coprescription of aspirin in the context of cardiovascular
risk were also missing from data analysis.
An algorithm incorporating NSAIDs and COX2s to aid
decision making in pain management has been proposed
in an excellent study [24]. The authors propose choos-ing a therapy that provides good pain relief, minimizes
cardiovascular risk as much as possible and preserves the
gastrointestinal mucosa; no mean task. If acetaminophen
is insufficient and NSAIDs are felt to be unsuitable for
the patient, alternative analgesics should be used. If
NSAIDs are appropriate, those with a low risk of gastro-
intestinal bleeding should have ibuprofen prescribed and
then naproxen in case of inadequate benefit. Paracetamol
and/or opioid can be used in a stepwise progression. They
suggest that those at risk of gastrointestinal bleeding
should have NSAID prescribed with PPI cover.
Nonsteroidal anti-inflammatory drugs, cyclo-
oxygenase-2 inhibitors and aspirin coprescription
The use of aspirin in primary and secondary cardioprotec-
tion is well established. Aspirin irreversibly inhibits
COX1-mediated production of thromboxane A2
(TXA2); 95% inhibition of TXA2 completely inhibits
platelet aggregation. NSAIDs reversibly inhibit COX1
in platelets and so the subsequent effects on platelet
aggregation depends on the half-life of the individual
anti-inflammatory. It has been demonstrated that ibupro-
fen given before aspirin inhibited the beneficial effects of
irreversibleplatelet inhibition [25].On thebasis of this and
other studies, theUSFood andDrugAgency (FDA) issued
a warning in September 2006 regarding the coadministra-
tion of aspirin and ibuprofen [26]. They recommend that
aspirin should be taken before any NSAID or that the
doses should be given separately. Earlier study [27] has
shown aspirin and COX2 prescribed concomitantly can
reduce the incidence of MI. There were concerns of the
gastrointestinal effects ofCOX2andaspirin versusNSAID
and gastroprotection in those who were coprescribed
aspirin. Endoscopic studies [28] have shown that the
incidence of gastrointestinal ulcers did not differ between
patients on celecoxib and aspirin combination compared
with those on NSAID, aspirin and PPI. It has therefore
been suggested that the use of low-dose aspirin with
COX2s is preferable to nonselectiveNSAIDs [29], given
similar anti-inflammatory properties, superior gastrointes-
tinal tolerability and absence of interaction with aspirin.Opioids
Opioids are considered essential for the control of severe
pain. They can be classified as weak (codeine, dextro-
propoxyphene and tramadol) or strong (morphine and
oxycodone). Ameta-analysis [30] evaluating the analgesic
effect of opioids in chronic noncancer pain demonstrated
that all subgroups were better than placebo. One third of
patients, however, abandoned the therapy because of
side effects such as nausea (14%), constipation (9%)
and drowsiness (6%). Solomon et al. [31] reviewed opiate
use from a database of Medicare beneficiaries in Penn-
sylvania. Four percent of the patients with RA used
opioids regularly during one calendar year (2001); up
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review. The most commonly prescribed preparations
were tramadol, dextropropoxyphene, codeine and hydro-
codone. An association between chronic opioid use and
psychiatric medication coprescription was observed.
Tramadol
Tramadol is a weak opioid with serotonin-releasing and
noradrenaline reuptake inhibitory properties. It is used to
treat moderate to severe pain and has an advantage over
codeine in that it has less effects on the gastrointestinal
tract. Tramadol has no effect on the renal system but can
lower seizure threshold. In clinical practice, tramadol is
often prescribed for patients with rheumatic conditions in
whom a combination analgesic such as paracetamol and
low-dose codeine combination is ineffective. The Oxford
League Table for the efficacy of oral analgesics in acute pain
was created from information gathered from systematic
reviews of randomized, double-blind, single-dose studies
[32]. This table gives tramadol 50mg a low ranking in
efficacy; number needed to treat of approximately 8. This
value is comparable with the value of number needed to
treat in the range of 1.6–3.0 for a number of NSAIDs. The
drawbacks of such an analysis of analgesic efficacy include
the large variation in study size for each individual prep-
aration. A Cochrane review analysed 11 randomized con-
trolled trials of tramadol use in osteoarthritis [33]. One
thousandandnineteenparticipants received tramadol and/
or paracetamol, whereas 920 received placebo or active
control. Patients randomized to tramadol had a 12%
relative decrease in pain intensity from baseline. Side
effects were reported relatively commonly; the most com-
mon were nausea, vomiting, dizziness, constipation, tired-
ness and headache. The number needed to harm formajor
adverse events was eight.
The efficacy and tolerability of tramadol and paracetamol
combination tablets in patients with RA with pain inade-
quately controlled by NSAIDs and disease-modifying
antirheumatic drugs (DMARDs) alone has been studied
[34]. Mean daily pain relief scores by the end of week
1 were greater in the tramadol group compared with the
placebo group (P¼ 0.037). There was a 19% discontinu-
ation rate with tramadol: nausea and dizziness were the
most commonly reported adverse events. Incremental
dose titration of tramadol may be useful and may reduce
discontinuation rates and side effects over a short intro-
ductory period, as shown in a 2-week intervention period
by Choi et al. [35]. It appears that tramadol, if tolerated,
provides a helpful increment in the analgesic ladder for
patients with rheumatic conditions.
Fentanyl patch
Fentanyl is usually given by the transdermal route as its
intravenous form has a very short duration of action.
Transdermal fentanyl patches provide continuous drugdelivery (over a 3-day period) in a convenient manner
that may aid patient compliance when compared with
intermittent dosing with oral opioids.
Two recent studies examined the potential benefit of
fentanyl in the rheumatic diseases. Langford et al. [36], in
the first placebo-controlled trial of fentanyl in chronic
nonmalignant pain, randomized patients fulfilling the
American College of Rheumatology criteria of osteoar-
thritis of hip or knee whowere awaiting joint replacement
to either transdermal fentanyl (n¼ 202) or placebo
(n¼ 197). Previously prescribed NSAIDs and paraceta-
mol could continue. Fentanyl therapy was associated
with significantly improved pain scores. Seventy-eight
percent of those randomized to fentanyl reported at least
one adverse event (P< 0.001 versus placebo), with nau-
sea, vomiting and somnolence as most commonly
reported. Fifty-five patients (26%) discontinued fentanyl
secondary to side effects.
A second, prospective open-labelled study [37] reviewed
226 patients with RA with ‘severe pain’. Transdermal
fentanyl patch was added to their ongoing RA therapy for
30 days and pain evaluated on an 11-point numerical
scale. Fentanyl significantly reduced pain scores from
8.0 (7.82–8.18) to 4.0 (3.75–4.25). Mean functional
impairment because of pain also decreased significantly
from ‘severe’ to ‘mild to moderate’. Seventeen percent of
the study participants reported at least one adverse event,
nausea and vomiting being the most frequent. In this
study, 23 patients (10%) discontinued tramadol because
of side effects. These studies have shown the potential
benefit of fentanyl in controlling pain but have high-
lighted the frequency of discontinuation secondary to
adverse effects.
Opioids for low back pain
A systematic study [38] published the previous year
reviewed the prevalence and effectiveness of opioid
therapy in chronic back pain. The occurrence of sub-
stance misuse was also analysed. Eleven studies
described the prevalence of opioid treatment for chronic
back pain. Prescribing practice varied widely, ranging
from 3 to 66%, with higher percentages seen in specialist
treatment centres and lower prescription in primary care
centres. Fifteen studies reviewed the efficacy of opioid
treatment. The average opioid dose used (in morphine
units) was 73mg per day. Only four studies compared the
efficacy of opioids with a nonopioid control or placebo.
No significant reduction in pain with opioids was seen
(P¼ 0.136). Lifetime substance misuse disorders ranged
from 36 to 56%. An important fact highlighted by this
systematic review is that no study evaluated the benefit
of opioid prescription beyond 16 weeks; therefore, long-
term efficacy is not known. A Cochrane review of opioids
in chronic low back pain [39] concludes that there are
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authors voice the same concerns as those expressed in
the above studies in calling for high-quality studies of
longer duration in this area.Table 1 Treatment options for pain related to the rheumatic disord
Simple analgesia Anti-inflammatories O
No gastrointestinal or cardiovascular risk Fir
Paracetamol Ibuprofen Co
1g p.o. q.i.d. 400–600mg p.o. t.i.d. 30
Anchor analgesic Can be used in combination with
paracetamol/cocodamol
Ca
Minimal gastrointestinal
symptoms
Avoid concomitant administration
with aspirin [25,26]
Co
Risk of abnormal liver
function tests at
therapeutic doses [8,9]
Co
Tw
St
Co
Tr
50
Co
Gastrointestinal risk, no cardiovascular risk Se
Celecoxib Tr
200–400mg p.o. 12
Shown to have better gastroprotection
than traditional NSAIDs
Ch
Consider adding proton pump inhibitor if
high risk gastrointestinal bleeding [23].
Ca
IbuprofenþPPI St
For example, ibuprofen 400–600mg
p.o. t.i.d. and omeprazole 20mg p.o. o.d.
Si
O
Fo
Cardiovascular and gastrointestinal risk
Each patient requires to be reviewed on an
individual basis
Avoid anti-inflammatories if possible or use
lowest possible dose for shortest
period of time
If patient on aspirin either naproxen or a
COX2 selective agent would be preferable
given similar anti-inflammatory properties,
superior gastrointestinal tolerability and
absence of interaction with aspirin
[28,29]
COX2, cyclo-oxygenase-2; DMARDs, disease-modifying antirheumatic dru
circumstances; PIP, proton pump inhibitor; TENS, transcutaneous electricaA review [40] of the evidence for medications in chronic
low back pain by the American Pain Society and Amer-
ican College of Physicians clarified further the evidence
for use of opioid in this condition. Both tramadol anders
pioids Other strategies
st line: oral, weak opioids Nonpharmacological
deine Lifestyle advice
–60mg p.o. q.i.d. Weight loss if appropriate
n be used with paracetamol Footwear
mmonly reported side effects
include constipation and nausea
Walking aids
codamol (8/500 or 30/500) Education
o tablets p.o. q.i.d. Employment
ep-up from paracetamol alone Self-management schemes
mmonly reported side effects
include constipation and nausea
Exercise
amadol Physiotherapy
–100mg p.o. q.i.d. Acupuncture
mmonly reported side effects
include constipation and
nausea [33,34,35]
cond line: stronger opioids Local treatment
ansdermal fentanyl Intra-articular steroid
injection(s)
–100mg/h Contra-indicated in sepsis
ange patch every 72h Topical NSAIDs or capsaicin
n be used with paracetamol TENS machine
art at lowest dose and up-titrate
if necessary
Surgical intervention for
diseased joint
de effects of nausea and
somnolence reported [36,37]
If appropriate, for example,
total knee replacement
ral morphine
r example, morphine sulfate
tablets 20mg p.o. b.i.d.þ sevredol
5mg p.o. p.r.n. for breakthrough pain
Management of underlying
condition
Maximize DMARD therapy in
rheumatoid arthritis: alone
or in combination
Guided as per symptoms,
disease activity, blood
monitoring and
side-effects [41,42]
Biologic therapy (anti-tumour
necrosis factor)
If patient meets guidelines
for use in rheumatoid
arthritis, psoriatic arthritis,
ankylosing spondylitis. Can
reduce pain scores by
reducing disease activity
[43–46,47]
Amitriptyline 10–100mg
p.o. at night. Good for
neuropathic pain or
persisting pain that
disturbs sleep
gs; NSAIDs, nonsteroidal anti-inflammatory drugs; p.r.n., according to
l nerve stimulator.
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only two of the 11 studies reviewed compared either drug
with placebo. Their overall recommendations are that
paracetamol should be tried first for mild to moderate
back pain. For more severe pain, the benefits of improved
analgesia from NSAIDs need to be balanced with the
documented gastrointestinal and cardiovascular risks of
such therapy. A trial of opioids is recommended for
severe, disabling pain in properly selected patients.
The authors conclude that treatment choices for low
back pain should be made after considering the potential
risk and benefit of such therapies for the individual
patient.Disease-modifying antirheumatic drugs and
biologic therapies’ effect on pain control
DMARDs and biologic therapies not only reduce synovitis
but also slow disease progression, with concomitant
reduction in pain. This, in turn, reduces the need for
analgesics. TheMASCOT study [41] showed a reduction
in pain score by a median of eight points when sulfasala-
zine and methotrexate combination was used. This was
statistically significant when compared with patients on
sulfasalazine alone (P¼ 0.071). The CAMERA study [42]
reviewed the impact of intensive methotrexate treatment
as guided by a strict protocol and computer program
(n¼ 92) versus conventional methotrexate treatment
(n¼ 113). There was a significant difference in pain score
between the two groups by 3 months: intensive arm¼ 12
(interquartile range 5–24.3), conventional arm¼ 19
(9.5–34.1), P¼ 0.001.
Studies with adalimumab [43], etanercept [44], infliximab
[45] and abatacept [46] in RA have all demonstrated
improved pain control with a reduction in patient’s assess-
ment of pain on a visual analogue scale. A study [47]
specifically assessing patient’s health status improvements
with commencement of tumour necrosis factor-blocking
agents has provided helpful confirmatory information in
real-life prescribing. Arthritis ImpactMeasurement Scales
2 (AIMS2) arthritis pain scores at 3 and 6 months of anti-
tumour necrosis factor therapy were significantly lower
than the baseline values (P< 0.05). At baseline, 88% of
patients listed pain as a priority for improvement; this
decreased to 71% by 12 months. This study confirms that
pain relief canbeachievedwith anti-tumournecrosis factor
therapy and pain control remains the most important
priority for patients with RA even after 12 months of
treatment.Conclusion
In the complex setting of choosing an analgesic for
patients with rheumatic disorders, physicians need to
take into account a number of issues including thepatient’s personal cardiovascular and gastrointestinal
risks, the potential benefit of treatment and ultimately
the cost-effectiveness of the chosen therapy. We hope to
have illustrated the options for analgesia in this group of
patients in a succinct tabular form (see Table 1). Further
research is required into the long-term risks of hepato-
toxicity and hypertension observed with long-term para-
cetamol use; especially, as this is the therapy most often
used when the risk of anti-inflammatory drugs is
deemed unacceptable.Acknowledgements
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Abstract: Celecoxib is a selective cyclo-oxygenase 2 inhibitor licensed for use in musculoskeletal 
symptoms as well as in primary dysmenorrhea and acute pain. One advantage celecoxib has over 
traditional nonsteroidal anti-inflammatory drugs is that of significantly fewer gastrointestinal 
side-effects associated with its use. Much has been published on the potential cardiovascular and 
cerebrovascular complications of its administration. This review details the available evidence 
to allow prescribers to make informed decisions in the light of potentially conflicting evidence. 
The overall cardiovascular risk is increased with higher doses of celecoxib but is comparable 
with nonselective nonsteroidal anti-inflammatory use. As with all of these drugs, the potential 
cardiovascular and gastrointestinal risks of prescription need to be weighed up against possible 
benefits for each individual patient and discussed with the patients themselves.
Keywords: arthritis, cardiovascular, celecoxib, gastrointestinal, nonsteroidal anti-inflammatory 
drugs, safety
Introduction
Celecoxib (Celebrex®; Pfizer Inc.) was the first selective cyclo-oxygenase (COX) 2 
inhibitor to be used in everyday clinical practice. It is approved for use for musculoskeletal 
symptoms in osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing 
spondylitis, as well as in the management of primary dysmenorrhea and acute pain. 
The advantages for selective COX2 inhibitor use has been well-documented in the 
literature; similar efficacy to nonsteroidal anti-inflammatory drugs (NSAIDs) but with 
less gastrointestinal (GI) side-effects. Celecoxib was the first of many selective COX2 
inhibitors most of which have now been withdrawn from clinical use (lumiracoxib 
rofecoxib and valdecoxib) because of concerns of serious side-effects. This review will 
discuss the evidence for the potential benefits of celecoxib use as well as scrutinizing 
the studies which detail its possible deleterious effects.
Clinical effectiveness in treating arthritis
Multiple clinical trials have demonstrated that celecoxib has similar efficacy as 
nsNSAIDs in the management of pain and inflammation, both acute and chronic. 
Emery et al in 19991 studied the efficacy of celecoxib in patients with RA. Three 
hundred twenty-six patients received celecoxib 200 mg twice daily and 329 received 
diclofenac, a NSAID, 75 mg twice daily for 24 weeks. There was no documented 
difference between the 2 drugs for physician’s assessment, patient assessment, number 
of swollen or tender joints, visual analogue scale (VAS) pain score, early morning 
stiffness, or C-reactive protein (CRP). The mean number of swollen and tender joints 
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did however decrease over the course of the study. ACR-20 
response at 24 weeks was scored as 25% in the celecoxib 
group and 22% in the diclofenac group. This paper was one 
of the initial studies to give credence to the use of celecoxib 
where traditional NSAIDs would have been used for the treat-
ment of arthritis symptoms. In the same year a second group2 
undertook a randomized, placebo-controlled, double-blind 
trial with approximately 200 patients in each arm. Placebo 
was compared with naproxen 500 mg twice daily, celecoxib 
100 mg twice daily, 200 mg twice daily, or 400 mg twice 
daily. Celecoxib produced a significant improvement in signs 
and symptoms of RA for all efficacy measures with maximal 
effects by 2 weeks and comparable with the benefits seen with 
naproxen. Withdrawals for treatment failure were lower for 
all active therapy groups than for placebo (P  0.001).
A few years later, Deeks et al3 performed a systematic 
review of the efficacy of celecoxib compared with another 
nonselective (ns) NSAID or placebo. Over 15,000 patients 
with either OA or RA who had received at least 12 weeks 
of therapy were identified. Efficacy was measured by 
the WOMAC score (Western Ontario and McMaster 
Osteoarthritis Index) and tolerability by rates of withdrawal 
for adverse events. Celecoxib and NSAIDs were equally 
effective for all efficacy outcomes. There were far fewer 
withdrawals in those taking celecoxib than other NSAIDs 
for GI side-effects.
A recently published review of celecoxib assessed the 
clinical and cost- effectiveness of selective COX2 inhibitors 
and NSAIDs for OA and RA treatment.4 Forty randomized 
controlled trials involving celecoxib compared to placebo, 
other selective COX2 inhibitors, or nonselective (ns) NSAIDs 
were identified. Compared with nsNSAIDs, celecoxib was 
equally efficacious and of superior GI tolerability. The 
base-case incremental cost per quality adjusted life year 
(QALY) results for celecoxib versus diclofenac was £151,000.
Celecoxib and the upper 
gastrointestinal system
The GI toxicity of traditional NSAIDs is due to the 
nonselective inhibition of both COX1 and COX2 isoenzymes 
involved in prostaglandin synthesis.5 Selective COX2 
inhibitors were developed to suppress prostaglandin 
production by the COX2 enzyme selectively, consequently, 
giving anti-inflammatory and analgesic benefits while 
protecting the gastroprotective activity of COX1. The clinical 
adverse GI effects of NSAIDs are well known. Clinical 
symptoms are poor predictors of actual gastrointestinal 
injury. Anti-inflammatory drug-induced peptic ulcers are 
frequently asymptomatic. Patients taking traditional NSAIDs 
were previously said to be 5 to 7 times more likely to be 
hospitalized for a GI complication than nonusers.6,7
One of the first studies on the potential lesser upper GI 
effects of celecoxib was published in 1999.2 Patients with RA 
were randomized to one of three differing doses of celecoxib 
(100 mg, 200 mg or 400 mg twice daily), naproxen or placebo. 
All doses of celecoxib were seen to have a reduced frequency 
of endoscopic ulcers than naproxen, the comparative NSAID 
in this study. Emery et al1 demonstrated significantly reduced 
reporting of abdominal pain, gastric ulceration and duodenal 
ulceration when celecoxib was compared with diclofenac 
(P  0.05, P  0.001, and P  0.009, respectively).
The celecoxib long-term arthritis safety study (CLASS) 
was a large double-blind randomized controlled trial. Patients 
with OA or RA were randomized to receive celecoxib 
400 mg twice daily (n  3987), ibuprofen 800 mg 3 times 
daily (n  1985) or diclofenac 75 mg twice daily (n  1996).8 
Initial data (at 6 months follow up) suggested that rates 
of symptomatic GI ulcers and ulcer complications were 
significantly lower with celecoxib compared with NSAIDs. 
However, full study results, when made available, showed 
that there was no difference at 1 year. The CLASS study had 
a high-dropout rate at 1 year which made the interpretation 
of these results somewhat difficult.
In 2002, Mamdani et al9 performed a retrospective 
observational cohort study to compare rates of upper GI 
hemorrhage in elderly patients prescribed NSAIDs and selective 
COX2 inhibitors who were previously anti-inflammatory 
naïve. They found no increased short-term risk with celecoxib 
(adjusted rate ratio 1.0, 95% confidence interval [CI] 0.7 to 1.6), 
unlike NSAIDs and rofecoxib. The risk of upper GI hemorrhage 
with celecoxib was similar to that of controls not using NSAIDs. 
Singh et al10 compared the GI side-effects of celecoxib with 
diclofenac and naproxen in a double-blinded, randomized 
clinical trial of over 13,000 patients (SUCCESS-I). Significantly 
more ulcer complications were seen in the NSAID than 
celecoxib group (0.8/1000-person years versus 0.1/1000-person 
years, odds ratio [OR] 7.02, P  0.008).
van der Linden et al11 performed a nested case-control 
study of a historical cohort of patients in The Netherlands 
to assess the incidence of first hospitalization for GI events 
in patient prescribed traditional NSAIDs and selective 
COX2 inhibitors (incorporating gastric and duodenal 
ulcers, ulceration of GI tract, gastritis, duodenitis, and 
GI hemorrhage). Adjusted OR for any GI with celecoxib 
therapy was 1.36 (95% CI 0.70 to 2.66). When compared 
with celecoxib, unsurprisingly, the risk was much higher with 
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the traditional NSAIDs, naproxen (OR 3.26, 95% CI 1.59 
to 6.70) and diclofenac (OR 3.50, 95% 1.76 to 6.98).
Management difficulties can arise when patients are 
admitted with a GI bleed but require anti-inflammatory 
management for musculoskeletal symptoms. Chan et al 
published on recurrent ulcer bleeding rates in patients 
subsequently given celecoxib, who were initially admitted 
with upper GI bleeding while on a traditional NSAID for 
arthritis treatment.12 Patients were either given celecoxib 
plus placebo or esomperazole, a proton-pump inhibitor 
(PPI). The combination group had a significantly reduced 
incidence of upper GI bleeding: 0 vs 12%, P  0.0004, 95% 
CI 4.1 to 13.7.
Potential prevention of colorectal 
malignancies with celecoxib
The APC study investigators investigated the potential 
benefits of celecoxib on reducing colorectal adenomatous 
polyps and cancer.13 This was on the basis that selective COX2 
inhibitors had been shown to reduce the number of colorectal 
adenomas in animals, as well as that the over expression of 
COX2 had been associated with colorectal adenomatous 
polyps and cancer. Patients who had previously had adeno-
mas removed were randomized to placebo, celecoxib 200 mg 
twice daily or 400 mg twice daily. The estimated cumulative 
incidence of detection of adenomas at year 3 was 43.2% in 
the 200 mg twice daily group (risk ratio [RR] 0.67, 95% CI 
0.59 to 0.77, P  0.001) and 37.5% in the 400 mg twice daily 
group (RR 0.55, 95% CI 0.48 to 0.64, P  0.001) compared 
with placebo. For advanced adenomas in the two treatment 
groups the estimated cumulative incidence was 7.8% (RR 
0.43, 95% CI 0.31 to 0.61, P  0.001) and 6.3% (RR 0.34, 
95% CI 0.24 to 0.50, P  0.001) respectively.
In the same issue of the NEJM, the PreSAP trial 
investigators reported their randomized placebo controlled 
trial. They demonstrated that the use of 400 mg celecoxib 
once daily significantly reduced the occurrence of colorectal 
adenomas within the 3 years after a polypectomy (relative 
risk 0.64, 95% CI 0.56 to 0.75 P  0.001).14
Potential hepatic side-effects
A number of individual case reports have been published 
detailing hepatoxicity secondary to celecoxib treatment.15–17 
More impressive however are the published data on larger-
scale investigatory groups such as the CLASS study where 
nearly 4000 patients took celecoxib at 800 mg/day without 
any significant elevation in aminotransferases compared 
with traditional NSAID.8 Importantly, the SUCCESS-1 study 
showed that the occurrence of transaminitis was much lower 
with celecoxib than with nsNSAIDs, 0.5% versus 1.3% 
(P  0.001).10 The FDA and WHO published a case/noncase 
analysis of spontaneous reports of hepatotoxicity of COX2s 
versus nsNSAIDs. The authors concluded that there was 
no increased safety concerns for celecoxib compared with 
NSAIDs, unlike diclofenac and nimesulide.18 While we 
should be alert to the potential development of abnormal 
liver function while a patient is taking celecoxib, the major 
studies do not show any noteworthy trend.
Celecoxib and acute myocardial 
infarction
Concern was initially raised of the potential cardiovascular 
(CV) toxicity of selective COX2 inhibitors and NSAIDs was 
raised by the publication of data from the VIGOR trial by 
Bombardier et al19 The CV risk of rofecoxib at that time was 
explained by being artefactual because of a presumed car-
dioprotective benefit of naproxen. Subsequent observational 
studies proved that this could not be true.20 The first firm 
evidence demonstrating the increased risk of selective COX2 
inhibitors compared with placebo was the APPROVe trial 
in 2004.21 The results of this trial confirmed many previous 
observational studies on the CV risks of rofecoxib and lead 
to the withdrawal of the drug. Subsequently, the APC13 and 
Pre-SAP14 studies showed that at high doses, celecoxib can 
also increase the risk of CV complications when compared 
to placebo.
The risk of high doses of celecoxib was confirmed in 
a pooled analysis published by Solomon et al.22 The data 
from 7950 patients enrolled in 6 placebo-controlled trials of 
celecoxib was analyzed. There was a clear increased risk of 
all CV events including acute myocardial infarction (AMI) 
with increasing doses of celecoxib (P  0.0005). It should 
be noted that the patients in these studies had conditions 
other than arthritis. Many observational studies have shown 
that the increase in risk is not limited to celecoxib, but 
indeed is present with most nsNSAIDs23 and that the risk 
with celecoxib may be of smaller magnitude than most 
other NSAIDs.24 There are a large number of observational 
studies in publication in which these conclusions are also 
borne out.4,11,25–30
As mentioned previously, a large amount of data related 
to celecoxib and AMI is available from studies investigating 
the potential benefits in colorectal neoplasia prevention. 
The first data were published by Solomon et al in 2005.31 
Deaths from CV causes and nonfatal AMI numbered 27 in 
patients exposed to celecoxib, calculated hazard ratio (HR) 
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3.4 (nonfatal AMI alone numbered 18). A further paper 
published by Bertagnolli et al13 the following year analyzed 
CV “disorders”, encompassing a variety of conditions 
including AMI, angina, cerebrovascular disease, and circula-
tory collapse. RR in the whole group for low-dose celecoxib 
was 1.5, compared with 1.8 in higher doses.
The much referenced systematic review and meta-analysis 
from McGettigan and Henry24 analyzed the risk of serious CV 
events with selective COX2 inhibitor therapy. They found 
that celecoxib was not associated with an increased risk 
of vascular occlusion (summary RR 1.06, 95% CI 0.91 to 
1.23). This compares with summary RR of 1.33 for low-dose 
rofecoxib (95% CI 1.00 to 1.79), 2.19 for high-dose rofecoxib 
(95% CI 1.64 to 2.91), 1.40 for diclofenac (95% CI 1.16 to 
1.70), 1.07 for ibuprofen (95% CI 0.97 to 1.18), and 0.97 for 
naproxen (95% CI 0.97 to 1.18).
As detailed from the many published works on this topic, 
the data on potential increased cardiovascular risk for patients 
taking celecoxib are inconsistent. It would seem clinically 
appropriate for the decision on prescription to be made on a 
patient by patient basis taking into account the individual’s 
CV history and risk profile, and with regular reviews of 
the need for therapy. While inconsistent, the evidence most 
likely points to an increase in risk of AMI with celecoxib 
compared to placebo when doses of at least 400 mg are 
used. No clinical trials have been able to show an increased 
risk when 200 mg/day or less is used, although this does not 
rule out such an effect in susceptible patients. The increased 
risk does not seem to be out of proportion to the risk seen 
with nsNSAIDs.
Celecoxib and heart failure
Anti-inflammatory drugs can be associated with a degree of 
fluid retention through an increased cortical expression of 
COX2. Mamdani’s population-based retrospective cohort 
study32 assessed nearly 19000 NSAID-naïve patients who 
were commenced on celecoxib. Less than 1% developed 
congestive heart failure (CHF) within 6 months of com-
mencement (identical to nonNSAID control group) and 
approximately 6% developed CHF over a 5-year period (not 
significant compared to the control group).
A population-based retrospective cohort study studied 
2256 patients aged over 66 who were prescribed NSAID, rofecoxib 
or celecoxib after an index admission for CHF.33 Crude event 
rates for recurrent CHF per 100 person-years were calculated 
and showed a difference between selective COX2 inhibi-
tors (celecoxib 27.6, rofecoxib 32.4) and NSAIDs 
(24.4). Within the Colorectal Adenoma Prevention 
trial31 the number of nonfatal heart failure events with 
the placebo group (n  2, 0.3%) was comparable to the 
events in the celecoxib 200 mg bd group (n  1, 0.1%). 
A case control study of patients admitted with congestive 
cardiac failure34 identified 25 first admissions in patients 
prescribed celecoxib. Two of these patients had taken less 
than 600 mg celecoxib in the week prior to admission, 
15 had taken between 601 and 1400 mg celecoxib, and 
4 taken greater than 1400 mg. Multivariate analysis and 
comparison with controls showed a weak and statistically 
nonsignificant association between celecoxib use and 
hospitalization for CHF (OR 1.47, 95% CI 0.86 to 2.53, 
P  0.160) – this was also seen for rofecoxib and other 
traditional NSAIDs.
Potential renal side-effects
The physiological interactions between COX2 and the 
renal system is complex. Increased cortical expression of 
COX2 is seen with sodium depletion, aortic coarctation, 
CHF, loop diuretic therapy and Bartter’s syndrome 
amongst others. COX2 expression is specifically linked to 
the renin-angiotensin system (RAS) and causes activation 
of this pathway. Decreased RAS activity causes increased 
COX2 expression and vice versa. COX2 is known to have 
critical roles at the cortical thick ascending limb of the loop 
of Henle, macula densa and in the medullary interstitium.35 
There is case-report documentation of renal side-effects 
secondary to celecoxib use,17 but much more robust data 
are available from a number of large-scale studies and 
reviews.
A randomized crossover trial of celecoxib with 
naproxen as the comparator looked specifically at renal 
function outcomes in an elderly population.36 A compa-
rable reduction in glomerular filtration rate was seen for 
both naproxen and celecoxib and therefore the selective 
COX2 inhibitor was not felt to be any more nephrotoxic. 
Similarly, the CLASS study did not show any significant 
elevation in serum creatinine in nearly 4000 celecoxib 
users when compared with NSAID users (ibuprofen or 
diclofenac).8 Zhang et al published a large meta-analysis of 
114 randomized, double-blind controlled trials of selective 
COX2 inhibitors, within which 37 celecoxib trial populations 
were identified.37 The RR of developing renal dysfunction 
with celecoxib was 0.61 (95% CI 0.4 to 0.94) compared 
with controls. No between-treatment difference in creatinine 
clearance or serum electrolytes was seen in a double-blind, 
placebo-controlled study of 85 patients assigned to naproxen, 
etoricoxib, or celecoxib.38
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As per prescribing guidelines, the use of celecoxib and 
NSAIDs is contra-indicated in patients with pre-existing 
renal impairment. The prescribing physician should remain 
alert to the development of abnormal renal function in a 
patient prescribed celecoxib, but its use is not associated 
with any increased nephrotoxicity compared with traditional 
NSAIDs.
Blood pressure effects of celecoxib
The effects of the addition of celecoxib on blood pressure 
(BP) control in patients on angiotension-converting enzyme 
inhibitors for hypertension has been studied via 24-hour 
ambulatory BP monitoring.39 Doses of celecoxib 200 mg 
twice daily made no difference on the anti-hypertensive 
effect of lisinopril. Wolfe et al have published data on the 
association of NSAID use with hypertension.40 In normo-
tensive and hypertensive patients, there was no increased 
OR of higher documented BP with celecoxib. This was not 
the case for rofecoxib. Zhang’s meta-analysis also failed 
to show any increased RR of hypertension with celecoxib 
therapy: 0.83.37
A number of meta-analyses have scrutinized the potential 
evidence connecting celecoxib with a rise in blood pressure. 
Aw et al published a meta-analysis in 2005 of 19 randomized 
control trials, which included 8 celecoxib trial populations.41 
Weighted mean differences (WMD) of systolic and diastolic 
BPs were calculated. Overall, a disproportionate increase in 
systolic rather than diastolic BP was seen with all nsNSAIDs. 
The overall RR of developing hypertension for celecoxib 
compared with placebo was not statistically significant 
(0.81, 95% CI 0.13 to 5.21). These data on hypertension 
compares well with the only other selective COX2 inhibitor 
still on the market, etoricoxib.
The CRESCENT investigators, lead by Sowers, did not 
show any difference with celecoxib on 24-hour ambulatory 
BP control in known hypertensives.42 However, the proportion 
of patients with controlled blood pressure at baseline who 
developed worsening of BP by week 6 was documented 
as 16% in the celecoxib arm (P  0.05), indicating that like 
all NSAIDs, BP monitoring is advised whenever treatment is 
initiated with celecoxib. Bertagnolli’s work on the potential 
role in colorectal adenoma prevention of celecoxib docu-
mented some blood pressure data.13 There was no significant 
increased RR of developing hypertension in the cohort and 
aspirin co-prescription made no difference. In contrast, 
Schwartz et al demonstrated a significant increase in ambula-
tory systolic BP with etoricoxib 90 mg once daily compared 
with celecoxib 200 mg twice daily and naproxen 500 mg 
twice daily (P  0.05).38 Additionally, recently published 
data from the MEDAL study documented an increase in 
systolic BP (average rise of 3.4 to 3.6 mmHg) with etoricoxib 
therapy.43
Celecoxib and stroke
Within the Colorectal Adenoma Prevention trial,31 the 
number of nonfatal strokes with the placebo group was 
identical to the events in the celecoxib 200 mg twice daily 
group (n  3, 0.4%), compared with 5 events (0.7%) in 
the celecoxib 400 mg twice daily group. Solomon et al’s 
cohort study of over 26,000 celecoxib users in the Medicare 
program identified 988 strokes and an adjusted RR of 1.00 
(95% CI 0.92 to 1.09).29
A landmark study from Andersohn and colleagues 
assessed nearly 500,000 patients on the UK GP research 
database between 2000 and 200444 to identify the risk of 
ischemic stroke with NSAID or selective COX2 inhibitor 
use. No increased risk was found with current celecoxib 
use (multivariate OR 1.07). An increased risk was seen with 
rofecoxib and etoricoxib (OR 1.71 and 2.38, respectively). 
As per the AMI data, a dose-dependent effect was seen. 
Celecoxib at 200 mg/day was associated with a multivariate 
OR 0.97 (95% CI 0.71 to 1.32) and 200 mg/day was asso-
ciated with a multivariate OR 1.20 (95% CI 0.46 to 3.11). 
Etoricoxib at 60 mg/day was associated with a much higher 
multivariate OR 2.04 (95% CI 0.87 to 4.80) and 60 mg/day 
was associated with a multivariate OR 3.27 (95% CI 0.59 
to 18.16). It is possible that these differences in stroke rates 
between celecoxib and etoricoxib reflect the differential effect 
on hypertension of these drugs.
Lee et al45 reviewed the impact of celecoxib prescrip-
tion on cerebrovascular disease incidence in patients with 
and without documented coronary artery disease (CAD). 
There was no increased risk of cerebrovascular event in the 
group without CAD prescribed celecoxib (OR 0.97, 95% 
CI 0.68 to 137). However, there was an increased risk of 
events in those with pre-existing CAD prescribed celecoxib 
(OR 1.40, 95% CI 0.96 to 2.03). A recently published study 
based on data from the population-based Rotterdam study 46 
assessed HR for ischemic stroke with NSAID and selective 
COX2 inhibitor prescription. Only 1 event was documented 
in celecoxib users and therefore there was no significant 
outcome.
Nadareishvili et al47 performed a nested case control 
analysis to determine the risk of stroke in patients with RA. 
Two hundred sixty-nine patients with first-ever stroke were 
identified, including 41 in patients with RA. The OR for 
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ischemic stroke in RA was 2.66 (95% CI 1.24 to 5.70, P  
0.012). Adjusted for cardiovascular, RA risk factors, and 
other co-variants, ischemic stroke was significantly associated 
with rofecoxib use (OR 3.66, P  0.27), but not significantly 
with celecoxib (OR 2.65, P  0.051). A recently published 
retrospective cohort study of over 300,000 Medicaid patients 
in Tennessee over a 5-year period48 documented 4354 
stroke admissions. Of these, 144 were patients who were 
prescribed celecoxib. Compared with nonusers of selective 
COX2 inhibitors or NSAIDs, the adjusted HR for stroke 
was only 1.04 (95% CI 0.87 to 1.23). A slightly higher HR 
of 1.12 (95% CI 0.83 to 1.52) in new users of celecoxib was 
documented.
Effects of co-prescription 
of celecoxib and aspirin
The benefit of aspirin in the primary and secondary preven-
tion of CV events is well established. As the prescription 
rates for aspirin will continue to climb, the number of patients 
potentially prescribed this as well as an anti-inflammatory 
drug will too.
Wilner et al49 published a double-blind, placebo-controlled 
trial of 16 healthy volunteers assigned to celecoxib 400 mg daily 
or placebo for 4 days. Aspirin 325 mg plus celecoxib 200 mg 
or placebo was prescribed on day 5. No significant difference 
in thromboxane inhibition between the 2 groups was noted. 
There was also no significant difference in the effect of aspirin 
on platelet aggregation due to ADP, collagen, or arachidonic 
acid between the groups. The groups summarized that cele-
coxib does not have an effect on the aspirin effects of platelet 
function. This is an important consideration in the selection of 
NSAIDs in patients on low-dose aspirin since, unlike celecoxib, 
several nsNSAIDs have been shown to cause pharmacodynamic 
interference with the anti-platelet effect of aspirin.
The population impact of any possible interaction is 
potentially large. In a sample of the general population 
prescribed selective COX2 inhibitors, analyzed by Cox 
et al50 48% were co-prescribed aspirin, 43% paracetamol, 
and, interestingly, 10% also were prescribed a nonselective 
NSAID. Unsurprisingly, the use of aspirin increased with 
increasing patient age.
Levesque51 documented the RR of first AMI in a cohort 
of over 113,000 elderly patients. Patients prescribed cele-
coxib with or without aspirin were identified. There was no 
significant difference in adjusted RR of AMI in those who 
were or were not prescribed aspirin alongside celecoxib. This 
differs from the low-dose rofecoxib group who showed a 
significantly reduced risk of AMI if prescribed aspirin – the 
same was not true for patients on high-dose rofecoxib. It must 
be pointed out that the actual number of patients who had 
an AMI while on aspirin was small and conclusions drawn 
from this study should be guarded. Rahme et al found that 
the combination of celecoxib and aspirin was less likely 
to be associated with hospitalization for GI events than 
NSAIDs with aspirin (HR 0.62, 95% 0.48 to 0.80).52,53 In fact, 
hospitalization rates for GI events were similar for celecoxib 
plus aspirin as NSAID without aspirin (HR 1.01, 95% CI 0.81 
to 1.25). A limitation of the study was that over-the-counter 
data for aspirin were not available.
Conclusion
Celecoxib continues to be an effective and valuable alternative 
to traditional NSAIDs in the treatment of acute and chronic 
pain. The superior GI tolerability is well-documented and com-
pelling. Data on potential increased CV risk for patients taking 
celecoxib are inconsistent, but do point to a small increase 
risk, especially when higher doses are prescribed. This risk 
is comparable with that of traditional nonselective NSAIDs.
As with all of these drugs, the potential CV and GI risks 
of prescription need to be weighed against possible benefits 
for each individual patient and discussed with the patient. 
If the CV risk increase with celecoxib is small and lower 
than that of most other NSAIDs, the concern would be of 
increasing the complications in a high CV risk patient if they 
were to be prescribed another NSAID. If such a high-risk 
patient must take aspirin, the argument for selective COX2 
inhibitors is stronger as nsNSAIDs may block the effect of 
aspirin. Concomitant PPI use should be considered in these 
patients. As is the case with all anti-inflammatories, the 
prescription of celecoxib for an individual patient should be 
reviewed regularly and the lowest dose used for the shortest 
possible period of time.
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Role for TNF in atherosclerosis? Lessons  
from autoimmune disease
Gayle E. McKellar, David W. McCarey, Naveed Sattar and Iain B. McInnes
Abstract | Inflammatory pathways have been implicated in the initiation and progression of cardiovascular 
diseases. Accelerated atherosclerosis has been described in patients with chronic inflammatory diseases, 
particularly rheumatoid arthritis, disproportionate to individuals’ detectable traditional vascular risk factors. 
This finding suggests that other pathways associated with inflammation might account for increased vascular 
risk in such diseases. Highly specific biologic agents can precisely block the activity of cytokines generated 
during inflammatory cascades; the effects of these inflammatory moieties on vascular physiology and 
overall risk of cardiovascular events has been directly evaluated. This Review summarizes key epidemiologic, 
physiologic and model data, which together suggest that tumor necrosis factor, a pivotal cytokine in the 
inflammatory cascade, is directly involved in vascular pathophysiology and that its inhibition might confer an 
overall advantage to the recipient. Moreover, such data obtained in chronic inflammatory diseases likely have 
relevance to primary atherosclerosis.
McKellar, G. E. et al. Nat. Rev. Cardiol. 6, 410–417 (2009); advance online publication 5 May 2009; doi:10.1038/nrcardio.2009.57
Introduction
Inflammatory pathways are considered of fundamental 
importance to atherogenesis initiation and propagation, 
and to the acute events that precede myocardial infarc-
tion and stroke. In parallel, it has been increasingly recog-
nized that patients with chronic inflammatory disorders 
such as rheumatoid arthritis (RA) and psoriasis exhibit 
higher than expected rates of cardiovascular disease 
morbidity and mortality that, at least in the context of 
RA, cannot be explained by traditional risk factors alone. 
Thus, these diseases might offer a unique insight into the 
capacity of inflammatory pathways to directly influence 
vascular pathology. In particular, the revolution in the 
use of biologic agents to target inflammatory cytokines 
in a highly specific manner provides molecular scal-
pels with which to dissect the role of specific cytokines 
in vascular disease, at the levels of both the individual 
patient and the population. In this Review, we discuss 
the accelerated comorbidity of atherosclerosis associ-
ated with autoimmune diseases, using RA as an exemp-
lar condition, as well as the immunobiology of tumor 
necrosis factor (TNF) in the context of atherogenesis. 
The evidence pertaining to vascular outcomes associated 
with TNF blockade, obtained primarily from small clini-
cal trials that investigated changes in vascular pathology 
and physiology, as well as from observational studies, is 
discussed. Finally, we speculate on the implications of 
these studies and the broader effects of inflammation 
modifiers on vascular disease for the development of 
novel, inflammation-targeted therapeutics.
Cytokines in chronic inflammatory diseases
Cytokines are small glycoproteins that function primar-
ily as messengers in the immune system via autocrine, 
paracrine or endocrine manners. Cytokines bind specific 
receptor complexes, which, in turn, signal via increas-
ingly well-characterized signal transduction pathways to 
modulate gene expression within target cells. More than 
100 cytokines within large, structurally related super-
families have been described, and these mediate a large 
variety of regulatory and effector functions within the 
immune system and beyond. Cytokines tend to be regu-
lated in a coordinated manner, facilitating their effec-
tor functions as an integrated cascade; however, some 
cytokines seem to occupy pivotal positions within this 
hierarchy, and hence offer important therapeutic oppor-
tunities.1 TNF is a homotrimeric cytokine that binds 
to two receptors, TNFRI and TNFRII, and can thereby 
influence a variety of molecular and cellular events that 
contribute to several disease states.2 After synthesis in 
the endoplasmic reticulum, TNF is trafficked to the cell 
membrane where it remains as a functional membrane 
protein, or is solubilized via the action of a membrane-
bound cleaving enzyme, TNFα converting enzyme 
(TACE; Figure 1). TNF regulates leukocyte activation, 
maturation, cytokine and chemokine release, and pro-
duction of reactive oxygen and nitrogen intermediates 
(Figure 2). As such, it is a central regulator of inflamma-
tory cascades during both initiation and amplification of 
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inflammatory reactions. TNF activates endothelial cells 
to express adhesion molecules as well as pro inflammatory 
cytokine and chemokine receptors, and promotes syn-
thesis and release of a variety of inflammatory cyto-
kines and chemokines to thereby support recruitment 
of activated leukocytes to an inflammatory lesion. TNF 
probably promotes the inflammatory cascade within 
the arterial wall during development of atherosclerosis, 
in part by promoting endothelial cell injury.3 It might 
directly promote endothelial cell apoptosis and suppress 
the activities of endothelial cell progenitors that could 
sustain endothelial repair.4 TNF has also been implicated 
in promoting endothelial injury through recruitment of 
immune cells, such as neutrophils, which can mediate 
tissue destruction.5 In addition, TNF promotes oxidative 
stress, and can directly impair nitric oxide bioavailability 
with consequent promotion of endothelial dysfunction. 
TNF impairs hemostasis, for example, by promoting the 
expression of tissue factor. It is a critical regulator of 
the acute phase response, acting in part via induction 
of interleukin (IL)-6 release. TNF has been implicated 
in the functional modulation of a variety of other tissue-
specific cell types, including chondrocytes, osteoclasts, 
hepatocytes, neurons and adipocytes. Through the latter 
cell type, TNF might contribute to regulation of lipid and 
glucose metabolism,6,7 which has direct clinical implica-
tions in the acute setting, for necessary advantageous 
metabolic responses to injury or severe infection, and in 
the chronic setting, for increased vascular risk. As such, 
TNF is considered a pleiotropic inflammatory cytokine 
with a central role in many pathophysiologic states and 
in associated comorbidities that affect more than just the 
primary target tissue.
Inflammatory arthritis and vascular risk
RA is a common arthropathy associated with articu-
lar synovial and bone marrow inflammation, cartilage 
and bone destruction, and consequent functional and 
social decline. It has been known for some time that 
RA is associated with reduced life expectancy, which 
cannot be explained only by the presence of tradi-
tional vascular risk factors.8 A study conducted in our 
own center described 50% mortality over a 20 year 
follow-up period in 123 patients with RA, primarily as 
a result of cardiovascular disease.9 A pooled analysis of 
the major studies available on the mortality of indivi-
duals with RA yielded a standardized mortality ratio of 
1.70, with cardio vascular causes found to predominate 
in all studies.8 A Scandinavian study, which followed 606 
patients for 15 years, derived a standardized mortality 
ratio specific to cardiovascular disease of 1.46,10 while 
a North American study by del Rincón et al. noted an 
approximate four-fold increase in cardiovascular events 
relative to the general population in 236 patients with 
RA over a period of 8 years.11 Critically, del Rincón’s 
study showed that the increase in vascular risk could 
not be accounted for by traditional cardiovascular risk 
factors, such as diabetes mellitus, smoking status, and 
Key points
A variety of chronic inflammatory disorders confer increased risk of  ■
cardiovascular disease and attendant early mortality
Tumor necrosis factor (TNF) is a key cytokine that mediates effector pathways in  ■
both inflammatory disease target tissues and in atherosclerotic vessels
Clinical TNF blockade for treating inflammatory arthritis modulates vascular risk  ■
factors, generally in a beneficial direction, but there is a need for further data
Epidemiologic data suggest that TNF blockade, and inflammatory suppression  ■
in general, might have beneficial effects on vascular outcomes in patients with 
inflammatory arthritis; however, definitive data are lacking
Current data do not support the use of TNF antagonists as the primary  ■
intervention for the treatment or prevention of cardiovascular disease
hyper cholesterolemia. This lends credence to the notion 
that RA or, perhaps, a high-grade, systemic inflammatory 
state per se, potentially along with a specific genetic com-
ponent,12 confers pre disposition to the pathogenesis of 
atherosclerotic disease, or at least accelerates the disease 
process in affected indivi duals, acting as an independent 
risk factor.13 Perhaps the best evidence for increased vas-
cular risk comes from a meta-analysis of observational 
studies, which suggests that individuals with RA have 
a 50% higher risk of mortality related to cardiovascular 
disease than the general population.14 Evidence from 
ultrasonography studies of carotid intima–media thick-
ness (cIMT) in patients with RA without clinical evidence 
of atherosclerotic disease supports this concept as well; 
extra-articular disease and C-reactive protein (CRP) 
levels near the time of RA onset were both correlated 
with greater cIMT.15 It is likely that this inflammatory 
amplification of vascular risk is mediated both by direct 
and indirect effects. For example, high levels of systemic 
cytokines can contribute directly to endothelial dys-
function and a state of hypercoagulation,13 but can also 
in directly contribute to vascular disease by influencing 
the qualitative nature of lipid particles.16
Inflamed synovium and unstable atherosclerotic plaque 
are strikingly similar in a number of respects. In both 
disea sed tissues, elevated levels of cytokines, such as TNF, 
IL-6, IL-12, IL-15 and IL-18, have been observed, reflect-
ing local stimulation of macrophages by activated T cells. 
In addition, the T cells implicated in the pathogenesis of 
atherosclerosis are predominantly of TH1 or TH17 pheno-
types, which mirrors the pattern observed in active RA.17 
Both lesions contain an exaggerated matrix response and 
involve local cellular components, including respectively, 
synovial fibroblasts, chondrocytes and osteoclasts, and 
vascular smooth muscle, fibroblast and endothelial cells.18 
High levels of matrix metallo proteinases are expressed 
in both lesions. These parallels suggest possible mecha-
nisms whereby patients with RA develop an increased risk 
of atherosclerosis and early death. The increased back-
ground level of chronic inflammation might confer pre-
disposition to cardio vascular disease and/or augment 
its pathogenesis and put an individual at greater risk of 
developing an acute coronary syndrome or suffering 
secon dary complications thereafter.
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Much interest has focused on strategies to reduce vas-
cular risk in RA. Most authorities now agree that such 
strategies must encompass aggressive modification of 
traditional vascular risk factors (at least as well as these 
same risk factors are managed in the general population) 
and optimal inflammatory disease control, aiming for 
clinical remission and normalization of inflammatory 
parameters. The introduction of biologic therapies, and 
specifically TNF antagonists, to the rheumato logist’s 
therapeutic armamentarium has made the latter a realis-
tic objective. Data suggest that targeting this key inflam-
matory cytokine, central to both disease processes, might 
also be effective in reducing vascular disease in patients 
with RA.
TNF in RA and atherosclerosis
Arguably the single greatest advance in the manage-
ment of RA in recent times has been the identification 
of the key role of TNF in its pathogenesis. A multitude of 
proinflammatory and anti-inflammatory mediators has 
been characterized in the rheumatoid synovium but, 
among these, TNF, as identified in late 1982,19 seems 
to be pivotal. TNF is localized in the lining layer and at 
the cartilage pannus junction. In vitro administration of 
neutralizing anti-TNF antibody to primary RA synovial 
cultures results in a marked reduction in local cytokine 
production.20 Transgenic mice that express human TNF 
develop an inflammatory arthritis that is reminiscent of 
RA.21 Furthermore, administration of anti-TNF antibody 
to DBA/1 mice with collagen-induced arthritis led to a 
substantial reduction in inflammation and damage.22 
This work led to the first human trials of infliximab, 
a chimeric monoclonal antibody that targets TNF, for 
treatment of RA—studies which demonstrated significant 
clinical benefit.23
Three TNF antagonists are currently licensed for the 
treatment of RA: infliximab, adalimumab (a fully human-
ized monoclonal antibody) and etanercept (a fusion 
protein of human soluble TNF receptor and the Fc com-
ponent of human IgG1). All of these biologic agents have 
been shown to be effective in controlling disease activity, 
improving physical function and attenuating radiological 
progression in RA.24–26 In addition, a number of studies 
have described the effects of these agents on vascular risk 
surrogates and rates of vascular disease.
Effects on endothelial dysfunction
Endothelial dysfunction has been touted as a possible 
early event in the evolution of atherogenesis, as well as a 
surrogate intermediate marker of risk of cardio vascular 
disease. A range of techniques aimed at estimating 
endothelial function have been employed, including 
plethysmography, ultrasonography- determined flow-
mediated dilation (FMD), laser Doppler imaging with 
iontophoresis and more laterally, measures of pulse wave 
velocity (arterial stiffness) and pulse wave analyses. 
Reduced forearm blood flow has been demon strated in 
studies where patients with either RA or systemic vasculi-
tis who were taking standard RA therapy were compared 
with healthy controls.27,28 In 2007, Gonzalez-Juanatey 
et al.29 observed that flow mediated endothelium-
 dependent vasodilation was significantly impaired in 
individuals with psoriatic arthritis compared to con-
trols (P = 0.008). This body of work has confirmed that 
patients with inflammatory rheumatic conditions have 
evidence of endothelial dysfunction.
Moreover, observational studies have demonstrated 
that TNF has an important role in endothelial dysfunc-
tion, and subsequent clinical trials have assessed the 
potential benefits of anti-TNF therapy for ameliorating 
this disease process. One of the first groups to investigate 
the effects of anti-TNF on endothelial function studied 11 
patients with RA receiving infliximab.30 A significantly 
increased FMD (P = 0.018), significant reductions in 
erythrocyte sedimentation rate (P = 0.04), CRP (P = 0.08) 
and disease activity score (P = 0.002), and no associated 
change in endothelium-independent vaso dilation were 
demonstrated. Another study of infliximab for RA con-
firmed an increased FMD after first intravenous infusion 
(3.7 versus 17.5%, P <0.01), with similar results following 
the second and third infusions.31
Figure 1 | TNF remains on the cell membrane as a functional membrane protein, or 
is solubilized via the action of a membrane-bound cleaving enzyme (TACE). It can 
thereby influence a variety of molecular and cellular events that contribute to 
several disease states. Anti-TNF therapies, such as etanercept, infliximab and 
adalimumab, bind to TNF and prevent the molecule from interacting with its two 
receptors, TNFRI and TNFRII, thus stopping signaling events. These large inhibitor 
molecules prevent binding of either sTNF or proTNF to their membrane receptor 
targets. Abbreviations: sTNF, soluble TNF; TACE, TNFα converting enzyme; TNF, 
tumor necrosis factor; TNFRI, TNF receptor I; TNFRII, TNF receptor II. Permission 
obtained from Nature Publishing Group © Moss, L. M., Sklair-Tavron, L. & 
Nudelman, R. Nat. Clin. Pract. Rheum. 4, 300–309 (2008). 
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Effects on arterial stiffness
Arterial stiffness can be measured noninvasively. Pulse 
wave velocity (PWV) is a measure of the speed at which 
the arterial pressure wave travels. Higher values are 
associ ated with established cardiovascular risk factors 
and with cardiovascular mortality.32 Augmentation 
index (AIx) is a quantitative index of systemic arterial 
compliance that refers to the difference between the 
first and second systolic peak of the central waveform, 
expressed as a percentage of the pulse pressure.33 In a 
prospective study of 465 consecutive males undergoing 
coronary angiography, higher AIx was associated with 
an increased risk for coronary artery disease (multi-
variate analysis: odds ratio [OR] 6.91, P <0.05, 95% CI 
1.41–33.70).34
Analysis of the association between RA and arterial 
stiffness has confirmed an increased aortic (carotid 
to femoral) PWV compared with controls (P = 0.005), 
and similar increased brachial (carotid to radial) PWV 
(P = 0.02), with no significant difference in augmenta-
tion index or augmentation pressure observed.35 More 
recently, Avalos et al. observed that patients with a 
disease duration of greater than 10 years had a signifi-
cantly higher AIx than patients with a disease duration 
of less than 5 years (P = 0.008) or controls (P <0.001)—an 
association that remained significant even after adjusting 
for cardiovascular risk factors (P = 0.02).36
Ongoing studies over the last 4 years have assessed the 
effect of anti-TNF therapy on arterial elasticity in RA. 
Van Doornum and her group did not detect a signifi cant 
change in AIx in 14 anti-TNF-naive patients with RA who 
underwent 6 weeks of biologic therapy.37 The same group 
had previously shown a significant reduction in AIx in 
a cohort of 29 patients with RA who received 20 mg 
atorva statin daily for 12 weeks (P = 0.0002).38 Further 
study in this area has produced corroborative results; 
commencement of etanercept in a group of 9 patients 
with RA lead to a reduction in disease activity score, CRP 
and erythrocyte sedimentation rate as well as aortic PWV 
(P = 0.0003) along with an increased FMD (P = 0.003), but 
no significant change in augmentation index.35
It seems that anti-TNF therapy might reduce PWV but 
have less, if any, affect on Alx; however, the current data 
are limited by the small cohorts studied.
Carotid intima–media thickness
Noninvasive B-mode ultrasonography of the carotid arte-
rial system is now an FDA-approved surrogate marker 
of vascular disease for the purposes of clinical trials of 
therapies for coronary heart disease. cIMT is increased 
in patients with inflammatory conditions such as RA, 
psoriatic arthritis and systemic lupus erythematosus,39,40 
with cIMT severity associated with inflammatory burden 
and disease duration.40 Studies are ongoing regarding 
the potential relationship between carotid plaque and 
these variables.
Gonzalez-Juanatey and colleagues failed to demon-
strate a significant difference between the control group 
given standard therapy and a cohort of patients switched 
from standard RA treatment to infliximab; cIMT 
progres sion was not significantly different between the 
groups.41 A more recent small study identified 30 patients 
with RA commencing anti-TNF (14 on infliximab, 16 
on etanercept) and compared their disease progres-
sion and cIMTs over the course of a year’s therapy with 
10 controls. Anti-TNF therapy was associated with a 
signifi cant and remarkable reduction in cIMT after one 
year of treatment (P <0.0001); a significant correlation 
between disease activity score in 44 joints and cIMT was 
also found (r = 0.435, P <0.05).42 However, owing to the 
limitations of the currently available studies, larger, well-
designed trials are needed to establish the true extent of 
benefit of anti-TNF therapies on cIMT.
Insulin sensitivity and obesity
A number of studies have confirmed an association 
between obesity, increased insulin sensitivity and 
elevated TNF levels.43,44 Investigators have confirmed 
an improvement in insulin sensitivity with infliximab 
therapy in both patients with RA and those with ankylos-
ing spondylitis.45–47 Kiortis et al. demonstrated that those 
patients with the highest tertile of insulin resistance had 
the greatest reduction in HOMA (HOmeostasis Model 
Assessment, negatively correlated with insulin sensi-
tivity; P <0.01) and the greatest increase in QUICKI 
(Quantitative Insulin Sensitivity Check Index; P <0.01).47 
Once again, however, such studies have been small and 
larger studies are required to improve the evidence base. 
Additionally, it should be noted that the wealth of prior 
studies suggest at best a modest association between 
insulin resistance (as measured by fasting insulin) and 
risk for vascular events.48
Endothelial
injury and
dysfunction
TNF
Leukocytes
 Activation
 Maturation
 Cytokine and
  chemokine release
 Production of reactive
  oxygen and nitrogen
  intermediates
Endothelial cells
 Activation to support
  recruitment of
  activated leukocytes
 Apoptosis?
 Suppression of
  endothelial cell
  progenitors?
? Atherosclerosis ?
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Figure 2 | TNF might cause atherosclerosis through actions on leukocytes, 
endothelial cells and adipocytes. Abbreviation: TNF, tumor necrosis factor.
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Biologic agents and lipid profiles
In the general population, it is well established that 
elevated cholesterol and low HDL-cholesterol levels are 
predictive of vascular event risk. The ratio of elevated 
total cholesterol to HDL cholesterol is thus reflective of 
lipid-associated vascular risk and is incorporated into 
many cardiovascular risk algorithms, for example the 
Joint British Societies’ guidelines.49
Disease-modifying antirheumatic drug therapy has 
been associated with changes in lipid levels in multiple 
studies, as summarized in Table 1. Infliximab has been 
shown to significantly increase total cholesterol and 
HDL-cholesterol levels in patients with RA,50,51 as has 
adalimumab.52 A double-blinded, placebo-controlled 
trial of anti-TNF (onercept 50 mg or 100 mg) for treating 
psoriatic arthritis demonstrated significantly increased 
circulating levels of apolipoprotein A-I (P = 0.002), 
which is the main antiatherogenic protein in HDL par-
ticles. Significantly increased levels of triglycerides and 
apolipoprotein-B, the main protein in LDL particles, were 
also noted, which was an unexpected outcome and sug-
gests that the biochemical lipid changes associated with 
anti-TNF therapies might be more complicated than orig-
inally thought.53 Interestingly, significant reductions in 
homocysteine (–1.72 versus 0.34 mol/l with placebo) and 
lipoprotein(a) (–3.11 versus 1.52 mg/dl with placebo) 
were noted with TNF blockade. Further studies54,55 
suggest that treatment with anti-TNF leads to increases 
not only in HDL cholesterol, but also other lipid moieti es, 
including total and LDL cholesterol, and perhaps tri-
glycerides. Such changes in lipid levels might be the 
predictable response to attenuation of inflammation, 
because in untreated RA reductions in HDL cholesterol, 
LDL cholesterol and total cholesterol have been noted.56 
Moreover, these changes mirror lipid profile modifica-
tions associated with other pathologies/ conditions that 
involve inflammation or infection, such as sepsis, cancer, 
trauma or post-operation.57–59 Qualitative changes in lipid 
particles during inflammation complicate further inter-
pretations, but it seems as if TNF blockade reverses many 
of the antiatherogenic effects of inflammation upon HDL 
particles.16,60 Continued research on the nature and extent 
of lipids changes with biologics is needed.
In 2008, Jick et al. published a case–control study that 
evaluated whether statins were associated with a pro-
tective effect on the development of RA.61 Patients with 
hyperlipidemia who were taking statins were less likely 
to develop RA than untreated patients (OR 0.59, 95% CI 
0.37–0.96).
Biologic registry data 
A number of large registries of patients with rheumatic 
conditions receiving biologic therapies have been estab-
lished, with aims of producing long-term data on efficacy 
and toxicity. These registries include the South Swedish 
Arthritis Treatment Group (SSATG), the British Society 
for Rheumatology Biologics Register (BSRBR) and the 
German biologics register (RABBIT). Published data 
from the latter on the risk of heart failure with anti-TNF 
therapy has been discussed previously.62
In 2005, Jacobsson and colleagues from SSATG 
published the available data on the first incidence of 
cardio vascular events and deaths related to cardio-
vascular disease in patients included in their registry.63 
In the cohort of 531 patients exposed to anti-TNF, 13 
such events, including 2 deaths, occurred. In parallel, 
85 cardio vascular events, including 12 deaths, occurred 
among 543 control patients not exposed to anti-TNF 
therapy from a similar RA registry in Malmö, Sweden. 
The age–sex adjusted incidence rate of the first cardio-
vascular event among the anti-TNF-treated patients was 
14 per 1,000 person-years (95% CI 5.7–22.4) compared 
with 35.4 per 1,000 person-years (95% CI 15.5–55.4) in 
the anti-TNF-naive group. However, the small sample 
size did not allow subgrouping for individual cardio-
vascular events, and data on lipid profiles, smoking status 
and blood pressure were lacking in this report.
The BSRBR conducted a UK-wide, prospective, 
observa tional study of patients commencing anti-TNF 
therapy, with a comparator group of biologic-drug-
naive patients with active RA.64 First-line analysis of the 
data confirmed a reduced rate of myocardial infarction 
in patients treated with anti-TNF (4.8 per 1,000 years) 
Table 1 | Lipid changes with anti-TNF treatments in autoimmune conditions
Study Patients Treatment  
and dosing
Changes in lipids
Allanore 
et al.50
Patients with RAa 
n = 59
3 mg/kg in!iximab 
Weeks 0, 2, 6, 14, 
22, 30
 Total cholesterol 
 HDL-C 
 LDL-C 
 Triglyceride 
 Total cholesterol/HDL-C 
 LDL/HDL-C
Vis 
et al.51
Patients with RAb 
n = 69
3 mg/kg in!iximab 
Weeks 0, 2, 6
 Total cholesterol 
 HDL-C 
 Total cholesterol/HDL-C
Popa 
et al.52
Patients with RA 
n = 33
Adalimumab (dose 
not speci"ed) 
Weeks 0, 2
 HDL-C 
 LDL-C 
 Triglyceride
Sattar 
et al.53
Patients with 
psoriatic arthritis 
n = 126
100 mg onercept 
3 times weekly for 
12 weeks with 
placebo control
 Total cholesterol but  apo Bc 
 HDL-C but  apo A-I 
 Triglyceride
Peters 
et al.54
Patients with RA 
n = 80
3 mg/kg in!iximab 
Weeks 0, 2, 6, and 
every 8 weeks 
thereafter
 Total cholesterol 
 HDL-C 
 Triglyceride 
 Total cholesterol/HDL-C
Popa 
et al.55
Patients with RA 
n = 67
3 mg/kg in!iximab 
Weeks 0, 2, 6 and 
every 8 weeks 
thereafter
 Total cholesterol 
 HDL-C 
 LDL-C 
 Triglyceride 
 Total cholesterol/HDL-C 
 LDL/HDL-C
aExclusions: lipid lowering therapy, diabetes mellitus, hypothyroidism, alcoholism, chronic liver disease, 
Cushing syndrome. bActive RA, 32 patients on steroids at baseline. cApo B and apo A-I are the main 
proteins in LDL-C and HDL-C particles, respectively. The apo B:apo A-I ratio is potentially more strongly 
linked to cardiovascular disease risk than the total cholesterol:HDL-C ratio. Abbreviations: Apo A-1, 
apolipoprotein A-1; apo B, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; RA, rheumatoid arthritis; TNF, tumor necrosis factor.
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compared with those individuals only treated with 
disease- modifying antirheumatic drugs (5.9 per 
1,000 years). The BSRBR patients who had received 
anti-TNF were then assigned into ‘responder’ or ‘non-
responder’ groups (n = 5,877 and n = 1,638, respectively). 
Further analysis after this categorization demonstrated 
a significantly lower incidence of myocardial infarction 
in the anti-TNF responders: 3.5 per 1,000 person-years 
versus 9.4 per 1,000 person-years (95% CI 2.5–4.9 and 
5.5–15.0, respectively). Dixon et al. also reviewed the 
incidence of cerebro vascular accidents in patients from 
the same registry.65 The crude incidence of cerebro-
vascular accidents was 3.9 per 1,000 years in the anti-
TNF group (95% CI 2.9–5.3) and 9.9 per 1,000 years in 
the control (disease-modifying antirheumatic drugs) 
group (95% CI 5.3–16.9).
The information presented from registry databases has 
demonstrated results that broadly support the hypothesis 
that anti-TNF therapy might lessen cardiovascular risk, 
potentially through a reduction in inflammatory load.
Heart failure
TNF, along with other inflammatory molecules, is 
known to alter cardiac function through a number of 
mechanisms.66 Levine and colleagues were one of the first 
groups to document the significantly elevated levels of 
TNF in a cohort of patients with chronic heart failure 
compared with controls.67 Clinical trials to evaluate the 
efficacy of anti-TNF therapy in patients with NYHA 
class II or greater heart failure (including ATTACH, 
RECOVER and RENAISSANCE), were halted prema-
turely owing to the lack of clinical benefit and worsening 
of the patients’ conditions.68,69 An initial case series of 
47 patients with new onset or exacerbated heart failure 
secondary to anti-TNF therapy prompted a review of pre-
scribing protocols,70 and guidelines incorporated heart 
failure as exclusion to therapy.
It has previously been shown that patients with RA are 
at twice the risk of congestive heart failure than indivi-
duals without the disease.71 Investigators reviewing data 
from a German registry of anti-TNF therapy found a 
2.2% 3 year incidence of heart failure in patients with 
pre-existing cardiovascular disease and a 0.4% 3-year 
incidence in those without.62 After adjusting for tradi-
tional cardiovascular risk factors, a nonsignificant risk 
remained for development of heart failure (adjusted 
hazard ratio 1.66, 95% CI 0.67–4.1, P = 0.28). A number 
of confounders can be found in this analysis, such as a 
lack of a standardized definition for heart failure, a small 
number of actual events, and the exclusion of smoking as 
a risk factor owing to the lack of available data.
Prospects for the future
The foregoing evidence, as summarized in Figure 3, clearly 
implicates TNF in the accelerated athero genesis and other 
cardiovascular events associated with RA. Many data indi-
cate that heart disease has also been linked to other auto-
immune disorders, including psoriasis. Yet, the corollary 
to these associations might not be true, namely that TNF 
and related cytokines have a pivotal role in the patho-
genesis of atherogenesis in nonautoimmune populations. 
Studies of commonly used therapeutics in the vascular 
therapeutic area suggest that inflammation modulation 
might be useful. Most evidence exists on the use of statins 
in primary and secon dary preventative proto cols, although 
most experts firmly believe that statin effects on outcomes 
(and possibly CRP) are mediated primarily via reduction 
in LDL cholesterol. Although large biologic therapeutics as 
currently investi gated, or indeed envisaged, are unlikely to 
be appropriate for long-term vascular modification, they 
might be helpful in proof-of-concept studies. Moreover, 
small-molecule entities are being developed by many 
pharmaceutical companies, which should target cytokine 
effector pathways and thereby improve clinical outcomes. 
To this end, agents that target mitogen activated phospho-
kinases (for example, p38, JNK) or proximal signal trans-
duction targets (for example, JAK1–3, syk kinase) are 
under going clinical development for treating a range of 
inflammatory disorders, particularly RA. If proven effica-
cious in inflammatory diseases a priori, such agents might 
provide an opportunity to formally test the potential of 
inflammation modulation in atherogenesis progression 
in the general population.
It will also be important to evaluate the effect of other 
novel biologic agents on vascular function, as well as their 
efficacy at treating autoimmune diseases. For example, 
intriguing phenomena are emerging with the advent of 
IL-6 blocking agents in RA that suppress disease acti vity 
Decreased RA synovitis
TNF blockade in autoimmune disease
Reduction in
CVD events?
(more data
needed)
Reduction in
systemic
in!ammatory
mediators
 Improved endothelial function
 Reduced vascular stiffness
 Reductions in !brinogen
 Reductions in homocysteine 
 Reduction in lipoprotein(a)
 Increased lipids (HDL-C and LDL-C)
  but ratio relatively stable 
 Compositional lipid changes?
 Decreased insulin resistance?
 Decreased oxidative stress?
 Effects on adipokines? 
 Reduced IMT progression?
TNF
TNF
Figure 3 | Effects of TNF blockade on systemic inflammation, surrogate vascular 
and metabolic markers and CVD events. Abbreviations: CVD, cardiovascular 
disease; HDL-C, high-density lipoprotein cholesterol; IMT, intima–media thickness; 
LDL-C, low-density lipoprotein cholesterol; RA, rheumatoid arthritis; TNF, tumor 
necrosis factor.
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very effectively,72 but that also lead to rapid and sustained, 
albeit modest in most cases, increases of chol esterol and 
triglyceride levels (as reviewed in 2009).73 Whether such 
changes have any pathophysiologic signifi cance is as yet 
unclear, although studies are underway to address these 
questions directly. The outcome of such studies should be 
informative not only to the relevant use of these agents in 
RA, but will also speak to the extensive vascular literature 
implicating IL-6 as a net proatherogenic factor. Indeed, 
other novel cytokines that might have a role, as implicated 
by vascular epidemiologic and pathophysiologic studies, 
could also be tested in the near future in this context—
IL-17, IL-18, IL-12/IL-23 are all being investi gated in 
clinical trials for managing RA and psoriasis, and vascu-
lar surrogates should be measured during their studies. 
Finally, the vascular effects of other types of RA treat-
ments, such as cell targeting therapeutics, including abata-
cept (which modulates T cell costimulation via blockade of 
the CD28 and CD80/86 pathway), and rituximab (which 
selectively targets and depletes CD20-positive B cells),74 
will be submitted to detailed analysis.
In conclusion, considerable advances in understanding 
of the potential role of cytokines in atherogenesis have 
been made since the view of RA as an accelerated model 
of atherogenesis was proffered. Data from clinical TNF 
blockade have supported the principle that inflammation 
modulation can positively modulate vascular pathology. 
As the cytokine medicine field continues to broaden, 
attentive future analyses will demonstrate the general 
use of inflammation modulation in ameliorating primary 
vascular diseases.
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Editorial
Non-steroidal anti-inflammatory drugs—changes in
prescribing may be warranted
Non-steroidal anti-inflammatory drugs (NSAIDs) are among
one of the most frequently prescribed classes of drugs. Both their
benefits and harms arise due to inhibition of cycloxygenase
(COX) of which there are two isoenzymes, COX 1 and 2.
Both COX isoenzymes have a hydrophobic tunnel, through
which the substrate accesses the active site. The tunnel is larger in
the COX 2 isoenzyme with a side pocket, a property exploited in
the development of specific COX 2 inhibitors [1]. The premise
of the initial, COX 2 hypothesis was that the gastrointes-
tinal side effects arose due to inhibition of COX 1 whereas their
anti-inflammatory or analgesic properties were COX 2 mediated.
Although now appreciated to be rather naı¨ve, the superiority
of the selective COX 2 inhibitors in preventing gastro-duodenal
mucosal ulceration over the non-selective NSAIDs is striking [2, 3].
There has been continuing scientific and media attention on
reports that selective COX 2 inhibitors increase the risk of
cardiovascular events. In an early study of major gastrointestinal
events, an unexpected 5-fold increase in the risk of acute
myocardial infarction (AMI) with rofecoxib was observed when
compared with naproxen [4]. At the time, many suggested and
aggressively pursued the hypothesis that the increased frequency
of events was a spurious observation not due to any prothrombo-
tic effects of rofecoxib, but the cardioprotective properties of
naproxen. However, subsequent placebo-controlled studies of
both rofecoxib, and celecoxib in chemoprevention also reported
an approximate 2-fold increase in cardiovascular events with
both drugs [5, 6].
More recently, attention has turned to the effects of the non-
selective NSAIDs. As aspirin confers its cardiovascular benefits
by inhibiting COX 1 [7], received wisdom has never considered
the possibility that the non-selective NSAIDs could increase the
risk of cardiovascular events. However, in February 2005,
the Food and Drugs Administration (FDA) decided to advise
that the risk of cardiovascular events for both selective COX 2
and non-selective NSAIDs is similar and has taken the step to
categorize this as a class effect [8]. In the US, all COX 2 selective
and non-selective NSAIDs now carry a black-boxed warning
on the package insert advising patients of the potential increased
cardiovascular risk [9]. The European Agency for the Evaluation
of Medicine Products (EMEA) [10] and the Medicines and
Healthcare Products Regulatory Agency (MRHA) [11] have,
however, been much more reassuring with regard to non-selective
NSAIDs and advised that ‘the data are insufficient to warrant
changes in current prescribing’.
The association between increased AMI risk and non-selective
NSAIDs has been evaluated predominantly in observational
studies [12–28]. These were primarily based on data from large
population and hospital databases that recorded the prevalence
of NSAID use combined with confirmed AMI diagnosis. While
most studies also accounted for the presence of other risk factors,
confounders and use of aspirin, few recorded the indication
and duration of NSAID use [15, 16, 18]. Overall, a general
direction of effect has been reported from the observational
studies—with the exception of one study [21], which reported
no effect between non-selective NSAID use and AMI, all
studies showed a similar trend of increased risk of AMI
compared with remote and non-use, ranging from relative risk
of 1.00 (95% CI: 0.73–1.37) [21] to 1.47 (95% CI: 1.00–2.16) [22].
Although the size of the overall relative risk appears small,
however, due to the large number of patients prescribed NSAIDs,
the absolute risk may be considerable. In addition, these studies
have presented data that suggested a differential risk between
individual NSAID such as diclofenac, naproxen and ibuprofen,
but there is insufficient evidence to conclude whether this truly
represents a class effect.
The main concern in the context of these studies is whether
the small effect observed is a real one or due to unknown or
unmeasured confounding factors, a limitation that is inherent
to all observational studies. However, such studies may be the
only feasible method to determine the potential harms of drugs
if the effects are small.
It has been advocated that the only method to resolve the
issue would be to undertake a large randomized-control trial of
non-selective NSAIDs vs placebo [29]. However, it is unlikely that
such trial would ever be funded, and it would be unethical
to randomize patients to an intervention that may be potentially
harmful.
Kearney et al. [30] have undertaken a meta-analysis of data
of vascular events from randomized-controlled trials of selective
COX 2 inhibitors. They found that in all studies selective COX 2
inhibitors increased the risk of vascular events, mainly AMI
by 42% (rate ratio 1.42; 95% CI: 1.13–1.78). Trials that compared
a COX 2 inhibitor with a traditional NSAID (n¼ 91 trials)
showed no significant difference in the risk of vascular events
(rate ratio 1.16; 95% CI: 0.97–1.38). There were no significant
differences whether all non-selective NSAIDs were considered
together, in combination, or alone when compared with COX 2
inhibitors. However, a comparison of non-selective NSAIDs
with placebo showed differences between NSAIDs—naproxen
was associated with the lowest risk (0.92; 95% CI: 0.67–1.21), but
there were insufficient data to show a cardioprotective effect;
whereas the rate ratios for ibuprofen and diclofenac were 1.51
(95% CI: 0.96–2.37) and 1.63 (95% CI: 1.12–2.37), respectively.
This study thus confirms the findings of the epidemiological
studies, but the number of cardiovascular events were small,
a limitation acknowledged by the investigators. Furthermore,
none of the comparative studies of COX 2 inhibitors with
non-selective studies were conducted in patients with high
cardiovascular risk or specifically powered to evaluate cardio-
vascular events.
The MEDAL programme and PRECISION studies are
pharmaceutical industry sponsored trials designed to address
these concerns. The MEDAL programme consists of three studies
(EDGE, EDGE II and MEDAL), and is a non-inferiority
comparison of cardiovascular events between etoricoxib and
diclofenac [31]. The EDGE studies where originally designed to
compare the gastrointestinal tolerability of etoricoxib compared
with diclofenac in osteoarthritis and rheumatoid arthritis, whereas
the MEDAL study is specifically designed to compare cardio-
vascular events in 17 804 osteoarthritis and 5700 rheumatoid
arthritis patients treated with either etoricoxib or diclofenac.
All three studies will continue until the total number of confirmed
thrombotic reaches 635 with at least 430 in the MEDAL study.
The PRECISION study is a multi-centre comparative study
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of celecoxib, diclofenac or ibuprofen coordinated by the Cleveland
Clinic which is to report in 4 yrs time [32].
Common to both non-selective NSAIDs and COX 2 inhibitors
is the adverse event of hypertension [33, 34]. Most NSAIDs
raise blood pressure by approximately 3–5mmHg [34]. Even such
a modest rise will result in a significantly increased frequency of
cardiovascular events; a 3mmHg rise in systolic blood pressure
increases the frequency of congestive cardiac failure by 10–20%,
increases the risk of stroke up to 20% and angina by 12% [35].
It has also been predicted that a 3mmHg in blood pressure in
rheumatoid arthritis patients in the US will result in an additional
21 390 ischaemic heart disease and stroke events [36]; when
extrapolated to the UK rheumatoid arthritis population, this is
equivalent to 2058 potentially avoidable fatal events.
The current evidence strongly suggests that the risk for
cardiovascular events to be similar for both non-selective
NSAIDs and COX 2 inhibitors. The potential size of the problem
is substantial. Physicians should reconsider their prescription of
non-selective NSAIDs in line with those advocated by the FDA.
Any other advice on current prescribing is unwarranted.
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